=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehac244.pdf",
  "converted_date": "2026-01-31T14:50:52.746326",
  "file_size_bytes": 10880665,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehac244.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
EuropeanHeartJournal(2022)43,4229–4361
https://doi.org/10.1093/eurheartj/ehac244
2022 ESC Guidelines on cardio-oncology
developed in collaboration with the European
Hematology Association (EHA), the European
Society for Therapeutic Radiology and
Oncology (ESTRO) and the International
Cardio-Oncology Society (IC-OS)
Developed by the task force on cardio-oncology of the European
Society of Cardiology (ESC)
†
Authors/Task Force Members: Alexander R. Lyon* (Chairperson) (United
†
Kingdom),TeresaLópez-Fernández* (Chairperson)(Spain),LiamS.Couch(Task
Force Coordinator) (United Kingdom), Riccardo Asteggiano (Italy),
Marianne C. Aznar1 (United Kingdom), Jutta Bergler-Klein (Austria),
Giuseppe Boriani (Italy), Daniela Cardinale (Italy), Raul Cordoba2 (Spain),
Bernard Cosyns (Belgium), David J. Cutter (United Kingdom),
EvandrodeAzambuja(Belgium),RudolfA.deBoer(Netherlands),SusanF.Dent3
fi
(United States of America), Dimitrios Farmakis (Cyprus), So e A. Gevaert
(Belgium), Diana A. Gorog (United Kingdom), Joerg Herrmann3 (United States of
America), Daniel Lenihan3 (United States of America), Javid Moslehi (United
States of America), Brenda Moura (Portugal), Sonja S. Salinger (Serbia),
Richard Stephens (United Kingdom), Thomas M. Suter (Switzerland),
Sebastian Szmit (Poland), Juan Tamargo (Spain), Paaladinesh Thavendiranathan
(Canada), Carlo G. Tocchetti (Italy), Peter van der Meer (Netherlands),
fi
Helena J.H. van der Pal (Netherlands), and ESC Scienti c Document Group
*Correspondingauthors:AlexanderR.Lyon,NationalHeartandLungInstitute,ImperialCollegeLondonandCardio-OncologyService,RoyalBromptonHospital,London,United
Kingdom.Tel:+442073528121,E-mail:a.lyon@imperial.ac.uk.
TeresaLópez-Fernández,CardiologyDepartment,LaPazUniversityHospital,IdiPAZResearchInstitute,Madrid,Spain.Tel:+34619227076,E-mail:tlfernandez8@gmail.com.
†Thetwochairpersonscontributedequallytothedocumentandarejointcorrespondingauthors.
Author/TaskForceMemberaffiliationsarelistedinAuthorinformation.
1RepresentingtheEuropeanSocietyforTherapeuticRadiologyandOncology(ESTRO);2representingtheEuropeanHematologyAssociation(EHA);3representingtheInternational
Cardio-OncologySociety(IC-OS).
ESCClinicalPracticeGuidelines(CPG)Committee:listedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AssociationforAcuteCardioVascularCare(ACVC),EuropeanAssociationofCardiovascularImaging(EACVI),EuropeanAssociationofPreventiveCardiology(EAPC),
EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),EuropeanHeartRhythmAssociation(EHRA),HeartFailureAssociation(HFA).
Councils:CouncilofCardio-Oncology,CouncilonHypertension,CouncilonValvularHeartDisease.
WorkingGroups:AortaandPeripheralVascularDiseases,CardiovascularPharmacotherapy,e-Cardiology,MyocardialFunction,PulmonaryCirculationandRightVentricularFunction,
Thrombosis.
PatientForum
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 2 ---
4230 ESCGuidelines
DocumentReviewers:PatrizioLancellotti(CPGReviewCoordinator)(Belgium),FranckThuny(CPGReview
Coordinator)(France),MagdyAbdelhamid(Egypt),VictorAboyans(France),BertheAleman1(Netherlands),
JoachimAlexandre(France),AnaBarac3(UnitedStatesofAmerica),MichaelA.Borger(Germany),
RubenCasado-Arroyo(Belgium),JenniferCautela(France),JolantaČelutkienė(Lithuania),MajaCikes
(Croatia),AlainCohen-Solal(France),KreenaDhiman(UnitedKingdom),StéphaneEderhy(France),
ThorEdvardsen(Norway),LaurentFauchier(France),MichaelFradley3(UnitedStatesofAmerica),JuliaGrapsa
(UnitedKingdom),SigrunHalvorsen(Norway),MichaelHeuser2(Germany),MarcHumbert(France),
TinyJaarsma(Sweden),ThomasKahan(Sweden),AleksandraKonradi(RussianFederation),
KonstantinosC.Koskinas(Switzerland),DipakKotecha(UnitedKingdom),BonnieKy3(UnitedStates
ofAmerica),UlfLandmesser(Germany),BasilS.Lewis(Israel),AlesLinhart(CzechRepublic),GregoryY.H.Lip
(UnitedKingdom),Maja-LisaLøchen(Norway),KatarzynaMalaczynska-Rajpold(UnitedKingdom),
MarcoMetra(Italy),RichardMindham(UnitedKingdom),MarieMoonen(Belgium),TomasG.Neilan
(UnitedStatesofAmerica),JensCosedisNielsen(Denmark),Anna-SoniaPetronio(Italy),EvaPrescott
(Denmark),AminaRakisheva(Kazakhstan),Joe-ElieSalem(France),GianluigiSavarese(Sweden),MartaSitges
(Spain),JurrientenBerg(Netherlands),RhianM.Touyz(Canada/UnitedKingdom),AgnieszkaTycinska
(Poland),MatthiasWilhelm(Switzerland),andJoseLuisZamorano(Spain)
AllexpertsinvolvedinthedevelopmentoftheseGuidelineshavesubmitteddeclarationsofinterest.Thesehave
beencompiledinareportandpublishedinasupplementarydocumentsimultaneouslytotheGuidelines.The
reportisalsoavailableontheESCwebsitewww.escardio.org/Guidelines
SeetheEuropeanHeartJournalonlineforsupplementarydatathatincludesbackgroundinformationand
detaileddiscussionofthedatathathaveprovidedthebasisoftheguidelines.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines (cid:129) Androgendeprivationtherapy (cid:129) Anthracycline (cid:129) Atrialfibrillation (cid:129) Arrhythmias (cid:129) Biomarkers (cid:129)
Cancer (cid:129) Cancersurvivors (cid:129) Carcinoidsyndrome (cid:129) Amyloidlight-chaincardiacamyloidosis (cid:129) Cardiacmagnetic
resonance (cid:129) Cardiactumour (cid:129) Cardio-oncology (cid:129) Cardiotoxicity (cid:129) Coronaryarterydisease (cid:129) Chemotherapy (cid:129)
Echocardiography (cid:129) Fluoropyrimidine (cid:129) Heartfailure (cid:129) Haematopoieticstemcelltransplantation (cid:129) Hormonetherapy
(cid:129) Hypertension (cid:129) Immunotherapy (cid:129) Ischaemicheartdisease (cid:129) Myocarditis (cid:129) Pericardialdisease (cid:129) Pulmonary
hypertension (cid:129) Thrombosis (cid:129) Riskstratification (cid:129) Trastuzumab (cid:129) Valvularheartdisease (cid:129) Vascularendothelial
growthfactorinhibitors(VEGFi) (cid:129) Venousthromboembolism (cid:129) Pericardialdisease (cid:129) Proteasomeinhibitors (cid:129) QTc
prolongation (cid:129) Radiotherapy (cid:129) Strain
ThecontentoftheseEuropeanSocietyofCardiology(ESC)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.NopartoftheESC
GuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESC.PermissioncanbeobtaineduponsubmissionofawrittenrequesttoOxfordUniversity
Press,thepublisheroftheEuropeanHeartJournalandthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.permissions@oup.com).
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavailableatthe
timeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancyand/orambiguitybetweentheESCGuidelinesandanyotherofficialrecommendations
orguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsareencouragedtotakethe
ESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgement,aswellasinthedeterminationandtheimplementationofpreventive,diagnosticortherapeuticmedicalstrat-
egies;however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedecisionsinconsid-
erationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scaregiver.NordotheESCGuidelinesexempthealth
professionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublichealthauthorities,inorderto
manageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itisalsothehealthprofessional’sresponsibilityto
verifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
Thisarticlehasbeenco-publishedwithpermissionintheEuropeanHeartJournalandtheEuropeanHeartJournal–CardiovascularImaging.©TheEuropeanSocietyofCardiology2022.All
rightsreserved.Thearticlesareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournal’sstyle.Eithercitationcanbeusedwhencitingthisarticle.For
permissionspleasee-mail:journals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 3 ---
ESCGuidelines 4231
Table of contents 6.1.Cancertherapy-relatedcardiacdysfunction.......................... 4282
6.1.1.Anthracyclinechemotherapy-relatedcardiac
1.Preamble........................................................................................................ 4236 dysfunction......................................................................................... 4282
2.Introduction ................................................................................................. 4238 6.1.2.Humanepidermalreceptor2-targetedtherapy-
2.1.Cancerandcardiovascularneedsofpatientswithcancer 4238 relatedcardiacdysfunction......................................................... 4284
2.2.Roleofcardio-oncologyservices ............................................... 4238 6.1.3.Immunecheckpointinhibitor-associated
2.3.Generalprinciplesofcardio-oncology..................................... 4239 myocarditisandnon-inflammatoryheartfailure............... 4286
3.Cancertherapy-relatedcardiovasculartoxicitydefinitions ..... 4242 6.1.4.ChimericantigenreceptorTcellandtumour-
4.Cardiovasculartoxicityriskstratificationbeforeanticancer infiltratinglymphocytestherapiesandheartdysfunction 4290
therapy................................................................................................................. 4244 6.1.5.Heartfailureduringhaematopoieticstemcell
4.1.Generalapproachtocardiovasculartoxicityriskinpatients transplantation ................................................................................. 4291
withcancer ................................................................................................... 4244 6.1.6.Takotsubosyndromeandcancer................................ 4291
4.2.Historyandclinicalexamination................................................. 4249 6.2.Coronaryarterydisease................................................................. 4291
4.3.Electrocardiogram............................................................................. 4249 6.2.1.Acutecoronarysyndromes............................................ 4291
4.4.Cardiacserumbiomarkers............................................................ 4251 6.2.2.Chroniccoronarysyndromes ....................................... 4293
4.5.Cardiovascularimaging ................................................................... 4252 6.3.Valvularheartdisease...................................................................... 4293
4.6.Cardiopulmonaryfitnessassessment ....................................... 4253 6.4.Cardiacarrhythmias......................................................................... 4294
4.7.Cardiovascularriskevaluationbeforecancersurgery ...... 4254 6.4.1.Atrialfibrillation................................................................... 4294
4.8.Genetictesting ................................................................................... 4254 6.4.2.LongcorrectedQTintervalandventricular
5.Preventionandmonitoringofcardiovascularcomplications arrhythmias........................................................................................ 4298
duringcancertherapy ................................................................................... 4254 6.4.3.Bradyarrhythmias................................................................ 4300
5.1.Generalprinciples ............................................................................. 4254 6.5.Arterialhypertension....................................................................... 4300
5.2.Primarypreventionstrategies...................................................... 4256 6.6.Thrombosisandthromboembolicevents .............................. 4303
5.2.1.Primarypreventionofcancertherapy-related 6.6.1.Venousthromboembolism............................................. 4303
cardiovascular toxicityduringanthracycline 6.6.2.Arterialthromboembolism ............................................ 4304
chemotherapy .................................................................................. 4256 6.6.3.Intracardiacthrombosis ................................................... 4304
5.2.2.Primarypreventionofradiation-induced 6.6.4.Anticoagulationtherapy................................................... 4305
cardiovasculartoxicity .................................................................. 4256 6.7.Bleedingcomplications.................................................................... 4306
5.3.Secondarypreventionstrategies ................................................ 4257 6.7.1.High-riskpatients................................................................ 4306
5.4.Cardiovascularsurveillanceduringcancertherapies ......... 4257 6.7.2.Antiplatelettherapy........................................................... 4306
5.4.1.Cardiacserumbiomarkers ............................................. 4257 6.7.3.Managementofbleeding.................................................. 4306
5.4.2.Cardiacimaging.................................................................... 4257 6.8.Peripheralarterydisease................................................................ 4307
5.5.Cancertherapy-relatedcardiovasculartoxicitymonitoring 6.9.Pulmonaryhypertension ................................................................ 4307
protocols ....................................................................................................... 4259 6.10.Pericardialdiseases......................................................................... 4308
5.5.1.Anthracyclinechemotherapy......................................... 4259 6.10.1.Pericarditis........................................................................... 4308
5.5.2.HER2-targetedtherapies................................................. 4259 6.10.2.Pericardialeffusion........................................................... 4308
5.5.3.Fluoropyrimidines............................................................... 4261 7.End-of-cancertherapycardiovascularriskassessment ............. 4309
5.5.4.Vascularendothelialgrowthfactorinhibitors........ 4261 7.1.Cardiovascularevaluationduringthefirstyearafter
5.5.5.MultitargetedkinaseinhibitorstargetingBCR-ABL 4264 cardiotoxicanticancertherapy ............................................................ 4309
5.5.6.Brutontyrosinekinaseinhibitors................................. 4267 7.2.Whichcancersurvivorsrequirecardiovascularsurveillance
5.5.7.Multiplemyelomatherapies........................................... 4268 inthefirstyearaftercancertreatment?.......................................... 4309
5.5.8.Rapidlyacceleratedfibrosarcomaandmitogen- 7.3.Managementofcancertherapy-relatedcardiacdysfunction
activatedextracellularsignal-regulatedkinaseinhibitor attheend-of-therapyassessment ...................................................... 4310
treatment............................................................................................ 4271 7.4.Cardiopulmonaryexercisetestingandfitnessduringthe
5.5.9.Immunecheckpointinhibitors ...................................... 4273 end-of-therapyassessment.................................................................... 4310
5.5.10.Androgendeprivationtherapiesfor prostate 7.5.Theroleofcardiacrehabilitation............................................... 4310
cancer................................................................................................... 4274 8.Long-termfollow-upandchroniccardiovascularcomplications
5.5.11.Endocrinetherapiesforbreastcancer ................... 4276 incancersurvivors.......................................................................................... 4312
5.5.12.Cyclin-dependentkinase4/6inhibitors .................. 4276 8.1.Cancersurvivors................................................................................ 4312
5.5.13.Anaplasticlymphomakinaseinhibitors................... 4277 8.1.1.Adultsurvivorsofchildhoodandadolescent
5.5.14.Epidermalgrowthfactorreceptorinhibitors ...... 4277 cancer................................................................................................... 4312
5.5.15.Chimericantigenreceptor 8.1.2.Adultcancersurvivors...................................................... 4313
Tcellandtumour-infiltratinglymphocytestherapies ..... 4278 8.2.Myocardialdysfunctionandheartfailure................................ 4315
5.5.16.Radiotherapy...................................................................... 4279 8.3.Coronaryarterydisease................................................................. 4316
5.5.17.Haematopoieticstemcelltransplantation ............ 4279 8.4.Valvularheartdisease...................................................................... 4317
5.5.18.Othercancertreatments ............................................. 4282 8.5.Peripheralarterydiseaseandstroke ........................................ 4317
6.Diagnosisandmanagementofacuteandsubacute 8.6.Pericardialcomplications................................................................ 4317
cardiovasculartoxicityinpatientsreceivinganticancertreatment 4282 8.7.Arrhythmiasandautonomicdisease......................................... 4318
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 4 ---
4232 ESCGuidelines
8.8.Metabolicsyndrome,lipidabnormalities,diabetesmellitus, RecommendationTable12—Recommendationsforbaseline
andhypertension........................................................................................ 4318 riskassessmentandmonitoringduringBrutontyrosinekinase
8.9.Pregnancyincancersurvivors ..................................................... 4318 inhibitortherapy.............................................................................................. 4267
8.10.Pulmonaryhypertension.............................................................. 4319 RecommendationTable13—Recommendationsforbaseline
9.Specialpopulations.................................................................................... 4319 riskassessmentandmonitoringduringmultiplemyeloma
9.1.Cardiactumours................................................................................ 4319 therapies ..................................................................................................... 4271
9.2.Pregnantpatientswithcancer..................................................... 4319 RecommendationTable14—Recommendationsforbaseline
9.2.1.Leftventriculardysfunctionandheartfailure ........ 4320 riskassessmentandmonitoringduringcombinedrapidly
9.2.2. Venous thromboembolism and pulmonary acceleratedfibrosarcomaandmitogen-activatedextracellular
embolism ..................................................................................... 4320 signal-regulatedkinaseinhibitortherapy............................................... 4272
9.3.Carcinoidvalvularheartdisease ................................................. 4323 RecommendationTable15—Recommendationsforbaseline
9.4.Amyloidlight-chaincardiacamyloidosis .................................. 4324 riskassessmentandmonitoringduringimmunotherapy............... 4274
9.5.Cardiacimplantableelectronicdevices.................................... 4326 RecommendationTable16—Recommendationsforbaseline
10.Patientinformation,communication,andself-management 4330 riskassessmentandmonitoringduringandrogendeprivation
11.Theroleofscientificsocietiesinthepromotionand therapyforprostatecancer ....................................................................... 4276
developmentofcardio-oncologyinmodernmedicine .................. 4331 RecommendationTable17—Recommendationsforbaseline
12.Keymessages ............................................................................................ 4331 riskassessmentandmonitoringduringendocrinetherapyfor
13.Futureneeds.............................................................................................. 4332 breastcancer .................................................................................................... 4276
14.Gapsinevidence...................................................................................... 4333 RecommendationTable18—Recommendationsforbaseline
15.‘Whattodo’and‘whatnottodo’messagesfromthe riskassessmentandmonitoringduringcyclin-dependentkinase
Guidelines........................................................................................................... 4333 4/6inhibitortherapy...................................................................................... 4277
16.Qualityindicatorsforcardio-oncology.......................................... 4342 RecommendationTable19—Recommendationsforbaseline
17.Supplementarydata................................................................................ 4342 riskassessmentandmonitoringduringanaplasticlymphoma
18.Dataavailabilitystatement................................................................... 4342 kinaseandepidermalgrowthfactorreceptorinhibitors............... 4277
19.Authorinformation................................................................................ 4342 RecommendationTable20—Recommendationsforbaseline
20.Appendix..................................................................................................... 4342 riskassessmentandmonitoringinpatientsreceivingchimeric
21.References.................................................................................................. 4343 antigenreceptorTcellandtumour-infiltratinglymphocytes
therapies ............................................................................................................. 4279
RecommendationTable21—Recommendationsforbaseline
Tables of Recommendations riskassessmentofpatientsbeforeradiotherapytoavolume
includingtheheart.......................................................................................... 4279
RecommendationTable1—Recommendationsforageneral RecommendationTable22—Recommendationsforbaseline
approachtocardiovasculartoxicityriskcategorization................. 4249 riskassessmentinhaematopoieticstemcelltransplantation
RecommendationTable2—Recommendationsfor patients................................................................................................................ 4281
electrocardiogrambaselineassessment ................................................ 4251 RecommendationTable23—Recommendationforthe
RecommendationTable3—Recommendationforcardiac managementofcardiovasculardiseaseandcancer
biomarkerassessmentpriortopotentiallycardiotoxictherapies . 4252 therapy-relatedcardiovasculartoxicityinpatientsreceiving
RecommendationTable4—Recommendationsforcardiac anticancertreatment..................................................................................... 4282
imagingmodalitiesinpatientswithcancer .......................................... 4253 RecommendationTable24—Recommendationsforthe
RecommendationTable5—Recommendationsfor managementofcancertreatment-relatedcardiacdysfunction
primarypreventionofcancertherapy-relatedcardiovascular duringanthracyclinechemotherapy........................................................ 4284
toxicity......................................................................................................... 4256 RecommendationTable25—Recommendationsforthe
RecommendationTable6—Recommendationforsecondary managementofcancertreatment-relatedcardiacdysfunction
preventionofcancertherapy-relatedcardiovasculartoxicity..... 4257 duringhumanepidermalreceptor2-targetedtherapies ............... 4286
RecommendationTable7—Recommendationsforbaselinerisk RecommendationTable26—Recommendationsforthe
assessmentandmonitoringduringanthracyclinechemotherapy diagnosisandmanagementofimmunecheckpoint
andinthefirst12monthsaftertherapy .............................................. 4259 inhibitor-associatedmyocarditis............................................................... 4289
RecommendationTable8—Recommendationsforbaselinerisk RecommendationTable27—Recommendationsforthe
assessmentandmonitoringduringhumanepidermalreceptor diagnosisandmanagementofTakotsubosyndromeinpatients
2-targetedtherapiesandinthefirst12monthsaftertherapy... 4260 withcancer ........................................................................................................ 4291
RecommendationTable9—Recommendationsforbaselinerisk RecommendationTable28—Recommendationsforthe
assessmentandmonitoringduringfluoropyrimidinetherapy..... 4261 managementofacutecoronarysyndromesinpatientsreceiving
RecommendationTable10—Recommendationsforbaseline anticancertreatment..................................................................................... 4292
riskassessmentandmonitoringduringvascularendothelial RecommendationTable29—Recommendationforthe
growthfactorinhibitors............................................................................... 4264 managementofchroniccoronarysyndromesinpatientsreceiving
RecommendationTable11—Recommendationsforbaseline anticancertreatment..................................................................................... 4293
riskassessmentandmonitoringduringsecond-and RecommendationTable30—Recommendationsforthe
third-generationbreakpointclusterregion–Abelsononcogene managementofvalvularheartdiseaseinpatientsreceiving
locustyrosinekinaseinhibitors................................................................. 4267 anticancertreatment..................................................................................... 4293
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 5 ---
ESCGuidelines 4233
RecommendationTable31—Recommendationsforthe Table6Factorsthatcouldinfluenceperi-operativeriskduring
managementofatrialfibrillationinpatientsreceivinganticancer cancersurgeryandpreventivestrategies ............................................. 4254
treatment............................................................................................................ 4297 Table7Cancertreatmentsthatpredisposetoacutecoronary
RecommendationTable32—Recommendationsforthe syndromes.......................................................................................................... 4291
managementoflongcorrectedQTintervalandventricular Table8Riskfactorsfordrug-inducedQTprolongationand
arrhythmiasinpatientsreceivinganticancertreatment................. 4300 torsadedepointes.......................................................................................... 4298
RecommendationTable33—Recommendationsforthe Table9ClassificationofcorrectedQTintervalprolongation
managementofarterialhypertensioninpatientsreceiving inducedbycancerdrugtherapy............................................................... 4298
anticancertreatment..................................................................................... 4302 Table10Riskfactorsforfuturecardiovasculardiseaseatthe
RecommendationTable34—Recommendationsforthe end-of-cancertherapycardiovascularriskassessment................... 4310
managementofvenousthromboembolisminpatientsreceiving Table11Riskcategoriesforasymptomaticadultswhoare
anticancertreatment..................................................................................... 4305 childhoodandadolescentcancersurvivors......................................... 4313
RecommendationTable35—Recommendationsforvenous Table12Riskcategoriesforasymptomaticadultcancersurvivors 4314
thromboembolismprophylaxisduringanticancertreatment...... 4306 Table13Managementstrategiesandsurgeryindicationsfor
RecommendationTable36—Recommendationformanagement symptomaticandasymptomaticpatientswithbenignand
ofperipheralarterydiseaseduringanticancertreatment.................. 4307 malignantcardiactumours.......................................................................... 4321
RecommendationTable37—Recommendationsforthe
fi
managementofpulmonaryhypertensionduringanticancer List of gures
treatment............................................................................................................ 4308
RecommendationTable38—Recommendationsforthe Figure1Video1CentralIllustration:Dynamicsof
managementofpericardialdiseasesinpatientsreceiving cardiovasculartoxicityriskofpatientswithcancerovertheir
anticancertreatment..................................................................................... 4309 therapycontinuum.................................................................................. 4239
RecommendationTable39—Recommendationsfor Figure2Cardio-oncologycarepathways............................................. 4240
end-of-cancertherapycardiovascularriskassessment................... 4312 Figure3Baselinecardiovasculartoxicityriskassessmentchecklist 4241
RecommendationTable40—Recommendationsfor Figure4Dimensionsofcancertherapy-relatedcardiovascular
cardiovascularsurveillanceinasymptomaticadultswhoare toxicityriskanddiseaseseverity.............................................................. 4242
childhoodandadolescentcancersurvivors......................................... 4313 Figure5Baselinecardiovasculartoxicityriskassessmentbefore
RecommendationTable41—Recommendationsfor anticancertherapy.......................................................................................... 4245
cardiovascularsurveillanceinasymptomaticadultcancersurvivors 4314 Figure6Generalcardio-oncologyapproachafterHeartFailure
RecommendationTable42—Recommendationsforadult Association–InternationalCardio-OncologySociety
cancersurvivorswhodevelopcancertherapy-relatedcardiac cardiovasculartoxicityriskassessment ................................................ 4248
dysfunctionlateaftercardiotoxiccancertherapy............................ 4316 Figure7Baselinescreeningrecommendationsforpatientswith
RecommendationTable43—Recommendationsforadult cancertreatedwithpotentiallycardiotoxicdrugs............................ 4250
cancersurvivorswithcoronaryarterydisease .................................. 4316 Figure8Recommendedtransthoracicechocardiographyand
RecommendationTable44—Recommendationsforadult cardiacmagneticresonanceimagingparametersintheevaluationof
cancersurvivorswithvalvularheartdisease....................................... 4317 patientswithcancer ............................................................................................... 4252
RecommendationTable45—Recommendationforadultcancer Figure9Primaryandsecondarycancertherapy-related
survivorswithpericardialcomplications............................................... 4318 cardiovasculartoxicityprevention .................................................................. 4255
RecommendationTable46—Recommendationsfor Figure10Cardiovasculartoxicitymonitoringinpatientsreceiving
cardiovascularmonitoringincancersurvivorsduringpregnancy 4319 anthracyclinechemotherapy...................................................................... 4258
RecommendationTable47—Recommendationsforcardiovascular Figure11Cardiovasculartoxicitymonitoringinpatientsreceiving
assessmentandmonitoringofpregnantwomenwithcancer............. 4323 humanepidermalreceptor2-targetedtherapies.............................. 4260
RecommendationTable48—Recommendationsforcarcinoid Figure12Vascularendothelialgrowthfactorinhibitors-related
valvularheartdiseases................................................................................... 4323 cardiovasculartoxicities ............................................................................... 4262
RecommendationTable49—Recommendationsforamyloid Figure13Cardiovasculartoxicitymonitoringinpatientsreceiving
light-chaincardiacamyloidosisdiagnosisandmonitoring.............. 4326 vascularendothelialgrowthfactorinhibitors ..................................... 4263
RecommendationTable50—Recommendationsforrisk Figure14Breakpointclusterregion–Abelsononcogenelocus
stratificationandmonitoringforpatientswithcardiacimplantable tyrosinekinaseinhibitor-relatedcardiovasculartoxicities ............ 4265
electronicdevicesundergoingradiotherapy .................................................... 4330 Figure15Second-andthird-generationbreakpointcluster
region–Abelsononcogenelocustyrosinekinaseinhibitors
surveillanceprotocol ..................................................................................... 4266
List of tables Figure16Multiplemyelomadrug-relatedcardiovasculartoxicities 4268
Figure17Cardiovascularmonitoringinpatientswithmultiple
Table1Classesofrecommendations.................................................... 4237 myelomareceivingproteasomeinhibitors........................................... 4269
Table2Levelsofevidence.......................................................................... 4237 Figure18Riskfactorsforvenousthromboemboliceventsin
Table3Cancertherapy-relatedcardiovasculartoxicitydefinitions 4243 patientswithmultiplemyeloma ............................................................... 4270
Table4HeartFailureAssociation–InternationalCardio-Oncology Figure19Rapidlyacceleratedfibrosarcomaandmitogen-activated
Societybaselinecardiovasculartoxicityriskstratification............... 4246 extracellularsignal-regulatedkinaseinhibitor-relatedcardiovascular
Table5Anthracyclineequivalencedose............................................... 4247 toxicities........................................................................................................................ 4272
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 6 ---
4234 ESCGuidelines
Figure20Cardiovascularsurveillanceinpatientstreatedwith Abbreviations and acronyms
immunecheckpointinhibitors................................................................... 4273
Figure21Androgendeprivationtherapy-relatedcardiovascular 2D Two-dimensional
toxicities.............................................................................................................. 4275 3D Three-dimensional
Figure22Anaplasticlymphomakinaseandepidermalgrowth 5-FU 5-fluorouracil
factorreceptorinhibitor-relatedcardiovasculartoxicities ........... 4278 5HIAA 5-hydroxyindoleaceticacid
Figure23Radiotherapymeanheartdoseandassociated a′ Latediastolicvelocityofmitralannulus
cardiovasculartoxicityrisk.......................................................................... 4280 obtainedbytissueDopplerimaging
Figure24Riskfactorsandcardiovascularsurveillanceinpatients ABC AtrialfibrillationBetterCare
referredforhaematopoieticstemcelltransplantation .................. 4281 ABI Ankle–brachialindex
Figure25Managementofanthracyclinechemotherapy-related AC Anthracyclinechemotherapy
cardiacdysfunction......................................................................................... 4283 ACE-I Angiotensin-convertingenzymeinhibitors
Figure26Managementofhumanepidermalreceptor2-targeted ACS Acutecoronarysyndromes
therapy-relatedcardiacdysfunction........................................................ 4285 ADT Androgendeprivationtherapy
Figure27Directandindirectimmunecheckpoint ADVANCE ActioninDiabetesandVascularDisease:
inhibitor-relatedcardiovasculartoxicity................................................ 4287 PreteraxandDiamicron-MRControlled
Figure28Diagnosisandmanagementofimmunecheckpoint Evaluation
inhibitor-relatedmyocarditis...................................................................... 4288 AF Atrialfibrillation
Figure29Diagnosisandmanagementworkupincancer-related AI Aromataseinhibitors
Takotsubosyndrome .................................................................................... 4290 AL-CA Amyloidlight-chaincardiacamyloidosis
Figure30Pathophysiologyofatrialfibrillationassociatedwith ALK Anaplasticlymphomakinase
cancer................................................................................................................... 4295 ANS Autonomicnervoussystem
Figure31Structuredapproachtoanticoagulationforatrial ARB Angiotensinreceptorblockers
fibrillationinpatientswithcancer............................................................ 4296 ARISTOTLE ApixabanforReductioninStrokeandOther
Figure32CorrectedQTintervalmonitoringbeforeandduring ThromboembolicEventsinAtrialFibrillation
treatmentwithcorrectedQTinterval-prolonginganticancerdrugs 4299 ASCVD AtheroScleroticCardiovascularDisease
Figure33Recommendedthresholdforasymptomatic ASPIRE Carfilzomib,Lenalidomide,and
hypertensiontreatmentindifferentclinicalscenarios.................... 4301 Dexamethasonevs.Lenalidomideand
Figure34Treatmentofarterialhypertensioninpatientswith DexamethasonefortheTreatmentof
cancer................................................................................................................... 4302 PatientswithRelapsedMultipleMyeloma
Figure35Riskfactorsforvenousthromboembolisminpatients ASTCT AmericanSocietyforTransplantationand
withcancer ........................................................................................................ 4303 CellularTherapy
Figure36Structuredapproachtoanticoagulationforvenous ATAC ‘Arimidex’andTamoxifenAloneorin
thromboembolisminpatientswithactivecancer ............................ 4304 Combination
Figure37Managementofcancertherapy-relatedcardiac ATE Arterialthromboembolism
dysfunctionaftercancertherapy ............................................................. 4311 AV Atrioventricular
Figure38Long-termfollow-upincancersurvivors......................... 4315 BB Beta-blockers
Figure39Locationofprimaryandsecondarycardiactumours. 4320 BC Breastcancer
Figure40Diagnosticalgorithmforcardiacmasses.......................... 4321 BCR-ABL Breakpointclusterregion–Abelsononcogene
Figure41Cardiacmonitoringprotocolforpregnantwomen locus
receivinganthracycline-basedchemotherapy ..................................... 4322 BIG BreastInternationalGroup
Figure42Carcinoidheartdisease:clinicalfeaturesanddiagnostic BLEED Increasedbleedingrisk
tests....................................................................................................................... 4324 BMI Bodymassindex
Figure43Non-invasivediagnosisofamyloidlight-chaincardiac BNP B-typenatriureticpeptide
amyloidosis......................................................................................................... 4325 BP Bloodpressure
Figure44Riskstratificationinpatientswithacardiacimplantable BTK Brutontyrosinekinase
electronicdeviceundergoingradiotherapy ......................................... 4327 C Chemotherapycycle
Figure45Managementofpatientswithacardiacimplantable CABG Coronaryarterybypassgraft
electronicdevicelocatedintheradiotherapytreatmentbeam. 4328 CAD Coronaryarterydisease
Figure46Managementofpatientswithacardiacimplantable CARDIOTOX CARDIOvascularTOXicityinducedby
electronicdevicelocatedoutsidetheradiotherapytreatment cancer-relatedtherapies
volume ................................................................................................................. 4329 CAR-T ChimericantigenreceptorTcell
Figure47Patientinformation,communication,and CCB Calciumchannelblockers
self-management.............................................................................................. 4330 CCS Chroniccoronarysyndromes
Figure48Theroleofscientificsocietiesinthepromotionand CCTA Coronarycomputedtomography
developmentofcardio-oncology............................................................. 4331 angiography
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 7 ---
ESCGuidelines 4235
CCU Coronarycareunit ESC-CCO EuropeanSocietyofCardiologyCouncilof
CDK Cyclin-dependentkinase Cardio-Oncology
CHA DS -VASc Congestiveheartfailure,Hypertension,Age ESH EuropeanSocietyofHypertension
2 2
≥75years(2points),Diabetesmellitus, EuroSCORE EuropeanSystemforCardiacOperative
Stroke(2points)—Vasculardisease,Age RiskEvaluation
65–74years,Sexcategory(female) FAC Fractionalareachange
CIED Cardiacimplantableelectronicdevice FDA FoodandDrugAdministration
CML Chronicmyeloidleukaemia FLT3 FMS-liketyrosinekinase3
CMR Cardiacmagneticresonance FWLS Freewalllongitudinalstrain
COMPASS-CAT ProspectiveCOmparisonofMethodsfor GI Gastrointestinal
thromboembolicriskassessmentwithclinical GLS Globallongitudinalstrain
PerceptionsandAwareneSSinreal-life GnRH Gonadotropin-releasinghormone
patients—CancerAssociatedThrombosis GU Genitourinary
CPET Cardiopulmonaryexercisetesting GVHD Graftvs.hostdisease
CrCl Creatinineclearance Gy Gray
CRF Cardiorespiratoryfitness HAS-BLED Hypertension,Abnormalrenalandliver
CRS Cytokinereleasesyndrome function,Stroke,BleedingLabile
CS Cancersurvivors internationalnormalizedratio,Elderly,
CT Computedtomography Drugsoralcohol
CTLA-4 CytotoxicTlymphocyte-associated HbA1c Glycatedhaemoglobin
antigen-4 HDU High-dependencyunit
cTn Cardiactroponin HER2 Humanepidermalreceptor2
CTRCD Cancertherapy-relatedcardiac HF Heartfailure
dysfunction HFA HeartFailureAssociation
CTR-CVT Cancertherapy-relatedcardiovascular HFmrEF Heartfailurewithmildlyreducedejection
toxicity fraction
CV Cardiovascular HFpEF Heartfailurewithpreservedejectionfraction
CVD Cardiovasculardisease HFrEF Heartfailurewithreducedejectionfraction
CVRF Cardiovascularriskfactors HG Hyperglycaemia
DAPT Dualantiplatelettherapy HIIT High-intensityintervaltraining
DASISION DASatinibvs.ImatinibStudyIn HSCT Haematopoieticstemcelltransplantation
treatment-Naïvechronicmyeloid hs-cTn High-sensitivitycardiactroponin
leukaemiapatients HTN Hypertension
DL Dyslipidaemia ICD Implantablecardioverterdefibrillator
DM Diabetesmellitus ICI Immunecheckpointinhibitors
DNR Donotresuscitate ICOS InternationalCardio-OncologySociety
DVT Deepveinthrombosis ICU Intensivecareunit
E Mitralinflowearlydiastolicvelocity IHD Ischaemicheartdisease
obtainedbypulsedwave IMiD Immunomodulatorydrugs
e′ Earlydiastolicvelocityofthemitralannulus i.v. Intravenous
obtainedbytissueDopplerimaging IVC Inferiorvenacava
EACTS EuropeanAssociationforCardio-Thoracic IVS Intraventricularseptum
Surgery LA Leftatrial
EBC Earlybreastcancer LAA Leftatrialappendage
ECG Electrocardiogram LGE Lategadoliniumenhancement
Echo Echocardiography LIMA Leftinternalmammaryartery
ECV Extracellularvolumefraction LMWH Low-molecular-weightheparins
eGFR Estimatedglomerularfiltrationrate LQTS LongQTsyndrome
EGFR Epidermalgrowthfactorreceptor LS Longitudinalstrain
EMA EuropeanMedicinesAgency LV Leftventricular
EMB Endomyocardialbiopsy LVD Leftventriculardysfunction
ENGAGEAF-TIMI48 EffectiveAnticoagulationwithFactor LVEDD Leftventricularenddiastolicdiameter
XaNextGenerationinAtrialFibrillation- LVEF Leftventricularejectionfraction
ThrombolysisinMyocardialInfarction48 LVV Leftventricularvolume
ENOXACAN EnoxaparinandCancer M Months
EoL Endoflife MACE Majoradversecardiovascularevents
ERS EuropeanRespiratorySociety MCS Mechanicalcirculatorysupport
ESC EuropeanSocietyofCardiology MDT Multidisciplinaryteam
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 8 ---
4236 ESCGuidelines
MedDRA Medicaldictionaryforregulatoryactivities SMART Secondmanifestationsofarterialdisease
MEK Mitogen-activatedextracellular sPAP Systolicpulmonaryarterypressure
signal-regulatedkinase SPEP Serumproteinelectrophoresis
MHD Meanheartdose STEMI ST-segmentelevationmyocardialinfarction
MI Myocardialinfarction STIR Shorttauinversionrecovery
MM Multiplemyeloma STSPROM SocietyofThoracicSurgeons–Predicted
MUGA Multigatedacquisitionnuclearimaging RiskofMortality
N No SVT Supraventriculartachycardia
NOAC Non-vitaminKantagonistoral SYNTAX SYNergybetweenpercutaneouscoronary
anticoagulants interventionwithTAXusandcardiacsurgery
NP Natriureticpeptides TAPSE Tricuspidannularplanesystolicexcursion
NSTE-ACS Non-ST-segmentelevationacutecoronary TAVI Transcatheteraorticvalveimplantation
syndromes TBIP Thromboembolicrisk,Bleedingrisk,drug–
NT-proBNP N-terminalpro-B-typenatriureticpeptide drugInteractions,Patientpreferences
PAD Peripheralarterydisease TdP Torsadedepointes
PAH Pulmonaryarterialhypertension TIL Tumour-infiltratinglymphocytes
PAP Pulmonaryarterialpressure TKI Tyrosinekinaseinhibitors
PCI Percutaneouscoronaryintervention TRV Tricuspidregurgitationvelocity
PD-1 Programmeddeath-1 TTE Transthoracicechocardiography
PD-L1 Programmeddeath-ligand1 TTS Takotsubosyndrome
PE Pulmonaryembolism tx Treatment
Peric-E Pericardialeffusion ULN Upperlimitofnormal
PET Positronemissiontomography UPEP Urineproteinelectrophoresis
PH Pulmonaryhypertension VA Ventriculararrhythmias
PI Proteasomeinhibitors VascTox Vasculartoxicity
Pleu-E Pleuraleffusion VEGF Vascularendothelialgrowthfactor
PRECISE-DAPT PREdictingbleedingComplicationsIn VEGFi Vascularendothelialgrowthfactorinhibitors
patientsundergoingStentimplantationand VH Veryhighrisk
subsEquentDualAntiPlateletTherapy VHD Valvularheartdisease
PRONOUNCE ATrialComparingCardiovascularSafety VKA VitaminKantagonists
ofDegarelixVersusLeuprolideinPatients VTE Venousthromboembolism
WithAdvancedProstateCancerand Y Yes
CardiovascularDisease
PW Leftventricularposteriorwall
QI Qualityindicator 1. Preamble
↑QTc CorrectedQTintervalprolongation
QTc CorrectedQTinterval Guidelinessummarizeandevaluateavailableevidencewiththeaimof
QTcF CorrectedQTintervalusingFridericia assistinghealthprofessionalsinproposingthebestmanagementstrat-
correction egiesforanindividualpatientwithagivencondition.Guidelinesand
RA Rightatrial theirrecommendationsshouldfacilitatedecisionmakingofhealthpro-
RAF Rapidlyacceleratedfibrosarcoma fessionalsintheirdailypractice.However,guidelinesarenotasubsti-
RCT Randomizedcontrolledtrial tute for the patient’s relationship with their practitioner. The final
RIMA Rightinternalmammaryartery decisions concerninganindividual patient mustbe madebythe re-
ROCKETAF RivaroxabanOnceDailyOralDirectFactor sponsiblehealthprofessional(s),basedonwhattheyconsidertobe
XaInhibitionComparedwithVitaminK the most appropriate in the circumstances. These decisions are
AntagonismforPreventionofStrokeand madeinconsultationwiththepatientandcaregiverasappropriate.
EmbolismTrialinAtrialFibrillation Guidelinesareintendedforusebyhealthprofessionals.Toensure
RT Radiotherapy thatallusershaveaccesstothemostrecentrecommendations,the
RV Rightventricular ESC makes its Guidelines freely available. The ESC warns readers
RVEF Rightventricularejectionfraction thatthetechnicallanguagemaybemisinterpretedanddeclinesany
RVV Rightventricularvolume responsibilityinthisrespect.
s′ Systolicvelocityoftricuspidannulus Agreatnumberofguidelineshavebeenissuedinrecentyearsbythe
obtainedbydopplertissueimaging ESC.Becauseoftheirimpactonclinicalpractice,qualitycriteriaforthe
SBr Sinusbradycardia developmentofguidelineshavebeenestablishedtomakealldecisions
SCORE2 SystematicCoronaryRiskEstimation2 transparenttotheuser.Therecommendationsforformulatingandis-
SCORE2-OP SystematicCoronaryRiskEstimation2— suingESCGuidelinescanbefoundontheESCwebsite(https://www.
OlderPersons escardio.org/Guidelines).TheESCGuidelinesrepresenttheofficialpos-
SEER Surveillance,Epidemiology,andEndResults itionoftheESConagiventopicandareregularlyupdated.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 9 ---
ESCGuidelines 4237
Table1 Classesofrecommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table2 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
InadditiontothepublicationofClinicalPracticeGuidelines,theESC Considerationwasgiventodiversityandinclusion,notablywithrespect
carriesouttheEURObservationalResearchProgrammeofinternation- togenderandcountryoforigin.Acriticalevaluationofdiagnosticand
alregistriesofcardiovasculardiseasesandinterventions,whicharees- therapeutic procedures was performed, including assessment of the
sential to assess diagnostic/therapeutic processes, use of resources risk–benefitratio.Thelevelofevidenceandthestrengthoftherecom-
andadherencetoguidelines.Theseregistriesaimatprovidingabetter mendationofparticularmanagementoptionswereweighedandscored
understanding of medical practice in Europe and around the world, accordingtopredefinedscales,asoutlinedbelow.TheTaskForcefol-
basedonhigh-qualitydatacollectedduringroutineclinicalpractice. lowedtheESCvotingprocedures.Allrecommendationssubjecttoa
Furthermore, the ESC develops sets of quality indicators (QIs), voteachievedatleast75%amongvotingmembers.
whicharetoolstoevaluatethelevelofimplementationoftheguide- Theexpertsofthewritingandreviewingpanelsprovideddeclar-
linesandmaybeusedbytheESC,hospitals,healthcareprovidersand ationofinterestformsforallrelationshipsthatmightbeperceivedas
professionals to measure clinical practice, and in educational pro- realorpotentialsourcesofconflictsofinterest.Theirdeclarationsof
grammes, alongside the key messages from the guidelines, to im- interestwerereviewedaccordingtotheESCdeclarationofinterest
provequalityofcareandclinicaloutcomes. rulesandcanbefoundontheESCwebsite(http://www.escardio.org/
TheMembersofthisTaskForcewereselectedbytheESCtore- Guidelines)andhavebeencompiledinareportandpublishedina
presentprofessionalsinvolvedwiththemedicalcareofpatientswith supplementarydocumentsimultaneouslytotheguidelines.
thispathology.Theselectionprocedureaimedtoensurethatthereis Thisprocessensurestransparencyandpreventspotentialbiasesin
arepresentativemixofmemberspredominantlyfromacrossthewhole thedevelopmentand review processes.Anychanges in declarations
oftheESCregionandfromrelevantESCSubspecialtyCommunities. of interest that arise during the writing period werenotified to the
snoitadnemmocer
fo
sessalC
2202
CSE©
2202
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 10 ---
4238 ESCGuidelines
ESCandupdated.TheTaskForcereceiveditsentirefinancialsupport aftertheircancertreatmentswithrespecttotheircardiovascular(CV)
fromtheESCwithoutanyinvolvementfromthehealthcareindustry. healthandwellness.Thisguidelineprovidesguidanceonthedefinitions,
TheESCCPGsupervisesandcoordinatesthepreparationofnew diagnosis,treatment,andpreventionofcancertherapy-relatedCV
guidelines.TheCommitteeisalsoresponsiblefortheapprovalpro- toxicity (CTR-CVT), and the management of CV disease (CVD)
cessoftheseguidelines.TheESCGuidelinesundergoextensivere- causeddirectlyorindirectlybycancer.Thisareaofmedicinehaslim-
view by the CPG and external experts, including a mix of ited trials and evidence on which to base decision-making and,
membersfromacrossthewholeoftheESCregionandfromrelevant whereevidenceislimited,thisguidelineprovidestheconsensusof
ESCSubspecialtyCommunitiesandNationalCardiacSocieties.After expertopiniontoguidehealthcareprofessionals.
appropriaterevisions,theguidelinesaresignedoffbyalltheexperts ThisguidelineincludesthedefinitionsofCTR-CVT(Section3),1and
involvedintheTaskForce.Thefinalizeddocumentissignedoffby provides a personalized approach to care based upon the baseline
theCPGforpublicationintheEuropeanHeartJournal.Theguidelines CVtoxicityriskassessment(Section4)andnewprotocolsforCVsur-
weredevelopedaftercarefulconsiderationofthescientificandmed- veillanceduringcancertreatment(Section5).Themanagementofacute
icalknowledgeandtheevidenceavailableatthetimeoftheirwriting. CTR-CVTisaddressedinSection6,wherepatientswithactivecancerare
ThetaskofdevelopingESCGuidelinesalsoincludesthecreationof those receiving anticancer treatment. Throughout these sections,
educationaltoolsandimplementationprogrammesfortherecommen- decision-making depends upon the risk/benefit balance of oncology
dations,includingcondensedpocketguidelineversions,summaryslides, treatmentefficacyandtheseverityandimpactofCTR-CVT.Guidance
summarycardsfornon-specialistsandanelectronicversionfordigital isprovidedforthefirst12monthsaftercompletionofcardiotoxictreat-
applications(smartphones,etc.).Theseversionsareabridgedandthus, ments(Section7),whensubacuteCVDcanemerge,andwhenpatients
formoredetailedinformation,theusershouldalwaysaccessthefull- who developed CTR-CVT during cancer treatment are reviewed.
textversionoftheguidelines,whichisfreelyavailableviatheESCweb- Diagnosisandmanagementofthelong-termCVcomplicationsofprevi-
siteandtheEuropeanHeartJournal.TheNationalCardiacSocietiesof ousoncologytreatments,beyond12monthsaftercompletingthecardi-
theESCareencouragedtoendorse,adopt,translateandimplementall otoxictreatments,andintegrationintotheoverallsurvivorshipstrategy
ESC Guidelines. Implementation programmes areneeded because it forcancersurvivors(CS)ispresentedinSection8withnewlong-term
hasbeenshownthattheoutcomeofdiseasemaybefavourablyinflu- surveillancerecommendationsforhigh-riskpatients.
encedbythethoroughapplicationofclinicalrecommendations. InSection9,weaddressspecialpopulationswhereCVDsaredir-
HealthprofessionalsareencouragedtotaketheESCGuidelines ectlycausedbythecancer,orwherespecialconsiderationsarere-
fully into account when exercising their clinical judgement, as well quired.Section10providesinformationforpatients’involvementin
asinthedeterminationandtheimplementationofpreventive,diag- theirowncare.ThefinalsectionhighlightstheroleoftheESCand
nostic or therapeutic medical strategies. However, the ESC theESCCouncilofCardio-Oncology(ESC-CCO).
Guidelinesdonotoverrideinanywaywhatsoevertheindividualre- CTR-CVTriskisadynamicvariable,andtheriskchangesthrough-
sponsibilityofhealthprofessionalstomakeappropriateandaccurate out the pathway of care (Figure 1, Video 1). Absolute risk of
decisionsinconsiderationofeachpatient’shealthconditionandin CTR-CVTisimportanttounderstandandbalanceagainsttheabso-
consultationwiththatpatientorthepatient’scaregiverwhereap- lute benefit of the cancer treatment before and during treatment.
propriate and/or necessary. It is also the health professional’s re- However,CTR-CVTriskcan beinfluencedbyseveralvariables, in-
sponsibility to verify the rules and regulations applicable in each cludingimplementationofprimarypreventiontreatments,optimiza-
countrytodrugsanddevicesatthetimeofprescriptionandtore- tionofpre-existingCVD,dose,frequency,anddurationofoncology
specttheethicalrulesoftheirprofession. treatment, emergence of CV complications during treatment and
Off-labeluseofmedicationmaybepresentedinthisguidelineif theirseverity,andinCS,theoverallcumulativetreatmentreceived,
sufficientlevelofevidenceshowsthatitcanbeconsideredmedically thetimesincetreatment,andtheinteractionwithotherCVDs.
appropriatetoagivenconditionandifpatientscouldbenefitfrom
therecommendedtherapy.However,thefinaldecisionsconcerning
2.1. Cancer and cardiovascular needs of
anindividualpatientmustbemadebytheresponsiblehealthprofes-
patients with cancer
sionalgivingspecialconsiderationto:
Since the 1990s, there has been a steady decline in cancer-related
(1) thespecificsituationofthepatient.Inthisrespect,itisspecified mortality mirrored by a steady increase in CS.2,3 In this context,
that,unlessotherwiseprovidedforbynationalregulations,off- treatment-related side effects have gained more significance.
labeluseofmedicationshouldbelimitedtosituationswhereit ManagementofCTR-CVThasatremendousimpactonthetypeof
isinthepatient’sinteresttodoso,withregardtothequality,
anticancertherapiesthatpatientscanreceiveaswellasthelong-term
safetyandefficacyofcare,andonlyafterthepatienthasbeenin-
morbidityandmortalityoutcomesofpatientswithcancer.Effective
formedandhasprovidedconsent; managementofpatientswithbothcancerandCVDrequirestheun-
(2) country-specifichealthregulations,indicationsbygovernmental iqueinterestandexpertiseofhealthcareproviders,whichhasledto
drug regulatory agencies and the ethical rules to which health theformationofanewdiscipline:cardio-oncology.4,5Arecentlypub-
professionalsaresubject,whereapplicable. lishedESC-CCOdocumentdescribesappropriatecriteriafortheor-
ganizationandimplementationofcardio-oncologyservices.5
2. Introduction
ThisisthefirstEuropeanSocietyofCardiology(ESC)guidelineon 2.2. Role of cardio-oncology services
cardio-oncology.Theaimofthisguidelineistohelpallthehealthcare Theoverarchinggoalofthecardio-oncologydisciplineistoallowpa-
professionalsprovidingcaretooncologypatientsbefore,during,and tientswithcancertoreceivethebestpossiblecancertreatmentssafely,
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 11 ---
ESCGuidelines 4239
Baseline DDuring cardiotoxic Long-termfffollow-up after
risk cancertherapppppppppyyyy cancer treatment
Primary and Cancer treatment
CCTTRR--CCVVTT secondary surveillance Cancer survivorship programmes
rriisskk prevention Early CTR-CVT
strategies management
High risk
Low risk
Time
Figure1Video1CentralIllustration:Dynamicsofcardiovasculartoxicityriskofpatientswithcancerovertheirtherapycontinuum.CS,cancer
survivors;CTR-CVT,cancertherapy-relatedcardiovasculartoxicity;CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfac-
tors;CTR-CVTriskisadynamicvariablethatchangesthroughthepathwayofcare,andisinfluencedbyseveralconditionsincludingage,cancer
history,pre-existingCVRForCVD,andpreviouscardiotoxiccancertherapy.TheCTR-CVTriskchangesduringandaftertreatmentaccording
totype,dose,frequency,anddurationofoncologytreatment(bluesolidline).Pre-existingCVRF,CVD,orpreviouscancertreatmentsmayincrease
themagnitudeofacuteandlong-termCVtoxicityrisk(purplesolidline).CTR-CVTriskremainsvariableinextentduringanticancertreatmentand
mayormaynotgraduallyincreaseovertime(dottedlines).Cardio-oncologystrategymayreducethemagnitudeofCTR-CVTby:(1)optimizingCVD
andCVRFmanagement(greenarrows);(2)consideringcardioprotectivestrategiesinhigh-riskpatients(greenarrows);(3)organizingcancertreat-
mentsurveillance;and(4)introducingearlycardioprotectionafterthedetectionofsubclinicalCTR-CVT(purplearrows).CVriskassessmentwithin
thefirstyearaftercompletionofcardiotoxiccancertherapyidentifiesCSwhorequirelong-termfollow-up.Cancersurvivorshipprogrammesthat
includeannualCVriskassessmentandCVRF/CVDmanagementarerecommendedtominimizelong-termCVadverseevents(brownarrows).
minimizing CTR-CVT across the entire continuum of cancer care.5 therapieswithCVtoxicityrisk,surveillanceshouldcontinueuntilthe
BeforeinitiationofcancertherapieswithaknownCVtoxicityprofile, treatmentisfinished.6–8Thereisalsotheneedforre-assessmentof
the cardio-oncology team should identify and treat CV risk factors CVrisksinpatientsrequiringtreatmentforsecondarymalignancies.
(CVRF)andpre-existingCVDsanddefineanappropriateprevention
andsurveillanceplanforearlyidentificationandappropriatemanage-
2.3. General principles of
mentofpotentialCVcomplications(Figure2).Anotherimportantas-
pect is the participation in interdisciplinary discussions regarding the cardio-oncology
benefitsandrisksofcertaincancertreatmentsandtheircontinuation Aguidingprincipleofcardio-oncologyistheintegrationofclinicaldis-
or interruption should side effects become apparent. After cancer ciplines. Cardio-oncology providers must have knowledge of the
treatment has been completed, the focus shifts to co-ordination of broadscopeofcardiology,oncology,andhaematologymanagement.5
long-termfollow-upandtreatment.Forpatientsonlong-termcancer Recommendationsareformedregardingthemostpermissible(froma
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 12 ---
4240 ESCGuidelines
Cardio-Oncology Care Pathways
New cancer During cancer First year after Long term
diagnosis treatmenta cancer treatmentb follow-up
Informing, advising, and supporting patients to promote a healthy lifestyle
Baseline CV
toxicity risk
assessmentc Management of CVRF and CVD according to ESC Guidelines
Annual CVRF
Assessment at 1 year assessmente
Low risk Standard
after completion of
patients surveillance
cancer therapy Reassessment if new CV
signs/symptoms
Annual CVRF assessmente
CV toxicity re-stratification
Assessment at 1 year
Moderate risk at 5 years
Cardiology referrald after completion of
patients
cancer therapy
TTE every 5 years
Annual CVRF
Assessment at 3
High and assessmente
Cardiology referrald months and 1 year
very high risk
CVD prevention after completion of
patients TTE at years 1, 3, 5 and
cancer therapy
every 5 years
Cardiology referrald if new CV signs/symptoms or CTR-CVT develop
Class 1 Class 1Ia Class 1Ib
Figure2Cardio-oncologycarepathways.BP, blood pressure; CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity;
CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; ESC, European Society of
Cardiology; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic pep-
tides; RT, radiotherapy; TTE, transthoracic echocardiography. aCV surveillance according to baseline CV toxicity risk, type of cancer, cancer
stage, and cancer therapy. bCTR-CVT risk assessment is recommended during the first year after cardiotoxic cancer treatment to establish a
long-termfollow-upcareplan.cTheuseofHFA-ICOSriskassessmenttoolsshouldbeconsideredtoassessCTR-CVTriskinpatientswithcan-
cer scheduled to receive cardiotoxic anticancer therapy. Clinical assessment and ECG arerecommended at baseline in all patients with cancer
andechocardiography,cardiacbiomarkers,orothercardiacimagingtestsinselectedpatientsaccordingtobaselineCVtoxicityriskandcancer
treatment type (see Figure 7). dCardio-oncology referral is recommended when available, alternatively patients should be referred to a specia-
lizedcardiologistwithexpertiseinmanagingCVDinpatientswithcancer.eAnnualCVriskassessment(includingclinicalreview,BP,lipidprofile,
HbA1c,ECG,andNP)andCVRFmanagementisrecommendedinCSwhoweretreatedwithapotentiallycardiotoxiccancerdrugorRTtoa
volume exposing the heart.
CVDperspective)andthemosteffective(fromanoncologicalper- scope of CV therapies, including healthy lifestyle promotion and
spective)cancertreatment.AdjudicationofCVeventsoccurringinpa- pharmacological,device,andsurgicaltreatments.4,9,10
tients on active therapy is another important aspect of TheprincipleunderlyingthedynamiccourseofCTR-CVTdevelop-
cardio-oncology practice.1,3 Thisisinadditionto recommendations mentinpatientswithcanceristhattheabsoluteriskdependsontheir
onbesttreatmentand managementpractices.Thisincludesthefull baselineriskandchangeswithexposuretocardiotoxictherapiesover
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 13 ---
ESCGuidelines 4241
Baseline CV toxicity risk assessment checklist
Age, sex,
genetics
Previous Medical
CVD CVRF
CTR-CVT
risk factors
Previous
Lifestyle
cardiotoxic
risk factors
therapies
ECG,TTE, and
cardiac biomarkers
abnormalities
Clinical assessment Complementary tests
Cancer treatment history BNP or NTTT-proBNPb
CV history cTnb
CVRF ECG
Physical examination Fasting plasma glucose / HbA1c
Vital signs measurementa Kidney function / eGFR
Lipid profile
TTEc
Figure3Baselinecardiovasculartoxicityriskassessmentchecklist.BNP,B-typenatriureticpeptide;cTn,cardiactroponin;CTR-CVT,cancertherapy-related
cardiovasculartoxicity;CV,cardiovascular;CVD,CVdisease;CVRF,cardiovascularriskfactors;ECG,electrocardiogram;eGFR,estimatedglomerularfiltration
rate;HbA1c,glycatedhaemoglobin;NT-proBNP,N-terminalpro-BNP;TTE,transthoracicechocardiography.aIncludingbloodpressure,heartrate,height,
weight,andbodymassindex.bCardiacbiomarkers(troponinandNP)shouldbemeasuredinpatientsatriskofCTRCDwhereavailableandresultsshould
beinterpretedaccordingtothepatientclinicalstatus,typeofcancertreatment,andkidneyfunction.cConsiderotherCVcomplementarytestsinselected
patients:cardiacmagneticresonance,coronarycomputedtomographyangiography,CPET(inselectedpatientsforpre-operative[lung,colon,andrectalcan-
cers]riskstratification).SeeSection4.6.
time(Figure3).11Thishasbeenrecognizedinconceptualmodels,with stillbeathighriskaccordingtotheseverityoftheevent,whichwould
risk stratification tools designed to grade patients with cancer into leadtointerruptionofcancertreatment,e.g.asignificantdeclinein
low,moderate,high,andveryhighriskofCVcomplicationspriorto leftventricular(LV)ejectionfraction(LVEF)to,40%withanthracy-
startingtreatment.These have been published bythe Heart Failure clinechemotherapy.Thetimelineofthesedevelopmentsmayalsobe
Association(HFA)oftheESCincollaborationwiththeInternational rather different. After the cardiotoxic cancer treatment has been
Cardio-Oncology Society (ICOS) (see Section 4).12,13 Severity, dur- completed,anewriskassessmentisrecommendedtoestablishdiffer-
ation,andtypeofmanifestationofCTR-CVTvarybytypeofmalig- ent long-term trajectories of CV health. These trajectories are im-
nancy and cancer treatment. The risk itself can be understood in pacted by the permanent CV toxic effects and cardiac or vascular
twoways:(1)thelikelihoodofitsoccurrenceand(2)theseverityof injuryofsomecancertherapies,patient-relatedCVRF,environmental
thecomplication(Figure4).Forexample,apatientcouldbeverylikely factors,andstressors(e.g.acuteviralinfections).Theaimshouldbeto
toexperienceaCTR-CVT,butifthiseventismild,oncologytreat- personalize approaches to minimize CTR-CVT and improve both
mentshouldcontinue.Conversely,apatientatlowlikelihoodcould cancerandCVoutcomes.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 14 ---
4242 ESCGuidelines
Clinical severity of CTR-CVT
Severe and
Mild Moderate
very severe
Likelihood of
CTR-CVT
Low
Intermediate
High
Figure4Dimensionsofcancertherapy-relatedcardiovasculartoxicityriskanddiseaseseverity.CTR-CVT,cancertherapy-relatedcardiovasculartox-
icity;CV,cardiovascular.Theultimateriskisthecombinationofthelikelihood(basedonreportedincidence)anddegree(severityorgrade)oftheadverse
event.Themostvulnerablepatientgroupsarethoseathighlikelihoodofexperiencingasevereadverseevent.Thelevelofattentionthatneedstobe
devotedtothesepatientsvariesaccordingly.TheriskandtypeofCTR-CVT,aswellasthepotentialforreversibility,dependsondifferentfactors,listedin
Figure3,thatshouldbeconsideredtodefineglobalCVandoncologicalprognosisandtoindividualizeCTR-CVTsurveillance.Additionalfactorsthataddto
thecomplexityofCTR-CVTriskassessmentarethecancertypeandprognosis,andtype,duration,andintensityofcancertreatment.
3. Cancer therapy-related (HF),myocarditis,vasculartoxicities,hypertension,cardiacarrhyth-
fi mias,andcorrectedQTinterval(QTc)prolongation.Thedefinitions
cardiovascular toxicity de nitions
ofotherCTR-CVT,includingpericardialandvalvularheartdiseases
Severalterminologiesanddefinitionshavepreviouslybeenproposed (VHDs),arethesameasthoseusedforthegeneralcardiologypopu-
todescribethespectrumofCTR-CVT,leadingtoinconsistenciesin lation. For cardiac injury, cardiomyopathy, and HF, the descriptive
diagnosisandmanagement.Theneedtoharmonizethesedefinitions termcancertherapy-relatedcardiacdysfunction(CTRCD)isrecom-
hasfrequentlybeenstatedandrecognized,andresultedintherecent mendedasitcapturesthebroadspectrumofpossiblepresentations
international definitions of CTR-CVT1 supported by this guideline andtheaetiologicallinkwiththebroadscopeofvariouscancerther-
(Table 3; Supplementary data, Table S1). This document will focus apies, including chemotherapy, targeted agents, immune therapies,
on consensus definitions for cardiomyopathy and heart failure andradiationtherapy.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 15 ---
ESCGuidelines 4243
Table3 Cancertherapy-relatedcardiovasculartoxicitydefinitions
CTRCD
SymptomaticCTRCD(HF)a,b Verysevere HFrequiringinotropicsupport,mechanicalcirculatorysupport,or
considerationoftransplantation
Severe HFhospitalization
Moderate NeedforoutpatientintensificationofdiureticandHFtherapy
Mild MildHFsymptoms,nointensificationoftherapyrequired
AsymptomaticCTRCD Severe NewLVEFreductionto,40%
Moderate NewLVEFreductionby≥10percentagepointstoanLVEF
of40–49%
OR
NewLVEFreductionby,10percentagepointstoanLVEFof40–
49%ANDeithernewrelativedeclineinGLSby.15%frombaseline
ORnewriseincardiacbiomarkersc
Mild LVEF≥50%
ANDnewrelativedeclineinGLSby.15%frombaseline
AND/ORnewriseincardiacbiomarkersc
ICImyocarditis(eitherpathohistologicaldiagnosisorclinicaldiagnosis)
Pathohistologicaldiagnosis(EMB) Multifocalinflammatorycellinfiltrateswithovertcardiomyocytelossbylightmicroscopy
Clinicaldiagnosisd cTnelevation(neworsignificantchangefrombaseline)ewith1majorcriterionor2minorcriteria,
afterexclusionofACSandacuteinfectiousmyocarditisbasedonclinicalsuspicionf
Majorcriterion:
(cid:129) CMRdiagnosticforacutemyocarditis(modifiedLakeLouisecriteria)g
Minorcriteria:
(cid:129) Clinicalsyndrome(includinganyoneofthefollowing:fatigue,myalgias,chestpain,diplopia,ptosis,
shortnessofbreath,orthopnoea,lower-extremityoedema,palpitations,light-headedness/dizziness,
syncope,muscleweakness,cardiogenicshock)
(cid:129) Ventriculararrhythmia(includingcardiacarrest)and/ornewconductionsystemdisease
(cid:129) DeclineinLVsystolicfunction,withorwithoutregionalwallmotionabnormalitiesinanon-Takotsubo
pattern
(cid:129) Otherimmune-relatedadverseevents,particularlymyositis,myopathy,myastheniagravis
(cid:129) SuggestiveCMRh
Severityofmyocarditis (cid:129) Fulminant:Haemodynamicinstability,HFrequiringnon-invasiveorinvasiveventilation,completeor
high-gradeheartblock,and/orsignificantventriculararrhythmia
(cid:129) Non-fulminant:includingsymptomaticbuthaemodynamicallyandelectricallystablepatientsand
incidentalcasesdiagnosedatthesametimeasotherimmuno-relatedadverseevents.Patientsmayhave
reducedLVEFbutnofeaturesofseveredisease
(cid:129) Steroidrefractory:non-resolvingorworseningmyocarditis(clinicalworseningorpersistenttroponin
elevationafterexclusionofotheraetiologies)despitehigh-dosemethylprednisolone
Recoveryfrommyocarditis (cid:129) Completerecovery:Patientswithcompleteresolutionofacutesymptoms,normalizationof
biomarkers,andrecoveryofLVEFafterdiscontinuationofimmunosuppression.CMRmaystillshowLGE
orelevatedT1duetofibrosis,butanysuggestionofacuteoedemashouldbeabsent
(cid:129) Recovering:Ongoingimprovementinpatientclinicalsymptoms,signs,biomarkers,andimaging
parameters,butnotyetnormalized,whileontaperingdosesofimmunosuppression
Vasculartoxicity(forgeneralcardiologydefinitions,seeSupplementarydata,TableS1)
Asymptomaticvasculartoxicity CAD Symptomaticvascular Stroke
PAD toxicity Transientischaemicattack
Carotidarterydisease MI
Venousthrombosis ACS
Arterialthrombosis CCS
Peripheralvasoreactivity PAD
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 16 ---
4244 ESCGuidelines
Coronaryepicardial Vasospasticangina
vasoreactivity
Coronarymicrovascular Microvascularangina
vasoreactivity Raynaud’sphenomenon
Arterialhypertension
Treatmentthresholdfor InpatientswithhighCVriski:≥130mmHgsystolicand/or≥80mmHgdiastolic
hypertensionbefore,during,and Otherwise:≥140mmHgsystolicand/or≥90mmHgdiastolic
aftertherapy
Cancertherapyholdingthreshold ≥180mmHgsystolicand/or≥110mmHgdiastolic
Hypertensiveemergency (Veryhigh)BPelevationassociatedwithacutehypertension-mediatedorgandamage(heart,retina,brain,
kidneys,andlargearteries),requiringimmediateBPreductiontolimitextensionorpromoteregressionof
targetorgandamage
Cardiacarrhythmias
QTprolongation Prolonged:QTcF.500msj
Bradycardia Forgeneralcardiologydefinitions,seeSupplementarydata,TableS1
Supraventriculartachycardia
Ventriculararrhythmias
AF
ACS,acutecoronarysyndromes;AF,atrialfibrillation;BNP,B-typenatriureticpeptide;BP,bloodpressure;CAD,coronaryarterydisease;CCS,chroniccoronarysyndromes;CMR,
cardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,
endomyocardialbiopsy;ESC,EuropeanSocietyofCardiology;GLS,globallongitudinalstrain;HF,heartfailure;HFmrEF,HFwithmildlyreducedejectionfraction;HFpEF,heart
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left
ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,
correctedQTintervalusingFridericiacorrection;SCORE2,SystematicCoronaryRiskEstimation2;SCORE2-OP,SystematicCoronaryRiskEstimation2—OlderPersons.
SeeSupplementarydata,TableS1forexpandeddefinitions.
aWithLVEFandsupportivediagnosticbiomarkersbasedonthe2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicHF.14
bSymptomaticCTRCDrepresentsHF,whichisaclinicalsyndromeconsistingofcardinalsymptoms(e.g.breathlessness,ankleswelling,andfatigue)thatmaybeaccompaniedbysigns(e.g.
elevatedjugularvenouspressure,pulmonarycrackles,andperipheraloedema)andhastraditionallybeendividedintodistinctphenotypesbasedonthemeasurementofLVEF:≤40%=
HFrEF;41–49%=HFmrEF;≥50%=HFpEF.
ccTnI/cTnT.99thpercentile,BNP≥35pg/mL,NT-proBNP≥125pg/mLornewsignificantrisefrombaselinebeyondthebiologicalandanalyticalvariationoftheassayused.
dClinicaldiagnosesshouldbeconfirmedwithmagneticresonanceimagingorEMBifpossibleandwithoutcausingtreatmentdelays.Treatmentwithimmunosuppressionshouldbe
promptlyinitiatedwhileawaitingfurtherconfirmatorytestinginsymptomaticpatients.
eBothtroponinIandtroponinTcanbeused;however,clinicalobservationssuggestthattroponinTmaybefalselyelevatedinpatientswithconcomitantmyositisandwithoutmyocarditis.15–17
fAccordingtolocalprotocols.
gDiagnosticCMR:BasedonupdatedLakeLouisecriteria18:T2-basedcriterion+T1-basedcriterion+supportivecriteria(T2-basedcriteria:regionalorglobalincreaseofnativeT2,orT2signal
intensity;T1-basedcriteria:regionalorglobalincreaseofnativeT1,orregionalorglobalincreaseintheECV,orpresenceofLGE;supportivecriteria:pericarditisand/orregionalorglobalLV
systolicdysfunction).
hSuggestiveCMR:meetingsomebutnotallofthemodifiedLakeLouisecriteria.ThepresenceofT2-orT1-basedcriteriamaysupportadiagnosisofacutemyocardialinflammationinthe
appropriateclinicalscenario.
iSCORE2(,70years),SCORE2-OP(≥70years)orequivalent.19CVriskstratification:,50years:lowrisk,2.5%,moderaterisk2.5%to,7.5%,highrisk≥7.5%;50–69years:lowrisk,5%;
moderaterisk5%to,10%;highrisk≥10%;≥70years:lowrisk,7.5%,moderaterisk7.5%to,15%,highrisk≥15%.
jQTcF480–500ms:correctreversiblecauses,minimizeotherQTprolongingmedications,closeQTcFmonitoring.Fridericiacorrectionisrecommended(QTcF=QT/3√RR).20
4. Cardiovascular toxicity risk CVDpreventionstrategiesrequireapersonalizedapproach.Risk
fi assessmentisachallengingtaskanditisvitalthatcliniciansadopta
strati cation before anticancer
systematicapproachwithoutdelayingoncologicaltreatment.12,21,22
therapy Figure 5 provides a comprehensive approach to risk assessment.
Thechoiceofthecardiactests(electrocardiogram[ECG],biomar-
TheoptimaltimetoconsiderCVDpreventionstrategiesinpatients kers, and imaging) should be individualized based on CV risk and
withcancerisatthetimeofcancerdiagnosisandpriortotheiniti- theplannedcancertreatments.
ationofcancertreatment.4,5Thisenablestheoncologyteamtocon-
sider CV risk while making cancer treatment choices, educating
4.1. General approach to cardiovascular
patients regarding their CV risk, personalizing CV surveillance and
follow-upstrategies,andmakingappropriatereferralsofhigh-riskpa- toxicity risk in patients with cancer
tients to cardio-oncology services. These strategies are needed to Pre-treatment CTR-CVT risk assessment should ideally be per-
mitigate CVD risk, and improve the adherence to effective cancer formedusingarecognizedriskstratificationmethodwheremultiple
treatmentsandtheoverallsurvival. risk factors are incorporated to determine patient-specific risk.23
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 17 ---
ESCGuidelines 4245
Baseline cardiovascular toxicity risk assessment
HFA-ICOS risk
assessment:
CVRFa
CVD history
Cancer history
Cancer treatment history
ECG Physical and metabolic Pre-existing CVD or
(Class I) assessmentb at risk of CTRCDc
New, untreated or TTE
Arrhythmias Suspected cTn and NP
uncontrolled medical, and (LVEF and GLS)
Prolonged QTcF CVD increasedd
lifestyle CVRF reducede
Check and correct Ref Ref rdiologistg
Aggressive management of
precipitant factorsf cardiologistg (Class I)
CVRF and pre-existing CVD
(Class I) (Class I)
according to ESC Guidelines
Healthy lifestyle promotion
(Class I)
Consider primary vs secondary preventive strategies according to CV toxicity risk,
pre-existing CVD, and cancer treatment type
Figure5Baselinecardiovasculartoxicityriskassessmentbeforeanticancertherapy.BNP,B-typenatriureticpeptide;cTn,cardiactroponin;CTRCD,
cancertherapy-relatedcardiacdysfunction;CV,cardiovascular;CVD,CVdisease;CVRF,CVriskfactors;ECG,electrocardiogram;ESC,European
SocietyofCardiology;GLS,globallongitudinalstrain;HFA,HeartFailureAssociation;ICOS,InternationalCardio-OncologySociety;LVEF,leftven-
tricularejectionfraction;NP,natriureticpeptides(includingBNPandNT-proBNP);NT-proBNP,N-terminalpro-BNPpeptide;QTc,correctedQT
interval;QTcF,correctedQTintervalusingFridericiacorrection;TTE,transthoracicechocardiography.aWhenassessingCVRF,includeinformation
aboutunhealthylifestyleincludingsedentarybehaviour,smoking,andalcoholintake.bSeeFigure3.cAccordingtocancertreatmentandHFA-ICOS
riskassessment.dcTnI/T.99thpercentile, BNP≥35pg/mL,NT-proBNP≥125pg/mL.ePatientswithbaselineLVEF,50%orinthelownormal
range(LVEF50–54%)shouldbereferredtoaspecializedcardiologistorcardio-oncologist.WhenTTEisused,ideallythree-dimensional-LVEFandGLS
shouldbemeasured.IfGLSassessmentisnotavailable,other markersoflongitudinal function(e.g.annularDoppler velocity)shouldbeconsidered.
Cardiacmagneticresonanceshouldbeconsideredifechocardiographyisofnon-diagnosticquality.fAnaemia,infections,electrolyteabnormalities,meta-
bolicproblems,otherQTc-prolongingdrugs.gCardio-oncologyreferralisrecommendedwhenavailable;alternatively,patientsshouldbereferredtoa
specializedcardiologistwithexpertiseinmanagingCVDinpatientswithcancer.
Onlyalimitednumberofretrospectiveriskscoreshavebeenpub- validationisneeded,HFA-ICOSriskassessmenttoolsshouldbecon-
lishedinpatientswithcancer.Mostofthesescoreshavebeendevel- sidered to determine pre-treatment risk of CTR-CVT as they are
opedforspecificcancer-patientgroupsandcannotbereadilyapplied easy to use and implement in oncology and haematology services
or extrapolated to other type of malignancies.24–29 While further (Table 4; Supplementary data, Tables S2–S7).12,13 Other CV risk
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 18 ---
4246 ESCGuidelines
Table 4 Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk
stratification
BaselineCVtoxicity Anthracycline HER2-targeted VEGF BCR-ABL Multiple RAFand
riskfactors chemotherapy therapies inhibitors inhibitors myeloma MEK
therapies inhibitors
PreviousCVD
HF/cardiomyopathy/ VH VH VH H VH VH
CTRCD
SevereVHD H H – – – H
MIorPCIorCABG H H VH – – H
Stableangina H H VH – – H
Arterialvasculardisease – – VH VH VH –
Abnormalankle-brachial – – – H – –
pressureindex
PH – – – H – –
ArterialthrombosiswithTKI – – – VH – –
Venousthrombosis – – H M2 VH –
(DVT/PE)
Arrhythmiaa – M2 M2 M2 M2 M1
QTc≥480ms – – H H – –
450≤QTc,480ms(men); – – M2 M2 – –
460≤QTc,480ms
(women)
PriorPICVtoxicity – – – – VH –
PriorIMiDCVtoxicity – – – – H –
Cardiacimaging
LVEF,50% H H H H H H
LVEF50–54% M2 M2 M2 – M2 M2
LVhypertrophy – – – – M1 –
Cardiacamyloidosis – – – – VH –
Cardiacbiomarkers
ElevatedbaselinecTnb M1 M2 M1 – M2 M2
ElevatedbaselineNPb M1 M2 M1 – H M2
AgeandCVRF
Age≥80years H H – – – M1
Age65–79years M2 M2 – – – M1
Age≥75years – – H H H M1
Age65–74years – – M1 M2 M1 M1
Age≥60years – – – M1 – –
CVD10-yearriskscore – – – H – –
.20%
Hypertensionc M1 M1 H M2 M1 M2
Chronickidneydiseased M1 M1 M1 M1 M1 M1
Proteinuria – – M1 – – –
DMe M1 M1 M1 M1 M1 M1
Hyperlipidaemiaf – – M1 M1 M1 –
Familyhistoryof – – – M1 M1 –
thrombophilia
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 19 ---
ESCGuidelines 4247
Currentcancertreatment
Dexamethasone.160mg/ – – – – M1 –
month
Includesanthracycline – M1g – – – –
beforeHER2-targeted
therapy
Previousexposureto
Anthracycline H M2h H – H H
Trastuzumab – VH – – – –
RTtoleftchestor H M2 M1 – M1 M2
mediastinum
Non-anthracycline M1 – – – – –
chemotherapy
Lifestyleriskfactors
Currentsmokeror M1 M1 M1 H M1 M1
significantsmokinghistory
Obesity(BMI.30kg/m2) M1 M1 M1 M1 M1
M1
AF,atrialfibrillation;BCR-ABL,breakpointclusterregion–Abelsononcogenelocus;BMI,bodymassindex;BNP,B-typenatriureticpeptide;BP,bloodpressure;CABG,coronaryartery
bypassgraft;cTn,cardiactroponin;CTRCD,cancertherapy-relatedcardiacdysfunction;CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfactors;DM,diabetes
mellitus;DVT,deepveinthrombosis;eGFR,estimatedglomerularfiltrationrate;H,highrisk;HbA1c,glycatedhaemoglobin;HER2,humanepidermalreceptor2;HF,heartfailure;IMiD,
immunomodulatorydrugs;LV,leftventricular;LVEF,leftventricularejectionfraction;M,moderaterisk;MEK,mitogen-activatedextracellularsignal-regulatedkinase;MI,myocardial
infarction;MM,multiplemyeloma;NP,natriureticpeptides(includingBNPandNT-proBNP);NT-proBNP,N-terminalpro-B-typenatriureticpeptide;PCI,percutaneouscoronary
intervention; PE, pulmonary embolism; PH, pulmonary hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; RAF, rapidly accelerated fibrosarcoma; RT,
radiotherapy;TKI,tyrosinekinaseinhibitors;ULN,upperlimitofnormal;VEGFi,vascularendothelialgrowthfactorinhibitors;VH,veryhighrisk;VHD,valvularheartdisease.
AnexpandedversionofthistableisprovidedinSupplementarydata,TablesS2–S7.
Risklevel:Lowrisk=noriskfactorsORonemoderate1riskfactor;moderaterisk(M)=moderateriskfactorswithatotalof2–4points(Moderate1[M1]=1point;Moderate
[M2]=2points);highrisk(H)=moderateriskfactorswithatotalof≥5pointsORanyhigh-riskfactor;very-highrisk(VH)=anyvery-highriskfactor.
aAF,atrialflutter,ventriculartachycardia,orventricularfibrillation.
bElevatedabovetheULNofthelocallaboratoryreferencerange.
cSystolicBP.140mmHgordiastolicBP.90mmHg,orontreatment.
deGFR,60mL/min/1.73m2.
eHbA1c.7.0%or.53mmol/mol,orontreatment.
fNon-highdensitylipoproteincholesterol.3.8mmol/L(.145mg/dL)orontreatment.
gHighriskifanthracyclinechemotherapyandtrastuzumabdeliveredconcurrently.
hPreviousmalignancy(notcurrenttreatmentprotocol).
Table5 Anthracyclineequivalencedose
Doxorubicin Epirubicin Daunorubicin Mitoxantrone Idarubicina
CVtoxicitydoseratio 1 0.8 0.6 10.5 5
Isoequivalentdose 100mg/m2 125mg/m2 167mg/m2 9.5mg/m2 20mg/m2
Thistablereferstoanthracyclineequivalencedoseusingdoxorubicinasareference.NotethattheseisoequivalentdosesarederivedfrompaediatricCS.
CS,cancersurvivors;CV,cardiovascular.
aDataforidarubicinarebaseduponanestimatedanticancerefficacyratio,notderivedfromcardiotoxicitydata.TheCVtoxicitydoseratioprovidesthevaluethatshouldbeusedto
multiplythedoseoftheanthracyclineofinteresttoconverttoisoequivalentdosesofdoxorubicin;e.g.toconvert125mg/m2ofepirubicintodoxorubicinisoequivalent,multiplythedose
by0.8(125mg/m2×0.8=100mg/m2ofdoxorubicin).
calculators(e.g.SMART[Secondmanifestationsofarterialdisease] assessment of CV risk, considering that cancer itself may increase
risk score, ADVANCE [Action in Diabetes and Vascular Disease: thelikelihoodofCVD.19,23,30,31
Preterax and Diamicron-MR Controlled Evaluation] risk score, Baselineriskassessmentshouldbeconsideredbythetreatingon-
SCORE2 [Systematic Coronary Risk Estimation 2], SCORE2-OP cologyorhaematologyteamforallpatientsdiagnosedwithcancer
[SystematicCoronaryRiskEstimation2—OlderPersons],ASCVD who are scheduled to receive a cancer treatment identified to
[AtheroSclerotic Cardiovascular Disease] risk score, U-Prevent, haveaclinicallysignificantlevelofCRT-CVT,orbyacardiologistif
andlifetimeriskcalculators)maybeconsideredatbaselineforthe appropriate. In the case of patients scheduled to receive
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 20 ---
4248 ESCGuidelines
Patient with cancer
CV risk stratification befffore anticancer therapppy
(Class I)
HFFFA-ICOS baseline risk assessment
(Class IIa)
HFFFA-ICOS results
Low risk Moderate risk High/very high risk
Cardiologyareffferral
Routine oncologyfffollow-up Closer oncology fffollow-up
(Class I)
AND AND AND
Discussion of the risk/benefit
Cardiologyareffferral if Cardiologyareffferral if
balance of cardiotoxic
CV toxicity develops CV toxicity develops
anticancer treatment
(Class I) (Class I)
(Class I)
AND AND
Cardiology reffferrala Cardioprotective strategies
(Class IIb) (Class IIa)
Communicate the CV toxicity risk assessment results (Class I)
Educate patients regarding risks and protective healthy lifffestyle (Class I)
Management of CVRF and CVD according to ESC Guidelines(Class I)
Figure6Generalcardio-oncologyapproachafterHeartFailureAssociation–InternationalCardio-OncologySocietycardiovasculartoxicityriskassess-
ment. CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society of Cardiology; HFA, Heart Failure Association; ICOS,
InternationalCardio-OncologySociety.aCardio-oncologyreferralisrecommendedwhenavailable;alternatively,patientsshouldbereferredtoaspe-
cializedcardiologistwithexpertiseinmanagingCVDinpatientswithcancer.
anthracyclinechemotherapy,thetotalplannedcumulativeanthracy- recommended for patients identified to be at high or very high
cline dose is also relevant, and ≥250mg/m2 of doxorubicin or riskforCTR-CVTatbaseline(Table4)toinstitutestrategiestomiti-
equivalentshouldbeconsideredhigherrisk(Table5).32 gaterisk.33Patientsatmoderateriskcanbenefitfromclosercardiac
CVriskstratificationresultsshouldbediscussedwiththepatient monitoring, strict management of traditional CVRF, and selected
anddocumentedinclinicalnotes.Thisprocesswillalsoenablefuture moderate-riskpatientsmayalsobenefitfromacardio-oncologyre-
validationofthesetools. ferral(Figure6).Low-riskpatientscanbefollowedwithintheoncol-
Cardiology referral (cardio-oncology programme or cardiolo- ogy programme with appropriate referral to cardio-oncology if a
gist with expertise in managing CVD in patients with cancer) is CTR-CVTemergesorneworuncontrolledCVRFappear.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 21 ---
ESCGuidelines 4249
RecommendationTable1—Recommendationsfora prevention includes interventions in patients with prior or active
general approach to cardiovascular toxicity risk CVDorpreviousCTR-CVT.12
categorization
Reviewing traditional risk factors for CVD is recommended.
Wherepresent,theefficacyoftreatmentandcontrolofthesemodi-
Recommendations Classa Levelb
fiableriskfactorsshouldbedeterminedtoensureoptimalcontrol
CVtoxicityriskstratificationcbeforestarting during cancer therapy.4,34 Although recent SCORE2 and
potentiallycardiotoxicanticancertherapyis SCORE2-OP19tablesarenotfocusedonpatientswithcancer,risk
I B
recommendedinallpatientswith calculationisrecommendedforpatientswithcancer.40yearsof
cancer.12,14,19,21,25,28,31 age (unlesstheyareautomatically categorizedasbeing athighrisk
CommunicatingtheresultsoftheCVtoxicityrisk or very high risk based on documented CVD, diabetes mellitus
assessmenttothepatientandotherappropriate I C [DM],kidneydisease,orahighlyelevatedsingleriskfactor)asaref-
healthcareprofessionalsisrecommended. erencetooptimizeCVRFtreatmentgoals.19,31,35Afamilyhistoryof
TheuseofHFA-ICOSriskassessmentshouldbe prematureCVDshouldbeconsideredbecausegeneticabnormalities
consideredtostratifyCVtoxicityriskinpatients associatedwithCVDmaypredisposepatientswithcancertoahigh-
withcancerscheduledtoreceivecardiotoxic
IIa C erriskofCTR-CVT.36–38Lifestylefactorssuchassmoking,alcohol
anticancertherapy.12 consumption, sedentary lifestyle, exposure to pollution, and frailty
are important shared risk factors for both cancer and CVD.
Itisrecommendedthatpatientscategorizedtobe
atlowCVtoxicityriskshouldproceedto I C Informationonpriorhistoryofcancer,cardiotoxiccancertherapies,
and their respective doses should be collected. Patients should be
anticancertherapywithoutdelay.
askedabouttypicalcardiacsymptoms(e.g.chestpainwithactivity,
InpatientscategorizedatmoderateCVtoxicity
IIb C
risk,cardiologyreferraldmaybeconsidered.e dyspnoeaonexertion,orthopnoea,palpitations,andperipheraloe-
dema), which can guide clinical examination and investigations.
Cardiologyreferraldisrecommendedinhigh-risk
Physicalexaminationshoulddocumentvitalsignsandlookforpoten-
andveryhigh-riskpatientsbeforeanticancer I C
tialindicatorsofundiagnosedCVDsuchasHF,pericardialdisease,
therapy.f
VHD,andarrhythmias.39–42
Discussionoftherisk/benefitbalanceof
The second scenario is secondary prevention in patients with a
cardiotoxicanticancertreatmentinhigh-andvery
I C priorhistoryofCVD.Thesepatientswithcancerarepotentiallyat
high-riskpatientsinamultidisciplinaryapproach
high or very high risk of future CV events,12 and require a more
priortostartingtreatmentisrecommended.
comprehensive clinical evaluation of their CVD, its severity, and
Cardiologyreferraldisrecommendedforpatients
priorandcurrenttreatments.Dependingonthetypeandseverity
withcancerandpre-existingCVDorabnormal ofCVD,additionalinvestigations—includingrestingorstressecho-
findingsatbaselineCVtoxicityriskassessmentg I C
cardiography,cardiacmagneticresonance(CMR),nuclearperfusion
whorequirepotentiallycardiotoxicanticancer
imaging,andcoronarycomputedtomographyangiography(CCTA)
therapy. —maybeindicatedtodetermineriskstatus.IdentifyingpriorCVD
CV,cardiovascular;CVD,CVdisease;ECG,electrocardiogram;GLS,globallongitudinal should not automatically be a reason to withhold cancer therapy
strain; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS, butconsideredanopportunitytooptimizeCVriskpriortoanddur-
InternationalCardio-OncologySociety;LVEF,leftventricularejectionfraction;TTE, ing treatment. Risk/benefit discussions should include the patient,
transthoracic echocardiography; ULN, upper limit of normal; VHD, valvular heart
disease. oncologist or haematologist, and—where available—a specialized
aClassofrecommendation.
cardio-oncologyservice.
bLevelofevidence.
cIncludingclinicalhistoryandphysicalexamination,ECG,generalbloodtest,HbA1c, AdditionalfactorsthataddtothecomplexityofbaselineCVrisk
lipid profile, and cardiac serum biomarkers and/or TTE (according to cancer drug assessment are the cancer type and prognosis, and type, duration,
typeandCVtoxicityrisk). and intensity of cancer treatment (Figure 1).4,12,43 Clinical history,
dCardio-oncologyreferralisrecommendedwhenavailable;alternatively,thepatients
physical examination features, and treatment-related risk factors
shouldbereferredtoaspecializedcardiologistwithexpertiseinmanagingCVDin
patientswithcancer. thatcontributetoCTR-CVTforvariouscancertherapiesaresum-
eWithoutdelayingcancertreatments.
marizedinSupplementarydata,TableS8.Theseriskfactorsshould
fUnlessthereisanoncologyemergencyrequiringimmediatecancertreatment.
gModerate-to-severepre-existingCVDsornewabnormalfindings(baselinecardiac becollectedandconsideredalongwithbaselineECG,cardiacserum
serum biomarkers.ULN, LVEF≤50%, GLS under normal local values, previously biomarkers, and cardiac imaging tests (summarized in Figure 7) to
undiagnosedmoderate-to-severemyocardial,pericardial,orVHDs,abnormalbaseline completebaselineCTR-CVTevaluation.
ECG).
4.3. Electrocardiogram
Abaseline12-leadECGisareadilyavailabletestthatcanprovideim-
4.2. History and clinical examination portantcluestounderlyingCVD.ECGevidenceofchamberenlarge-
Acarefulclinicalhistoryandphysicalexaminationisrecommendedas ment, conduction abnormalities, arrhythmias, ischaemia, or prior
part of the baseline risk assessment. Oncology patients can be di- myocardial infarction (MI), and low voltages should be interpreted
videdintotwocohortswithrespecttothepresenceorabsenceof in the clinical context. A baseline ECG is recommended prior to
pre-existingCVD.Aprimarypreventionstrategycanbeconsidered
startingacancertreatmentknowntocauseQTcprolongation.44–49
in patients without previous CVD or CTR-CVT while secondary Measurement of QTc using the Fridericia correction (QTcF) is
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 22 ---
4250 ESCGuidelines
Baseline clinical CV assessment,,physical exam and ECG are recommended
in all cancer patients scheduled fffor cardiotoxic therapiesa
Patient risk level TTEb NP cTn
Anthracyclines
HER2-targeted therapiesc
Fluoropyrymidines Previous
CVD
VEGFi
Second- and third-generation BCR-ABLTKId All
patients
BTK inhibitors
PIe
RAF and MEK inhibitors
ICI
All other
patients
Osimertinib All
patients
CAR-T andTIL Previous
CVD
All other
patients
RRRT to a volume including the heart Previous
CVD
HSCT All
patients
High and Moderate Low Other
Class I Class IIa Class IIb
very high risk risk risk conditions
Figure7Baselinescreeningrecommendationsforpatientswithcancertreatedwithpotentiallycardiotoxicdrugs.3D,three-dimensional;ADT,andro-
gendeprivationtherapy;AL-CA,amyloidlight-chaincardiacamyloidosis;BC,breastcancer;BCR-ABL,breakpointclusterregion-Abelsononcogenelocus;
BNP,B-typenatriureticpeptide;BTK,Brutontyrosinekinase;CAR-T,chimericantigenreceptorTcell;CDK,cyclin-dependentkinase;CMR,cardiacmag-
neticresonance;cTn,cardiactroponin;CV,cardiovascular;CVD,cardiovasculardisease;ECG,electrocardiogram;GLS,globallongitudinalstrain;HER2,
humanepidermalreceptor2;HSCT,haematopoieticstemcelltransplantation;ICI,immunecheckpointinhibitors;LVEF,leftventricularejectionfraction;
MEK, mitogen-activated extracellular signal-regulated kinase; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal
pro-B-typenatriureticpeptide;PI,proteasomeinhibitors;RAF,rapidlyacceleratedfibrosarcoma;RT,radiotherapy;TIL,tumour-infiltratinglymphocytes;
TKI,tyrosinekinaseinhibitors;TTE,transthoracicechocardiography;VEGFi,vascularendothelialgrowthfactorinhibitors.aIncludingpatientsscheduledto
receiveADTforprostatecancer,CDK4/6inhibitors,endocrinehormonetherapyforBCandanaplasticlymphomakinaseinhibitors.bTTEisrecom-
mendedasthefirst-linemodalityfortheassessmentofcardiacfunction.3DechocardiographyisrecommendedtomeasureLVEF.GLSisrecommended
inallpatientswithcancerhavingechocardiography,ifavailable.CMRshouldbeconsideredwhenechocardiographyisunavailableornotdiagnostic.
cBaselinecTnmeasurementshouldbeconsidered(ClassIIa,LevelA)inlow-andmoderate-riskpatientspost-anthracyclinechemotherapybutprior
tostartingHER2-targetedtherapies.BaselineNPandcTnmeasurementmaybeconsidered(ClassIIb,LevelC)inlow-andmoderate-riskpatients.
dBaselineechocardiographyisrecommendedinpatientsscheduledtoreceivedasatinib(ClassI,LevelC).eNPandcTnmeasurementsarerecommended
atbaselineinpatientswithAL-CA(ClassI,LevelB).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 23 ---
ESCGuidelines 4251
recommended.44–48
When baseline QTcF prolongation is recog- A few studies of paediatric and adult patients requiring an-
nized, the correction of reversible causes and the identification of thracycline chemotherapy have reported that patients with can-
genetic conditions that prolong QT is recommended (see Section cerwithanincreasedcTnbeforetreatmentwere morelikelyto
6.4.2).45 develop CTRCD.56–58 However, most published studies have
Left atrial enlargement on baseline ECG before ibrutinib has not reported on the prognostic value of baseline cTn measure-
beenshowntobeapredictorforthedevelopmentofatrialfibril- ments, possibly due to the low prevalence of patients with pre-
lation (AF) during chemotherapy.50,51 The presence of atrioven- vious CVD or CVRF in these studies.55,59,60 A study of 251
tricular (AV) conduction delays and premature atrial complexes women receiving trastuzumab for early HER2-positive breast
are associated with the development of atrial arrhythmias in pa- cancer (BC) reported that 19% of the patients who developed
tientsundergoingautologoushaematopoieticstemcelltransplant- cardiac dysfunction during trastuzumab therapy had positive ul-
ation(HSCT).52 trasensitive troponin I at baseline (.80ng/L).61 Furthermore,
baseline high cTnI level was a predictor of lack of recovery des-
pite optimal HF therapy.61 These findings have been confirmed
Recommendation Table 2 — Recommendations for in a subsequent study of 533 patients with BC who had serial
electrocardiogrambaselineassessment high-sensitivity cTn (hs-cTn) I and T measurements during tras-
tuzumab therapy.62 Increased baseline cTn (.40ng/L and
Recommendations Classa Levelb
.14ng/L for hs-cTnI and hs-cTnT, respectively) was associated
AnECGisrecommendedinallpatientsstarting with a four-fold risk of developing LV dysfunction (LVD).62
cancertherapyaspartoftheirbaselineCVrisk I C However, given the high proportion of patients with previous
assessment. anthracyclineexposureinbothstudies,theseelevatedcTnlevels
InpatientswithanabnormalbaselineECG,c arenotatruebaselineastheyreflectpre-trastuzumabbutpost-
I C
referraltoacardiologistdisrecommended. anthracycline chemotherapy. It is unclear whether pre-
treatmentcTnlevelswillbepredictiveofLVDinpatientsbefore
AF,atrialfibrillation;CV,cardiovascular;ECG,electrocardiogram;LV,leftventricular;
any treatment, or for those BC patients treated with trastuzu-
QTc,correctedQTinterval;QTcF,correctedQTintervalusingFridericiacorrection.
aClassofrecommendation. mab without prior anthracyclines.
bLevelofevidence. NP are another potential biomarker for CV risk stratification.
cAdvancedconductiondisease(leftbundlebranchblock,rightbundlebranchblock,
second degree heart block, severe first degree heart block with a PR interval SeveralstudieshaveshowntheroleofNPmeasurementatbaseline
.300ms); Q waves in two or more contiguous leads; LV hypertrophy; AF/atrial
orNPchangestopredictfutureCTR-CVT.63–65Inpatientswithmul-
flutter if previously undiagnosed; QTc prolongation using Fridericia correction tiplemyeloma(MM),pre-treatmentNPmaybeapredictivemarker
formula(QTcF=QT/3√RR).450msformenand.460msforwomenorother
forsubsequentCVadverseevents.In109patientswithrelapsedMM,
ECGabnormalityraisingconcern.
dCardio-oncologyreferralisrecommendedwhenavailable;alternatively,thepatients BNP.100pg/mL or NT-proBNP.125pg/mL levels before initi-
shouldbereferredtoaspecializedcardiologistwithexpertiseinmanagingCVDin ationofcarfilzomibwereassociatedwithanoddsratioof10.8for
patientswithcancer. subsequentCVadverseevents.66Therefore,baselineNPmeasure-
mentisrecommendedinhigh-andveryhigh-riskpatientsandshould
be considered in low- and moderate-risk patients before PI
4.4. Cardiac serum biomarkers treatment.
TheliteratureontheuseofbiomarkersforCTR-CVTriskstrati- Baseline elevated values of CV functional peptides (including
fication before cancer therapy is limited, and recommendations NT-proBNP)andhs-cTnTwerestronglyrelatedtoall-causemortal-
aremostlybasedonexpertopinion.12,43,53–55Fourrecentposition
ityin555patientswith differenttypesoftumours,suggestingthat
papersbasedoncollaborationamongtheCardio-OncologyStudy the presence of a subclinical myocardial injury might be directly
GroupoftheHFAoftheESC,theESC-CCO,andICOShavesug- linked to disease progression.67 However, in the CARDIOTOX
gested that measurement of cardiac serum biomarkers—cardiac (CARDIOvascular TOXicity induced by cancer-related therapies)
troponin (cTn) I or T and natriuretic peptides (NP) (e.g. B-type registry, in 855 patients treated with a range of oncological treat-
natriuretic peptide [BNP] or N-terminal pro-BNP ments,includingradiotherapy(RT),bothNT-proBNPandcTneleva-
[NT-proBNP])—helpinbaselineCVriskstratificationofpatients tionatbaselinewerenotassociatedwiththedevelopmentofsevere
scheduled for cancer therapies including anthracyclines, human CTRCD(LVEF,40%orclinicalHF).68
epidermal receptor 2 (HER2)-targeted therapies, vascular endo- There has also been interest in other novel biomarkers for
thelialgrowthfactor(VEGF)inhibitors(VEGFi),proteasomeinhi- CTR-CVT risk stratification before cancer treatment; however,
bitors (PI), immune checkpoint inhibitors (ICI), chimeric antigen the literature is limited. Candidates include myeloperoxidase,
receptor T cell (CAR-T) and tumour-infiltrating lymphocytes C-reactive protein, galectin-3, arginine–nitric oxide metabolites,
(TIL) therapies, allowing identification of those who may benefit growth differentiation factor-15, placental growth factor,
from cardioprotective therapy.12,43,53,54 Baseline cardiac serum fms-like tyrosine kinase-1, micro-ribonucleic acids, and immuno-
biomarkermeasurementsarerequiredifthedegreeofchangein globulin E.60,69–71 Currently, there is no evidence to support
thebiomarkers isto beused toidentifysubclinical cardiacinjury routine measurement of these novel biomarkers and more re-
duringcancertreatment. search is required.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 24 ---
4252 ESCGuidelines
Recommendation Table 3 — Recommendation for 4.5. Cardiovascular imaging
cardiacbiomarkerassessmentpriortopotentiallycar-
CVimaginghasanimportantroleinidentifyingpatientswithsubclin-
diotoxictherapies
icalCVD,determiningthedegreeofpre-existingcardiaccomorbidity
Recommendation Classa Levelb priortodecisionsregardingcancertherapy,andservesasareference
foridentificationofchangesduringtreatmentandlong-termfollow-
BaselinemeasurementofNPcand/orcTndis up.12,54,72–74Transthoracicechocardiography(TTE)isthepreferred
recommendedinallpatientswithcanceratriskof imagingtechniqueforbaselineriskstratificationasitprovidesquan-
CTRCDifthesebiomarkersaregoingtobe I C titativeassessmentofLVandrightventricular(RV)function,cham-
measuredduringtreatmenttodetect
ber dilation, LV hypertrophy, regional wall motion abnormalities,
CTRCD.e,53,55
diastolicfunction,VHD,pulmonaryarterialpressure(PAP),andperi-
cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; NP, cardial disease, which may influence the therapeutic decision.22,72
natriureticpeptides. Suggestions for the components of a baseline echocardiography
aClassofrecommendation.
studyareprovidedinFigure8.
bLevelofevidence.
cNPsincludingB-typenatriureticpeptideorN-terminalpro-B-typenatriureticpeptide. CurrentdefinitionsofCTRCDarebasedonareductionofLVEF
dcTnincludesanyoftroponinI,troponinT,orhs-cTnT. and/orrelativechangesingloballongitudinalstrain(GLS)(Table3).
eSpecificrecommendationsforbaselinecardiacbiomarkersinpatientswithcancerat
Three-dimensional(3D)echocardiographyisthepreferredechocar- low, moderate, high, and very high risk of cancer therapy-related cardiovascular
toxicityareincludedinSection5. diography modality for the assessment of LVEF and cardiac
Right ventricle-right atriuma Left ventricle-left atriuma
TTE TTE
RV dimensions LVV and LV mass
S´ 3D-LVEF (2D-LVEF if
TAPSE 3D not available)
FAC Contrast echo if inadequate
RV-FWLS TTE image quality
RA area GLS
PeakTRV E/e´, LAV
CMR CMR
RVV LVV and LV mass
RVEF LVEF
LS and circumferential strain
if available
Myocardial Characterization
T2w (STIR),T1,T2 maps, LGE
Other parameters
TTE CMR
IVC diameter, and respiratory Valvular and pericardial
changes diseases
Valvular and pericardial
diseases
Figure8Recommendedtransthoracicechocardiographyandcardiacmagneticresonanceimagingparametersintheevaluationofpatientswithcancer.
2D,two-dimensional;3D,three-dimensional;BP,bloodpressure;CMR,cardiacmagneticresonance;E,mitralinflowearlydiastolicvelocityobtainedbypulsed
wave;e′,earlydiastolicvelocityofthemitralannulusobtainedbytissuedopplerimaging;echo,echocardiography;FAC,fractionalareachange;FWLS,freewall
longitudinalstrain;GLS,globallongitudinalstrain;IVC,inferiorvenacava;LAV,leftatrialvolume;LGE,lategadoliniumenhancement;LS,longitudinalstrain;LV,
leftventricular;LVEF,leftventricularejectionfraction;LVV,leftventricularvolume;RA,rightatrial;RV,rightventricular;RVEF,rightventricularejectionfraction;
RVV,rightventricularvolume;s′,systolicvelocityoftricuspidannulusobtainedbydopplertissueimaging;STIR,shorttauinversionrecovery;TAPSE,tricuspid
annularplanesystolicexcursion;TTE,transthoracicechocardiography;TRV,tricuspidregurgitationvelocity.aChangesinsystemicarterialBPandloadingcon-
ditionsmayinfluencecardiacfunctionmeasurements.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 25 ---
ESCGuidelines 4253
volumes.54,75–79If3Dechocardiographyisnotfeasible(e.g.unavail-
cardiomyopathy), CMR should be considered for further risk
able or poor tracking), the modified two-dimensional (2D) assessment.
Simpson’sbiplanemethodisrecommended.80,81Inpatientswithin- Functional imaging tests for myocardial ischaemia—including
adequate TTE image quality, ultrasound-enhancing contrast agents stressechocardiography,perfusionCMR,ornuclearmyocardialper-
shouldbeaddedtoimproveevaluationofLVfunctionandvolumes fusion imaging—should be performed to assess for ischaemia in
iftwoormoreLVsegmentsarenotwellvisualized.82Alternatively,in symptomaticpatients(stableangina,limitingdyspnoea)ifclinicalsus-
subjectswithpoor-qualityechocardiographywindows,whenavail- picion of coronary artery disease (CAD)exists, especially prior to
able, CMR should be considered (Figure 8).14,72,83,84 If TTE and useofcancertherapiesassociatedwithvasculartoxicity(e.g.fluoro-
CMRarebothunavailablefortheassessmentofLVEF,multigatedac- pyrimidines,VEGFi,breakpointclusterregion–Abelsononcogenelo-
quisitionnuclearimaging(MUGA)canbeconsideredasathird-line cus [BCR-ABL], tyrosine kinase inhibitors [TKI]). Alternatively, in
modality. MUGA scans should be avoided whenever possible due patients with low to intermediate pre-test probability of CAD,
toradiationexposureandtheinabilitytoobtainotherimportantin- CCTA is a robust alternate modality with high sensitivity to rule
formation(e.g.VHD,PAP,orGLS). outobstructiveCAD.100,101
BaselineLVEFandGLSarerecommendedinallpatientsevaluated
withTTE beforecardiotoxiccancer treatmentinitiationtostratify
CTR-CVT risk and to identify significant changes during treat- Recommendation Table 4 — Recommendations for
ment.8,64 Changes in loading conditions occur frequently during cardiacimagingmodalitiesinpatientswithcancer
chemotherapy(e.g.volumeincreaseduetointravenous[i.v.]fluids,
General Classa Levelb
volumelossduetovomitingordiarrhoea,bloodpressure[BP]and
heart rate changes with pain or stress) and may affect cardiac vo- Echocardiographyisrecommendedasthe
lumes,LVEF,andGLSquantification.SystemicarterialBPmeasure- first-linemodalityfortheassessmentofcardiac I C
ment is recommended with all resting TTE as it can influence functioninpatientswithcancer.4,12,54,94
cardiac function measurements and should be recorded on the 3Dechocardiographyisrecommendedasthe
TTE report. A baseline borderline (50–54%) or reduced (,50%) preferredechocardiographicmodalitytomeasure I B
LVEFisariskfactorforfutureCTR-CVTfrommostcardiotoxiccan- LVEF.77–79,89
certherapies,inparticularwithanthracyclinesortrastuzumab.12,24,74
GLSisrecommendedinallpatientswithcancer
IncreasedbaselineindexedLVend-diastolicvolumecanbeapredict- havingechocardiography,if I C
orofmajorCVevents(symptomaticHForcardiacdeath)duringan- available.75,80,81,89,90,92,93,102,103
thracyclinechemotherapyinpatientswithpreservedLVEF.85
CMRshouldbeconsideredfortheassessmentof
AnormalLVEFdoesnotexcludeCTRCDanddeformationpara- cardiacfunctionwhenechocardiographyis IIa C
meterscandetectearlysystolicimpairmentwithsufficienttestreli-
unavailableornon-diagnostic.83,104,105
ability.86–89
Determination of GLS using speckle tracking is
MUGAmaybeconsideredwhenTTEisnot
recommended at baseline, using three apical views,90 particularly diagnosticandCMRisnotavailable.106–108 IIb C
in moderate- and high-risk patients. Baseline GLS can predict
LVD89–94
in patients receiving anthracyclines and/or trastuzumab.
Baselinecardiacimagingpriortopotentiallycardiotoxic
therapiesc
Strain measurements may be subject to inter-vendor variability95
BaselinecomprehensiveTTEisrecommendedin and serial GLS measurement for each patient is recommended to
allpatientswithcancerathighriskandveryhigh be performed using the same machine/software. A median GLS I C
riskofCVtoxicitybeforestartinganticancer
changeof13.6%predictedafuturefallinLVEFwitha95%upperlimit
ofGLSreductionof15%.93Usingthe15%cut-offimprovesspecifi- therapy.d,54
cityandisthereforethethresholdrecommendedwhenmonitoring 3D, three-dimensional; CMR, cardiac magnetic resonance; CTR-CVT, cancer
GLSduringcancertherapy.Globalcircumferentialstrain96hasbeen therapy-relatedCVtoxicity;CV,cardiovascular;GLS,globallongitudinalstrain;LVEF,
leftventricularejectionfraction;MUGA,multigatedacquisitionnuclearimaging;TTE,
reportedtoidentifypatientsatriskofCTRCD,butdataarecurrently
transthoracicechocardiography.
insufficient to recommend its use routinely. Baseline LV diastolic aClassofrecommendation.
functionmaybeassociatedwithasmallriskofsubsequentsystolic bLevelofevidence.
cSpecificrecommendationsforbaselineCVimaginginpatientswithcanceratlowor
dysfunction, especially with anthracyclines and trastuzumab, al-
moderateriskofCTR-CVTareincludedinSection5.
thoughtheevidenceisnotconsistent.97,98Chestcomputedtomog- dExceptasymptomaticpatientsreferredtobreakpointclusterregion-Abelsononcogene
raphy(CT)orCMRmaybehelpfulforidentifyingsubclinicalCVD locustherapy(BCR-ABL)wherebaselineTTEshouldbeconsidered(seeFigure7
andSection5.5.5).
suchascoronarycalciumorintracardiacmassesonreadilyavailable
routineimagingperformedforcancerstaging.99
Inthesecondarypreventionsettingorpatientswithsymptomsor
4.6.Cardiopulmonaryfitnessassessment
signsofpre-existingCVD,acarefulevaluationshouldbeginwitha Maximalcardiopulmonaryexercisetesting(CPET)assessestheinte-
comprehensive TTE.73 This is both to obtain baseline assessment grativecapacityoftheCVsystemtotransportoxygenandenergy
asintheprimarypreventionsettingandtodeterminetheseverity substratetoskeletalmuscleduringexercise,109describedascardio-
of the underlying CVD. In case of poor-quality or uninterpretable respiratoryfitness(CRF).CPETcanthereforeprovideamoreglobal
TTE images, or if a specific CVD is identified (e.g. hypertrophic assessment of CV health than organ-specific tools. CPET-derived
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 26 ---
4254 ESCGuidelines
CRF—typically measured as the peak rate of oxygen consump- dysfunction.37,126–128 It should be noted that with the advent of
tion110,111 or metabolic equivalents111,112 during exercise—is one immunotherapies,germlinegenesmaynotbetheonlygeneticpre-
of the most robust predictors of CV health and longevity,113,114 dispositionstoCTR-CVT.AstudyofpatientswithICI-associated
and improves risk classification.115–121 Evidence for CPET pre- myocarditis identified that the selective clonal T-cell populations
treatment is limited to pre-operative risk stratification particularly infiltratingthemyocardiumwereidenticaltothosepresentintu-
forpatientswithlung,122colon,123andrectal124cancers.Whether moursandskeletalmuscle,withribonucleicacidsequencingstud-
CPETperformedpriortocardiotoxiccancertherapiesisprognostic iesrevealingexpressionofcardiac-specificgenesinthetumour,129
offutureCVeventsisunknown. raisingthe intriguing possibilitythat somatic mutationsin thetu-
mouritselfcouldcontributetoCTR-CVT.Alistofgeneticvariants
4.7. Cardiovascular risk evaluation associated with CVD during cancer therapy is provided
before cancer surgery (Supplementarydata,TableS9)andhasrecentlybeenreviewed.38
Cancer surgery remains the primary treatment modality for many RoutineuseofgenetictestingfortheassessmentofCTR-CVTrisk
cancers.Cardio-oncologyteamsshouldbeinvolvedinpre-operative priortoinitiationofcancertherapyisnotcurrentlyrecommended.
CV risk stratification to identify and provide appropriate manage- Inthefuture,apersonalizedgeneticapproachmayhelpdefineindi-
mentandsurveillanceofthepotentialriskfactors.5 vidual susceptibility to CVD in patients with cancer and more re-
In patients undergoing oncological surgery, peri-operative car- searchisrequired.
diaccomplicationsaredeterminedbypatient-relatedriskfactors,
thetumourtype,concomitantcancertherapies,andtheexpected
surgicalrisk.Toensuresafecancersurgery,consultationsshould 5. Prevention and monitoring of
bedirectedat:(1)patientswithprevioussignificantorsymptom-
cardiovascular complications
atic CVD; (2) patients at high and very high CV toxicity risk, ac-
cording to baseline HFA-ICOS risk assessment tools,12 when during cancer therapy
adjuvant (post-surgery) cancer treatment is planned; and (3) pa-
tients who have received neoadjuvant (prior to surgery) cancer 5.1. General principles
therapythatispotentiallycardiotoxic.Pre-operativeclinicalevalu- CTR-CVTriskmayvaryaccordingtocancertypeandstage,antic-
ationshouldnotdelaysurgery.Complementarytestsrequiredfor ancerdrugs,doses,andunderlyingcomorbidities.Certaintherapy
thepatientsincludedingroups1and2shouldbeguidedbygeneral combinations(drug–drugordrug–radiation)mayhaveasynergis-
ESC Guidelines.125 However, in group 3 patients, the pre- ticallytoxiceffectontheheart,possiblydependingonthetiming
operativeevaluationshould beaimedatconfirmingthatnorele- of these therapies (sequential or concomitant) and previous co-
vant events have occurred during CV monitoring (Section 5). morbidities.ThepathophysiologyofCTR-CVTisoutofthescope
Table 6 summarizes factors that could influence peri-operative of this guideline and is extensively reviewed in the ESC
riskduringcancersurgery. CardioMedtextbook.130
CVD and cancer share common modifiable and non-modifiable
4.8. Genetic testing risk factors (Figure 3).4,131,132 The first step is to optimize lifestyle
Candidate gene and genome-wide association studies have re- CVRF,smokingcessation,restrictingalcoholconsumptiontoamax-
sultedintheidentificationof40candidategenesandsinglenucleo- imum of 100g per week, and maintaining adequate physical activ-
tidepolymorphismsassociatedwithanthracycline-relatedcardiac ity.30 Exercise prescription seems to be a promising treatment to
Table6 Factorsthatcouldinfluenceperi-operativeriskduringcancersurgeryandpreventivestrategies
Factorsthatcouldinfluenceperi-operativeriskduringcancersurgery Preventivestrategies
Patient-related (cid:129) Lifestyleriskfactors:smoking,obesity,sedentarylifestyle (cid:129) OptimalmanagementofCVRFand
factors (cid:129) PoorlycontrolledCVRF:hypertension,DM CVD(Section5)
(cid:129) Pre-existingCVDincludingCTR-CVT (cid:129) OptimizeVTEandATEpreventive
(cid:129) Cardiacmedicationsthatincreaseperi-operativebleedingrisk(e.g.antiplateletsand strategies(Section6)
anticoagulants)
(cid:129) Historicalprimarymalignancy
(cid:129) Currentcancertype,stageandlocation
Neoadjuvantcancer (cid:129) Neoadjuvantcardiotoxiccancertreatments(seeSection5;especiallyanthracycline (cid:129) EnsureoptimalCVmonitoringof
therapy chemotherapyand/ortrastuzumab,ICI,VEGFi,fluoropyrimidine,andthoracicRT) neoadjuvanttherapy(Section5)
(cid:129) Cancertreatmentsthatincreaseperi-operativebleedingrisk(e.g.VEGFi,BTK (cid:129) OptimizeVTEandATEpreventive
inhibitors)
strategies(Section6)
(cid:129) Thrombocytopaeniacausedbycancertreatment
ATE,arterialthromboembolism;BTK,Brutontyrosinekinase;CTR-CVT,cancertherapy-relatedcardiovasculartoxicity;CV,cardiovascular;CVD,cardiovasculardisease;CVRF,
cardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous
thromboembolism.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 27 ---
ESCGuidelines 4255
counteractanticancertreatmentsideeffectsanddifferenttypesof Poor CRF is associated with a higher prevalence of acute and
trainingcanbeprescribedduringcancertherapyaccordingtoapa- chronic CTR-CVT and exercise positively impacts CRF during
tient’sindividualcharacteristics.133Ahealthylifestyledecreasesthe chemotherapy,althoughinarecentmeta-analysis,theabilityofexer-
risksofcancer,CVD,andtransitionfromdiagnosedcancertosubse- cisetopreventCTRCDisunclear.136,137CVRFmustbecorrected
quentCVD.134,135 with intensive treatment of arterial hypertension,138 DM,139 and
Primary and secondary cancer-therapy related CV toxicity prevention strategies
Management of CVD and CVRF
Primary vs secondary prevention
according to ESC Guidelines
Baseline CV risk
assessment
In patients at high and very high
1°prevention risk of CTRCD
Minimize the use of cardiotoxic drugs
2°prevention
ACE-I/ARB and beta-blockers
Dexrazoxane/liposomal anthracyclines
(patients treated with anthracyclines)
Statins
1st cancer requiring cardiotoxic cancer therapy
2nd cancer requiring cardiotoxic cancer therapy
CVD
CTR-CVT Class I Class IIa
Figure9Primaryandsecondarycancertherapy-relatedcardiovasculartoxicityprevention.ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angio-
tensinreceptorblockers;CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfactors;CTR-CVT,cancertherapy-relatedcardiovascular
toxicity;CTRCD,cancertherapy-relatedcardiacdysfunction;ESC,EuropeanSocietyofCardiology.12Leftpanelrepresentsexamplesoffivedifferentprimary
orsecondarypreventionstrategiesdefinitionbasedonthehistoryofpre-existingCVDand/orpriorCTR-CVT.Rightpaneldescribesgeneralstrategiesto
mitigateCTR-CVTriskinpatientsathighandveryhighriskofCTRCD.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 28 ---
4256 ESCGuidelines
dyslipidaemia,140andunderlyingCVDandmodifiablecomorbidities Pegylated and non-pegylated liposomal doxorubicin164,165,168
shouldbemanagedaccordingtoappropriate2021ESCGuidelines modify pharmacokinetics and tissue distribution without com-
onCVDpreventioninclinicalpractice(Figure9).19 promisingantitumourefficacy.Pegylatedandnon-pegylatedliposo-
Special attention should also be paid to the polypharmacy fre- mal doxorubicin are approved for metastatic BC and pegylated
quently seen in patients with cancer, reducing the use of drugs liposomal doxorubicin is also approved for advanced ovarian can-
that may interfere with cancer therapies to the essential and ac- cer, acquired immune deficiency syndrome-related Kaposi sar-
tively monitoring their CV side effects and drug–drug interac- coma, and MM. In a recent meta-analysis of 19 trials, in both the
tions.141 Electrolyte imbalances such as hypokalaemia and adjuvant and metastatic context, liposomal doxorubicin was re-
hypomagnesaemiashouldbecorrected.TheCVriskmanagement ported to be less cardiotoxic than conventional doxorubicin.165
plan should be shared with the cancer specialist team, the pri- Liposomal daunorubicin is also available for acute leukaemia pa-
mary care physician, and the patient to coordinate treatment tients in place of daunorubicin when pre-existing LVD is
strategies. present.164,165
5.2. Primary prevention strategies
5.2.2.Primarypreventionofradiation-induced
PrimarypreventionofCTR-CVTaimstoavoidorminimizethede- cardiovasculartoxicity
velopment of CV damage due to therapy in patients without PrimarypreventionofRT-induceddamagetotheCVsystemde-
CVD12,142 and requires a multidisciplinary team (MDT) discussion pendsontechnologicaladvancesthatallowimprovedtargetingof
between oncologists and cardiologists for complex patients with RTdelivery,therebymaintainingorincreasingoncologicalefficacy
cancerwithmultiplecomorbidities.4,21,22,43,143,144 while reducing CTR-CVT.169,170 Modern techniques strive to
minimize the mean heart dose (MHD), either by shaping the
5.2.1.Primarypreventionofcancer
dose distribution (intensity-modulated RT) or by using respira-
therapy-relatedcardiovasculartoxicityduring tory management (gating or breath-hold).171,172 Proton therapy
anthracyclinechemotherapy
offersthepotentialtofurtherdecreaseexposuretosurrounding
Neurohormonaltherapiesduringanthracyclinechemotherapy(with healthy organs.173 However, complete cardiac avoidance is not
orwithoutsubsequenttrastuzumabtreatment)reducedtheriskof always possible due to the proximity of the tumour (e.g. central
significantLVEFdeclineduringfollow-upinseveralsmallrandomized
lung tumours, mediastinal lymphomas, irradiation of the internal
controlled trials (RCTs) (Supplementary data, Table
S10).145–154
mammary chain in BC). In patients where RT only has a consoli-
Recentmeta-analysesincludingpatientswithcancertreatedwithan- datingroleandtheriskofRT-inducedCVinjuryisveryhigh(e.g.
thracycline chemotherapy and HER2-targeted therapies reported due to baseline risk factors), a MDT is needed to consider the
thatrenin–angiotensin–aldosteronesystemblockers,beta-blockers, risk/benefit of RT.171,174
andmineralocorticoidreceptorantagonistshaveasignificantbenefit
TherearenoprovenmedicaltherapiestopreventRT-inducedCV
inpreventingLVEFreduction,butnostatisticaldifferencesinthein- toxicity.OnecomponentofRT-inducedCVtoxicityisaccelerating
cidenceofovertHForotherclinicaloutcomesweredemonstrated pre-existing CAD, and therefore tight control of CVRFs is
(Supplementarydata,TableS11).155–160Thismaybedue,inpart,to
recommended.
thefactthatmosttrialsincludedpatientswithalowbaselineCTRCD
riskandthereforelargerRCTsareneededinhigh-riskpopulations.
RecommendationTable5—Recommendationsfor
Fromtheoncologicalperspective,somestrategiesthathavebeen
primary prevention of cancer therapy-related car- investigated include managing anthracycline-related toxicity by ad-
diovasculartoxicity
justingtheinfusiontimeanddoseintensity.161Dexrazoxaneandlipo-
somalanthracyclinesarecurrentlyapprovedinpatientswithhighand Recommendations Classa Levelb
veryhighCTRCDriskorwhohavealreadyreceivedhighcumulative
anthracyclines
doses.158,162–167
Dexrazoxane is protective against
ManagementofCVRFaccordingtothe2021ESC
GuidelinesonCVDpreventioninclinicalpractice
anthracycline-induced CTRCD. Currently, dexrazoxane is formally I C
isrecommendedbefore,cduring,andaftercancer
approved in adult patients with advanced or metastatic BC who
therapy.19
havealreadyreceivedaminimumcumulativeanthracyclinedoseof
300mg/m2 of doxorubicin or equivalent (Table 5; Supplementary Dexrazoxaneshouldbeconsideredinadult
data,TableS12).163Inclinicalpractice,dexrazoxaneinfusion(dosage patientswithcancerathighandveryhighCV
IIa B
ratiodexrazoxane/doxorubicinis10/1;e.g.500mg/m2dexrazoxane toxicityriskwhenanthracyclinechemotherapyis
per 50mg/m2 doxorubicin) should be considered (at least 30 min indicated.d,158
priortoeachanthracyclinecycle)inadultpatientswithcancersched- Liposomalanthracyclinesshouldbeconsideredin
uledtoreceiveahightotalcumulativeanthracyclinedoseforcurative adultpatientswithcancerathighandveryhighCV
IIa B
treatment,andinpatientswithhighandveryhighCTRCDrisk(in- toxicityriskwhenanthracyclinechemotherapyis
cluding those with pre-existing HF or low-normal or reduced indicated.e,164,165,168
LVEF)whereanthracyclinechemotherapyisdeemedessential.163 Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 29 ---
ESCGuidelines 4257
5.4. Cardiovascular surveillance during
ACE-IorARBandbeta-blockersrecommended
forHFfshouldbeconsideredforprimary cancer therapies
preventioninhigh-andveryhigh-riskpatients IIa B A careful clinical evaluation and physical examination is recom-
receivinganthracyclinesand/oranti-HER2 mendedduringcancertreatmenttodetectearlysignsandsymptoms
therapies.145,150,155–157,159,160,175
ofCTR-CVT.ECGmonitoringisrequiredinpatientsatriskofcar-
ACE-IorARBandbeta-blockersrecommended diacarrhythmiasaccordingtospecificdrugprotocols.
forHFfshouldbeconsideredforprimary
preventioninhigh-andveryhigh-riskpatients IIa C 5.4.1.Cardiacserumbiomarkers
receivingtargetedcancertherapiesthatmaycause
Duringtherapy,NPandcTnshouldbeusedforCTRCDscreening
HF.g anddiagnosisandtheymayalsoservetoguidetherapy.55,63,191–194
Statinsshouldbeconsideredforprimary The release of cTn and NP differ for different cancer treatments.
preventioninadultpatientswithcancerathigh IIa B Therefore, anincreaseinbiomarkerlevel shouldbeinterpreted in
andveryhighCVtoxicityrisk.h,149,176–185
the patient clinical context (cancer treatment timing and
comorbidities).
ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angiotensinreceptorblockers;
CV,cardiovascular;CVD,CVdisease;CVRF,CVriskfactors;ESC,EuropeanSociety Itisimportanttoconsiderthatgenerallyacceptedcut-offsandref-
of Cardiology; HER2, human epidermal receptor 2; HF, heart failure; HFA, Heart erencevaluesofCVbiomarkershavenotbeenestablishedforpa-
Failure Association; ICOS, International Cardio-Oncology Society; MEK,
tients with cancer or for those who receive cancer therapies. In
mitogen-activated extracellular signal-regulated kinase; PI, proteasome inhibitors;
RAF, rapidly accelerated fibrosarcoma; VEGFi, vascular endothelial growth factor addition,levelsofNPandcTnmaydifferaccordingtolocallabora-
inhibitors. toriesandmaybealteredbymanyfactors,includingage,sex,renal
aClassofrecommendation.
bLevelofevidence. function, obesity, infections, and comorbidities such as AF and
cWithoutdelayingcancertreatments. pulmonaryembolism(PE).53,63,195–197
dAspertheEuropeanMedicineAgency:≥350mg/m2doxorubicinorequivalent;asperthe
UnitedStatesFoodandDrugAdministration:≥300mg/m2doxorubicinorequivalent.
eSeeSection5.2.1forspecificliposomaldoxorubicintypeandmalignancies. 5.4.2.Cardiacimaging
fCarvedilol(preferredbeta-blockerforCVprotectionifthereisnocontraindication),186
Cardiacimagingplaysacriticalroleinclinicaldecision-makingduring
b gVis Eo Gpr Fo ilo al n, dco bn etr vo al cle izd u/ mex at be ,nd Re Ad F-re inle ha is be itom re ,to Mp Er Kolo il ns hu ibc ic ti on ra ,te Pa I,nd dan se ab tii nv io bl ,ol p.
onatinib, and
thecancerprocess.72,198Imagingtechniques—particularlyadvanced
osimertinib. echocardiographyandCMR—facilitateearlydiagnosisandmanage-
hAccordingtoHFA-ICOSriskassessmenttools(Section4.1;Table4). mentofCTR-CVT.22,54,94Thefrequencyofcardiacimagingmonitor-
ing during therapy should be adapted according to the estimated
baselinerisk12andtheexpectedCTR-CVTmanifestation.54Thecar-
5.3. Secondary prevention strategies
diacimagingtechniqueusedshouldbebasedonlocalexpertiseand
Secondary prevention refers to interventions in patients with pre- availability, and the same imaging modality (i.e. 3D-TTE, 2D-TTE,
existing CVD, including prior CTR-CVT, and new emerging CMR)isrecommendedthroughouttheentiretreatmenttodecrease
CTR-CVTduringcancertherapy.CVDandcomorbiditiesshouldre- inter-technique variability.94,199,200 Cardiac imaging should be per-
ceivetheoptimaltherapybeforeandduringcancertherapyasdis- formedatanytimeifpatientsreceivingcardiotoxictherapiespresent
cussed in previous sections. Regular clinical assessments, physical withnewcardiacsymptoms.
examinations, and CV investigations (including 12-lead ECG, TTE, New definitions of CTRCD are presented in Section 3.1 Early
andcardiacbiomarkers)arerecommendedinpatientsreceivingspe- recognitionofasymptomaticCTRCDallowsclinicianstoincorp-
cificcardiotoxiccancertherapies,withthefrequencyofsurveillance oratecardioprotectivetherapybeforethereisasignificantdecline
guided by baseline risk and the emergence of new inLVEF,whichmayormaynotbereversible,andalsodecreases
CTR-CVT.5,12,33,53,54,187–190 theriskofinterruptionsincancertherapy,whichcouldotherwise
affect patients’ survival.22,43,72,94 For the diagnosis and manage-
Recommendation Table 6 — Recommendation for
mentofasymptomaticCTRCDduringcancertreatment,TTE—in-
cluding3D-LVEFandGLSassessment—isthepreferredtechnique
secondary prevention of cancer therapy-related car-
diovasculartoxicity to detect and confirm cardiac dysfunction.72,83,93,102 GLS evalu-
ation is particularly important in patients with low-normal LVEF
Recommendation Classa Levelb to confirm or not asymptomatic myocardial damage.201 It is re-
commendedtousethesamevendortoanalyseGLSduringcancer
ManagementofCVDaccordingtoapplicableESC
treatmenttoaccuratelycomparevaluesovertime.73Therefore,a
Guidelinesisrecommendedbefore,cduring,and I C
relativechangeinGLShasbeensuggestedastheidealtooltoiden-
aftercancertherapy.
tify asymptomatic mild CTRCD.1,4,94 Different thresholds have
CVD,cardiovasculardisease;ESC,EuropeanSocietyofCardiology. been considered in the literature in recent years.93,202,203
aClassofrecommendation.
Currently,arelativeGLSdecreaseof.15%comparedwithbase-
bLevelofevidence.
cWithoutdelayingcancertreatments. line is the recommended threshold as it reflects the 95% upper
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 30 ---
4258 ESCGuidelines
Anthracycline chemotherapy surveillance protocol
3 M 12 M
Baseline C1 C2 C3 C4 C5 C6
post tx post tx
ECG
Low
TTEa
risk
cTnb / NPb
ECG
Moderate
TTEa
risk
cTnb / NPb
ECG
High and
very high TTEa
risk
cTn / NP
Class 1 Class 1Ia Class 1Ib
Figure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy. cTn, cardiac troponin; C, chemotherapy cycle;
ECG, electrocardiogram; M, months; NP, natriuretic peptides; TTE, transthoracic echocardiography; tx, treatment. Biomarker and TTE assessment
shouldideallybeperformedbeforethecorrespondinganthracyclinecycle(C1–C6).aCardiacmagneticresonanceshouldbeconsideredfortheassess-
mentofcardiacfunctionwhenTTEisunavailableornotdiagnostic.Inmoderate-riskpatients,TTEshouldbeconsideredafteracumulativedoseof
≥250mg/m2ofdoxorubicinorequivalent.Inlow-riskpatients,TTEmaybeconsideredafteracumulativedoseof≥250mg/m2ofdoxorubicinorequiva-
lent.bMeasurementofNPand/orcTnisrecommendedinallpatientswithcancerifthesebiomarkersaregoingtobeusedduringtreatmentmonitoring.
cTnandNPmonitoringeverytwocyclesduringanthracyclinechemotherapyandwithin3monthsaftertherapycompletionmaybeconsideredinlow-risk
patients(ClassIIb,LevelC).cTnandNPmonitoringeverytwocyclesduringanthracyclinechemotherapyandwithin3monthsaftertherapycompletion
shouldbeconsideredinmoderate-riskpatientsandinlow-riskpatientsreceivingacumulativedoseof≥250mg/m2ofdoxorubicinorequivalent(ClassIIa,
LevelC).
limitinthemeta-analysisofGLStopredictfuturesignificantLVEF InpatientswithpoorTTEimagequalityorwhenTTEisnotdiag-
reduction.93Usingthe15%thresholdwillmaximizespecificityand nostic, CMR should be considered, including fast strain-encoded
minimize overdiagnosis of CTRCD and guide cardioprotective
CMRwhenavailable.105,204–206MUGAcanbeconsideredasathird-
therapy.1,4,93 linemodality.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 31 ---
ESCGuidelines 4259
5.5. Cancer therapy-related
BaselinemeasurementofNPandcTnshouldbe
cardiovascular toxicity monitoring consideredinlow-andmoderate-riskpatients IIa C
protocols
priortoanthracyclinechemotherapy.211
cTnandNPmonitoringbeforeeverycycleduring
5.5.1.Anthracyclinechemotherapy
anthracyclinechemotherapyand3and12months
Anthracycline-inducedCTRCDisadose-dependentandcumulative I B
aftertherapycompletionisrecommendedinhigh-
process of variable onset that may present with symptomatic or
andveryhigh-riskpatients.55,175,211
asymptomaticCTRCD.4
cTnandNPmonitoringeverytwocyclesduring
Figure 10 summarizes the recommended monitoring protocol
anthracyclinechemotherapyandwithin3months
during anthracycline therapy according to baseline CTRCD risk
aftertherapycompletionshouldbeconsideredin
(Table 4). Clinical assessment combined with cardiac biomarkers IIa C
moderate-riskpatientsandinlow-riskpatients
(cTn and NP) and TTE (including 3D-LVEF and GLS when avail-
receivingacumulativedoseof≥250mg/m2of
able) can identify both symptomatic and asymptomatic CTRCD
doxorubicinorequivalent.55,59,212,213
with a reasonably high negative predictive value. This topic has
cTnandNPmonitoringeverytwocyclesduring
been extensively reviewed in two recent HFA position
statements.53,54 Classifying patients based on their risk of anthracyclinechemotherapyandwithin3months IIb C
aftertherapycompletionmaybeconsideredin anthracycline-inducedCVtoxicityhasallowedtheearlyimplemen-
tation of personalized preventive strategies (Section 5.2.1).14
low-riskpatients.55,59,212,213
Patientswithpre-existingCVDshouldbetreatedwithguideline- cTn,cardiactroponin;NP,natriureticpeptides;TTE,transthoracicechocardiography.
basedmedicaltherapy.14,19,207 aClassofrecommendation.
bLevelofevidence.
cIfechocardiographyisunavailableornon-diagnostic,followgeneralcardiacimaging
Recommendation Table 7 — Recommendations for modalitiesrecommendations(seeSection4.5).
baseline risk assessment and monitoring during an-
thracycline chemotherapy and in the first 12 months
aftertherapy
5.5.2.HER2-targetedtherapies
Recommendations Classa Levelb HER2-targeted therapies are a crucial part of the treatment of
patients with HER2-positive invasive BC in both early and meta-
TTE static settings. In the neoadjuvant and/or adjuvant settings, drugs
Baselineechocardiographycisrecommendedinall currently approved are trastuzumab, pertuzumab, trastuzumab
patientswithcancerbeforeanthracycline I B emtansine, and neratinib. In the metastatic setting, trastuzumab,
chemotherapy.12,24,208–210 pertuzumab, trastuzumab emtansine, tucatinib, and trastuzumab
deruxtecan are currently
approved.214–216
Trastuzumab can
Inalladultsreceivinganthracyclinechemotherapy,
anechocardiogramisrecommendedwithin12 I B also be used in patients with HER2-overexpressing metastatic
monthsaftercompletingtreatment.208 gastric adenocarcinomas in combination with platinum-based
chemotherapy and either capecitabine or 5-fluorouracil (5-FU).
Inhigh-andveryhigh-riskpatients,
It is recognized that anti-HER2 therapies may lead to LVD in
echocardiographyisrecommendedeverytwo
I C up to 15–20% of patients and to overt HF if surveillance is
cyclesandwithin3monthsaftercompleting
treatment.24,208–210 missed, or in high- and
veryhigh-riskpatients.217–220LV
function
surveillance based on LVEF and GLS is recommended prior to
Inmoderate-riskpatients,additional
and every 3 months during HER2-targeted therapies treatment
echocardiographyshouldbeconsideredaftera
IIa C surveillance (Figure 11).22 However, this single algorithm has cumulativedoseof≥250mg/m2ofdoxorubicin
not been tested in low- or high-risk patients and increased fre-
orequivalent.7
quency of assessment (according to local availability) is recom-
Inlow-riskpatients,additionalechocardiography
mended in high-risk patients.
maybeconsideredafteracumulative
IIb C The use of cardiac serum biomarkers to identify CTRCD is
doseof≥250mg/m2ofdoxorubicinor
less well-defined during anti-HER2 treatments.217 Measurement
equivalent.7
of cTn in BC patients after anthracycline-based chemotherapy
Cardiacserumbiomarkers
but prior to trastuzumab should be considered, as an elevated
BaselinemeasurementofNPandcTnis cTn identifies patients at higher risk of trastuzumab-induced
recommendedinhigh-andveryhigh-riskpatients I B CTRCD. Serial NP measurement was more sensitive than cTn
priortoanthracyclinechemotherapy.55,65,211 at predicting subsequent declines in LVEF during trastuzumab
Continued
treatment.74
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 32 ---
4260 ESCGuidelines
HER2-targeted therapy surveillance protocol
3 M 12 M
Baseline 3 M 6 M 9 M 12 M
post tx post tx
ECG
Low and
moderate TTEc
riska
e
cTnd / NPd
ECG
High and
TTEc
very high
riskb
cTn / NP
Class 1 Class 1Ia Class 1Ib
Figure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies. cTn, cardiac troponin; CV,
cardiovascular;EBC,earlybreastcancer;ECG,electrocardiogram;HER2,humanepidermalreceptor2;M,months;NP,natriureticpeptides;TTE,trans-
thoracicechocardiography;tx,treatment.ThisprotocolreferstoCVtoxicitymonitoringinpatientsreceivingneoadjuvantoradjuvantanti-HER2tar-
geted therapies for non-metastatic disease or first year in metastatic disease. Biomarker assessment should ideally be performed before the
correspondingtrastuzumabcycle.TTEshouldbeperformedinweek2or3ofa3-weeklytrastuzumabcycle.aInlow-riskHER2+EBCpatientswho
areasymptomaticandwithanormalassessmentafter3months,reducingTTEmonitoringtoevery4monthsmaybeconsidered(ClassIIb,LevelC).
Inlow-andmoderate-riskmetastaticHER2+disease,TTEsurveillancecanbereducedtoevery6monthsafterthefirstyearinasymptomaticpatients
withnormalTTEassessment(ClassI,LevelC).bInhigh-andveryhigh-riskmetastaticHER2+disease,TTEmonitoringevery2–3cyclesmaybeconsidered
dependingontheabsoluteriskandlocalavailability.cCardiacmagneticresonanceshouldbeconsideredfortheassessmentofcardiacfunctionwhenTTE
isunavailableornotdiagnostic.dMeasurementofNPand/orcTnisrecommendedinallpatientswithcancerifthesebiomarkersaregoingtobeused
duringtreatmentmonitoring.eBaselinecTnmeasurementshouldbeconsideredinlow-andmoderate-riskpatientsafteranthracyclinechemotherapy
butpriortostartinganti-HER2targetedtherapiesforCVtoxicityriskprediction.
For patients requiring adjuvant chemotherapy and Recommendation Table 8 — Recommendations for
anti-HER2-targetedtherapy,theuseofnon-anthracyclinechemo- baseline risk assessment and monitoring during hu-
man epidermal receptor 2-targeted therapies and in
therapy should be considered by the MDT according to
thefirst12monthsaftertherapy
risk of relapse, cardiac risks, and in discussion with the
treating oncologist.217 When anthracycline chemotherapy in the Recommendations Classa Levelb
(neo)-adjuvantsettingisnecessary,sequentialuse(anthracyclines
followed by taxanes and anti-HER2 agents) has been shown TTE
to significantly decrease the incidence of CTRCD in several Baselineechocardiographycisrecommended
I B
adjuvant trials, compared with concomitant use in earlier beforeHER2-targetedtherapiesinallpatients.225
trials.220–224
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 33 ---
ESCGuidelines 4261
Inpatientsreceivingneoadjuvantoradjuvant is up to 10%.232 Among the several mechanisms responsible for
HER2-targetedtherapies,echocardiographyis 5-FU-induced myocardial ischaemia are coronary vasospasm and
I B
recommendedevery3monthsandwithin12
endothelialinjury.233ChestpainandischaemicECGchangesusually
monthsaftercompletingtreatment.225,226 occuratrest(lesstypicallyduringexercise)withindaysofdrugad-
Inlow-riskHER2+EBCpatientsdwhoare ministrationandsometimespersistevenaftertreatmentcessation.
CTR-CVTriskmarkedlyincreasesinpatientswithcancerwithpre-
asymptomaticandwithanormalassessmentafter
IIb C existingCAD.AggressivecontrolofmodifiableCVRFs,accordingto
3months,reducingmonitoringtoevery4months
the2021ESCGuidelinesonCVDpreventioninclinicalpractice,19is
maybeconsidered.
Inhigh-andveryhigh-riskHER2+EBCpatients,d recommended during and after treatment. A baseline TTE is
recommended in patients with a history of symptomatic CV to
morefrequentechocardiographymonitoringe IIa C
confirm the presence of pre-existing regional wall motion
shouldbeconsideredduringtreatment.
abnormalities or LVD. Screening for CAD may be considered in
InmetastaticHER2+disease,echocardiographyis
selectedhigh-andveryhigh-riskpatientsbeforetheadministration
recommendedevery3monthsduringthefirst
of these drugs and according to local protocols and current
year;ifthepatientremainsasymptomaticwithout I C
recommendations.12,234,235
CVtoxicity,thensurveillancecanbereducedto
every6monthsduringfuturetreatment.f
InmetastaticHER2+diseasepatientsathigh-and
Recommendation Table 9 — Recommendations for
veryhigh-risk,morefrequentechocardiography IIb C baselineriskassessmentandmonitoringduringfluor-
monitoringemaybeconsidered. opyrimidinetherapy
Cardiacbiomarkers
Recommendations Classa Levelb
BaselineNPandcTnmeasurementare
recommendedinhigh-andveryhigh-riskpatients I C BaselineCVriskassessmentandevaluation
priortoanti-HER2-targetedtherapies.227,228 includingBPmeasurement,ECG,lipidprofile,
NPandcTnmonitoringevery2–3cyclesduring HbA1cmeasurement,andSCORE2/ I C
therapyand3and12monthsaftertheendof
SCORE2-OPcorequivalentisrecommended19
IIa C
therapyshouldbeconsideredinhigh-andvery
beforestartingfluoropyrimidines.
high-riskHER2+EBCpatients.d,55 Abaselineechocardiogramisrecommendedin
BaselinecTnmeasurementshouldbeconsidered patientswithahistoryofsymptomaticCVD I C
inlow-andmoderate-riskpatients
beforestartingfluoropyrimidines.
IIa A post-anthracyclinechemotherapybutpriorto ScreeningforCADdmaybeconsideredinpatients
startinganti-HER2-targetedtherapies.55,62 athighandveryhighriskofCADcbefore IIb C
NPandcTnmonitoringatbaseline,every3
fluoropyrimidines.
months,and12monthsaftertherapymaybe
IIb C BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVD,
consideredinlow-andmoderate-riskHER2+ cardiovascular disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
EBCpatients.d,55 SCORE2,SystematicCoronaryRiskEstimation2;SCORE2-OP,SystematicCoronary
RiskEstimation2—OlderPersons.
BC,breastcancer;cTn,cardiactroponin;CV,cardiovascular;EBC,earlybreastcancer;
aClassofrecommendation.
HER2, human epidermal receptor 2; NP, natriuretic peptides; TTE, transthoracic
bLevelofevidence.
echocardiography.
cSCORE2(,70years)orSCORE2-OP(≥70years)CVriskstratification:,50years:
aClassofrecommendation. lowrisk,2.5%,moderaterisk2.5%to,7.5%,highrisk≥7.5%;50–69years:lowrisk
bLevelofevidence. ,5%; moderate risk 5% to,10%; high risk ≥10%; ≥70 years: low risk,7.5%,
cIfechocardiographyisunavailableornon-diagnostic,followgeneralcardiacimaging moderaterisk7.5%to,15%,highrisk≥15%.
modalitiesrecommendations(seeSection4.5).
dAccordingtopre-existingCVDandlocalprotocols.234
dTheserecommendationsarealsoapplicableforHER2+non-BCpatients.
eEvery2–3cyclesdependingontheabsoluteriskandlocalavailability.
fPatientsatlowandmoderaterisk.
5.5.4.Vascularendothelialgrowthfactorinhibitors
Aberrantactivationofkinasesplaysacriticalroleinboththedevel-
5.5.3.Fluoropyrimidines opmentofnumerouscancertypesandinCVandmetabolichomeo-
Fluoropyrimidines such as 5-FU and its oral prodrug capecitabine stasis. Inhibition of the VEGF signalling pathway is achieved with
aremainlyusedforgastrointestinal(GI)malignanciesandadvanced either monoclonal antibodies (administered i.v.) against circulating
BC. The most common CTR-CVTs are angina pectoris, VEGForwithsmall-moleculeTKI(takenorally)targetingVEGFre-
ischaemia-relatedECGabnormalities,hypertension,Takotsubosyn- ceptors.236VEGFiareusedforthetreatmentofnumerouscancer
drome(TTS),andMI(eveninpatientswithnormalcoronaryarter- types, including renal, thyroid, and hepatocellular carcinomas.
ies),1,4,10,43,229,230 with rarer CTR-CVT including myocarditis, However,theiruseisassociatedwithawidearrayofCVcomplica-
arrhythmias,andperipheralarterialtoxicity(Raynaud’sphenomenon tionsincludinghypertension,HF,QTcprolongation,andacutevascu-
andischaemicstroke).231Theincidenceofmyocardialischaemiavar- lar events (Figure 12).131,237–240 It can be challenging to assess the
iesaccordingtothedose,scheduling,androuteofadministrationand prognosis of patients experiencing severe CV side effects because
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 34 ---
4262 ESCGuidelines
VEGFi-related cardiovascular toxicities
HTN HF QTc VTE ATE MI
Monoclonal antibodies
Aflibercept
Bevacizumaba
Ramucirumaba
VEGFTKI
Axitinib
Cabozantinib
Lenvatinib
Pazopanib
Regorafenib
Sorafenib
Sunitinib
Vandetanib
Very common:≥10% incidence Uncommon: 0.1% to < 1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure12Vascularendothelialgrowthfactorinhibitors-relatedcardiovasculartoxicities.ATE,arterialthromboembolism;EMA,EuropeanMedicines
Agency;FDA,FoodandDrugAdministration;HF,heartfailure;HTN,hypertension;MedDRA,medicaldictionaryforregulatoryactivities;MI,myocardial
infarction;↑QTc,correctedQTintervalprolongation;TKI,tyrosinekinaseinhibitors;VEGF,vascularendothelialgrowthfactor;VEGFi,vascularendothe-
lialgrowthfactorinhibitors;VTE,venousthromboembolism.Adversereactionsreportedinmultipleclinicaltrialsorduringpost-marketingusearelisted
bysystemorganclass(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromtheavailabledata,ablankspacehasbeenleft.
aBevacizumab:hypertensionfrequency5–42%(EMA);60–77%ofthepatientswhoreceivedbevacizumabincombinationwitherlotinib.Pre-existing
hypertensionshouldbeadequatelycontrolledbeforestartingtreatment.Ramucirumab:hypertensionfrequency16–26%(EMA/FDA);incombination
witherlotinib,theincidenceofhypertensionwas24–45%.Patientswithuncontrolledhypertensionwereexcludedfromthetrials.Figuredeveloped
fromEMAprescribinginformation,252FDAprescribinginformation.253
thesedrugsareoftenusedinpatientswithadvancedcancer.Thegoal LVDandHFoccurinaminorityofpatientsinRCTs,245butarere-
mustbetocontinueVEGFitreatmentforaslongaspossiblewithini- portedmorefrequentlyinroutinepractice246andareoftenrevers-
tiationoroptimizationofCVtreatmentifindicated. ible.247 Acute arterial events (aortic dissection, stroke, arterial
Hypertension is a class effect and is the most reported adverse thrombosis, acute coronary events, vasospasm) and venous
eventunderVEGFitreatment.Itoccurswithinhoursordays,isdose- thromboembolism (VTE) can also complicate treatment with
dependent, and is usually reversed by VEGFi discontinu- VEGFi.248QTcprolongationhasbeendescribedwithsunitinib,sor-
ation.131,239,241–243 The risk is higher in patients with pre-existing afenib,andvandetanib,249butitisrarelyrelatedtoseverearrhythmic
hypertension or CVD, previous anthracycline treatment, advanced events, except with vandetanib.250 Some small-molecule TKI (e.g.
age,historyofsmoking,hyperlipidaemia,and/orobesity(Table4).4,244 sorafenibandsunitinib)cancauseAF251andHF.43,129,247
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 35 ---
ESCGuidelines 4263
A baseline CV risk assessment includes clinical examination, BP recommendedforhigh-andveryhigh-riskpatients.14Patientswith
measurement,andanECGwithbaselineQTcFmeasurement(see impairedLVfunctionand/orpatientsathighorveryhighriskofde-
Section 4).20 Especially in patients with known hypertension, BP veloping HF should be referred to the cardiologist before starting
should be controlled before VEGFi therapy. A baseline TTE is VEGFitherapy.14
VEGFi surveillance protocol
Every
Baseline 3 M 4 M 6 M 8 M 9 M 12 M
6–12 M
ECGa
Low
risk
TTEb
ECGa
Moderate
TTEb
risk
NPc
ECGa
High and
very high TTEb,d
risk
NPc,d
Class 1 Class 1Ia Class 1Ib
Figure13Cardiovasculartoxicitymonitoringinpatientsreceivingvascularendothelialgrowthfactorinhibitors.ECG,electrocardiogram;M,months;
NP,natriureticpeptides;QTc,correctedQTinterval;TTE,transthoracicechocardiography;VEGFi,vascularendothelialgrowthfactorinhibitors.aInpa-
tientstreatedwithVEGFiatmoderateorhighriskofQTcprolongation,ECGisrecommended(ClassI,LevelC)monthlyduringthefirst3monthsand
every3–6monthsthereafter(Section6.4).ConsideranECG2weeksafterstartingtreatmentinhigh-riskpatientsandnewmonitoringinthecaseofany
doseincrease(seeSection6.4.2).bCardiacmagneticresonanceshouldbeconsideredfortheassessmentofcardiacfunctionwhenTTEisunavailableornot
diagnostic.cMeasurementofNPisrecommendedinallpatientswithcancerifthesebiomarkersaregoingtobeusedduringtreatmentmonitoring.dTTE
andNPshouldbeconsideredat4weeksafterstartingtreatmentinveryhigh-riskpatients.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 36 ---
4264 ESCGuidelines
Monitoringduringandaftertreatmentisindicatedforallpatients Echocardiographymaybeconsideredevery4
treatedwithaVEGFiandisbasedoncloseclinicalfollow-upusing monthsduringthefirstyearinmoderate-risk IIb C
serial ECGs, biomarkers, and echocardiography. Early recognition patientsreceivingVEGFiorbevacizumab.
and treatment of hypertension are essential to prevent other CV Echocardiographyshouldbeconsideredevery3
complications,especiallyHF.HomeBPmonitoringisrecommended monthsduringthefirstyearinhigh-andvery
dailyduringthefirstcycle,aftereachincreaseofanticancertherapy
high-riskpatientsreceivingaVEGFior
IIa C
dose, and every 2–3 weeks thereafter.138,254,255 When treatment bevacizumab.e
with a VEGFi is stopped, a drop in BP must be anticipated and Echocardiographyevery6–12monthsshouldbe
BP-loweringtherapymustbereducedand/orinterruptedaccording-
consideredinmoderate-andhigh-riskpatients
IIa C
ly(Section6). withcancerwhorequirelong-termtreatment
InpatientsatriskofQTcprolongation,regularmonitoringofthe withaVEGFi.
QTcintervalisrecommendedafteradoseincrease,wheneverother
Cardiacbiomarker
QT-prolongingagentsareadded,orifelectrolyteimbalancesoccur
NPmaybeconsideredatbaselineandthenevery
(Section6).
4monthsduringthefirstyearinmoderate-risk IIb C
Patients treated with a VEGFi must also be screened regu-
patientsreceivingaVEGFi.
larly for symptoms and clinical signs of HF. Regular NP meas-
NPshouldbeconsideredatbaseline,4weeks
urement and echocardiography can be useful for the
afterstartingtreatment,andthemevery3months
detection of CTRCD, although evidence is weak IIa C
(Figure 13).138,254,255
duringthefirstyearinhigh-andveryhigh-risk
patientsreceivingaVEGFi.
BP,bloodpressure;ECG,electrocardiogram;NP,natriureticpeptides;QTc,corrected
QTinterval;QTcF,correctedQTintervalusingFridericiacorrection;VEGFi,vascular
RecommendationTable10—Recommendationsfor endothelialgrowthfactorinhibitors.
baselineriskassessmentandmonitoringduringvascu-
aClassofrecommendation.
bLevelofevidence.
larendothelialgrowthfactorinhibitors
cQTcintervalusingFridericiacorrection(QTcF=QT/3√RR)isthepreferredmethod.
dConsider an ECG 2 weeks after starting treatment in high-risk patients and new
Recommendations Classa Levelb monitoringinthecaseofanydoseincrease(seeSection6.4.2).
eAnadditionalechocardiography4weeksafterstartingtreatmentshouldbeconsidered
BPmonitoring inselectedhigh-andveryhigh-riskpatientsaccordingtolocalavailability,especiallyif
cardiacbiomarkersurveillanceisnotavailable.
BPmeasurementisrecommendedforpatients
treatedwithVEGFi,bevacizumab,or I C
ramucirumabateveryclinicalvisit.
5.5.5.Multitargetedkinaseinhibitorstargeting
DailyhomemonitoringofBPforpatientstreated BCR-ABL
withVEGFiduringthefirstcycle,aftereach
I C Chronic myeloid leukaemia (CML) results from aberrant acti-
increaseofVEGFidose,andevery2–3weeks
vation of ABL1 kinase due to a chromosomal translocation.
thereafterisrecommended. Small-molecule TKIs targeting BCR-ABL—including imatinib,
ECGmonitoring bosutinib, dasatinib, nilotinib, and ponatinib—have proven ef-
InpatientstreatedwithVEGFiatmoderateor fective in the treatment of CML. The toxicities associated
highriskofQTcprolongation,QTccmonitoringis with these TKIs are unique and due to ‘off-target’ effects of
I C
recommendedmonthlyduringthefirst3months each drug. Dasatinib is associated with group 1 pulmonary
andevery3–6monthsthereafter.d hypertension (PH), HF, and pleural and pericardial effusion,
Echocardiography whereas nilotinib and ponatinib are generally associated
with vascular events (Figure
14).131,256–259
Second-
Baselineechocardiographyisrecommendedin
generation BCR-ABL TKI may induce a QTc prolongation
high-andveryhigh-riskpatientstreatedwith I C
(see Section 6.4.2). CV toxicity risk is higher in patients
VEGFiorbevacizumab.
aged .65 years (relative risk 1.8) and in those with under-
Baselineechocardiographyshouldbeconsidered
lying DM (relative risk 2.5), hypertension (relative risk 3.2) or
inlow-andmoderate-riskpatientstreatedwitha IIa C
pre-existing CAD (relative risk
2.6).256–258,260
Before
VEGFiorbevacizumab.
BCR-ABL TKI therapy, it is critical to define baseline CV tox-
Continued
icity risk with special attention to BP, glucose, and lipids.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 37 ---
ESCGuidelines 4265
BCR-ABLTKI-related cardiovascular toxicities
HTN QTc AF HF HG DL Peric-E Pleu-E PH VascTox
1st generation
BCR-ABLTKI
Imatinib
2nd generation
BCR-ABLTKI
Nilotinib
Dasatinib
Bosutinib
3rd generation
BCR-ABLTKI
Ponatinib
Very common:≥10% incidence Uncommon: 0.1% to < 1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure14Breakpointclusterregion–Abelsononcogenelocustyrosinekinaseinhibitor-relatedcardiovasculartoxicities.AF,atrialfibrillation;BCR-ABL,
breakpointclusterregion–Abelsononcogenelocus;DL,dyslipidaemia;EMA,EuropeanMedicinesAgency;FDA,FoodandDrugAdministration;HF,heart
failure;HG,hyperglycaemia;HTN,hypertension;MedDRA,medicaldictionaryforregulatoryactivities;MI,myocardialinfarction;PAD,peripheralartery
disease;Peric-E,pericardialeffusion;PH,pulmonaryhypertension;Pleu-E,pleuraleffusion;↑QTc,correctedQTintervalprolongation;TKI,tyrosinekinase
inhibitors;VascTox,vasculartoxicity(stroke,MI,PAD).Adversereactionsreportedinmultipleclinicaltrialsorduringpost-marketingusearelistedby
systemorganclass(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromtheavailabledata,ablankspacehasbeenleft.261
FiguredevelopedfromEMAprescribinginformation,252FDAprescribinginformation.253
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 38 ---
4266 ESCGuidelines
Second and third generation(cid:2)BCR-ABLTKI surveillance protocol
Every
Baseline 3 M 6 M 9 M 12 M
6–12 M
Physical Bosutinib
examinationa Dasatinib
Nilotinib
BP
Ponatinib
ECG Bosutinib
Dasatinib Nilotinib
Nilotinib Ponatinib
Lipid profile/
HbA1c Ponatinib
Nilotinib Nilotinib Nilotinib
ABI
Ponatinib Ponatinib Ponatinib
TTE Dasatinib
High and very high risk patients Dasatinib
Bosutinib
treated with dasatinib or ponatinib Ponatinib
Nilotinib
Ponatinib
Class 1 Class 1Ia Class 1Ib
Figure15Second-andthird-generationbreakpointclusterregion–Abelsononcogenelocustyrosinekinaseinhibitorssurveillanceprotocol.ABI,ankle–
brachialindex;BCR-ABL,breakpointclusterregion-Abelsononcogenelocus;BP,bloodpressure;CV,cardiovascular;ECG,electrocardiogram;HbA1c,
glycatedhaemoglobin;M,months;TKI,tyrosinekinaseinhibitors;TTE,transthoracicechocardiography.aCoronaryarterycalciumscoringcanreclassify
CVriskupwardsanddownwardsinadditiontoconventionalriskfactors,andmaybeconsideredinmenandwomenwithcalculatedCVriskaround
decisionthresholds.19
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 39 ---
ESCGuidelines 4267
Baseline ECG is recommended in all patients and QTc mon- oral inhibitor of BTK, has proven highly effective in chronic
itoring in patients treated with second-generation BCR-ABL lymphocytic leukaemia and related B-cell malignancies including
TKI. Depending on the type of therapy used, specific CV as- mantlecelllymphoma,Waldenströmmacroglobulinemia,andmar-
sessments should be performed after drug initiation ginalzonelymphomas.262Thesedisordersareusuallydiagnosedin
(Figure 15).256 elderlypatientsinwhomfrequentcomorbiditiescoexistatdiagno-
sisthatincreasetheriskofCTR-CVT.263,264Ibrutinibhasbeenas-
sociatedwithbleedingdiathesis,infections,andanincreasedriskof
RecommendationTable11—Recommendationsfor hypertension,AF,andHF.265–267Ibrutinibmayalsocauseventricular
baseline risk assessment and monitoring during arrhythmiaswithoutprolongingQT.267,268Acalabrutinibisasecond-
second- and third-generation breakpoint cluster re-
generation BTK inhibitor with greater BTK selectivity. In a recent
gion–Abelson oncogene locus tyrosine kinase
phaseIII,randomized,multicentre,open-label,non-inferioritystudy,
inhibitors
acalabrutinib demonstrated a non-inferior progression-free survival
Recommendations Classa Levelb compared to ibrutinib in patients with previously treated chronic
lymphocytic leukaemia with a lower incidence of symptomatic CV
BaselineCVriskassessmentcisrecommendedin events.269 However, grade ≥3 AF (symptomatic AF where urgent
patientswhorequiresecond-orthird-generation I C interventionisindicated)270andAFinpatients≥75yearsoldorwith
BCR-ABLTKI.256,261
previous AF history were comparable between groups, as was the
Inpatientstreatedwithnilotiniborponatinib,CV risk of CV events in patients with pre-existing CVRFs or CVD.271
riskassessmentcisrecommendedevery3months
I C Therefore,wecurrentlydonothaveenoughdatatoestablishdifferent
duringthefirstyearandevery6–12months
monitoringstrategiesinpatientstreatedwiththesedrugs.
thereafter.256,261
Duetothelackofevidence-basedrecommendations,themanage-
QTcdmeasurementshouldbeconsideredat mentoftheseCVeventsischallenging.264Antihypertensiveinitiation
baseline,at2and4weeksafterstartingnilotinib, IIa C hasbeenassociatedwithalowerriskofamajoradverseCVevents
and2weeksafteranydoseincrease.259 (MACE).264OpportunisticscreeningforAFbypulse-takingorECG
Baselineechocardiographyshouldbeconsidered rhythmstripisrecommendedateveryclinicalvisitduringBTKinhibi-
inallpatientsbeforestartingsecond-and IIa C tortherapy.272
third-generationBCR-ABLTKI. Due to a higher bleeding risk, ibrutinib should be temporarily
Baselineechocardiographyisrecommendedin interrupted in patients requiring dual antiplatelet therapy (DAPT)
I C
patientsscheduledtoreceivedasatinib. and3–7daysbeforeinvasiveprocedures.Incaseofemergencyinter-
Echocardiographyshouldbeconsideredevery3 ventions, platelet transfusion should be considered to minimize
monthsduringthefirstyearinhigh-andvery IIa C bleedingrisks.262
high-riskpatientsreceivingdasatiniborponatinib.
Echocardiographymaybeconsideredevery6–12
monthsinpatientswhorequirelong-term(.12 IIb C
RecommendationTable12—Recommendationsfor
baseline risk assessment and monitoring during
months)ponatinibordasatinib.
Brutontyrosinekinaseinhibitortherapy
Serialassessmentofanklebrachialindexmaybe
consideredtodetectsubclinicalperipheral IIb C Recommendations Classa Levelb
vasculardisease.
BPmonitoringandmanagement
BCR-ABL,breakpointclusterregion–Abelsononcogenelocus;BP,bloodpressure;CV,
BPmeasurementisrecommendedforpatients
cardiovascular;ECG,electrocardiogram;HbA1c,glycatedhaemoglobin;HFA,Heart
Failure Association; ICOS, International Cardio-Oncology Society; QTc, corrected treatedwithBTKinhibitorsateveryclinical I B
QTinterval;QTcF,correctedQTintervalusingFridericiacorrection;TKI,tyrosine visit.264
kinaseinhibitors.
aClassofrecommendation.
WeeklyhomemonitoringofBPduringthefirst3
bLevelofevidence. monthsandeverymonththereaftershouldbe
IIa C
cPhysicalexamination,BPmeasurement,ECG,lipidprofile,andHbA1cmeasurement.
consideredforpatientstreatedwithBTK
CoronaryarterycalciumscoringcanreclassifyCVdiseaseriskupwardsanddownwards
inhibitors.
inadditiontoconventionalriskfactors,andmaybeconsideredatbaselineinlow-and
moderate-riskpatientsasperHFA-ICOSriskassessmenttools.19
Echocardiography
dQTc interval using Fridericia correction (QTcF=QT/3√RR) is the preferred
method. Baselineechocardiographyisrecommendedin
high-riskpatientscscheduledtoreceiveBTK I C
inhibitors.267,268
5.5.6.Brutontyrosinekinaseinhibitors TTEisrecommendedinallpatientswhodevelop I C
AFduringBTKinhibitortherapy.
Bruton tyrosine kinase (BTK) inhibitors are increasingly used to
treatlymphoidmalignancies.Ibrutinib,afirst-in-classirreversible Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 40 ---
4268 ESCGuidelines
5.5.7.Multiplemyelomatherapies
AF
Therearemanyclassesofpharmacotherapythatareapprovedfor
OpportunisticscreeningforAFbypulse-takingor
thetreatmentofMMusingarangeofcombinations.Theseinclude
ECGrhythmstripisrecommendedatevery I C
immunomodulatorydrugs(IMiD),dexamethasone,PI,andmonoclo-
clinicalvisitduringBTKinhibitortherapy.273
nalantibodies(e.g.daratumumab).PI—includingbortezomib,carfil-
AF,atrialfibrillation;BP,bloodpressure;BTK,Brutontyrosinekinase;DM,diabetes zomib, and ixazomib—have become a mainstay of therapy for
mellitus;ECG,electrocardiogram;HF,heartfailure;QTc,correctedQTinterval;TTE, newlydiagnosedMMaswellasrelapseddisease.276,277Severallarge
transthoracicechocardiography;VHD,valvularheartdisease.
aClassofrecommendation. studiesusingcombinationtherapyforMMhavedemonstratedanin-
bLevelofevidence. creasedriskofseriousCVadverseevents.278–281MMpatientsbeing
cMale,age≥65years,previoushistoryofhypertension,DM,QTc≥480ms,AF,HF,
treatedwithPIhaveahighincidenceofcoexistentCVcomorbidities
cardiomyopathy,orsevereVHD.263,274,275
Multiple myeloma drugs-related cardiovascular toxicities
HTN HG/DM HF AF MI VTE PH ATE
Alkylating agents
Cyclophosphamide
Melphalan
Immunomodulatory drugs
Lenalidomide
Pomalidomide
Thalidomide
Proteasome inhibitorsa
Bortezomib
Carfilzomib
Monoclonal antibodies
Daratumumab
Elotuzumab
Isatuximab
Very common:≥10% incidence Uncommon: 0.1% to < 1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure 16Multiplemyelomadrug-relatedcardiovasculartoxicities.AF,atrialfibrillation;ATE,arterialthromboembolism;DM,diabetesmellitus;EMA,
EuropeanMedicinesAgency;FDA,FoodandDrugAdministration;HF,heartfailure;HG,hyperglycaemia;HTN,hypertension;MedDRA,medicaldictionary
forregulatoryactivities;MI,myocardialinfarction;PH,pulmonaryhypertension;VTE,venousthromboembolism.Adversereactionsreportedinmultipleclinical
trialsorduringpost-marketingusearelistedbysystemorganclass(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromthe
availabledata,ablankspacehasbeenleft.aIxazomibproducesperipheraloedemainupto18%ofpatientsandhyperglycaemiaincombinationwithlenalidomide
orpomalidomideanddexamethasone.FiguredevelopedfromEMAprescribinginformation,252FDAprescribinginformation.253
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 41 ---
ESCGuidelines 4269
Proteasome inhibitors surveillance protocol
Baseline During therapy
Clinical assessment Clinical assessment
BP at every BP home
Low- BP and ECG
clinical visit monitoring
moderate
risk NP every cycle during the first 6 cycles
NP
under carfilzomib or bortezomiba
TTE TTE every 3 cycles under carfilzomib
Clinical assessment Clinical assessment
BP at every BP home
High and BP and ECG
clinical visit monitoring
very high
risk NP NP every cycle during the first 6 cycles
under carfilzomib or bortezomiba
TTE TTE every 3 cycles under carfilzomib
Clinical assessment Clinical assessment
BP at every BP home
BP and ECG
Cardiac clinical visit monitoring
amyloidosis
NP and cTn NP and cTn every 3-6 months
TTE and CMR TTE every 3 cycles
Class 1 Class 1Ia Class 1Ib
Figure17Cardiovascularmonitoringinpatientswithmultiplemyelomareceivingproteasomeinhibitors.BP,bloodpressure;CMR,cardiacmagnetic
resonance;cTn,cardiactroponin;ECG,electrocardiogram;NP,natriureticpeptides;TTE,transthoracicechocardiography.aEvery2monthsforpatients
treatedwithixazomib.
andincreasedbaselineCVrisk.282,283PIhavebeenassociatedwitha InasafetyanalysisofpatientswithMMbeingtreatedwithcarfilzo-
varietyofCVtoxicitiesincludinghypertension,HF,284acutecoron- mib, 7.2% of patients were found to have new HF.284 In another
ary syndromes (ACS),66 arrhythmias,285 PH,286 and VTE study,23%ofpatientswithMMtreatedwithcarfilzomibdeveloped
(Figure16).287,288During therapy, cardiacbiomarkers and TTE are clinical HF and/or LVD.289 The mechanism is not well understood
important diagnostic and prognostic tools that can inform clinical butispossiblyrelatedtoPI-inducedoxidativestresswithinmyocytes,
decision-making(Figure17).66 inhibition of the proteasome, or transient endothelial dysfunc-
HF—especiallyHFwithpreservedejectionfraction(HFpEF)—isa tion.281,283 Although no studies have yet addressed the optimal
frequent manifestation of cardiac amyloidosis, but it is also an im- follow-upschemeinpatientswithMMtreatedwithPI,acommon
portant adverse effect of PI therapy, especially under carfilzomib. scheme consists of 3–6-monthly visits with ECG, complete blood
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 42 ---
4270 ESCGuidelines
Risk factors for venous thromboembolic events in patients with multiple myeloma
Patient-related risk factors
Previous VTE
Acute infections
Autoimmune disease
Central venous catheter
Chronic renal disease
Cigarette smoking
CVD
DM
General surgery
History of inherited thrombophilia
Immobilization, surgery, trauma
Obesity (BMI >30 kg/m2)
Myeloma-related risk factors
Advanced disease status
Erythropoietin-stimulating agents
High dexamethasone doses
Hyper-viscosity state
Thalidomide/lenalidomide/ponalidomide
Figure18Riskfactorsforvenousthromboemboliceventsinpatientswithmultiplemyeloma.BMI,bodymassindex;CVD,cardiovasculardisease;DM,
diabetesmellitus;VTE,venousthromboembolism.
tests(includingNPandcTn)andechocardiographysurveillancedur- withacombinationofcarfilzomib,lenalidomide,anddexametha-
ing PI therapy.290 A recent prospective study of patients with re- sonehadhigherratesofVTEcomparedwiththosetreatedwith
lapsedMMconfirmedtheutilityofNPtoassistinriskstratification lenalidomide and dexamethasone (6.6% vs. 3.9%).279
as well as management of CV morbidity during treatment.66 Oncologicalguidelinesrecommendtheuseofaspirinorprophy-
Hypertension,anotheradverseeffectofPI,mayalsocontributeto lactic doses of low-molecular-weight heparins (LMWH) in low-
thedevelopmentofHFpEF. risk patients receiving thalidomide- or lenalidomide-based regi-
PatientswithMMareatelevatedriskofthrombosisduetoboth mens.298 In patients at high risk of VTE, therapeutic doses of
patient- and myeloma-related factors, particularly the combin- LMWHarerecommended.299Theroleofnon-vitaminKantagon-
ation of PI and IMiD (Figure
18).279,287,291–297
In the ASPIRE istoralanticoagulants(NOAC)inMMpatientsneedsfurtherval-
(Carfilzomib, Lenalidomide, and Dexamethasone vs. idationinlargertrials,butrecentsmallstudieshaveconfirmedthe
Lenalidomide and Dexamethasone for the Treatment of efficacyandsafetyoflowdosesofapixabanandrivaroxabanfor
PatientswithRelapsedMultipleMyeloma)study,patientstreated
VTEprevention.300–302
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 43 ---
ESCGuidelines 4271
RecommendationTable13—Recommendationsfor
Lowdosesofapixabanorrivaroxabanfmaybe
baselineriskassessmentandmonitoringduringmul-
consideredasanalternativetoLMWHoraspirin
tiplemyelomatherapies
inpatientswithMMwithVTE-relatedriskfactorse IIb C
Recommendations Classa Levelb (excludingpreviousVTE)atleastduringthefirst6
monthsoftherapy.300–302
BPmonitoring
AL-CA, amyloid light-chain cardiac amyloidosis; BP, blood pressure; cTn, cardiac
BPmeasurementisrecommendedforpatients
I C troponin; HF, heart failure; LMWH, low-molecular-weight heparins; MM, multiple
treatedwithPIateveryclinicalvisit. myeloma; NP, natriuretic peptides; PI, proteasome inhibitors; TTE, transthoracic
HomemonitoringofBPweeklyduringthefirst3 e aCch lao sc sa ord fi ro eg cr oa mph my; eV ndT aE t, iov ne .nousthromboembolism.
monthsandmonthlythereaftershouldbe IIa C bLevelofevidence.
cEvery2monthsforpatientstreatedwithoralixazomib.
consideredforpatientstreatedwithPI.
dDependingonHFseverityandtreatment.
Cardiacserumbiomarkers eSeeFigure18.295,296,299
fLowdosesofapixaban(2.5mgtwiceaday)orrivaroxaban(10mgonceaday).
MeasurementofNPisrecommendedpriortoPI
I C
inhigh-andveryhigh-riskpatients.66,303
MeasurementofNPshouldbeconsideredprior
IIa C
5.5.8.Rapidlyacceleratedfibrosarcomaand
toPIinlow-andmoderate-riskpatients.66
mitogen-activatedextracellularsignal-regulated
Inpatientsreceivingcarfilzomiborbortezomib, kinaseinhibitortreatment
measurementofNPshouldbeconsideredat Therapidlyacceleratedfibrosarcoma(RAF)inhibitors—vemurafenib,
IIa B
baselineandeverycycleduringthefirst6 dabrafenib,and encorafenib—areapprovedfor thetreatment of
cycles.c,66 metastatic melanoma with a BRAF V600 mutation. The mitogen-
activated extracellular signal-regulated kinase (MEK) inhibitors—
NPandcTnmeasurementsarerecommendedat
baselineandevery3–6monthsinpatientswith I B trametinib, cobimetinib, binimetinib, and selumetinib—have also
shownsignificantclinicalactivityinmelanomapatientswhosetu-
AL-CA.d,290
mour contains a BRAF V600 mutation, and are now largely used
TTE incombinationwithRAFinhibitors.ThemainCVeffectstobecon-
Baselineechocardiography,includingassessment sidered are hypertension, PE, and CTRCD, which are associated
forAL-CA,isrecommendedinallpatientswith I C with all combinations of RAF and MEK inhibitors, and QTc pro-
MMscheduledtoreceivePI. longation,associatedsolelywiththecoadministrationofcobimeti-
nibandvemurafenib(Figure19).12,308,309RAFinhibitortreatment
Echocardiographysurveillanceevery3cycles
aloneorincombinationwithaMEKinhibitorisassociatedwithan
shouldbeconsideredinhigh-andveryhigh-risk IIa B
increasedriskofMIandAF.308
patientsreceivingcarfilzomib.280
Patientswithcancerwithpre-existingCVDhaveanincreased
Echocardiographysurveillanceevery3cyclesmay
frequency of CV adverse events during treatment with MEK
beconsideredinlow-andmoderate-riskpatients IIb C and RAF inhibitors, and therefore baseline risk stratification is
receivingcarfilzomib. recommended.12 Most cardiac complications induced by admin-
Echocardiographysurveillanceshouldbe istration of MEK and RAF inhibitors seem to be attributable to
consideredevery3–6monthsinpatientswith IIa C the MEK inhibitor, with the RAF inhibitor enhancing the toxic
AL-CAtreatedwithPI.d,290 effects of the MEK
inhibitor.310–313
Hypertension and LVD
were twice as frequent when MEK and RAF inhibitors were
VTEprophylaxis
coadministeredcomparedwithsingletherapywithRAFinhibitor
TherapeuticdosesofLMWHarerecommended alone.314
inpatientswithMMwithprevious I B CTRCD can manifest any time from the first month of ther-
VTE.296,298,302,304,305 apy to 2 years after the end of the oncological treatment.315
ProphylacticdosesofLMWHarerecommended Baseline TTE is recommended in patients at moderate to high
inpatientswithMMwithVTE-relatedriskfactorse risk of CTR-CVT. During treatment, it is necessary to monitor
I A
(excludingpreviousVTE)atleastduringthefirst6 BP at each visit and promote weekly outpatient monitoring dur-
ingthefirst3monthsandmonthlythereafter.Inpatientstreated
monthsoftherapy.296,304,305
with cobimetinib/vemurafenib, an ECG is recommended at 2
Aspirinshouldbeconsideredasanalternativeto
and 4 weeks after initiation of treatment and every 3 months
LMWHinpatientswithMMwithnoriskfactors
thereafter. In high-risk patients, periodic monitoring of ven-
oroneVTE-relatedriskfactore(excluding IIa B
tricular function with echocardiography should be considered
previousVTE)atleastduringthefirst6monthsof every 6–12 months.
therapy.296,304–307
CV protective medications (such as angiotensin-converting
Continued enzymeinhibitors[ACE-I],angiotensinreceptorblockers[ARB],
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 44 ---
4272 ESCGuidelines
RAF inhibitor- and MEK inhibitor-related cardiovascular toxicities
HTN HF HG/DM SVT/SBra QTc BLEED VTE/PE
RAF inhibitors
Dabrafenib
Encorafenib
Vemurafenibb
MEK inhibitors
Binimetinib
Cobimetinib
Trametinibb
Very common:≥10% incidence Uncommon: 0.1% to < 1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure19Rapidlyacceleratedfibrosarcomaandmitogen-activatedextracellularsignal-regulatedkinaseinhibitor-relatedcardiovasculartoxicities.AF,atrial
fibrillation;BLEED,increasedbleedingrisk;DM,diabetesmellitus;EMA,EuropeanMedicinesAgency;FDA,FoodandDrugAdministration;HF,heartfailure;
HG,hyperglycaemia;HTN,hypertension;MedDRA,medicaldictionaryforregulatoryactivities;MEK,mitogen-activatedextracellularsignal-regulatedkinase;
PE,pulmonaryembolism;↑QTc,correctedQTintervalprolongation;RAF,rapidlyacceleratedfibrosarcoma;SBr,sinusbradycardia;SVT,supraventricular
tachycardia;VTE,venousthromboembolism.Adversereactionsreportedinmultipleclinicaltrialsorduringpost-marketingusearelistedbysystemorganclass
(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromtheavailabledata,ablankspacehasbeenleft.aDabrafenibisrelatedwith
SBr.EncorafenibisrelatedwithSVT.VemurafenibrarelycausesAF.Trametinibisrelatedwithbradycardiainsomepost-marketingreports.bPeripheraloe-
demaisverycommon.FiguredevelopedfromEMAprescribinginformation,252FDAprescribinginformation.253
and beta-blockers) have not been evaluated in patients treated by beta-adrenergic signalling, which also controls the p38 mito-
withMEKandRAFinhibitorsbut,fromamechanisticperspective, gen-activatedproteinkinasespathway,associatedwithcardiotoxic
beta-blockersmightpreventCTRCDinducedbyMEKinhibitors. effects. Beta-blockers might exert their cardioprotective effects
TheMEK/ERKpathwayhasacardiacprotectiveeffect,regulated byreducingp38signalling.315
RecommendationTable14—Recommendationsforbaselineriskassessmentandmonitoringduringcombinedrap-
idlyacceleratedfibrosarcomaandmitogen-activatedextracellularsignal-regulatedkinaseinhibitortherapy
Recommendations Classa Levelb
BPmonitoringateachclinicalvisitandweeklyoutpatientmonitoringduringthefirst3monthsoftreatmentandmonthlythereafteris
I C
recommended.
Inpatientstreatedwithcobimetinib/vemurafenib,anECGisrecommendedat2and4weeksafterinitiationoftreatmentandevery3
I C
monthsthereafter.c
Baselineechocardiographyisrecommendedinallhigh-andveryhigh-riskpatientsscheduledtoreceivecombinedRAFandMEK
I C
inhibitors.
Baselineechocardiographymaybeconsideredinlow-andmoderate-riskpatientsscheduledtoreceivecombinedRAFandMEK
IIb C
inhibitors.
Echocardiographyshouldbeconsideredevery4monthsduringthefirstyearinhigh-andveryhigh-riskpatientsreceivingcombinedRAF
IIa C
andMEKinhibitors.
BP,bloodpressure;ECG,electrocardiogram;MEK,mitogen-activatedextracellularsignal-regulatedkinase;RAF,rapidlyacceleratedfibrosarcoma.
aClassofrecommendation.
bLevelofevidence.
cConsideranECGandnewmonitoringinthecaseofanydoseincrease(seeSection6.4.2).
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 45 ---
ESCGuidelines 4273
5.5.9.Immunecheckpointinhibitors tremelimumab), programmed death-1 (PD-1) (nivolumab, ce-
Immunotherapies, which harness the immune system to des- miplimab, pembrolizumab), and programmed death-ligand 1
troy cancer cells, come in different forms but the most widely (PD-L1) (atezolizumab, avelumab, durvalumab) expressed in
used are ICI.316 The immune checkpoints are proteins ex- the cancer cells, with the consequent cytotoxic immune re-
pressed in the T cells that inhibit their activation when they sponse. By blocking these checkpoints from binding with their
contact a body cell. ICI include monoclonal antibodies that partner proteins, ICI inhibit the ‘off’ signal, activating T cells
block the immune brakes or regulators, cytotoxic T and promoting killing of cancer cells. Although their patho-
lymphocyte-associated antigen-4 (CTLA-4) (ipilimumab, physiology is not clearly defined, ICI may also trigger an
Immune checkpoint inhibitors surveillance protocol
Every
Every
Baseline C2 C3 C4 6 M–
3Cc
12 Md
CV assessmenta
ECG
Low
TTE
risk
cTn
NP
CV assessmenta
ECG
High
TTE
riskb
cTn
NP
Class 1 Class 1Ia Class 1Ib
Figure20Cardiovascularsurveillanceinpatientstreatedwithimmunecheckpointinhibitors.BNP,B-typenatriureticpeptide;BP,bloodpressure;C,
chemotherapycycle;cTn,cardiactroponin;CV,cardiovascular;CVD,cardiovasculardisease;CTRCD,cancertherapy-relatedcardiacdysfunction;
ECG,electrocardiogram;HbA1c,glycatedhaemoglobin;ICI,immunecheckpointinhibitors;M,months;NP,natriureticpeptides(includingBNPand
NT-proBNP);NT-proBNP,N-terminalpro-B-typenatriureticpeptide;TTE,transthoracicechocardiography.aIncludingphysicalexamination,BP,
lipidprofile,andHbA1c.bDualICI,combinationICI-cardiotoxictherapy,ICI-relatednon-CVevents,priorCTRCDorCVD.cEverythreecyclesuntil
completionoftherapytodetectsubclinicalICI-relatedCVtoxicity.dInpatientswhorequirelong-term(.12months)ICItreatment.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 46 ---
4274 ESCGuidelines
overactivation of T cells against non-cancerous tissues, leading SerialECGandcTnmeasurementsshouldbe
to immune-related adverse events.317 Immune-related CV side consideredbeforeICIdoses2,3,and4,andif
effects may lead to life-threatening CV complications such as normal,reducetoeverythreedosesuntil IIa B
fulminant myocarditis, myopericarditis, cardiac dysfunction, ar- completionoftherapytodetectsubclinical
rhythmias, or MI, which often results in the discontinuation of ICI-relatedCVtoxicity.333
ICI.318,319
CVassessmentdisrecommendedevery6–12
The largest case series of 122 patients with ICI-associated monthsinhigh-riskpatientscwhorequire
I C
myocarditis had early onset of symptoms (median of 30 days long-term(.12months)ICItreatment.321–
after initial exposure to ICI), and up to 50% died.320 Late CV 323,335,336
events (.90 days) are less well characterized but generally ex- CVassessmentdmaybeconsideredevery6–12
hibit a higher risk of non-inflammatory HF, progressive athero-
monthsinallpatientswhorequirelong-term IIb C
sclerosis, hypertension, and mortality rates.321 Other CV (.12months)ICItreatment.
toxicities described during ICI therapy are MI, AV block, supra-
ventricular and ventricular arrhythmias, sudden death, BNP,B-typenatriureticpeptide;BP,bloodpressure;cTn,cardiactroponin;CTRCD,
Takotsubo-like syndrome, non-inflammatory HF, hypercholes- cancertherapy-relatedcardiacdysfunction;CV,cardiovascular;CVD,cardiovascular
disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin; ICI, immune
terolaemia, pericarditis, pericardial effusion, ischaemic stroke, checkpointinhibitors;NP,natriureticpeptides;NT-proBNP,N-terminalpro-B-type
and VTE.322 A meta-analysis including 32518 patients receiving natriureticpeptide.
aClassofrecommendation.
ICI treatment reported an increased risk of myocarditis, peri- bLevelofevidence.
cardial diseases, HF, dyslipidaemia, MI, and cerebral arterial is- cDual ICI, combination ICI-cardiotoxic therapy; ICI-related non-CV events, prior
chaemia.323 Conditions related with high baseline ICI-related CTRCD,orCVD.
dPhysicalexamination,BP,NP(BNPorNT-proBNP),lipidprofile,HbA1c,andECG.
CV toxicity risk include dual ICI therapy (e.g. ipilimumab and ni-
volumab), combination ICI therapy with other cardiotoxic ther-
apies, and patients with ICI-related non-CV events or prior 5.5.10.Androgendeprivationtherapiesfor
CTRCD or CVD (Figure 20).324,325 All patients on ICI treat- prostatecancer
ment should have an ECG and troponin assay at baseline Androgendeprivationtherapy(ADT)isprescribedin40%ofmen
(Figure 20).326–329 High-risk patients should additionally have a with prostate cancer as neoadjuvant and/or adjuvant therapy to
TTE evaluation at baseline. Due to the lack of evidence-based RT or for biochemical relapse following prostate cancer surgery.
recommendations, the monitoring of ICI therapy is challenging. Gonadotropin-releasinghormone(GnRH)agonistsarethemostfre-
Once started on therapy, ECG, cTn, and NP should be quently prescribed ADT. However, GnRH agonists are associated
checked.330–332 In the JAVELIN trial, which assessed avelumab with an increased CV risk and mortality, particularly in patients
plus axitinib vs. sunitinib, no clinical value was observed for on-
withprostatecanceraged.60years.337,338Baselineriskstratifica-
treatment routine TTE monitoring in asymptomatic patients.333 tioninpatientsrequiringGnRHagonistsdependsonvasculardisease
However, in high-risk patients, and in those with high baseline risk(Figure21).339,340NodedicatedCVtoxicityriskcalculatorshave
cTn levels, TTE monitoring may be considered. In patients beendevelopedforpatientsreceivingADT.Itwastheconsensusof
who develop ECG abnormalities, new biomarker changes, or theauthorstorecommendSCORE2orSCORE2-OPtostratifyCV
new cardiac symptoms at any time, prompt cardio-oncology riskinpatientsreceivingADTwithoutpreviousCVD.19
evaluation is strongly recommended, including TTE for the The use of GnRH antagonists represents an alternative in the
evaluation of LVEF and GLS, and CMR when myocarditis is sus- treatment of prostate cancer, and preclinical and clinical (HERO
pected (Table 3).334 trial)341datasuggestthatGnRHantagonistuseisassociatedwithsig-
nificantlyloweroverallmortalityandCVeventscomparedwithago-
nists.342 However, more research is needed in this field. In the
PRONOUNCEtrial,nodifferenceinMACEat1yearwasobserved
RecommendationTable15—Recommendationsfor
between degarelix (a GnRH antagonist) and leuprolide (a GnRH
baseline risk assessment and monitoring during
agonist), although the trial was stopped early.343 Lower CV event
immunotherapy
ratesweredetectedcomparedwithpreviousstudiesandallpatients
Recommendations Classa Levelb were reviewed by a cardiologist at enrolment (leading to optimal
CVRFmanagement).343
ECG,NP,andcTnmeasurementsare
ThemainCVeffectstobeconsideredarehypertension,DM,ischae-
recommendedinallpatientsbeforestartingICI I B micheartdisease(IHD)andCTRCD.339,344ADTisuncommonlyasso-
therapy.333
ciated with QTc prolongation and rarely causes torsade de pointes
Baselineechocardiographyisrecommendedin I B (TdP)throughblockadeoftestosteroneeffectsonventricularrepolar-
high-riskpatientscbeforestartingICItherapy.333 ization.345,346ECGmonitoringandcorrectionofQTprolongationpre-
Baselineechocardiographymaybeconsideredin cipitant factors (see Section 6.4.2; Table 9; Supplementary data,
IIb C
allpatientsbeforestartingICItherapy. TableS13)isrecommended340,347,348duringprostatecancertreatment
Continued ifthebaselineQTcintervalisprolonged.49,339,340,347,349,350
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 47 ---
ESCGuidelines 4275
Androgen deprivation therapy-related cardiovascular toxicities
HTN HG/DM HF IHD/MI AF QTca
GnRH agonist
Goserelin
Histrelin
Leuprorelin
Triptorelin
GnRH antagonist
Degarelix
Relugolix
1st generation antiandrogens
Bicalutamide
Flutamide
Nilutamide
2nd generation
androgen deprivation therapy
Apalutamide
Darolutamide
Enzalutamide
Androgen metabolism inhibitor
Abirateroneb
Very common:≥10% incidence Uncommon: 0.1% to < 1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure21Androgendeprivationtherapy-relatedcardiovasculartoxicities.ADT,androgendeprivationtherapy;AF,atrialfibrillation;DM,diabetesmel-
litus;EMA,EuropeanMedicinesAgency;FDA,FoodandDrugAdministration;GnRH,gonadotropin-releasinghormone;HF,heartfailure;HG,hypergly-
caemia; HTN, hypertension; IHD, ischaemic heart disease; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; ↑QTc,
correctedQTintervalprolongation;TdP,torsadedepointes.Adversereactionsreportedinmultipleclinicaltrialsorduringpost-marketingusearelisted
bysystemorganclass(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromtheavailabledata,ablankspacehasbeenleft.
aADTmayprolongtheQTcinterval.InpatientswithahistoryofriskfactorsforQTprolongationandinpatientsreceivingconcomitantmedicinalpro-
ductsthatmightprolongtheQTinterval,physiciansshouldassessthebenefit/riskratioincludingthepotentialforTdPpriortoinitiatingthetreatment.
bIncreasedriskofQTcprolongationincombinationwithADT.49,339,340,349,350FiguredevelopedfromEMAprescribinginformation,252FDAprescribing
information.253
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 48 ---
4276 ESCGuidelines
RecommendationTable16—Recommendationsfor high-dose tamoxifen were found to prolong QTc interval339,340;
baseline risk assessment and monitoring during an- however,noriskdatahavebeenpublishedinpatientstreatedwith
drogendeprivationtherapyforprostatecancer
thestandardtamoxifendoseusedinBC(20mg/day).
TherisksofVTE,hypercholesterolaemia,andCVDshouldbedis-
Recommendations Classa Levelb
cussedwithpatients,whilerecognizingthattheabsolutebenefitsof
BaselineCVriskassessmentcandestimationof preventingBC recurrence usually outweigh theCV risks.339In pa-
10-yearfatalandnon-fatalCVDriskwith tients,70yearsoldwithoutclinicalmanifestationsofatherosclerot-
SCORE2orSCORE2-OPdisrecommendedin I B ic disease, estimation of 10-year fatal and non-fatal CVD risk with
patientstreatedwithADTwithoutpre-existing SCORE2 (if ≥70 years, SCORE2-OP) is recommended.19
CVD.19,341,342 CholesterollevelsandBPshouldbemonitoredregularlyinpatients
BaselineandserialECGsarerecommendedin receivingAI.356Physicalactivityandhealthydietarealsoadvisedto
patientsatriskofQTcprolongationduringADT I B reduceweightandcholesterollevels.Smokingcessationisstrongly
therapy.e,339–342 recommendedtoreduceCVrisk(e.g.CADduringAItherapyand
AGnRHantagonistshouldbeconsideredin VTEduringtamoxifentherapy).
patientswithpre-existingsymptomaticCADf IIa B
whorequireADT.341,342
AnnualCVriskassessmentcisrecommended RecommendationTable17—Recommendationsfor
duringADT.19,339,341,342 I B baselineriskassessmentandmonitoringduringendo-
crinetherapyforbreastcancer
ACS, acute coronary syndromes; ADT, androgen deprivation therapy; BP, blood
pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CV, Recommendations Classa Levelb
cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GnRH,
gonadotropin-releasinghormone;HbA1c,glycatedhaemoglobin;QTc,correctedQT BaselineCVriskassessmentcandestimationof
interval;SCORE2,SystematicCoronaryRiskEstimation2;SCORE2-OP,Systematic
10-yearfatalandnon-fatalCVDriskwith
CoronaryRiskEstimation2—OlderPersons.
aClassofrecommendation. SCORE2orSCORE2-OPd,eisrecommendedin I C
bLevelofevidence. BCpatientsreceivingendocrinetherapieswithout
cBP,lipids,fastingglucose,HbA1c,ECG,andpatienteducationonhealthylifestyleand
pre-existingCVD.19
lifestyleriskfactorcontrolisrecommended.
dSCORE2(,70years)orSCORE2-OP(≥70years)CVriskstratification:,50years: AnnualCVriskassessmentcisrecommended
lowrisk,2.5%,moderaterisk2.5%to,7.5%,highrisk≥7.5%;50–69years:low
duringendocrinetherapyinBCpatientswithhigh
risk,5%;moderaterisk5%to,10%;highrisk≥10%;≥70years:lowrisk,7.5%, I C
moderaterisk7.5%to,15%,highrisk≥15%. 10-yearriskof(fatalandnon-fatal)CVevents
eSeeTable9. accordingtoSCORE2/SCORE2-OP.d,e
fCCSandACS. CVriskassessmentcshouldbeconsideredevery5
yearsinBCpatientswithlowormoderate
IIa C
10-yearriskof(fatalandnon-fatal)CVevents
5.5.11.Endocrinetherapiesforbreastcancer accordingtoSCORE2/SCORE2-OP.d,e
Endocrinetherapyisacommontreatmentas65–70%ofallearly
BC,breastcancer;BP,bloodpressure;CV,cardiovascular;CVD,cardiovasculardisease;
and metastatic BC patients develop hormone receptor-positive
ECG, electrocardiogram; HbA1c, glycated haemoglobin; SCORE2, Systematic
disease.22 Selective oestrogen receptor modulators (tamoxifen, CoronaryRiskEstimation2;SCORE2-OP,SystematicCoronaryRiskEstimation2—
toremifene) or aromatase inhibitors (AI) (letrozole, anastrozole, Olderpersons.
aClassofrecommendation.
or exemestane) are recommended in early BC (EBC) according
bLevelofevidence.
tomenopausalstatus,comorbidities,andtheriskofdiseaserelapse. cBP,lipids,fastingglucose,HbA1c,ECGandpatienteducationonhealthylifestyleand
TheuseofAIincombinationwithcyclin-dependentkinase(CDK) lifestyleriskfactorcontrol.
4/6 inhibitors is recommended as first- or second-line therapy dOrothervalidatedCVriskscores.
eSCORE2(,70years)orSCORE2-OP(≥70years)CVriskstratification:,50years:
in patient with hormone receptor-positive/HER2-negative meta- lowrisk,2.5%,moderaterisk2.5%to,7.5%,highrisk≥7.5%;50–69years:low
staticBC. risk,5%;moderaterisk5%to,10%;highrisk≥10%;≥70years:lowrisk,7.5%,
moderaterisk7.5%to,15%,highrisk≥15%.19
TheuseofAIincreasestheriskofdyslipidaemia,metabolicsyn-
drome,hypertension,HF,andMI.339IntheATAC(‘Arimidex’and
TamoxifenAloneorinCombination)trial,anastrozole-treatedpa-
tients with pre-existing CAD experienced more CV events (17% 5.5.12.Cyclin-dependentkinase4/6inhibitors
vs.10%)andcholesterollevelelevation(9%vs.5%)thanthosetrea- TheuseofCDK4/6inhibitors(palbociclib,ribociclib,andabemaci-
tedwithtamoxifen.351,352Similarly,HFwassignificantlymorecom- clib) in combination with endocrine therapy is approved for the
mon with letrozole compared with tamoxifen in the BIG (Breast treatment of patients with hormone receptor-positive/
International Group) 1–98 trial.353 Longer AI treatment duration HER2-negativemetastaticBC.Thiscombinationhasresultedinim-
wasassociatedwithincreasedoddsofdevelopingCVDintwolarge provementsinprogression-freesurvivaland,insometrials, overall
meta-analyses.354,355SignificantlyincreasedVTEriskhasbeencon- survival.357–359 CDK 4/6 inhibitors have demonstrated a potential
sistently demonstrated with tamoxifen351,353 and it is not recom- for QT prolongation,339,360 particularly with ribociclib. The phase
mended in patients with thrombotic risks. Toremifene and III trials of ribociclib incorporated routine ECG
monitoring.361–368
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 49 ---
ESCGuidelines 4277
BaselineECGisrecommendedandECGsshouldberepeatedatday crizotinib treatment should have cholesterol levels checked every
14ofthefirstcycle,beforethesecondcycle,withanydoseincrease 3–6monthsandtreatedifelevated.
andasclinicallyindicated.357
Inpatientswhoalreadyhave,orareatsignificantriskofdevelop-
5.5.14.Epidermalgrowthfactorreceptorinhibitors
ing,QTprolongation(Section6.4.2),therisks/benefitsforribociclib
Osimertinibisanoralirreversible,epidermalgrowthfactorreceptor
should be discussed by a MDT. Importantly, the use of ribociclib
(EGFR)-TKIapprovedforpatientswithnon-smallcelllungcancerex-
should be avoided in combination with drugs known to prolong
pressingEGFRmutations.Recentdatahaveshownthatosimertinibis
QTintervaland/orstrongCYP3Ainhibitors.357
associatedwithanincreasedriskofQTcprolongation,AF,VTE,LVD,
The prescribing information does not recommend ribociclib in
andHF(Figure22).373,374Astudyof123patientswithEGFR-mutant
combination with tamoxifen due to a higher risk of QTc
non-smallcelllungcancertreatedwithosimertinibreporteda4.9%
prolongation.252,367
incidence of HF or MI and a significant decrease in LVEF ,53% in
11%ofpatientswithTTEsurveillance.375Pre-existinghypertension
andolderageareriskfactorsforLVDandHF(3.9%and2.6%inci-
RecommendationTable18—Recommendationsfor
dence, respectively).376 LVD and HF were more common during
baselineriskassessmentandmonitoringduringcyclin-
thefirstyearoftherapy.376
dependentkinase4/6inhibitortherapy
BaselineCVriskstratification,ECGandTTEpriortostartingosi-
Recommendations Classa Levelb mertinib is recommended. Three-monthly echocardiographic sur-
veillance for new LVD during osimertinib treatment should be
QTcc,dmonitoringisrecommendedatbaseline
considered. Close monitoring of magnesium levels is also recom-
and14and28daysinallpatientswithcancer I A
mended to minimize the risk of osimertinib-induced hypomagnes-
receivingribociclib.361,365,367,368
aemiaandQTcprolongation.
QTcc,dmonitoringisrecommendedinpatients
treatedwithribociclibwithanydose I B
increase.361,365,367,368 RecommendationTable19—Recommendationsfor
QTccmonitoringshouldbeconsideredinpatients baseline risk assessment and monitoring during ana-
plasticlymphomakinaseandepidermalgrowthfactor
treatedwithpalbocicliborabemaciclibwhohavea
IIa C receptorinhibitors
baselineQTcabovethenormalrangecorother
conditionsthatmayprolongtheQTcinterval.e Recommendations Classa Levelb
QTc,correctedQTinterval;QTcF,correctedQTintervalusingFridericiacorrection. BaselineCVriskassessmentcisrecommendedin
aClassofrecommendation.
bLevelofevidence. patientsbeforeALKinhibitorsandEGFR I C
cQTintervalusingFridericiacorrection(QTcF=QT/3√RR)isthepreferredmethodin inhibitors.
patients with cancer. Upper 99% limit of normal for QTc values in the general Baselineechocardiographyisrecommendedinall
populationare450msformenand460msforwomen.369 I B
dAccordingtotheEuropeanMedicinesAgency:(1)ribociclibshouldbeinterrupted
patientswithcancerbeforestartingosimertinib.376
when QTcF.480ms; (2) if QTcF prolongation resolves to ,481ms, resume HomeBPmonitoringshouldbeconsideredfor
treatmentatthesamedoselevel;(3)ifQTcF≥481msrecurs,interruptdoseuntil
patientstreatedwithbrigatinib,crizotinib,or IIa C
QTcFresolvesto,481msandthenresumeribociclibatnextlowerdoselevel.
eSeeSection6.4.2andTable8. lorlatinib.
Cholesterolprofileassessmentevery3–6months
shouldbeconsideredforpatientsoncrizotinib IIa C
5.5.13.Anaplasticlymphomakinaseinhibitors andlorlatinib.
Patients with cancer treated with anaplastic lymphoma kinase Echocardiographyshouldbeconsideredevery3 IIa B
(ALK) inhibitors may develop adverse CV events including sinus
monthsinpatientsduringosimertinibtherapy.376
bradycardia,AVblock,QTcprolongation,hypertension,hypergly- ECGshouldbeconsidered4weeksafterstarting
caemia,anddyslipidaemia.370,371ACSandHFhaverarelybeende- therapyandevery3–6monthsinpatientsduring IIa C
scribed under crizotinib.372 A baseline ECG is recommended in ALKinhibitortherapy.
patients prior to starting an ALK inhibitor, especially crizotinib,
ALK, anaplastic lymphoma kinase; BP, blood pressure; CV, cardiovascular; ECG,
andpatientsmayhaveanECG4weeksafterthestartoftreatment electrocardiogram; EGFR, epidermal growth factor receptor; HbA1c, glycated
andevery3–6monthsthereafter,particularlyifthebaselineECGis haemoglobin.
aClassofrecommendation.
abnormal.HomeBPmonitoringshouldbeconsideredinpatients bLevelofevidence.
treated with brigatinib or lorlatinib. Patients receiving lorlatinib or cPhysicalexamination,BPmeasurement,ECG,lipidprofile,andHbA1cmeasurement.
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 50 ---
4278 ESCGuidelines
ALK inhibitor- and EGFR inhibitor-related cardiovascular toxicities
HTN HG/DM DL HF SBr AF QTc VTE
ALK inhibitors
Alectinib
Brigantinib
Ceritinib
Crizotinib
Lorlatinib
EGFR inhibitors
Osimertiniba
Very common: ≥10% incidence Uncommon: 0.1% to <1% incidence
Common: 1% to <10% incidence Rare: <0.1% incidence
Figure22Anaplasticlymphomakinaseandepidermalgrowthfactorreceptorinhibitor-relatedcardiovasculartoxicities.AF,atrialfibrillation;ALK,ana-
plasticlymphomakinase;DL,dyslipidaemia;DM,diabetesmellitus;EGFR,epidermalgrowthfactorreceptor;EMA,EuropeanMedicinesAgency;FDA,
Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities;
↑QTc,correctedQTintervalprolongation;SBr,sinusbradycardia;VTE,venousthromboembolism.Adversereactionsreportedinmultipleclinicaltrials
orduringpost-marketingusearelistedbysystemorganclass(inMedDRA)andfrequency.Ifthefrequencyisunknownorcannotbeestimatedfromthe
availabledata,ablankspacehasbeenleft.aOsimertinibincreasestheriskofhypomagnesaemia.FiguredevelopedfromEMAprescribinginformation,252
FDAprescribinginformation.253
5.5.15.Chimericantigenreceptor CRSandtodistinguishitfromotherconditionsthatoccurinthese
Tcellandtumour-infiltratinglymphocytes settings(infections,HF,drugreactions,andPE).378,386Amongadults,
therapies therewasarelationshipbetweenCRSandCVevents.Anelevationin
CAR-Ttherapyisusedforthetreatmentofacutelymphocyticleu- cTniscommonlyseeninpatientswithCRSandisassociatedwithan
kaemiaandaggressiveB-celllymphomas.377Althoughthereported increasedriskforsubsequentCVevents.378Inarecentretrospective
incidenceisvariable,thereisagrowingrecognitionoftheassociation pharmacovigilancestudy,CAR-Twasassociatedwithtachyarrhyth-
betweenCAR-TtherapyandCTR-CVT,includingLVD,HF,cardiac mias (AF the most common, followed by ventricular arrhythmias),
arrhythmias,pericardialeffusion,TTS,andcardiacarrest.378–383The cardiomyopathy, and pleural and pericardial diseases.379 Globally,
majorityofthedescribedCVtoxicitieshavebeenshowntobeasso- the fatality rate of CV and pulmonary adverse events was
ciated with the occurrence of cytokine release syndrome 30.9%.378,379,387EarlycardiacevaluationinpatientswithcTnincrease
(CRS).377,384BaselineCVevaluationincludingECG,NP,andcTnis shouldincludeNP,ECG,andechocardiography(seeSection6.1.4for
recommended in all patients. Baseline TTE should also be consid- management).388
ered,especiallyinpatientswithpre-existingCVRFandCVD.After Adoptive cellular therapy with TIL has emerged as an effective
receivingCAR-Ttherapy,patientsmaydevelopsystemicinflamma- treatmentoptionforunresectablestageIII/IVmetastaticmelanoma.
torysyndromes.385CRSshouldbesuspectedwhenapatientdevel- WithTILs,theCVtoxicityappearstoberelatedtodirectmyocardial
ops fever, with or without tachypnoea, tachycardia, hypotension, andvasculartoxicity.380BaselineassessmentandCVsurveillancein
hypoxia, and/or other end-organ dysfunction hours to days after patients before TIL therapies is the same pathway recommended
treatment.385 A high index of suspicion is necessary to diagnose forCAR-Ttherapies.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 51 ---
ESCGuidelines 4279
RecommendationTable20—Recommendationsfor (1) ModificationofcancermanagementtoomitRT.Thisemphasizes
baseline risk assessment and monitoring in patients the importance of integrating a personalized cardio-oncology
receivingchimericantigenreceptorTcellandtumour- evaluation.402–404
infiltratinglymphocytestherapies
(2) Modificationofthe dose andvolume ofRT treatmentswhere
Recommendations Classa Levelb possible. RT protocols should target the minimum volume re-
quiredtotheminimumdoseneededtoobtainthedesiredclin-
BaselineECG,NP,andcTnarerecommendedin icalbenefit.
allpatientswithcancerbeforestartingCAR-Tand I C (3) Modificationofdeliverytechniquestoreducecardiacradiation
TILtherapies.388
exposure should lead to a considerable reduction in risk.
Abaselineechocardiographyisrecommendedin Modernheart-sparingRTstrategiesinclude:theoptimaluseof
patientswithpre-existingCVDbeforestarting I C modern intensity-modulated photon RT technologies; the use
CAR-TandTILtherapies.388 ofdeepinspirationbreath-holdorrespiratory-gatedtechniques
Abaselineechocardiographyshouldbe inBC,405lymphoma,406andlungcancer407;ortheuseofimage-
consideredbeforestartingCAR-TandTIL IIa C guided RT to ensure accuracy of delivery and proton beam
therapies.388 therapy.408
MeasurementofNP,cTn,andechocardiography
arerecommendedinpatientswhodevelopCRS I C TheincidenceofcardiaceventsfollowingRTmayvaryaccording
ofASTCT≥2.c,378,388 topatientriskfactorsandsynergisticeffectsofradiationwithother
cardiotoxiccancertreatments.12,173
ASTCT,AmericanSocietyforTransplantationandCellularTherapy;CAR-T,chimeric There are no known RT-specific secondary preventative mea-
antigenreceptorTcell;CRS,cytokinereleasesyndrome;cTn,cardiactroponin;CVD,
sures (e.g. drug treatments) to reduce the riskof CV events fol-
cardiovascular disease; ECG, electrocardiogram; NP, natriuretic peptides; TIL,
tumour-infiltratinglymphocytes. lowing RT. However, given the known importance of
aClassofrecommendation.
conventional CVRF on the incidence of RT-related events, opti-
bLevelofevidence.
cDetermineCRSgradeaccordingtoASTCTgrading:Grade1:fever;Grade2:fever mization of modifiable CVRF is recommended in all patients
ANDhypotensionnotrequiringvasopressorsAND/ORhypoxiarequiringlow-flow before and after RT.
nasal oxygen; Grade 3: fever AND hypotension requiring one vasopressor +
vasopressin AND/OR hypoxia requiring high-flow nasal cannula or facemask or
non-rebreathermaskorVenturimask;Grade4:feverANDhypotensionrequiring RecommendationTable21—Recommendationsfor
multiplevasopressors,notincludingvasopressinAND/ORhypoxiarequiringpositive
baselineriskassessmentofpatientsbeforeradiother-
airwaypressure.
apytoavolumeincludingtheheart
Recommendations Classa Levelb
5.5.16.Radiotherapy
BaselineCVriskassessmentcandestimationof
RTincreasestheriskofdevelopingsubsequentCVDandperiph- 10-yearfatalandnon-fatalCVDriskwith I B
eral artery disease
(PAD).173,389–394
There is ongoing debate re- SCORE2orSCORE2-OPdisrecommended.19,389
garding the safest radiation dose, which cardiac substructures
Baselineechocardiographyshouldbeconsidered
aremostsensitivetoRT-inducedinjury,andthemostappropriate
inpatientswithpreviousCVDbeforeRTtoa IIa C
strategiestominimizeRT-relatedCVD.395,396Theheartisconsid-
volumeincludingtheheart.
eredaradiosensitive‘organatrisk’duringRTandradiationexpos-
ure to the heart should be kept as low as reasonably achievable BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; ECG,
becausethereisno‘safe’dose(Figure23).389,390RT-inducedCV electrocardiogram; HbA1c, glycated haemoglobin; RT, radiotherapy; SCORE2,
Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk
toxicityriskcategorizationbasedonMHD389,397isrecommended Estimation2—OlderPersons.
overcategorizationbasedonprescribeddose,whichmaynotac- aClassofrecommendation.
curatelyreflectcardiacradiationexposure(e.g.35Gray[Gy]pre-
bLevelofevidence.
cBP,lipids,fastingglucose,HbA1c,ECGandpatienteducationonhealthylifestyleand
scribed dose to approximately 70% of the heart is equivalent to lifestyleriskfactorcontrol.
approximately25GyMHD,whereas35Gyprescribeddosetoap-
dSCORE2(,70years)orSCORE2-OP(≥70years)CVriskstratification:,50years:
lowrisk,2.5%,moderaterisk2.5%to,7.5%,highrisk≥7.5%;50–69years:low
proximately40%oftheheartisequivalenttoapproximately15Gy risk,5%;moderaterisk5%to,10%;highrisk≥10%;≥70years:lowrisk,7.5%,
MHD). However, MHD is not a perfect metric, and in some pa- moderaterisk7.5%to,15%,highrisk≥15%.19
tients, a very small portion of the heart might be irradiated to a
very high dose, still conveying a substantial risk despite a low
MHD.398Therefore,dependingondosedistributionandexposure 5.5.17.Haematopoieticstemcelltransplantation
ofspecificcardiacsubstructuresandCVRFs,thecancertreatment HSCTconstitutesapotentiallycurativetherapeuticoptionformany
team may judge the patient to belong to a higher-risk cat- haematologicalmalignancies.ImprovementsinHSCTtechniquesand
egory.397,399–401
supportive strategies have markedly decreased treatment-related
Strategies to prevent and attenuate CV complications of RT mortality(Supplementarydata,TableS14).409,410Thereisagrowing
have focused on reducing radiation exposure of the heart and recognitionofHSCT-relatedCVtoxicitiesandHSCTsurvivorscon-
CV substructures during cancer treatment and include the stituteapopulationathighfutureCVrisk.Severalfactorscontribute
following. todefinetheriskofHSCT-relatedCVtoxicities,includingtheHSCT
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 52 ---
4280 ESCGuidelines
Very high risk High risk
>25 Gy MHDb >15 to 25 Gy MHDb
>15 Gy MHDb + 5 to 15 Gy MHDd(cid:2)+
cumulative doxorubicinc cumulative doxorubicinc
≥100 mg/m2 ≥100 mg/m2
RT doses CVa
toxicity risk
5 to 15 Gy MHDd
<5 Gy MHDe +
<5 Gy MHDe
cumulative doxorubicinc
≥100 mg/m2
Moderate risk LLooww rriisskk
Figure23Radiotherapymeanheartdoseandassociatedcardiovasculartoxicityrisk.CV,cardiovascular;Gy,Gray;MHD,meanheartdose;RT,radio-
therapy.aRTriskcategorizationbasedonMHDisrecommendedovercategorizationbasedonprescribeddose,whichmaynotaccuratelyreflectcardiac
radiationexposure.Dependingondosedistributionandexposureofspecificcardiacsubstructures(aswellasclinicalriskfactors)thetreatmentteammay
judgethepatienttobelongtoahigherriskcategory.Inaddition,apatientmaybejudgedtobelongtoalowerriskcategoryifonlyasmallpartoftheheart
wasexposedtoarelativelylowprescribeddose.397,399–401bOrprescribedRT≥35GytoavolumeexposingtheheartifMHDisnotavailable.Notethat
inthiscase,thelimitedinformationaboutcardiacexposuredoesnotallowonetodistinguishbetweenhigh-andveryhigh-riskcategories.cOrequivalent.
dOrprescribedRT15–34GytoavolumeexposingtheheartifMHDisnotavailable.eOrprescribedRT,15GytoavolumeexposingtheheartifMHD
isnotavailable.
type (higher risk after allogeneic HSCT), multiple uncontrolled data, Table S14) and the development of graft vs. host disease
CVRF,pre-existingCVconditions(AForatrialflutter,sicksinussyn- (GVHD),thromboticmicroangiopathy,orsepsis.410,412Intheearly
drome,ventriculararrhythmias,CAD,MI,moderate-to-severeVHD, phase following HSCT (,100 days), the most frequent CV event
andHForLVEF,50%),411directcardiotoxiceffectsofanticancer is AF, although some patients may experience HF, hypertension,
therapies received prior to and during HSCT (anthracycline- hypotension, pericardial effusion, or VTE.413,414 Late toxicities in-
combinedinductionregimen,mediastinalRT,totalbodyirradiation, clude DM, dyslipidaemia, metabolic syndrome, hypertension, HF,
orcyclophosphamide-basedconditioningregimen)(Supplementary CAD, conductions disorders, and pericardial effusion.410 Acute
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 53 ---
ESCGuidelines 4281
Cardiovascular surveillance in patients referred for haematopoietic
stem cell transplantation
3 M 12 M
Before after after >12 M
HSCT HSCT HSCT (yearly)
CV assessmenta
ECG
Low risk
If new cardiac symptoms
TTE occur at any time
If new cardiac symptoms
NP
occur at any time
CV assessmenta
High risk
ECG
Allogenic HSCT
Pre-existing CVD In selected
TTE
Multiple uncontrolled CVRF patients
Cancer treatment historyb
Conditioning schemesc NP
GVHD
In selected
CPET
patients
Class 1 Class 1Ia Class 1Ib
Figure24Riskfactorsandcardiovascularsurveillanceinpatientsreferredforhaematopoieticstemcelltransplantation.BNP,B-typenatriureticpep-
tide;BP,bloodpressure;CPET,cardiopulmonaryexercisetesting;CV,cardiovascular;CVD,CVdisease;CVRF,cardiovascularriskfactors;ECG,elec-
trocardiogram; GVHD, graft vs. host disease; HbA1c, glycated haemoglobin; HSCT, haematopoietic stem cell transplantation; M, months; NP,
natriureticpeptides(includingBNPorNT-proBNP);NT-proBNP,N-terminalpro-BNP;TTE,transthoracicechocardiography.aIncludingphysicalexam-
ination,BP,lipidprofile,andHbA1c.bMediastinalormantlefieldradiation,alkylatingagents,.250mg/m2doxorubicinorequivalent.cTotalbodyirradi-
ation,alkylatingagents.
GVHDisassociatedwiththrombosisandinflammatorymyocardial
RecommendationTable22—Recommendationsfor
damage (myocarditis, HF, conduction abnormalities, arrhythmias,
baseline risk assessment in haematopoietic stem cell
andpericardialeffusions),andchronicGVHDhasbeenlinkedwith
transplantationpatients
increasingriskofhypertension,DM,anddyslipidaemia.415,416
AcomprehensiveCVevaluation,includingNPassessment,ECG, Recommendations Classa Levelb
andTTE,hasbecomeacorecomponentofthepre-HSCTassess-
BaselineandserialCVriskassessment(3and12
ment409,410 to detect undiagnosed CVD, stratify CTR-CVT risk,
andoptimizepre-existingCVconditions.411,417–420Inearlysurveil- months,thenyearly)includingBPmeasurement, I C
ECG,lipidmeasurement,andHbA1cis
lance,TTEmonitoringisrecommendedinhigh-riskHSCTrecipients
recommendedinHSCTpatients.
at3and12monthsasLVEFandGLScandecreaseaftertransplant
Echocardiographyisrecommendedinallpatients
(seeSection7).Independentfactorsassociatedwithlong-termCVD I C
beforeHSCT.
inHSCTsurvivorsareallogenicHSCT,pre-existingCVDormultiple
BaselineNPmeasurementshouldbeconsidered
uncontrolledCVRF,cancertreatmenthistory(mediastinalorman- IIa C
tle field radiation, alkylating agents, .250mg/m2 doxorubicin or
beforeHSCT.417,418
equivalent), high-risk conditioning schemes (totalbody irradiation, BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA1c, glycated
alkylating agents), and GVHD.410 Figure 24 summarizes strategies haemoglobin;HSCT,haematopoieticstemcelltransplantation;NP,natriureticpeptides.
aClassofrecommendation.
forthepreventionandattenuationofCVcomplicationsinpatients
bLevelofevidence.
undergoingHSCT.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 54 ---
4282 ESCGuidelines
5.5.18.Othercancertreatments (medication, devices) needs to include consideration of a range of
SeveralothercancertherapiesmayalsoinduceclinicallyrelevantCV factorsincludingbothcancerandCVsymptomburden,cancerprog-
events.Cyclophosphamide,cisplatin,ifosfamide,andtaxanes(pacli- nosis,ongoingcancertreatmentrequirementsincludingalternative
taxel and docetaxel) can induce myocardial dysfunction and HF.4 options, possible adverse drug reactions, drug–drug interactions,
CyclophosphamideCVtoxicityisprimarilyseeninpatientsreceiving andpatientpreferences.Anextensivelistofdrug–druginteractions
highdoses(.140mg/kg)beforeHSCTandtypicallyoccurswithin isprovidedinSupplementarydata,TablesS15–S17.
daysofdrugadministration.410
Platinum-containing chemotherapy (cisplatin, carboplatin, oxali-
platin)maycausevasculardisease(vasospasm,MI,andvenousand
RecommendationTable23—Recommendationfor
themanagementofcardiovasculardiseaseandcancer
arterial thrombosis). These may occur during treatment and also
therapy-relatedcardiovasculartoxicityinpatientsre-
contribute to increased long-term risk of CAD in survivors.
ceivinganticancertreatment
Patients with testicular cancer treated with cisplatin have a higher
riskforvasculardiseaseatlong-termfollow-up.421Theriskofthein- Recommendation Classa Levelb
dividual patient is still hard to predict, but lifestyle interventions, a
AspecialistCVassessmentcisrecommendedfor
high degree of clinical suspicion in patients who experience chest
optimaldiagnosticworkupandmanagementof
pain,andcloseCVRFmonitoringisrecommendedduringandafter I C
therapy.422 Cisplatin422 infrequently causes HF; however, because patientswithcancerwhopresentwithnewCV
toxicityduringandaftercancertreatment.5
itrequirestheadministrationofahighi.v.volumetoavoidrenaltox-
icity,patientswithpre-existingCVDmaydevelopsymptomaticHF. CV,cardiovascular;CVD,cardiovasculardisease.
Arsenictrioxideisusedtotreatsomeleukaemiasandmyelomas. aClassofrecommendation.
ArsenictrioxidefrequentlyprolongstheQTinterval(26–93%ofpa-
bLevelofevidence.
cCardio-oncologyreferralisrecommendedwhenavailable;alternatively,patientsshould
tients),andlife-threateningventriculartachyarrhythmiashavebeen bereferredtoaspecializedcardiologistwithexpertiseinmanagingCVDinpatientswith
reported.45,259QTcprolongationwasobserved1–5weeksafterar- cancer.
senictrioxideinfusionandthenreturnedtowardsbaselinebytheend
of8weeks.Patientsreceivingtreatmentwitharsenictrioxideshould
6.1. Cancer therapy-related cardiac
bemonitoredweeklywithECGduringthefirst8weeksoftherapy.
dysfunction
Electrolytemonitoringisalsorequiredasarsenictrioxidemayinduce
hypokalaemia,hypomagnesaemia,andrenaldysfunction.Riskfactors 6.1.1.Anthracyclinechemotherapy-relatedcardiac
forQTprolongationshouldbecontrolledbefore,during,andafter dysfunction
cancertreatment(Section6.4.2). CTRCDduringanthracyclinechemotherapymaypresentclinicallyor
SeveralFMS-liketyrosinekinase3(FLT3)inhibitors(first-generation: bedetectedinasymptomaticpatientsduringsurveillance(Figure10;
midostaurin;second-generation:gilteritinib)havebeentestedforthe Table3).4Thediagnosisofanthracyclinechemotherapy-relatedcar-
treatment of acute myeloid leukaemias. Gilterinib-induced differenti- diacdysfunctionincludesnewCVsymptoms,newabnormalitiesin
ationsyndrome(fever,dyspnoea,pleuropericardialeffusion,pulmon- cardiacfunctiononCVimaging,and/ornewincreasesincardiacbio-
aryoedema,peripheraloedema,hypotension,renaldysfunction,and markers(Table3).AMDTdiscussionisrecommendedtoconsider
rash)requiresearlycorticosteroidtherapyandhaemodynamicmoni- the risk/benefit ratio of continuing anthracycline chemotherapy in
toring until resolution of symptoms. Midostaurin and gilterinib may patientswhodevelopnewCTRCD.
prolongQTcintervalandcloseelectrolytesurveillanceandminimizing Discontinuationofanthracyclinechemotherapyisrecommended
drug–drug interactions are required (see Section 6.4.2; Table 9; inpatientswithcancerwhodevelopseveresymptomaticCTRCD.22
Supplementarydata,TablesS15andS16).423 Therearerareexceptionswhererechallengewithfurtheranthracy-
clinechemotherapymaybeconsideredafteraMDTdiscussion,using
preventionstrategiesdescribedbelowandunderclosemonitoring
6. Diagnosis and management of
witheachcycleofanthracyclinechemotherapy.Temporaryinterrup-
acute and subacute cardiovascular tionofanthracyclinechemotherapyisrecommendedinpatientswho
develop moderate symptomatic CTRCD, and in patients who de-
toxicity in patients receiving
velopmoderateorsevereasymptomaticCTRCD.AMDTapproach
anticancer treatment regardinginterruptionvs.continuationofanthracyclinechemother-
apy is recommended in patients who develop mild symptomatic
AcoordinatedMDTisrecommendedtodiscusspatientswithcancer CTRCD.
who develop acute CV complications of their cancer treatment.5 Guideline-basedHFtherapyisrecommendedinpatientswhode-
Referral to a specialized cardio-oncology service is recommended velop symptomatic CTRCD or asymptomatic moderate or severe
for patients with cancer who present with new CTR-CVT during CTRCD during anthracycline chemotherapy. The use of an ACE-I/
and after cancer treatment.12 The prevention and management of ARB or angiotensin receptor–neprilysin inhibitor, a beta-blocker, a
CVDinpatientswithcancershouldgenerallyfollowpublishedESC sodium–glucoseco-transporter2inhibitor,andamineralocorticoidre-
Guidelines for specific CVD. This chapter provides guidance on ceptor antagonist is recommended unless the drugs are contraindi-
themanagementofCTR-CVTthatoccurduringcancertreatment, cated or not tolerated. Up-titration to target doses as described in
and highlights where management differs for patients with cancer the 2021 ESC Guidelines for the diagnosis and treatment of acute
comparedwiththosewithout.ThedecisiontoinitiateCVtreatment andchronicHFisrecommended.14ACE-I,ARB,and/orbeta-blockers
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 55 ---
ESCGuidelines 4283
shouldbeconsideredinmildasymptomaticCTRCDwhileanthracy- symptomatic CTRCD, or moderate or severe asymptomatic
cline chemotherapy continues uninterrupted (Figure 25).1,14,102,424 CTRCD,afterrecoveryofLVfunctionunderHFtreatment.Ifthere
Thebeneficialeffectsofaerobicexercisebeforeandduringanthracy- is a compelling reason to continue anthracycline chemotherapy,
cline chemotherapy have been demonstrated and is recommended three other strategies exist in addition to continuing ACE-I/ARB
forpatientswithcancerwhodevelopCTRCD.11 and beta-blockers at target doses for HF.14 First, minimizing the
A MDT is recommended to discuss restarting anthracycline doseofanthracyclinechemotherapyadministered.Second,switch-
chemotherapy in patients who developed mild or moderate ing to liposomal anthracycline preparations. Third, pre-treatment
Management of patients withAC-related cardiac dysfunction
Symptomatic CTRCDa Asymptomatic CTRCDa
VVVery severe/severe Moderate Mild Severe/moderate Mild
Oncological
strategy
Discontinue Interrupt Interrupt
MDTapproach
AC AC AC Continue
regarding interruption
(Class I) (Class I) (Class I) AC
vs.. continuation
with CV monitoring
ofAC
AND AND AND (Class I)
(Class I)
MDTb MDTc MDTc
CV
strategy
GLS decrease >15%
NP increase
orcTn increase
ACE-I/ARB ACE-I/ARB
HF therapppy
and/or BB and/or BB
(Class I)
(Class IIa) (Class IIb)
Figure25Managementofanthracyclinechemotherapy-relatedcardiacdysfunction.AC,anthracyclinechemotherapy;ACE-I,angiotensin-converting
enzymeinhibitors;ARB,angiotensinreceptorblockers;BB,beta-blockers;cTn,cardiactroponin;CTRCD,cancertherapy-relatedcardiacdysfunction;
CV,cardiovascular;GLS,globallongitudinalstrain;HF,heartfailure;LV,leftventricular;LVEF,leftventricularejectionfraction;MDT,multidisciplinary
team;NP,natriureticpeptides.aSeeTable3(Section3)forcompletedefinition(symptomaticCTRCD:symptomaticconfirmedHFsyndrome;asymptom-
aticsevereCTRCD:LVEF,40%;asymptomaticmoderateCTRCD:LVEF40–49%;asymptomaticmildCTRCD:LVEF.50%).bInrareexceptions,an-
thracyclinechemotherapymayberestartedafterrecoveryofLVfunctionwithoptimalHFtherapy.cAMDTdiscussionisrecommendedbeforerestarting
anthracyclinechemotherapyafterrecoveryofLVfunction.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 56 ---
4284 ESCGuidelines
withdexrazoxanebeforeeachfurthercycleofanthracyclinechemo- AsymptomaticpatientswhohaveLVEF≥50%
therapy(Section5.2.1). andwhohavedevelopedNP.ULNmaybe
Closecardiacmonitoringevery1–2cyclesisrecommendedinpa-
consideredforACE-I/ARBand/or
IIb C
tientswhorestartanthracyclinechemotherapyfollowinganepisode beta-blockers.d,211
of CTRCD and in patients with mild asymptomatic CTRCD while
Strategiesforrestartinganthracyclinechemotherapyin
theycontinueanthracyclinechemotherapy.
patientswithCTRCD
Liposomalanthracyclineemaybeconsideredin
RecommendationTable24—Recommendationsfor patientswithmoderateorseveresymptomaticor
themanagementofcancertreatment-relatedcardiac
asymptomaticCTRCDcwhorequirefurther IIb C
dysfunctionduringanthracyclinechemotherapy anthracyclinechemotherapytoreducetheriskof
furtherCVtoxicity.
Recommendations Classa Levelb Dexrazoxanefmaybeconsideredinpatientswith
moderateorseveresymptomaticor
Anthracyclinechemotherapy-inducedsymptomaticCTRCD
asymptomaticCTRCDcwhorequirefurther IIb C
HFtherapyisrecommendedforpatientswho
anthracyclinechemotherapytoreducetheriskof
developsymptomaticCTRCDduring I B
furtherCVtoxicity.
anthracyclinechemotherapy.c,208,425
Discontinuationofanthracyclinechemotherapyis ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angiotensinreceptorblockers;
CTRCD,cancertherapy-relatedcardiacdysfunction;CV,cardiovascular;GLS,global
recommendedinpatientswhodevelop I C
longitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction; NP,
symptomaticsevereCTRCD.c natriureticpeptides;ULN,upperlimitofnormal.
aClassofrecommendation.
Temporaryinterruptionofanthracycline
bLevelofevidence.
chemotherapyisrecommendedinpatientswho cSeeTable3.SignificantfallinGLS=relativereduction.15%.
developsymptomaticmoderateCTRCDcanda I C dAvoidhypotension.
eSeetextforspecificliposomaldoxorubicintypeandmalignancies(Section5.2).
multidisciplinaryapproachregardingthedecision
fAspertheEuropeanMedicinesAgency:≥350mg/m2doxorubicinorequivalent;as
torestartisrecommended. pertheUnitedStatesFoodandDrugAdministration:≥300mg/m2doxorubicinor
Amultidisciplinaryapproachregarding equivalent.
interruptionvs.continuationofanthracycline
I C
chemotherapyisrecommendedinpatientswho 6.1.2.Humanepidermalreceptor2-targeted
developmildsymptomaticCTRCD.c therapy-relatedcardiacdysfunction
The diagnosis of HER2-targeted therapy-related CTRCD can be
Anthracyclinechemotherapy-inducedasymptomatic
made using the combination of new CV symptoms, imaging, and
CTRCD
biomarkers. Patients may present with symptomatic CTRCD or
Temporaryinterruptionofanthracycline
may be asymptomatic.426 Early treatment of symptomatic and
chemotherapyandinitiationofHFtherapyis
I C asymptomatic severe CTRCD (LVEF,40%), according to the
recommendedinpatientswhodevelop
2021 ESC Guidelines for the diagnosis and treatment of acute
asymptomaticmoderateorsevereCTRCD.c,22
and chronic HF,14 is recommended to prevent worsening HF,425
Amultidisciplinaryapproachregardingthe particularly whentargetedcancer therapyiscontinued.427 In pa-
decisionwhentorestartisrecommendedinall
I C tients who develop CTRCD, a MDT is recommended to guide
patientswithmoderateorsevereasymptomatic
clinical decisions. Temporary interruption is recommended
CTRCD.c,22
in patients who develop moderate or severe symptomatic
Continuationofanthracyclinechemotherapyis CTRCD or severe asymptomatic CTRCD (LVEF,40%) during
recommendedinasymptomaticpatientswho
HER2-targeted therapy. In patients with mild symptomatic
haveLVEF≥50%andwhohavedevelopeda I C
CTRCD,aMDTapproachisrecommendedtocontinuevs.inter-
significantfallinGLScoratroponinoraNP
ruptHER2-targetedtherapy.Inpatientswithasymptomaticmod-
elevation.ULN. erate CTRCD (LVEF 40–49%), HER2-targeted treatment should
AsymptomaticpatientswhohaveLVEF≥50%
becontinued,andcardioprotectivetherapy(ACE-I/ARBandbeta-
andwhohavedevelopedasignificantfallinGLSc
IIa B blockers) is recommended with frequent cardiac monitor-
shouldbeconsideredforACE-I/ARBand/or ing.22,33,189 In patients with asymptomatic mild CTRCD (LVEF≥
beta-blockers.d,75,93,102 50%withasignificantnewGLSreductionand/orcardiacbiomark-
AsymptomaticpatientswhohaveLVEF≥50%
er increase), continuing HER2-targeted treatment is recom-
andwhohavedevelopedatroponinelevation mended and cardioprotective therapy (ACE-I/ARB and/or
IIa B
.ULNshouldbeconsideredforACE-I/ARBand/ beta-blockers)shouldbeconsidered.22,211,428,429
orbeta-blockers.d,147,211 Frequent cardiac surveillance with cardiac imaging and cardiac
Continued serum biomarkers is recommended in all patients with CTRCD
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 57 ---
ESCGuidelines 4285
Management of patients with HER2-targeted therapies related cardiac dysfunction
Symptomatic CTRCDa Asymptomatic CTRCDa
Moderaaate to very severe Mild Severe Moderate Mild
Oncological
strategy
Anti-HER2 MDT approach Anti-HER2
interruption regarding interruption
Continue anti-HER2 Continue anti-HER2
(Class I) interruption (Class I)
under CV monitoring under CV monitoring
vs.. continuation of
(Class IIa) (Class I)
AND anti-HER2 AND
(Class I)c
MDTb,c MDTb,c
CV
strategy
GLS decrease >15%
cTn and NP increase
ACE-I/ARB
HF therapppy
and/or BB
(Class I)
(Class IIa)
Figure26Managementofhumanepidermalreceptor2-targetedtherapy-relatedcardiacdysfunction.ACE-I,angiotensin-convertingenzymeinhibitors;
ARB,angiotensinreceptorblockers;BB,beta-blockers;cTn,cardiactroponin;CTRCD,cancertherapy-relatedcardiacdysfunction;CV,cardiovascular;
GLS,globallongitudinalstrain;HER2,humanepidermalreceptor2;HF,heartfailure;LVEF,leftventricularejectionfraction;MDT,multidisciplinaryteam;
NP,natriureticpeptides.aSeeTable3(Section3)(symptomaticCTRCD:symptomaticconfirmedHFsyndrome;asymptomaticsevereCTRCD:LVEF,
40%;asymptomaticmoderateCTRCD:LVEF40–49%;asymptomaticmildCTRCD:LVEF.50%).bForpatientsinwhomHER2-targetedtherapyhas
beeninterrupted,whosesignsandsymptomsofHFdonotresolveand/orLVEFremains,40%,resumptionofHER2-targetedtherapymaybeconsidered
ifnoalternativetherapeuticoptionexists.Inadvancedcancerthatonlyrespondswelltotrastuzumab,therisk/benefitratiomaywarrantcontinuedther-
apyifotheroptionsremainlimited.22cForpatientswhereHER2-targetedtherapyhasbeeninterruptedandwhohaverecoveredLVEF≥40%andare
nowasymptomatic,resumptionofHER2-targetedtherapyshouldbeconsidered,supportedbyHFtherapy,andechocardiographyandcardiacbiomarker
assessmenteverytwocyclesforthefirstfourcyclesafterrestartingandthenthefrequencycanbereduced.22
who continue HER2-targeted cancer therapies and in those who serum biomarker measurement every two cycles for the first
restart after an interruption following resolution of HF signs and four cycles after restarting HER2-targeted therapy is recom-
symptoms and recovery of LVEF≥40% (and ideally recovery to mended,andthenthefrequencycanbereducedifcardiacfunction
LVEF≥50%) (Figure 26).22,33,189 Echocardiography and cardiac andbiomarkerlevelsremainstable.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 58 ---
4286 ESCGuidelines
RecommendationTable25—Recommendationsfor
ACE-I/ARBand/orbeta-blockersshouldbe
themanagementofcancertreatment-relatedcardiac
consideredinasymptomaticpatientsreceiving
dysfunction during human epidermal receptor 2-tar-
HER2-targetedtherapieswhohaveLVEF≥50% IIa B
getedtherapies
butdevelopanewtroponinorNPrisewhile
Recommendations Classa Levelb continuingHER2-targetedtherapy.e,22,211,428
ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angiotensinreceptorblockers;
HER2-targetedtherapy-inducedsymptomaticCTRCD
CTRCD,cancertherapy-relatedcardiacdysfunction;GLS,globallongitudinalstrain;
HFtherapyisrecommendedforpatientswho HER2,humanepidermalreceptor2;HF,heartfailure;LV,leftventricular;LVEF,LV
developsymptomaticmoderate-to-severe ejectionfraction;NP,natriureticpeptides.
I B aClassofrecommendation.
CTRCDwithLVEF,50%cduringHER2-targeted
bLevelofevidence.
treatment.14,61,430,431 cSeeTable3.
dFor patients where HER2-targeted therapy has been interrupted and who have
TemporaryinterruptionofHER2-targeted
recovered LVEF≥40% and are now asymptomatic, resumption of HER2-targeted
treatmentisrecommendedinpatientswho therapyshouldbeconsideredsupportedbyHFtherapyandechocardiographyand
developmoderateorseveresymptomatic cardiac biomarkers assessment every two cycles for the first four cycles after
CTRCDcandthedecisiontorestartshouldbe I C restartingandthenfrequencycanbereduced.
eAvoidhypotension.
basedonamultidisciplinaryapproachafter
improvementofLVfunctionandsymptoms
resolved.d
6.1.3.Immunecheckpointinhibitor-associated
Inpatientswhodevelopmildsymptomatic myocarditisandnon-inflammatoryheartfailure
CTRCD,cHFtherapyandamultidisciplinary
Myocarditis is a severe complication of ICI with a high fatality
approachregardingthedecisiontocontinuevs. I C rate that most frequently develops during the first 12 weeks of
interruptHER2-targetedtherapyare treatment, although late cases (after week 20) may occur.386
recommended.d,431,432
OtherICI-relatedCVtoxicitiesincludedyslipidaemia,ACS,vascu-
HER2-targetedtherapy-inducedasymptomaticCTRCD litis, AV block, supraventricular and ventricular arrhythmias, sud-
TemporaryinterruptionofHER2-targeted den death, TTS, non-inflammatory LVD, pericarditis, pericardial
therapyandinitiationofHFtherapyis effusion, and ischaemic stroke, with higher risks for myocarditis
I C
recommendedinpatientswhodevelop (odds ratio 4.42) and dyslipidaemia (odds ratio 3.68)
asymptomaticsevereCTRCD.c (Figure 27).323,325
ThediagnosisofICI-associatedmyocarditisisinitiallybasedonthe
Amultidisciplinaryapproachregardingthe
presenceofsymptoms,anewincreaseintroponin(associatedwith
decisiontorestartHER2-targetedtreatmentis
I C
either CV symptoms or non-CV immuno-related adverse events),
recommendedinpatientswithsevere
asymptomaticCTRCD.c andnewECGabnormalities(AVorintraventricularconductiondis-
orders, bradycardia, tachyarrhythmias) (see Section 3;
ContinuationofHER2-targetedtherapyshouldbe
Table3).17,434,435AnyabnormalfindingshouldprompturgentCVim-
consideredinpatientswhodevelopasymptomatic
IIa B
moderate(LVEF40–49%)CTRCDcwithmore aging and other causes of myocardial injury (e.g. ACS, acute infec-
frequentcardiacmonitoring.33,189,428,433 tious myocarditis) should be excluded. Treatment with high-dose
methylprednisoloneshouldbepromptlyinitiatedinhaemodynamic- ContinuationofHER2-targetedtherapyis
ally unstable patients (including those with ventricular arrhythmias
recommendedinpatientswhodevelop
I C [VA] or complete AV block) while awaiting further confirmatory asymptomaticmild(LVEF≥50%)CTRCDcwith
testing.436TTEandCMRarerecommendedinallpatientswithsus-
morefrequentcardiacmonitoring.428
pectedICI-associatedmyocarditis.Currently,specificCMRfeatures
ACE-I/ARBandbeta-blockersarerecommended
forICI-inducedmyocarditisarenotwelldescribedandmodifiedLake
inpatientswhodevelopasymptomaticmoderate
I C Louisecriteriaarerecommended(Table3).18Cardiacfluorodeoxy-
(LVEF40–49%)CTRCDcduringHER2-targeted
glucose positron emission tomography (PET) may be consid-
treatment.e,189
ered437,438ifCMRisnotavailableorcontraindicated,althoughPET
ACE-I/ARBand/orbeta-blockersshouldbe
sensitivity is low and requires a strict 18-h carbohydrate-free
consideredinasymptomaticpatientsreceiving
fast.439Endomyocardialbiopsy(EMB)shouldbeconsideredincases
HER2-targetedtherapieswhohaveLVEF≥50% IIa B
wherethediagnosisissuspectedbutnotconfirmednon-invasively
butdevelopasignificantfallinGLScwhile
(e.g.conflictingresultsofcardiacimagingandbiomarkersorclinically
continuingHER2-targetedtherapy.e,22,428
unstablepatients).440AllcasesofICI-associatedmyocarditisshould
Continued beclassifiedaccordingtotheseverityofthemyocarditis(fulminant
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 59 ---
ESCGuidelines 4287
Direct CV Toxicity
AArrrrhhyytthhmmiiaass Myocarditis Non-inflammatory HF
Takotsubo syndrome Pericarditis Vascular
Indirect CV Toxicity
Thyroid Adrenal Pituitary
Pancreas Embolism
Figure27Directandindirectimmunecheckpointinhibitor-relatedcardiovasculartoxicity.CV,cardiovascular;HF,heartfailure.
ornon-fulminant,includingsymptomaticbuthaemodynamicallyand CessationofICItreatmentisrecommendedinpatientswithcan-
electricallystablepatientsandincidentalcasesdiagnosedatthesame cerwithfulminantornon-fulminantICI-associatedmyocarditisand
timeasotherimmune-relatedadverseevents)toguidethemanage- the patient should be admitted to hospital and a level 2 or 3 bed
mentpathway(Figure28).331 with continuous ECG monitoring is required. CV complications
Interruption of ICI treatment is recommended in all cases of shouldbetreatedasperspecificESCGuidelines(HF,14tachyarrhyth-
suspected ICI-associated myocarditis (any patient developing mias,441,442AVblock,443orpericardialeffusion444).
new cardiac symptoms, new cardiac arrhythmias, new heart Treatment of both non-fulminant and fulminant ICI-associated
blocks,ornewtroponinincreasewhohasreceivedanICItherapy myocarditis with methylprednisolone 500–1000mg i.v. bolus once
in the past 12 weeks) while investigations are performed. Once daily for the first 3–5 days should be started as soon as possible,
theabnormalfindingshaveresolved,aMDTdiscussionisrecom- once the diagnosis is considered likely, to reduce MACE including
mendedtodeterminetherisk/benefittopermanentstoppingvs. mortality.386,436 If clinical improvement is observed (cTn reduced
resuming ICI treatment in patients with suspected but not con- by.50%frompeaklevelwithin24–72handanyLVD, AVblock,
firmedmyocarditis. and arrhythmias resolved), switching to oral prednisolone is
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 60 ---
4288 ESCGuidelines
Management of patients with a definitive diagnosis of ICI-related myocarditis
Severity (fulminant vs.. non-fulminant)a
Discontinue ICI;; hospital admission;; ECG monitoring
(Class I)
Methylprednisolone 500–1000 mg i.vvv.. bolus once daily (minimum 3 daaays)
(Class I)
Haemodynamically unstable
Recoveringb Steroidrefractory
fulminant myocarditis
Switching to
Second-line immunosuppression Admission to ICU (level 3)
oral prednisolone (1 mg/kg/daaay)
(Class IIa) (Class I)
(Class IIa)
AND AND
WWWeaning protocolby 10 mg/week Optimal CV treatment
with troponin monitoring including MCS
(Class IIa) (Class I)
AND
Complete recovery Second-line immunosuppression
(Class I)
Figure28Diagnosisandmanagementofimmunecheckpointinhibitor-relatedmyocarditis.CMR,cardiacmagneticresonance;CV,cardiovascular;
ECG,electrocardiogram;HF,heartfailure;ICI,immunecheckpointinhibitor;ICU,intensivecareunit;i.v.,intravenous;LGE,lategadoliniumenhancement;
LVEF,leftventricularejectionfraction;MCS,mechanicalcirculatorysupport.aFulminant:haemodynamicinstability,HFrequiringnon-invasiveorinva-
siveventilation,complete orhigh-grade heartblock,and/orsignificant ventriculararrhythmia. Non-fulminant:includingsymptomatic buthaemo-
dynamically and electrically stable patients and incidental cases diagnosed at the same time as other immuno-related adverse events. Patients may
havereducedLVEFbutnofeaturesofseveredisease.bRecovering:ongoingimprovementinpatientclinicalsymptoms,signs,biomarkers,andimaging
parameters,butnotyetnormalized,whileontaperingdosesofimmunosuppression.Completerecovery:patientswithcompleteresolutionofacute
symptoms,normalizationofbiomarkers,andrecoveryofLVEFafterdiscontinuationofimmunosuppression.CMRmaystillshowLGEorelevatedT1due
tofibrosis,butanysuggestionofacuteoedemashouldbeabsent.
recommendedstartingat1mg/kgupto80mg/day.Althoughthe 5mg/day,andafinalreductionfrom5mg/dayin1-mgperweek
mostappropriateweaningoffprotocolisnotconfirmed,aweekly steps.
reduction of oral prednisolone (most commonly by 10mg per If the troponin does not reduce significantly (.50% reduction
week)underclinical,ECG,andcTnsurveillanceshouldbeconsid- frompeak)and/orAVblock,ventriculararrhythmias,orLVDpersist
ered(Figure28).AreassessmentofLVfunctionandcTnshouldbe despite 3 days of i.v. methylprednisolone plus cardiac treatments,
consideredwhentheprednisolonedoseisreducedto20mg/day then steroid-resistant ICI-associated myocarditis is confirmed and
andthencontinueweaningtheprednisoloneby5mgperweekto second-line immunosuppression should be considered.22,445,446
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 61 ---
ESCGuidelines 4289
Thereisalackofdatatorecommendaspecificsecond-lineimmunosup- EMBshouldbeconsideredtoconfirmthe
pressionregimenandMDTdiscussionisrecommended.Severalagents diagnosisofICI-associatedmyocarditisifthe
IIa C
arecurrentlybeinginvestigatedwithpromisingresultsfromcaseseries
diagnosisissuspectedbutnotconfirmedafter
includingi.v.mycophenolatemofetil,anti-thymocyteglobulin(anti-CD3
cardiacimagingandbiomarkers.c
InterruptionofICItreatmentisrecommendedin
antibody),i.v.immunoglobulin,plasmaexchange,tocilizumab,abatacept
patientswithconfirmedICI-associated I C
(CTLA-4agonist),alemtuzumab(anti-CD52antibody),andtofacitinib.
myocarditis.
Cautionisadvised againsttheuseofinfliximab forsteroid-refractory
ContinuousECGmonitoringtoassessfornew
myocarditisandHF.447,448PatientswithfulminantICI-associatedmyo-
AVblockandtachyarrhythmiasduringtheacute
I C
carditis,complicatedbyhaemodynamicand/orelectricalinstability,re- phaseisrecommendedforallpatientswith
quire admission to the intensive care unit (ICU) and cardiogenic symptomaticICI-associatedmyocarditis.
shockshouldbemanagedaccordingtothe2021ESCGuidelinesfor Earlyhigh-dosecorticosteroidsdare
thediagnosisandtreatmentofacuteandchronicHF.14Asingledose recommendedinpatientswithcancerand I C
ofi.v.methylprednisoloneshouldbeconsideredinclinicallyunstablepa-
confirmedICI-associatedmyocarditis.22,436,454
tientswithcancerwhereICI-inducedmyocarditisissuspectedatpres- Continuationofhigh-dosecorticosteroidsis
entationbutbeforedefinitivediagnosiscanbeconfirmed. recommendedforthetreatmentofICI-associated
myocarditisuntilresolutionofsymptoms,LV I C
FollowingrecoveryfromICI-associatedmyocarditisandweaning
systolicdysfunction,conductionabnormalities,
oforalsteroidtherapy,MDTdiscussionisrecommendedtoreview andsignificantcTnreduction.e
thedecisiononwhethertorestartICItreatment.Thisdependson Switchingfromi.v.tooralprednisoloneshouldbe
variousfactorsincludingtheseverityoftheICI-associatedmyocardi- consideredafterclinicalimprovement(resolution
IIa C
tis(fulminantvs.non-fulminantvs.asymptomatic),alternativeoncol- of:symptoms,LVsystolicdysfunction,conduction
ogy treatment options, metastatic vs. adjuvant/neoadjuvant abnormalities,andsignificantcTnreductione).f
indication,andreducingfromdualICItosingleICItreatmentiftrig- Second-lineimmunosuppressiontreatment
geredbycombinationICItreatment.449 shouldbeconsideredinpatientswith IIa C
Non-inflammatoryHFsyndromeshavealsobeenobservedinpa-
steroid-refractoryICI-associatedmyocarditis.g
tientstreated with ICI. These include TTS, non-inflammatory HF or AdmissiontoICU(level3),treatmentwithi.v.
methylprednisolone,andoptimalCVtreatment
LVD,450 and post-MI HF.451,452 Non-inflammatory HF is generally a
includingmechanicalsupport(whenindicated)is I C
lateevent andthe diagnostic workflow shouldbe based on defining
recommendedforpatientswithICI-associated
theHFphenotypeandexcludingmyocarditis,TTS,andACS.14There fulminantmyocarditis.14
is also evidence that vasculitis and CAD can occur after ICI treat- Asingledoseofi.v.methylprednisolonedshould
ment.335HFtreatmentasperthe2021ESCGuidelinesforthediagno- beconsideredinunstablehpatientswithcancer IIa C
sisandtreatmentofacuteandchronicHFisindicated,14butthereisno whereICI-inducedmyocarditisissuspected.
indication for immunosuppression if myocarditis has been excluded. Amultidisciplinarydiscussionisrecommended
Interruption vs. continuing ICI therapy depends on the severity of beforerestartingICItreatmentinselected I C
patientswithpreviousuncomplicated
the HF syndrome and each case should be reviewed by a MDT.
ICI-associatedmyocarditis.
Arrhythmias,suchasAF,canbeseeninpatientswithICItherapywith-
out myocarditis (e.g. ICI-associated thyroiditis with thyrotoxicosis, AV, atrioventricular; CMR, cardiac magnetic resonance; cTn, cardiac troponin;
ICI-associatedpericarditis,orICI-associatedseveresystemicinflamma- CV,cardiovascular;ECG,electrocardiogram;EMB,endomyocardialbiopsy;HF,heart
failure;ICI,immunecheckpointinhibitors;ICU,intensivecareunit;i.v.,intravenous;
tory syndromes). ICI treatment can be continued after excluding
LGE,lategadoliniumenhancement;LV,leftventricular;LVD,LVdysfunction;LVEF,
myocarditis. LVejectionfraction.
aClassofrecommendation.
bLevelofevidence.
cSeeTable3forICI-relatedmyocarditisdefinition.EMBshouldbeconsideredinunstable
RecommendationTable26—Recommendationsfor
patientsorwhenCMRiscontraindicated.
thediagnosisandmanagementofimmunecheckpoint dEarly:≤24h;high-dosecorticosteroids(methylprednisolone500–1000mg/day).
inhibitor-associatedmyocarditis eReductionofcTnby.50%frompeaklevel.
fComplete recovery: Patients with complete resolution of acute symptoms,
Recommendations Classa Levelb normalization of biomarkers, or reduction of cTn by .50% from peak level and
recovery of LVEF after discontinuation of immunosuppression are considered to
cTn,ECG,andCVimaging(echocardiographyand haveachievedcompleterecovery.CMRmaystillshowLGEorelevatedT1dueto
CMR)arerecommendedtodiagnose I B fibrosis but any suggestion of acute oedema should be absent. Incomplete
recovery:(1)anincreaseinsymptomsorbiomarkersofmyocarditisoraninability
ICI-associatedmyocarditis.320,434,435,453
totaperimmunosuppressionwithoutaclinicalorbiomarkerflare;(2)patientswith
InpatientswithsuspectedICI-associated persistentLVDdespiteresolutionofacutesymptomswithimmunosuppression.
myocarditis,temporaryinterruptionofICI gSteroidrefractory:non-resolvingorworseningmyocarditis(clinicalworseningor
I C
treatmentisrecommendeduntilthediagnosisis persistenttroponinelevationafterexclusionofotheraetiologies)despitehigh-dose
confirmedorrefuted. methylprednisolone(Table3;Supplementarydata,TableS1).
hUnstable:patientswithsymptomaticHF,ventriculararrhythmias,newcomplete
Continued heartblock.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 62 ---
4290 ESCGuidelines
6.1.4.ChimericantigenreceptorTcelland resting 12-lead ECG, continuous ECG monitoring, TTE, and cTn
tumour-infiltratinglymphocytestherapiesand and NP are recommended. Admission to ICU (level 3) is recom-
heartdysfunction mendedinseverecasesduetotheriskofmalignantcardiacarrhyth-
Although no large-scale studies on the multiple CV complications mias,circulatorycollapse,andmultiorgansystemfailure.Ingeneral,
among adults treated with CAR-T therapies exist, small studies thedegreeofelevationofcytokinescorrelateswiththeseverityof
and case reports have shown that CV complications represent CRS. C-reactive protein is not specific for CRS and changes in
around20%ofadverseevents.378CVcomplicationsareassociated C-reactiveproteinmaylagbehindclinicalchangesby≥12h.Adra-
withhighmortalityrates,andaresecondarytoCRSandimmuneef- maticelevationofinterleukin-6isasupportivefindingforthediagno-
fector cell-associated neurotoxicity syndrome. The most common sis of CRS. Management of the specific CV complication should
CVcomplicationsinpatientsreceivingCAR-Ttherapiesarearrhyth- follow ESC Guidelines, with additional management of the CRS
mias (77.6%), including QTc prolongation, ventricular arrhythmias, (e.g. the anti-interleukin-6 receptor antibody, tocilizumab, and
andAF;HF(14.3%);andMIandVTE(0.5%).455Whensuspected,a dexamethasone).381
Diagnosis and management workup in patients with cancerrr-related TTTakkkotsubo syndrome
Clinical evaluation Coronary angiography CMR
ECG (invasive orCCTTTA) to exclude myocarditis and
AND AND
TTE to excludeACS myocardial infarction
Cardiac serum biomarkkkers (Class I) (Class I)
CCU/HDU/ICU admission
ECG monitoring
AAAvoid QTTT-prolonging Interruption of the For ICI-relatedTTS:
drugs AND culprit cancer drug AND methylprednisolone
(Class III) (Class I) (1000 mg i.vvv.)
Y Recovery of function N
MDT
MDTapproach regarding
(Class I)
interruption vs resuming
the culprit cancer drug
Consider resuming cancer
treatment under close
monitoring
(Class I)
Figure29Diagnosisandmanagementworkupincancer-relatedTakotsubosyndrome.ACS,acutecoronarysyndromes;CCTA,coronarycomputed
tomographyangiography;CCU,coronarycareunit;CMR,cardiacmagneticresonance;ECG,electrocardiogram;HDU,high-dependencyunit;ICI,im-
munecheckpointinhibitor;ICU,intensivecareunit;i.v.,intravenous;MDT,multidisciplinaryteam;N,noTTE,transthoracicechocardiography;TTS,
Takotsubosyndrome;Y,yes.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 63 ---
ESCGuidelines 4291
AlthoughCVcomplicationsarecommonwithTILtherapies,sur- RecommendationTable27—Recommendationsfor
vivaldoesnotappeartobesignificantlyaffected.Themostfrequent the diagnosis and management of Takotsubo syn-
CVeventsarehypotensionthatmayrequiretreatmentwithi.v.fluids dromeinpatientswithcancer
andpressors,AF,andtoalesserextent,cTnelevationsuggestiveof
Recommendations Classa Levelb
myocardialdamage.380Furtherresearchisneededtodefinemechan-
ismsand potential prevention strategies to help clinicians with the Coronaryangiography(invasiveorCCTA)is
I C
managementoftheseCVevents. recommendedtoexcludeACS.
CMRisrecommendedtoexcludemyocarditisand
I B
MI.458
6.1.5.Heartfailureduringhaematopoieticstemcell QT-prolongingdrugsarenotrecommended
III C
transplantation duringtheacuteTTSphase.c
CVcomplicationsduringHSCT,includingcongestiveHF,456arterial
events,tamponade,andrhythmdisturbances(AF,atrialflutter,and ACS,acutecoronarysyndromes;CMR,cardiacmagneticresonance;CCTA,coronary
computed tomography angiography; LV, left ventricular; MI, myocardial infarction;
supraventricular tachycardia),457 are uncommon but clinically rele- QTc,correctedQTinterval;TTS,Takotsubosyndrome.
vant,andshouldbetreatedasperspecificESCGuidelines(HF,14ta- aClassofrecommendation.
chyarrhythmias,273,441 pericardial effusion,444 or acute coronary
bLevelofevidence.
cUntilfullrecoveryandnormalizationofLVfunctionandQTc.
syndrome458).StudiesoftreatmentsduringHSCTtopreventboth
acute and late CV toxicity are limited.145 ACE-I and beta-blockers
may be effective, but this requires further confirmation.
6.2. Coronary artery disease
Outpatientandhome-basedexerciseandeducationprogrammesin-
6.2.1.Acutecoronarysyndromes
stituted after HSCT can improve exercise capacity and quality of
life,459 and the role of exercise pre-habilitation prior to HSCT is PatientswithcancerareatincreasedriskofCADbecauseofshared
beinginvestigated.460,461 CVRFs34 and CV toxicity of cancer therapy12 compounded by a
cancer-induced pro-inflammatory and prothrombotic state
(Table7).467,468,470–473
6.1.6.Takotsubosyndromeandcancer Current knowledgeon ACS inpatients with cancer isbasedon
observational data and registries demonstrating that, especially
TheprevalenceofmalignantdiseasesishighinpatientswithTTS
whendiagnosedwithin1year,theyareatincreasedriskformajor
and is a risk factor for worse outcomes. Malignancy itself, some
CV events, bleeding, and cardiac and non-cardiac
mortality.474–480
cancer treatments (5-FU, ICI, VEGFi), and the stress associated
TheproportionofACSpatientswithadiagnosisofcancerisrising
with the diagnosis, investigations, and treatment are recognized
triggers or predisposing factors for
TTS.462–466
Diagnosis using
andconstitutesabout3%oflargeseries.475
generalTTScriteriaisrecommended.467,468Investigationsinapa- Diagnosis of ACS is based on the same principles as in patients
withoutcancer,includingsymptoms,anearly12-leadECG,andserial
tientwithcancerwithsuspectedTTSshouldincludeclinicalexam-
measurements of hs-cTn for patients presenting with possible
ination, ECG, TTE, cardiac biomarkers (cTn and NP), and CMR
(Figure29).468,469Mostpatientsrequireinvasivecoronaryangiog- non-ST-segment elevation ACS (NSTE-ACS).458 Clinical presenta-
tion can be atypical481 or masked by cancer or therapy-related
raphytoexcludeacuteMI.Inpatientswithadvancedmalignancyor
significant thrombocytopaenia where invasive coronary angiog- sideeffects;therefore,diagnosticsuspicionshouldbeincreasedinpa-
tientsathighCVriskortreatedwithvascularcardiotoxictherapies raphy is contraindicated, a CCTA is recommended. Cardiac im-
aging studies should be performed as early as possible when the
diagnosis is suspected as LVD can be transient, and if significant
LVD is detected then repeat imaging to confirm recovery is
Table7 Cancertreatmentsthatpredisposetoacute
recommended.
coronarysyndromes
InterruptionoftheculpritcancerdruginpatientswithTTSisre-
commended.QT-prolongingdrugsshouldbeavoided.467Incasesof Acceleratedatherosclerosis ADT(GnRHagonists),ICI,nilotinib,
andplaquerupture ponatinib,radiationtherapy,VEGFi
ICI-associatedTTS,theroleofimmunosuppressionisunknownand
ifmyocardialinflammationispresentinaTTSpatternonCMRthen Vasospasm Bleomycin,fluoropyrimidines,taxanes,
i.v.methylprednisoloneisrecommendedgiventheoverlapbetween VEGFi,vincaalkaloids
ICI-induced TTS and ICI-induced myocarditis. Limited information Coronarythrombosis Alkylatingagents(cisplatin,
existsregardingthefeasibilityofICIrechallengefollowingTTSand cyclophosphamide),erlotinib,ICI,IMiD
afterrecoveryofLVfunction. (lenalidomide,thalidomide),monoclonal
A MDT discussion is recommended after recovery from the antibodies(VEGFi,anti-CD20),nilotinib,
acutephaseofTTSand,ifrestartingtheculpritcancerdrugisre- platinumchemotherapy,PI,ponatinib,
quired from an oncology perspective, regular cardiac biomarker VEGFi.
monitoring is recommended (e.g. cTn and NP measured before
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; ICI,
everyICIcycle,andTTEifanewriseincardiacbiomarkersoccurs)
immune checkpoint inhibitors; IMiD, immunomodulatory drugs; PI, proteasome
(Figure29). inhibitors;VEGFi,vascularendothelialgrowthfactorinhibitors.
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 64 ---
4292 ESCGuidelines
(Table7).Echocardiographyimprovesthediagnosticprecisioninpa- Thrombocytopaenia (platelet count,100000/µL) is present in
tientswithatypicalsymptomsandassessesforothercardiaccauses about10%ofpatientswithcancerandmaycomplicateACSmanage-
ofchestpain. ment.Basedonasmallseries,coronaryangiographycanbesafelyper-
ManagementofACSinpatientswithcancercanbechallengingbe- formed in these patients when preventative measures to avoid
causeoffrailty,increasedbleedingrisk,thrombocytopaenia,increased bleeding are taken: platelet transfusion before catheterization (for
thrombotic risk,andthe possible need forfuturesurgery/interven- platelets ,20000/µL), radial access, careful haemostasis, and
tions.482 Cancer treatment should be temporarily interrupted, and theuseofalowerheparindose(30–50U/kg).486Antiplateletsshould
anurgentmultidisciplinaryapproach5isindicatedtoplananindividua- not be withheld unless platelet count is ,10000/µL for aspirin or
lizedguideline-basedmanagement,takingintoaccountcancerstatus, ,30000/µLforclopidogrel.ForPCIandCABG,expertsadvisemin-
prognosis,andthepatient’spreferencesregardinginvasivemanage- imumplateletcountsof30000/µLand50000/µL,respectively.484
ment.Asinpatientswithoutcancer,admissiontoamonitoredunit IncaseofMIwithnon-obstructivecoronaryarteries,CMRmaybe
andinitiationofappropriateanti-ischaemicandantithrombotictreat- considered to detect other causes of myocardial injury, especially
mentareindicated,intheabsenceofcontraindications. myocarditisandTTS.
A large retrospective propensity score-matching analysis Whenacuteischaemiaisprovokedbycancertherapy,alternative
found that percutaneous coronary intervention (PCI), despite cancertherapiesshouldbeconsideredafteraMDTdiscussion.Inthe
its lower use, was strongly associated with lower adjusted caseofcoronaryvasospasmsecondarytofluoropyrimidines,andin
MACE and all-cause mortality in patients with cancer theabsenceofanalternativetherapy,arechallenge,althoughcontro-
(Hodgkin and non-Hodgkin lymphomas and breast, lung, colon, versial,canbeconsideredinamonitoredunitafterexclusionofse-
and prostate cancers).483 Therefore, immediate coronary angi- vere CAD (CT or coronary angiography) and after initiation of
ography and PCI are recommended in patients with cancer prophylactic therapy with long-acting nitrates and calcium channel
and ACS ifcancer prognosis is≥6monthsor iftheyhave acute blockers(CCB).487–489
complications of ACS (cardiogenic shock, pulmonary oedema, Following ACS, a review of the cancer medications is recom-
ventricular tachyarrhythmias), where PCI offers palliation of mended, and any cancer drug associated with thrombosis and MI
symptoms.483 When stenting is indicated, third-generation should be stopped. Restarting cancer drugs associated with acute
drug-eluting stents are preferred because of the lower risk of thrombosis and MI after ACS (Table 7) should occur only after a
in-stent thrombosis. Balloon angioplasty is associated with MDT to explore other cancer therapies, with appropriate patient
worse outcome474 and should only be used in case of severe education and consent. Cancer therapies not associated with MI
thrombocytopaenia or need for urgent surgery. Fractional canberestartedoncerevascularization,whereindicated,hasbeen
flow reserve or instantaneous free wave ratio are advised by completedandthepatientisstabilizedonACSmedicaltherapywith-
experts484 to avoid unnecessary interventions while intravascu- outcomplications.
lar ultrasound and optical coherence tomography can be used
to ensure optimal stent apposition and expansion, to avoid
RecommendationTable28—Recommendationsfor
thrombotic complications.485
themanagementofacutecoronarysyndromesinpa-
Retrospective data have demonstrated a lower use of invasive tientsreceivinganticancertreatment
managementinpatientswithcancerwithST-segmentelevationMI
(STEMI), with a better outcome for invasively treated pa- Recommendations Classa Levelb
tients.475,480,483PCIhasnotdemonstratedamortalitybenefitinpa-
Aninvasivestrategyisrecommendedinpatients
tientswithadvancedcancerandNSTE-ACScomparedwithoptimal
withcancerpresentingwithSTEMIorhigh-risk
medical therapy.479 Therefore, a non-invasive approach can be at- I B
NSTE-ACSwithlifeexpectancy≥6
temptedinlow-risk(withoutsignsorsymptomsofongoingischae-
months.475,479,483
mia or haemodynamic instability) NSTE-ACS patients with poor
cancerprognosis(,6months). Aconservativenon-invasivestrategyshouldbe
consideredinpatientswithpoorcancer
Duetoapotentiallyhigherbleedingrisk(especiallyinpatientswith
prognosisc(withlifeexpectancy,6months)and/ IIa C
active GI cancer),477 the preferred antithrombotic strategy after
orveryhighbleedingriskpresentingwithSTEMI
drug-elutingstentconsistsofDAPTwithaspirinandclopidogrelin-
orNSTE-ACS.479
steadofnewerP2Y12antagonists.ThedurationofDAPTshouldbe
keptasshortaspossible(1–3months).458Inpatientswithneedfor Atemporaryinterruptionofcancertherapyis
recommendedinpatientswherethecancer
therapeutic anticoagulation and antiplatelet therapy, a NOAC and I C
therapyissuspectedasacontributing
singleoralantiplatelet(preferablyclopidogrel)isthedefaultstrategy
cause.d,10,490
afterashortperiodoftripleantithrombotictherapy(upto1weekin
hospital).458 Coronary artery bypass graft (CABG) surgery can be AshortDAPTstrategyshouldbeconsideredin
consideredinpatientswithextensiveCADwhoarenotamenable patientswithcancerwithveryhighbleedingrisk IIa C
with PCI, after MDT discussion and where cancer prognosis is
treatedwithPCIforanACS.e
.12months. Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 65 ---
ESCGuidelines 4293
Inpatientswithcancer,thrombocytopaenia,
RecommendationTable29—Recommendationfor
andACS,aspirinisnotrecommendedifplatelets III C the management of chronic coronary syndromes in
patientsreceivinganticancertreatment
,10000/µL.
Inpatientswithcancer,thrombocytopaenia,and Recommendation Classa Levelb
ACS,clopidogrelisnotrecommendedifplatelets
III C
,30000/µLandprasugrelorticagrelorarenot IndividualizeddurationofDAPTisrecommended
recommendedifplatelets,50000/µL. inpatientswithcancerwithCCS,following
revascularization,baseduponthrombotic/ I C
Ticagrelororprasugrelmaybeconsideredin
ischaemicandbleedingrisk,typeandstageof
patientswithcancerwithlowbleedingriskand
IIb C cancer,andcurrentcancertreatment.100,498
excessivethromboticriskwhoaretreatedwith
PCIforACS. CCS,chroniccoronarysyndromes;DAPT,dualantiplatelettherapy.
aClassofrecommendation.
ACS,acutecoronarysyndromes;CrCl,creatinineclearance;CV,cardiovascular;DAPT, bLevelofevidence.
dual antiplatelet therapy; GI, gastrointestinal; GU, genitourinary; NSTE-ACS,
non-ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary
intervention;STEMI,ST-segmentelevationmyocardialinfarction;ULN,upperlimitof 6.3. Valvular heart disease
normal.
aClassofrecommendation. New or worsening VHD in patients with cancer may be related
bLevelofevidence.
tocoexistingconditions,includingCTRCD,ACS,PH,endocarditis,
cRelatedtoadvancedcancerstageand/orsevereirreversiblenon-CVcomorbidities.
dAnticancer therapies associated with high risk of ACS (very common [.10%]):
cardiactumours,andmechanicalprostheticvalvethrombosis.499,500
capecitabine,paclitaxel,cisplatin,carfilzomib,bevacizumab,ramucirumab,aflibercept, Pre-existing severe VHD is associated with an increased risk of
axitinib,sorafenib,pazopanib,cabozantinib,lenvatinib,ponatinib,erlotinib. CTRCD,12,501–503andmayalsoposeariskforcancersurgeryout-
eHigh risk of GI or GU bleeding, significant drug–drug interactions, severe renal
dysfunction (CrCl,30mL/min), significant liver disease (alanine aminotransferase/ comes. In patients with mechanical prosthetic valves, the risk of
aspartate aminotransferase .2×ULN), or significant thrombocytopaenia (platelet thrombosisvs.bleedingshouldbecarefullybalancedduringchemo-
count,50000/µL).
therapytreatment.InpatientswithsevereVHDdiagnosedatbase-
line assessment, a MDT is required before cancer therapy to
decidethebesttreatmentoption.Cardiacsurgeryisfrequentlychal-
6.2.2.Chroniccoronarysyndromes lenginginpatientswithcancerbecauseofcomorbidities,frailty,me-
Several cancer treatments are associated with an increased risk of diastinalfibrosisduetopriorRT,impairedwoundhealing,andthe
stableanginaandchroniccoronarysyndromes(CCS).4915-FUand need for urgent oncology treatment (surgery, chemotherapy, tar-
capecitabine can precipitate effort angina in some cases.4,482,492 geted cancer therapies that effect wound healing). Transcatheter
Platinum-containingchemotherapy-inducedischaemiausuallyoccurs aorticvalveimplantation(TAVI)maybeaviableoptionforpatients
after one of the first three cycles and in patients with underlying withcancerwithsevereaorticstenosistolimitrecoverytimeandde-
CAD.493Theincidenceofcardiacischaemiais1–5%withantimicro- laysinstartingcancertreatment.504–506
tubule agents, 2–3% with small-molecule VEGF-TKI, and 0.6–1.5% PatientswithcancersuspectedofneworworseningVHD,suchas
with VEGFi monoclonal antibody therapies.492 Nilotinib, ponati- dyspnoeaoranewcardiacmurmur,orthosewithfeverandpositive
nib,494andICI335alsoaccelerateatherosclerosis,whichcanleadto bloodcultures,shouldbescreenedforendocarditisandmanagedac-
stableangina. cording to the recommendations from the 2021 ESC/European
Patientsreceivingcancertherapywhopresentwithnewstablean- Association for Cardio-Thoracic Surgery (EACTS) Guidelines for
gina should have careful clinical evaluation, with aggressive CVRF the management of VHD,507 while considering the cancer-related
modification and an initial medical management of their symp- prognosis.Ifvalvesurgeryorpercutaneousvalvetreatmentisindi-
toms.484ThediagnosisandmanagementofCADshouldfollowthe catedinapatientreceivingcancertreatment,thenaMDTisrecom-
2019ESCGuidelinesforthediagnosisandmanagementofchronic mended regarding type of valve treatment and periprocedural
coronarysyndromes.100 managementofcancertreatments.
The management of CCS is similar in patients with and with-
out cancer, in accordance with guideline recommendations.100
However, in the setting of CCS, decisions regarding coronary
RecommendationTable30—Recommendationsfor
themanagementofvalvularheartdiseaseinpatients
revascularization should be undertaken by a MDT that includes
receivinganticancertreatment
cardio-oncology, intervention, and oncology specialists.5 PCI in
patients with cancer is associated with an increased risk of
Recommendations Classa Levelb
bleeding,90-dayreadmissionsforacuteMI,in-hospitalandlong-
term mortality, and the need for repeat revascularization, with Inpatientswithcancerandpre-existingsevere
the magnitude of risk depending on both cancer type and VHD,managementaccordingtothe2021ESC/
stage.495,496 The excess bleeding risk should be mitigated by EACTSGuidelinesforthemanagementofVHDis I C
keeping the duration of DAPT as short as possible.497,498 The recommended,takingintoconsiderationcancer
risk is higher in patients with a cancer diagnosis within the pre- prognosisandpatientpreferences.507
ceding year.477 Continued
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 66 ---
4294 ESCGuidelines
InpatientswithcancerdevelopingnewVHD
mayhavealimitedefficacyifacancertherapyisthespecificcause
duringcancertherapy,managementaccordingto
oftheAF.508Amongrate-controldrugs,beta-blockersarepreferred,
the2021ESC/EACTSGuidelinesforthe especiallyifthecancertherapieshavepotentialCTRCDrisk,where-
I C managementofVHD507isrecommended,taking asdiltiazemandverapamilshouldbeavoidedwherepossibledueto
intoconsiderationcancerprognosisandpatient their drug–drug interactions and negative inotropic effects.508 The
comorbidities. possibility of AF ablation should be discussed in selected patients
withHF/LVDand/oruncontrolledsymptoms,takingintoconsider-
EACTS,EuropeanAssociationforCardio-ThoracicSurgery;ESC,EuropeanSocietyof
ation cancer status and prognosis in the context of a MDT
Cardiology;VHD,valvularheartdisease.
aClassofrecommendation. approach.522
bLevelofevidence. AcomplexissueinpatientswithcancerwithnewAFisriskstrati-
ficationforstroke/systemicembolism,whichaccordingtoguidelines,
shouldbebasedontheCHA DS -VAScscore(Congestiveheartfail-
2 2
6.4. Cardiac arrhythmias ure, Hypertension, Age≥75 years [2 points], Diabetes mellitus,
6.4.1.Atrialfibrillation Stroke[2points]—Vasculardisease,Age65–74years,Sexcategory
AFmayoccurinpatientswithcancerindifferentsettings:itmaybea [female]).273,523,524TheCHA DS -VAScscorehasnotbeenexten-
2 2
markerofcancertypeoroccultcancer,oritmaydevelopinpatients sivelyvalidatedinpatientswithcancer.525Inalargecohortofpatients
undergoingsurgery,chemotherapy,orRT.508,509Alltypesofcancer withAF,thepredictivevalueoftheCHA DS -VAScscorewaslower
2 2
showanincreasedriskofAFcomparedwiththecontrolgroup,but inpatientswithcancerthaninthosewithout,butaprogressivein-
theriskofAFdependsonthecancertypeandstage.510,511AFduring crease in the risk of ischaemic stroke according to the
acancertreatmentmaybecausedbyaspecifictherapyorinteraction CHA DS -VASc score was also found in AF patients with cancer
2 2
withapre-existingsubstrateinolderpatientswithcancer. (from 0.9% per year to 8.9% per year).519 However, the scope of
During cancer therapy AF may occur with a frequency ranging thisscoreisnottoidentifyhigh-riskpatients,butrathertoidentify
from 2% to 16%, according to a variety of
factors,4,490,508,512–514
low-riskindividualsinwhomanticoagulationcanbeavoided.Astudy
andmaypresenteitherasfirst-diagnosedAForasrecurrenceofpar- based on the Danish healthcare system data set found that
oxysmal AF. The risk of developing AF is greater in patients older CHA DS -VASc scores of 0 and 1 in patients with recent cancer
2 2
than65yearsand/orwithpre-existingCVD.4,509,512,515Cancersur- werelinkedwithhigherriskofstroke/thromboembolismat2years
gery is associated with a variable rate of AF occurrence, with the than in patients without recent cancer.526 This concept should be
highest incidence reported for lung surgery, ranging from 6% to consideredindefiningtherisk/benefitratioofanticoagulationinindi-
32%, but with occurrence also in cases of non-thoracic surgery vidualpatientswithcancer.Therefore,thedecisionforanticoagula-
(e.g.4–5%aftercolectomy).509 tioninpatientswithanactivemalignancyshouldtakeintoaccount
Manyanticancerdrugshavebeenassociatedwithanincreasedrisk theenhancedthromboticand/orbleedingriskandotherriskpredic-
of AF both in terms of incident and recurrent AF (Supplementary tionscoresusedforgeneralAFpopulations.509Forbleedingriskas-
data, Table S18).251 AF may occur shortly after treatment516 or sessment,theHAS-BLED(Hypertension,Abnormalrenalandliver
weeks or months after starting treatment.517,518 The pathophysi- function, Stroke, Bleeding Labile international normalized ratio,
ologyofAFassociatedwithcanceriscomplexandhasbeenexten- Elderly,Drugsoralcohol)scoremaybeconsidered.Aproposedap-
sivelyreviewedelsewhere(Figure30).509 proachtoanticoagulationtherapyincancer,basedontheacronymT
Inpatientswithcancer,theoccurrenceofAFisassociatedwitha (thromboticrisk),B(bleedingrisk),I(interactionsamongdrugs),P
two-foldhigherriskofsystemicthromboembolism/strokeandasix- (patientaccessandpreferences),isoutlinedinFigure31.519,527
foldincreaseintheriskofHF.4,509,512Thecoexistenceofcancerin- Long-termanticoagulationisrecommendedinadultpatientswith
creasestheriskofall-causemortality,majorbleeding,andintracranial CHA DS -VAScscore≥2inmenor≥3inwomenandmustbecon-
2 2
haemorrhage in patients withAF. The association betweencancer sideredalsowhenthescoreis1inmenand2inwomen.273Theclin-
and ischaemic stroke differs between cancer types, and in some ical pattern of AF (i.e. first detected, paroxysmal, persistent,
types, the risk of bleeding seems to exceed the thromboembolic long-standingpersistent,permanent,post-operative)shouldnotin-
risk.519ThemanagementofAFinpatientswithcancershouldfollow fluencetheindicationofthromboprophylaxis.273Thesameapproach
the2020ESCGuidelinesforthediagnosisandmanagementofatrial canbeproposedforpatientswithcancerandAF,alsoconsidering
fibrillation273andthe‘ABCpathway’(AtrialfibrillationBetterCare) thattheCHA DS -VAScscorelikelyunderestimatestheirthrombo-
2 2
approachshouldbeapplied(A:Anticoagulationtoavoidstroke/sys- embolicrisk.530Inthespecificsettingofcancer,decision-makingon
temic embolism, B: Better symptom control with rate- and/or long-term oral anticoagulation should also consider the cancer-
rhythm-controldrugsandinterventions,andC:Comorbiditiesand relatedtype,stage,prognosisandthepotentiallychangingthrombo-
CVRFmanagement,includinglifestylechanges).273,520 embolic or bleeding risk.508,509 The use of vitamin K antagonists
TheacutemanagementofAFinpatientswithcancershouldcon- (VKA)incancerislimitedbytheirdrawbacksinthissetting;however,
siderelectricalcardioversionincasesofhaemodynamicinstability,521 theyremaintheonlyindicatedanticoagulantsinpatientswithmod-
whileinothers,thealternativebetweenrateandrhythmcontrolhas erate to severe mitral stenosis or a mechanical prosthetic valve.
several important considerations specific to patients with cancer. LMWHconstitute a viableshort-term anticoagulationoption, par-
DrugsforrhythmcontrolmayleadtoQT-intervalprolongation,369 ticularlyinhospitalizedpatientswitharecentcancerdiagnosis,ad-
frequently have drug–drug interactions with cancer therapies, or vanced cancer disease, or during some cancer treatments (e.g.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 67 ---
ESCGuidelines 4295
Pathophysiology of AF associated with cancer
Ageing
Anticancer CV and metabolic
treatmentsa comorbiditiesb
AF
in cancer
Inflammation
Hypoxia
Cancer
ANS imbalance
surgery
Paraneoplastic
manifestations
Cancer
invasion
Figure30Pathophysiologyofatrialfibrillationassociatedwithcancer.AF,atrialfibrillation;ANS,autonomicnervoussystem;CV,cardiovascular;DM,
diabetesmellitus;HF,heartfailure;IHD,ischaemicheartdisease;VHD,valvularheartdisease.aSupplementarydata,TableS18.bObesity,hypertension,
DM,CVDs(HF,VHD,IHD,cardiomyopathies,cardiacamyloidosis),thyroiddiseases,obstructivesleepapnoea,chronicobstructivepulmonarydisease,
chronickidneydisease,autonomicdysfunction,alcoholconsumption,geneticpredisposition.
patientsreceivingmyelosuppressivechemotherapyorwithrecent Events in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective
activebleeding).However,LMWHefficacyforstrokeorsystemic Anticoagulation with Factor Xa Next Generation in Atrial
embolism prevention in AF has not been established and their Fibrillation–ThrombolysisinMyocardialInfarction48])andobser-
use is only based on their proven efficacy and safety in VTE. The vationaldatasuggestbettersafetyandatleastsimilareffectiveness
use of a NOAC for AF has not been evaluated in a dedicated oftheNOACwhencomparedwithVKAinpatientswithAFand
RCTinpatientswithcancer.However,secondaryanalysesofsem-
activecancer.531–538NOACuseincancerislimitedbydrug–drug
inal NOAC trials using direct factor Xa inhibitors (ROCKET AF interactions,508severerenaldysfunction,increasedriskofbleeding
[Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition in patients with unoperated or residual GIor genitourinary(GU)
Compared with Vitamin K Antagonism for Prevention of malignancies,orimpairedGIabsorption.
Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE Leftatrialappendage(LAA)occluderdevicesareusedinveryse-
[Apixaban for Reduction in Stroke and Other Thromboembolic lected patients with cancer in clinical practice. The potential
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 68 ---
4296 ESCGuidelines
Structured approach to anticoagulation for AF in patients with cancer
Long-term anticoagulation
Assess Thromboembolic risk:
according to CHADS-VASc score
2 2
Cancer-related risk (cancer type and stage, cancer treatment) ≥2 (men) or ≥3 (women) (Class I)
T
CHADS-VASc score for risk stratification (Class IIaa) 1 (men) or 2 (women) (Class IIa)
2 2
0 (men) or 1 (women) (Class IIb)
Assess Bleeding risk:
Thrombocytopaenia
GI/GU cancer, GI comorbidities, or GI toxicity
B Recent or evolving intracranial lesions
Active bleeding or recent major bleeding
Severe renal dysfunction (eGFR <30 mL/min/1.73 m2)
Bleeding risk scores (e.g., HAS-BLED)
Assess drug-drug Interactions (P-glycoprotein, CYP3A4):
I Anticancer agents
Supportive therapies
P Assess Patient preferences and drug availability
Thromboembolic and
Very high bleeding riskb Y No anticoagulation bleeding risk reassessment
(Class I)
N
Type of anticoagulant LAA oclusionc
treatment (Class IIb)
Moderate/severe mitral stenosis VKA
Y
or mechanical prosthetic valve (Class IIa)
N
Patients suitable NOAC
Y
for NOACd (Class IIa)
LMWH
N
(Class IIa)
Figure31Structuredapproachtoanticoagulationforatrialfibrillationinpatientswithcancer.AF,atrialfibrillation;CHA DS -VASc,Congestiveheart 2 2
failure,Hypertension,Age≥75years(2points),Diabetesmellitus,Stroke(2points)—Vasculardisease,Age65–74years,Sexcategory(female);CrCl,
creatinineclearance;eGFR,estimatedglomerularfiltrationrate;GI,gastrointestinal;GU,genitourinary;HAS-BLED,Hypertension,Abnormalrenaland
liver function, Stroke, Bleeding Labile international normalized ratio, Elderly, Drugs or alcohol; LA, left atrial; LAA, left atrial appendage; LMWH,
low-molecular-weightheparins;N,no;NOAC,non-vitaminKantagonistoralanticoagulant;VKA,vitaminKantagonists;Y,yes.aInselectedpatients,car-
diacimagingparametersrelatedtoincreasedthromboembolicriskshouldbeconsidered(LAAthrombus,severelydilatedleftatrium,severelyimpaired
LAstrain528).bVeryhighbleedingrisk:activeorrecentmajorbleeding(,1monthpreviously);recent/evolvingintracraniallesions;plateletcount,25
000/µL.AccordingtotheInternationalSocietyonThrombosisandHaemostasis,529majorbleedingisdefinedasafallinhaemoglobinlevel≥2g/dLand/or
transfusion of ≥2 units of red blood cells and/or fatal bleeding and/or bleeding in a critical area (intracranial, intraspinal, intraocular, pericardial,
intra-articular,intramuscularwithcompartmentsyndrome,orretroperitoneal).cPercutaneousleftappendageclosuremaybeconsideredinpa-
tientswithalifeexpectancyof.1yearwhoareathighthromboembolicandbleedingriskandinwhomanticoagulationiscontraindicated.dConditions
favouringLMWH:unoperatedGI/GUcancer;GIcomorbiditiesortoxicity;severerenaldysfunction(CrCl,15mL/min);NOACmajordrug–drug
interactions,plateletcount,50000/µL.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 69 ---
ESCGuidelines 4297
complicationsrelatedtotheimplant—includingdevice-relatedthrom- Long-termanticoagulationshouldbeconsidered
bosis—andthelackofprospectivedatainthesettingofpatientswith forstroke/systemicthromboembolism
preventioninpatientswithcancerwithAFanda
cancerhavetobetakenintoconsiderationforthisoption.Inarecent IIa C
CHADS -VAScscore=1(men)or=2
retrospectiveanalysisofpatientsreferredtoLAAocclusiontheriskof 2 2
(women)asperthe2020ESCGuidelinesforthe
in-hospitalischaemicstroke/transientischaemicattackwashigherin diagnosisandmanagementofatrialfibrillation.273
patientswithactivecancerthaninthosewithnocancerorpriorhis- Patientswithcancer,cAF,andCHADS -VASc
2 2
toryofcancer.Therateofin-hospitalcompositeoutcome(in-hospital score0(men)or1(women)mayhaveahigher
death,ischaemicstroke/transientischaemicattack,systemicembolism, thromboticriskthanpatientswithoutcancerand IIb C
maybeconsideredfortherapeuticanticoagulation
bleedingrequiringbloodtransfusion,pericardialeffusion/cardiactam-
afterconsiderationofthebleedingrisk.526
ponadetreatedwithpericardiocentesisorsurgically,andremovalof
Thromboembolicandbleedingriskreassessment
embolized device) and 30-day/180-day readmission outcomes were isrecommendedduringfollow-upinpatientswith I C
notsignificantlydifferentbetweenthegroups.539 cancerwithAF.d,273
TheonsetofAFmayberelatedtotransientfactors,suchasthe NOACshouldbeconsideredforstroke
peri-operativeperiodortheeffectofdrugsknowntofacilitateAF preventioninpreferencetoLMWHandVKA
(excludingpatientswithmechanicalheartvalves
onset.Thetraditionalassumptionthatinthesecases,AFmayoccur IIa B
ormoderate-to-severemitralstenosis)inpatients
asanisolatedeventwithoutrecurrencemaynotbevalidastheoc- withoutahighbleedingrisk,significantdrug–drug
currenceofAFmayoftenberelatedtoapre-existingatrialsubstrate interactions,orsevererenaldysfunction.531–537
with vulnerability to AF.540 Post-operative AF has been associated LMWHshouldbeconsideredinpatientswith
withafour-tofive-foldriskofAFrecurrenceinthefollowing5years, activecancereandAFwhoarenotsuitablefor IIa C
NOACf.525
alongwithacomparablelong-termthromboembolicriskwithAFnot
relatedtosurgery.273,540,541Anticoagulationtherapyyieldedasimi- LAAocclusionmaybeconsideredforstroke
preventioninpatientswithcancerwithAFand
larly lower risk of thromboembolic events and all-cause death in IIb C
contraindicationsforlong-termanticoagulation
both groups.541 In the absence of direct evidence, anticoagulation withalifeexpectancy.12months.273,539
topreventthromboemboliceventsshouldbeconsideredinpatients AntiplatelettherapyorprophylacticLMWHare
atriskforstrokewithAFaftercancersurgeryconsideringtheantici- notrecommendedforstrokeorsystemic III C
pated net clinical benefit and informed patient preferences.273 thromboembolismpreventioninAFwith
cancer.273
Similarly,inpatientswithAFapparentlyrelatedtotransientfactors
Heartratecontrolstrategy,preferablywith —such as chemotherapy, other drugs, or electrolyte disturbances
beta-blockers,shouldbeconsideredinpatients
—acarefulclinicalassessmentofthepropensitytofurtherdevelop
whodevelopwell-toleratedAFwhiletheyare
IIa C
AF is recommended, with need to revisit the risk/benefit ratio of receivingactivecancertreatmentg.
long-termprescriptionofanticoagulationafteraperiodof3months.
5-FU, 5-fluorouracil; AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASc,
InpatientswithcancerandnewlydetectedorrecurrenceofAF,de- Congestiveheartfailure,Hypertension,Age.75years(2points),Diabetesmellitus,
cisionmakingonanticancertreatmentrequiresacardio-oncologyMDT Stroke(2points)—Vasculardisease,Age65–74years,Sexcategory(female);CrCl,
management,5takingintoaccountthatneitherthepresencenortherisk creatinine clearance; eGFR, estimated glomerular filtration rate; EGFR, epidermal
growthfactorreceptor;ESC,EuropeanSocietyofCardiology;HF,heartfailure;LAA,
ofAFconstitutescontraindicationstoanticancertreatment.508,517
left atrial appendage; LMWH, low-molecular-weight heparins; LV, left ventricular;
MM,multiplemyeloma;NOAC,non-vitaminKantagonistoralanticoagulants;VKA,
vitaminKantagonists.
aClassofrecommendation.
RecommendationTable31—Recommendationsfor
bLevelofevidence.
the management of atrial fibrillation in patients re- cFactors that may increase thromboembolic risk in patients with cancer including
ceivinganticancertreatment comorbidities(proteinuria.150mg/24h,eGFR,45mL/min/1.73m2,BMI≥30kg/m2,
thrombophilia),cancertype(pancreatic,gastric,ovarian,brain,lung,MM),cancerstage
Recommendations Classa Levelb (metastatic disease) anticancer therapies: alkylating agents, aflibercept, bevacizumab,
anthracyclines, capecitabine, 5-FU, gemcitabine, methotrexate, EGFR inhibitors,
CHADS-VAScscoreshouldbeconsideredfor bleomycin, axitinib, lenvatinib, pazopanib, sorafenib, sunitinib, carfilzomib, irinotecan,
2 2
riskstratificationforstroke/systemic taxanes,tasonermin,tretinoin.
thromboembolismtakingintoaccountthatitmay IIa C
dStrokeandbleedingriskmaychangeduringbothcancertreatmentandthecourseofthe
underlyingdisease;reassessmentisimportanttoinformtreatmentdecisionsandaddress
underestimatetheactualthromboembolic
potentiallymodifiablebleedingriskfactors.
risk.519,526
ePatientsreceivingcancertreatment,patientsdiagnosedwithcancerinthepast6months,
Long-termanticoagulationisrecommendedfor andpatientswithprogressiveoradvanceddisease.
stroke/systemicthromboembolismpreventionin fHighbleedingrisk,severerenaldysfunction(CrCl,15mL/min);NOACmajordrug–drug
patientswithcancerwithAFanda interactions.
I C
CHADS-VAScscore≥2(men)or≥3(women) gAsymptomatic or mild symptomatic patients without HF signs or symptoms or
2 2
asperthe2020ESCGuidelinesforthediagnosis deteriorationofLVfunction.TheoptimalheartratetargetinAFpatientsisunclear.A
andmanagementofatrialfibrillation.273 restingheartrate,110 bpm(i.e.lenientrate control)should beconsideredasthe
initialheartratetargetforratecontroltherapy.Areviewofratevs.rhythmstrategy
Continued shouldbemadeattheendofcancertreatment.273
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 70 ---
4298 ESCGuidelines
6.4.2.LongcorrectedQTintervalandventricular Table9 ClassificationofcorrectedQTintervalpro-
arrhythmias longationinducedbycancerdrugtherapy
VA are not common during cancer, although their incidence in-
Classification Drugs
creases in patients with advanced cancer and CV comorbid-
ities.49,259,516,542 Mechanisms proposed to explain cancer Highrisk:QTcFprolongation≥10msandrisk (cid:129) Aclarubicin
therapy-induced VA include: (1) direct effects of cancer drugs on ofTdP (cid:129) Arsenictrioxide
theactivity/expressionofionicchannelsthatregulatetheventricular (cid:129) Glasdegib
action potential,4,369,442,516,542,543 and(2) a permanentarrhythmo- (cid:129) Nilotinib
genicsubstratecreatedbycancerandsystemicinflammationcaused (cid:129) Oxaliplatin
by cancer, pre-existing CV comorbidities, and/or a new (cid:129) Pazopanib
CTR-CVT.4,9,259,369,442,516,542,543 (cid:129) Ribociclib
Treatment of cancer therapy-induced VA should follow general (cid:129) Sunitinib
clinical guidelines.22,442,544 In patients with asymptomatic self- (cid:129) Toremifene
(cid:129) Vandetanib
terminating VA, drug discontinuation is not required unless they
have additional CVRF or persistent ECG abnormalities.270 Moderaterisk:QTcFprolongation≥10ms (cid:129) Abarelix
andlowornoriskofTdP(oruncertain) (cid:129) Belinostat
SymptomaticVArequirecancerdrugdosereductionordiscontinu-
(cid:129) Brigantinib
ationandpatientsshouldbereferredtothecardiologistforevalu-
ationandtreatment.4,442 (cid:129) Carbozantinib
(cid:129) Ceritinib
Recurrentsymptomaticlife-threateningVArequireurgentinter-
(cid:129) Crizotinib
vention.4,270,442,544 The administration of class IA, IC, and III anti-
(cid:129) Dovitinib
arrhythmic drugs is limited by the risk of drug–drug interactions
(cid:129) Entrectinib
andQTcprolongation.Beta-blockersandclassIBdrugsarelesslikely
(cid:129) Eribulin
tocausedruginteractionsorQTcprolongation.Beta-blockersare (cid:129) Gilteritinib
the preferred choice if the cancer drug is also associated with (cid:129) Ivosidenib
CTRCD.Amiodaroneistheantiarrhythmicdrugofchoiceinpatients (cid:129) Lapatinib
with structural heart disease and haemodynamic instability. (cid:129) Lenvatinib
(cid:129) Osimertinib
Table8 Riskfactorsfordrug-inducedQTprolonga- (cid:129) Panobinostat
tionandtorsadedepointes (cid:129) Rucaparib
(cid:129) Selpercatinib
Correctable Non-correctable (cid:129) Sorafenib
(cid:129) Tipiracil/
QT-prolongingdrugsa
Acutemyocardialischaemia trifluridine
(cid:129) Antiarrhythmics Age.65years (cid:129) Vemurafenib
(cid:129) Antibiotics
(cid:129)
(cid:129)
A An nt ti id fue np gr ae lsssants
B pra ose loli nn ge aQ tioT nc binterval Lowrisk:QTcFprolongation,10msa
(cid:129)
(cid:129)
A AD fatT
inib
Familyhistoryofsuddendeath (cid:129) Axitinib
(cid:129) Antiemetics (congenitalLQTSorgenetic (cid:129) Binimetinib
(cid:129) Antihistamines
polymorphism) (cid:129) Bortezomib
(cid:129) Antipsychotics Femalesex (cid:129) Bosutinib
(cid:129) Loopdiuretics
Impairedrenalfunction(for (cid:129) Carfilzomib
(cid:129) Opioids(methadone) renallyexcreteddrugs) (cid:129) Dabrafenib
Bradyarrhythmia Liverdisease(forhepatically (cid:129) Dasatinib
Electrolyteimbalance/ excreteddrugs) (cid:129) Encorafenib
abnormalities Personalhistoryofsyncopeor (cid:129) Midostaurin
(cid:129) Hypokalaemia(≤3.5mEq/L) drug-inducedTdP (cid:129) Pertuzumab
(cid:129) Hypomagnesaemia Pre-existingCVD(CAD,HF,LV (cid:129) Ponatinib
(≤1.6mEq/L) hypertrophy) (cid:129) Romidepsin
(cid:129) Hypocalcaemia(≤8.5mEq/L) (cid:129) Quizartinib
Inadequatedoseadjustmentof (cid:129) Tamoxifen
renalorhepaticcleared (cid:129) Vorinostat
QT-prolongingdrugs
ADT, androgen deprivation therapy; QTcF, corrected QT interval using Fridericia
correction;TdP,torsadedepointes.
CAD,coronaryarterydisease;CVD,cardiovasculardisease;HF,heartfailure;LQTS,
aADTmayprolongtheQTcinterval(GnRHagonist,GnRHantagonist,bicalutamide,
longQTsyndrome;LV,leftventricular;QTc,correctedQTinterval;TdP,torsadede
flutamide,apalutamide,darolutamide,enzalutamide,andabiraterone)(seeFigure21).
pointes.
aSeehttps://www.crediblemeds.org. Developed from EMA prescribing information,252 FDA prescribing information,253
bQTcusingFridericiacorrection(QTcF=QT/3√RR)isrecommendedinpatientswith andAZCERT.547
cancer.
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 71 ---
ESCGuidelines 4299
Decisionsontheuseofantiarrhythmicdrugsordevicetherapy(car- ,500ms.442 Although the incidence of QTc prolongation
dioverter defibrillators, catheter ablation) should consider life ex- ≥500msandTdPislowduringcancertherapy,QTcprolongation
pectancy,qualityoflife,andcomplicationrisks.349 to levels that require closer monitoring (QTc≥480ms) is more
Mostcancertherapy-inducedVAarerelatedtoaprolongationof common (Table 9).4,9,22,45,48,49,259,369,516,543,546 Changes in the QT
QTc leading to the development of TdP.259,516,542 Risk factors for intervalof.60msfrombaselineshouldnotroutinelyaffecttreat-
QTcprolongationandTdParesummarizedinTable8.4,22,45,48,516,543 mentdecisionsiftheQTcremains,500ms.1Cardiologyconsult-
The upper 99% limits of normal for QTc values in the general ationisadvisedinpatientswithanabnormalbaselineQTcinterval,
population are 450ms for men and 460ms for women.545 patients treated with drugs that prolong the QT interval, those
AlthoughthereisnothresholdofQTcprolongationatwhichTdP whodevelopnewcardiacsymptoms(syncopeorpre-syncope,rapid
canoccur,aQTc≥500msisassociatedwithatwo-tothree-fold palpitationsorQTcprolongationwithnew-onsetbradycardia,high
higher risk for TdP, while TdP rarely occurs when QTc is degreeofheartblock),and/orthosewithknowninheritedarrhythmia
QTc monitoring before and during(cid:2)treatment with(cid:2)QTc prolonging(cid:2)anticancer(cid:2)drugsa
Baseline 12-lead ECG: QTcF
Correct baseline risk factors for QTc prolongationb
Avoid/stop concomitant QTc prolonging drugsb
Ensure K+ >4.0 mmol/L, Mg2+ >2.0 mg/dL (>1.10 mmol/L) and normal values of corrected Ca2+
≤480 ms QTcF value >480 ms
Start therapy Cardio-oncology evaluation
ECG monitoringc Correct reversible causesb
QTcF value QTcF value
>480 ms and TdP or >480 ms and
≤480 ms ≥500 ms ≥500 ms
<500 ms sustainedVA <500 ms
Correct Drug Drug
reversible withhold interruption
QTcFmonitoring Consider
causesb Correct Correct Alternative
according to drug- alternative
Weekly ECG reversible reversible treatment
specific protocol treatment
monitoring causesb causesb
(Class I) (Class I) (Class I)
ECG after any QTcF value
dose increase of QTc-
prolonging drug Resume treatment at the same
(class I) ≤480 ms or reduced dose according
to drug-specific protocol
Consider restarting treatment
>480 ms and
If QTcF <500 ms <500 ms at reduced dose
Continue treatment at same or (Class IIb)
reduced dose according to MDT to discuss alternative
drug-specific protocol ≥500 ms cancer treatments
(Class I) (Class I)
Figure32CorrectedQTintervalmonitoringbeforeandduringtreatmentwithcorrectedQTinterval-prolonginganticancerdrugs.Ca2+,calcium;ECG,
electrocardiogram; K+, potassium; MDT, multidisciplinary team; Mg2+, magnesium; QTc, corrected QT interval; QTcF, corrected QT interval using
Fridericiacorrection;TdP,Torsadedepointes;VA,ventriculararrhythmias.QTintervalusingFridericiacorrection(QTcF=QT/3√RR)isrecommendedin
patients with cancer. Upper 99% limits of normal for QTc values in the general population are 450ms for men and 460ms for women.369 aTable 9.
bTable8andhttps://www.crediblemeds.org.cECGmonitoringatbaseline,oncesteady-stateanticancerdruglevelshavebeenachieved,aftereachdosemodi-
fication,oranytreatmentinterruption.2weeks;monthlyforthefirst3months,andthenperiodicallyduringtreatmentdependingonpatient-specificrisk
factorsandcancertreatment.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 72 ---
4300 ESCGuidelines
disorders.4,45,48,442,544 The challenges for the cardio-oncology teams
RestartingQTc-prolongingcancertherapy
aretoidentifypatientsmoresusceptibletodevelopingVA,determine
Amultidisciplinarydiscussionisrecommended
whetheraVAisdirectlyduetoCTR-CVT,individualizethetreatment
beforerestartingQTc-prolongingdrugsin
strategy,andoptimizeclinicalmonitoringduringtreatment.
patientswhohavedevelopedsignificantQTcF I C
Figure32showsthealgorithmforthemanagementofQTcpro-
prolongation,todiscussalternativecancer
longation during cancer therapy. In patients with cancer, the
treatments.4,22,259,349,442,546
Fridericiaformulaisrecommendedandhasdemonstratedlesserror
InpatientswhoexperiencedsignificantQTcF
thanothercorrectionmethodssuchasBazzettatbothhighandlow
heartrates.44InpatientstreatedwithQTc-prolongingdrugs,serum prolongation,restartingtheculprit
QTc-prolongingcancertreatmentmaybe IIb C
electrolytesandotherriskfactorsshouldbecloselymonitoredand
considered,ideallyatareduceddoseaccordingto
corrected, and concomitant QT-prolonging drugs avoided if pos-
sible.4,22,45,369,543Forselectedcancerdrugs,therearespecificmanu-
eachdrugrecommendation.45,259,349,442,546,549
WeeklyECGmonitoringduringthefirst4–6
facturer recommendations for ECG monitoring during treatment,
weeksandthenmonthlythereafteris
dosage adjustments, or discontinuation of therapy in case of QTc I C
prolongation.548 recommendedinpatientswithcancerafter
restartingQTc-prolongingcancertherapy.549
Although there are no recommendations, patients with cancer
withQTcprolongationassociatedwithseverebradycardiaorsinus ECG,electrocardiogram;QTc,correctedQTinterval;QTcF,correctedQTinterval
pauses may benefit from isoprenaline infusion or temporary pa- usingFridericiacorrection;TdP,torsadedepointes.
aClassofrecommendation.
cing. Despite present restrictions, the improved prognosis for
bLevelofevidence.
manymalignanciesisincreasingthenumberofpatientswithcancer cSeehttps://www.crediblemeds.organdTable8.
who are candidates for an implantable cardioverter defibrillator
(ICD), particularly when life expectancy is .1 year (including pa-
6.4.3.Bradyarrhythmias
tients who experienced resuscitated sudden cardiac death or se-
AVconductiondiseasecanbecausedbyICIinthepresenceorab-
vere VA from a QTc-prolonging drug with no alternative
senceofmyocarditis.IfthePRintervalincreases(new first-degree
treatment available).
heartblock)inpatientstreatedwithICI,serialECGmonitoringisre-
commended,andifPRprolongationto.300msdevelops,thepa-
tient should be hospitalized under close ECG monitoring and i.v.
methylprednisoloneisrecommended.550
RecommendationTable32—Recommendationsfor
IMiD(thalidomide,pomalidomide)285andALKinhibitors(crizoti-
the management of long corrected QT interval and
ventriculararrhythmiasinpatientsreceivingantican- nib, alectinib, brigatinib, or ceritinib)551 are associated with sinus
certreatment bradycardia. Holter ECG monitoring is recommended to exclude
significantsinuspausesinsymptomaticpatients.Inasymptomaticpa-
Recommendations Classa Levelb tientswithnormalLVfunction,sinusbradycardiaisusuallywelltol-
erated and treatment can continue. If patients are symptomatic
HowtomanageQTcprolongationinpatientswithcancer
(syncope,pre-syncopeofreducedexercisetolerancefromchrono-
DiscontinuationofQTc-prolongingcancer
tropicincompetence)thenatrialofcancerdrugwithdrawaltocon-
therapyisrecommendedinpatientswhodevelop I C firm causation with the symptoms is recommended. A MDT
TdPorsustainedventriculartachyarrhythmias discussion is needed to analyse risks/benefits of alternative cancer
duringtreatment.549
therapies vs. restarting the culprit cancer therapy at a lower dose
TemporaryinterruptionofQTc-prolonging withheartratemonitoring.Inselectedcases,whennocancertreat-
cancertherapyisrecommendedinpatientswho mentalternativeisavailable,pacingisindicated.
developasymptomaticQTcF≥500msandan I C
ECGshouldberepeatedevery24huntil 6.5. Arterial hypertension
resolutionoftheQTcFprolongation.549
Arterialhypertensioninpatientswithcancermaybecausedbytheir
Immediatewithdrawalofanyoffendingdrugand
cancer treatments (e.g. VEGFi, second- and third-generation
correctionofelectrolyteabnormalitiesandother
I C
BCR-ABLTKI,brigatinib,ibrutinib,fluoropyrimidines,cisplatin,abir-
riskfactorscisrecommendedinpatientswith
aterone, bicalutamide, enzalutamide), non-cancer drugs (e.g. corti-
cancerwhodevelopQTcF≥500ms.349,442,546 costeroids, non-steroidal anti-inflammatory drugs), and other
WeeklyECGmonitoringisrecommendedin factors including stress, pain, excessive alcohol consumption, renal
asymptomaticpatientswithcancerwithQTcF I C impairment, untreated sleep apnoea, obesity, and reduced exer-
480–500mswhoaretreatedwitha cise.552Inallpatientswithcancerwithnewhypertensionassessment,
QTc-prolongingcancertherapy.349,442,546
correction of these other factors is important before considering
A12-leadECGisrecommendedafteranydose interruptionofacancertreatment.
increaseofQTc-prolongingcancer I C Untreatedhypertension344isaconfirmedriskfactorofHFduring
therapy.270,442,544 treatmentwithanthracyclines,553ibrutinib,264andVEGFi.554Given
Continued thatmanyofthecancertherapiesthatcausehypertensionalsocause
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 73 ---
ESCGuidelines 4301
CTRCD,treatmentofhypertensionwithACE-IorARBasfirst-line In patients with resistant cancer therapy-related hypertension,
therapy is recommended to reduce the risk of CTRCD. spironolactone, oral or transdermal nitrates, and/or hydralazine
CombinationtherapywithanACE-IorARBandadihydropyridine should be considered. In patients with cancer with evidence of
CCB is recommended in patients with cancer with systolic BP≥ high sympathetic tone, stress, and/or pain, beta-blockers including
160mmHganddiastolicBP≥100mmHgduetothemorerapidon- carvedilol or nebivolol should be considered. Diuretics, preferably
setofBPcontrolwiththecombinationcomparedwithACE-I/ARB spironolactone, may be considered in patients with cancer with
monotherapy(Figures33and34). hypertensionandevidenceofincreasedfluidretention,withmoni-
Ifseverehypertensionisdiagnosed(systolicBP≥180mmHgor toringofBP,electrolytes,andrenalfunction.
diastolic BP≥110mmHg), the competing cancer and CV risks ThedecisionstoinitiateBPtreatmentandBPtargetsduringthe
shouldbeevaluatedbya MDT,andanycancertherapyassociated management of cancer-drug induced hypertension depend upon
withhypertensionshouldbedeferredortemporarilywithhelduntil thecontextofthecancerandprognosis(Figure34).CSshouldbe
the BP is controlled to values ,160mmHg (systolic BP) and treated according to the 2018 ESC/European Society of
,100mmHg(diastolicBP).Culpritcancertherapycanberestarted Hypertension (ESH) Guidelines for the management of arterial
onceBPiscontrolled,withconsiderationfordosereduction. hypertension.138
Recommended threshold for asymptomatic hypertension treatment
in different(cid:2)clinical(cid:2)scenarios
Home CS Curable cancer Metastatic cancer Metastatic cancer Metastatic cancer
BP mmHg during treatment Prognosis >3 years Prognosis 1–3 years Prognosis <1 year
160+ Treat Treat Treat Treat Treat
Consider
140–159 Treat Treat Treat May treat
treatment
Consider
135–139 Treat May treat May treat None
treatment
130–134 May treat None None None None
<130 None None None None None
Class 1 Class 1Ia Class 1Ib
Figure33Recommendedthresholdforasymptomatichypertensiontreatmentindifferentclinicalscenarios.BP,bloodpressure;CS,cancersurvivors.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 74 ---
4302 ESCGuidelines
TTTreatment of arterial hypertension in patients with cancer
Hypertension causedby cancer therappy
Systolic BP≥160 mmHg and diastolic BP≥100 mmHg BP target during cancer therappy
Y N
ACE-I orARB ACE-I orARB
BP target <140 mmHg systolic and
(Class I) (Class I)
<90 mmHg diastolic
AND (Class I)
Dihydropppyridine CCB OR
Dihydropppyridine CCB
(Class I)
as second-line therapppy
BP target <130 mmHg systolic and <80 mmHg
in patients with
diastolic if well tolerated
uncontrolled BP
(Class IIb)
(Class I)
OR
Ifresistant hypertensiona: In selected asymptomaticpatients with
metastatic cancer systolic BP 140–160 mmHg,
Beta-blockkkersb
and diastolic BP 90–100 mmHg
Spironolactone
(Class IIb)
Oral or transdermal nitrates and/or hydralazine
(Class IIa)
Figure34Treatmentofarterialhypertensioninpatientswithcancer.AF,atrialfibrillation;ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angio-
tensinreceptorblockers;BP,bloodpressure;CCB,calciumchannelblockers;HF,heartfailure;MI,myocardialinfarction;N,no;VEGFi,vascularendothelial
growthfactorinhibitors;Y,yes.aResistanthypertensionisdefinedasBPbeinguncontrolleddespitetreatmentwithoptimalorbest-tolerateddosesofthree
ormoredrugsincludingadiuretic,andconfirmedbyambulatoryandhomeBPmonitoring.bConsiderbeta-blockers(nebivololorcarvedilolarepreferredin
patientsonVEGFi)atanytreatmentstep,whenthereisaspecificindicationfortheiruse,e.g.HF,angina,post-MI,orAF.
RecommendationTable33—Recommendationsfor
the management of arterial hypertension in patients Cancertherapy-inducedarterialhypertensiontreatment
receivinganticancertreatment ACE-IorARBarethefirst-lineantihypertensive
drugscrecommendedforBPmanagementin I B
Recommendations Classa Levelb patientswithcancer.555–557
General DihydropyridineCCBarerecommendedas
second-lineantihypertensivedrugsforpatients I C
Effectivetreatmentofcancertherapy-induced
withcancerwithuncontrolledBP.
arterialhypertensiontopreventcancertreatment
I C
CombinationtherapywithACE-IorARBand
interruptionandCVcomplicationsis
dihydropyridineCCBisrecommendedinpatients
recommended. I C
ABPtarget,140mmHgsystolicand,90mmHg
withcancerwithsystolicBP≥160mmHgand
I C diastolicBP≥100mmHg.
diastolicisrecommendedduringcancertherapy.
ABPtarget,130mmHgsystolicand,80mmHg Diltiazemandverapamilarenotrecommendedto
treatarterialhypertensioninpatientswithcancer III C
diastolicmaybeconsideredduringcancertherapy IIb C
duetotheirdrug–druginteractions.d
providedthatthetreatmentiswelltolerated.
Inselectedasymptomaticpatientswithmetastatic ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angiotensinreceptorblockers;
cancer,asystolicBP140–160mmHganddiastolic BP,bloodpressure;CCB,calciumchannelblockers;CV,cardiovascular.
IIb C aClassofrecommendation.
BP90–100mmHgtreatmentthresholdmaybe
bLevelofevidence.
consideredprovidedthereisongoingBPmonitoring. cUnlesscontraindicated.
dInselectedpatientswithcancer,whoareintoleranttomultipleotherantihypertensive
ThecompetingcancerandCVriskevaluationis
drugs,diltiazemandverapamilmaybeconsideredwithclosemonitoringofdrug–drug
recommendedifthesystolicBPis≥180mmHgor
interactions.
diastolicBP≥110mmHg,andanycancertherapy
associatedwithhypertensionshouldbedeferred I C
ortemporarilywithhelduntiltheBPiscontrolled
tovalues,160mmHg(systolic)and
,100mmHg(diastolic).
Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 75 ---
ESCGuidelines 4303
6.6. Thrombosis and thromboembolic Cancerconfersafive-foldhigherriskofVTEandcancer-associated
events
VTErepresents30%ofallVTEcases.559,560TheriskofVTEvaries
inthecourseofcancer,withthehighestriskoccurringintheperiod
Thromboembolic events that develop during cancer and its treat-
followingcancerdiagnosis,duringhospitalizationandchemotherapy,
ment encompass both VTE and arterial thromboembolism (ATE)
and upon development of metastatic disease.561,562 Unprovoked
and are collectively referred to as cancer-associated thrombosis.
VTEmaybethefirstclinicalsignofamalignancy,followedbya5%
Cancer-associatedthrombosisisdeterminedbytheprothrombotic
incidenceofcancerdiagnosisduringthesubsequent12months.563
milieuinduced by cancer, theprothromboticproperties of certain
The risk factors for VTE in cancer are summarized in
anticancer and adjunctive therapies, and patient-related risk
Figure 35.564,565 Patients with symptoms or signs suggestive of
factors, including demographics, genetic predisposition, and
VTE,suchasunilaterallowerlimboedemaorunexplaineddyspnoea,
comorbidities.513
should be screened with lower-extremity venous ultrasonography
6.6.1.Venousthromboembolism orcontrast-enhancedCTforDVTandCTpulmonaryangiography
VTE, including deep vein thrombosis (DVT) and PE, is the forPE,accordingtothe2019ESCGuidelinesforthediagnosisand
second-leading cause of death in patients with malignancies.558 management of acute pulmonary embolism recommendations566
Risk factors for VTE in patients with cancer
Patient-related factors
Ageing
Comorbiditiesa
Sex (female)
Hereditary coagulation defectsb
Performance status
Prior VTE history
Cancer-related factors
Cancer type
Genetic characteristics (JAK2 or K-ras mutations)
Histology (adenocarcinoma)
Initial period after diagnosis
Primary site (pancreas, stomach, ovaries,
brain, lung, myeloma)
Stage (advanced, metastatic)
Treatment-related factors
Cancer therapyc
Central venous catheters
Hospitalization
Major surgery
Figure35Riskfactorsforvenousthromboembolisminpatientswithcancer.ATE,arterialthromboembolism;BMI,bodymassindex;CrCl,creatinine
clearance;IMiD,immunomodulatorydrugs;PI,proteasomeinhibitors;VTE,venousthromboembolism.aAcuteinfection,chronickidneydisease(CrCl,
45mL/min),pulmonarydisease,obesity(BMI≥30kg/m2),ATE.bFactorVLeiden,prothrombingenemutation.cChemotherapy(carboplatin,cyclophos-
phamide,anthracyclines,antimetabolites,irinotecan,taxanes,tasonermin),anti-angiogenicagents(bevacizumab,axitinib,lenvatinib,pazopanib,sorafenib,
sunitinib),IMiD(thalidomide,lenalidomide),PI(carfilzomib),hormonaltherapy,erythropoiesis-stimulatingagents.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 76 ---
4304 ESCGuidelines
andthesecondconsensusdocumentondiagnosisandmanagement 6.6.3.Intracardiacthrombosis
ofacutedeepveinthrombosis.567 Intracardiacthrombusinpatientswithmalignanciesmayresultfrom
theprothromboticpropertiesofcanceranditstreatmentandthe
6.6.2.Arterialthromboembolism useofcentralvenouscatheters.Thrombusisthemostcommonin-
Cancercarriesatwo-foldhigherriskofATE,includingMIandischae- tracardiacmassanditcanoccurwithinanycardiacchamber.Right
micstroke.568ATEriskishigherinmen,withadvancedage,andin atrial thrombi are often related to a venous catheter where the
patients with lung or kidney cancer. Pathologies related to ATE in line has inappropriately advanced into the right atrium.
cancer include ischaemic stroke induced by AF or RT-induced ca- Intraventricular thrombi usually occur in the setting of CTRCD.
rotidarterydisease,embolizationbytumourcellsornon-bacterial LAA thrombi are most commonly associated with AF, which may
thrombotic endocarditis, disseminated intravascular coagulation- alsoberelatedtocanceroritstherapy.
relatedperipheral microcirculatorythromboembolism,paradoxical Patientswithsystemicembolizationshouldbescreenedforcar-
cerebral embolism in the course of VTE, and cerebral sinus diac origin ofthrombus initially with TTE and/ortransoesophageal
thrombosis.569 echocardiography.528CMRismoresensitiveandspecificthanTTE
Structured approach to anticoagulation forVTE in patients with cancer
Assess Thromboembolic risk:
Patient-related factors
T Cancer-related factors
Treatment-related factors
Assess Bleeding risk:
Thrombocytopaenia
Thromboembolic and GI/GU cancer, GI comorbidities, or GI toxicity
bleeding risk reassessment B
Recent or evolving intracranial lesions
(Class I)
Active bleeding or recent major bleeding
Severe renal dysfunction (eGFR <30 mL/min/1.73 m2)
Assess drug-drug Interactions (P-glycoprotein, CYP3A4):
I Anticancer agents
Supportive therapies
P Assess Patient preferences
No anticoagulation Y Very high bleeding riska
N
LMWH Conditions favouring
Y
(Class I) LMWH over NOACb
N
Patient’s preference
NOAC or LMWH
(Class I)
Figure36Structuredapproachtoanticoagulationforvenousthromboembolisminpatientswithactivecancer.CrCl,creatinineclearance;eGFR,es-
timatedglomerularfiltrationrate;GI,gastrointestinal;GU,genitourinary;LMWH,low-molecular-weightheparins;N,no;NOAC,non-vitaminKantag-
onistoralanticoagulants;VTE,venousthromboembolism;Y,yes.aVeryhighbleedingrisk:activeorrecentmajorbleeding(,1month);recent/
evolvingintracraniallesions;plateletcount,25000/µL.AccordingtotheInternationalSocietyonThrombosisandHaemostasis,529majorbleedingis
definedas:fallinhaemoglobinlevel≥2g/dL,transfusionof≥2unitsofredbloodcells,fatalbleeding,orbleedinginacriticalarea(intracranial,intraspinal,
intraocular,pericardial,intra-articular,intramuscularwithcompartmentsyndrome,orretroperitoneal).bConditionsfavouringLMWH:unoper-
ated GI/GU cancer; GI comorbidities or toxicity; severe renal dysfunction (CrCl,15mL/min); NOAC major drug–drug interactions, platelet
count,50000/µL.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 77 ---
ESCGuidelines 4305
fordetectingintracardiacthrombiandlategadoliniumenhancement InVTErelapseunderanticoagulation,thepatientshouldbeinvesti-
(LGE)CMRwiththelonginversiontimetechniqueiscurrentlycon- gatedfortreatmentadherence,cancerprogressionorrelapse,whilea
sideredthegoldstandard.570,571 differentanticoagulationstrategyshouldbeendorsed(e.g.replacement
ofNOACwithLMWH).ThemanagementofpatientswithVTEanda
plateletcount,25000/µLshouldbeindividualizedbyaMDT.299
6.6.4.Anticoagulationtherapy
The duration of anticoagulation in patients with catheter-
Patientswithcancerfrequentlyhavebothanincreasedthromboticrisk
associated thrombosis depends upon whether the catheter is re-
andanincreasedbleedingriskassociatedwithcertaincancerlocations
moved or remains in situ. If removed, then anticoagulation should
(e.g.GI, intracranial), thrombocytopaenia,and other coagulation de-
continueforaminimumof3monthsanduntilfollow-upcardiacim-
fects(secondarytobonemarrowinvasion,cancertherapies,orcancer
agingconfirmsresolutionofthethrombus.Ifthecatheterremainsin
itself)andassociatedcomorbidities(e.g.renalorhepaticdysfunction,
situ,thenlong-termtherapeuticanticoagulationshouldcontinue.
GItoxicities).Severalanticanceragentsare further characterized by
drug–druginteractionswithanticoagulants.Allthesefactorsmayren-
deranticoagulationincancerquitechallenging.Aproposedapproach RecommendationTable34—Recommendationsfor
to anticoagulation therapy in cancer-associated venous thrombosis, themanagement ofvenousthromboembolism inpa-
based on the TBIP acronym (Thromboembolic risk, Bleeding risk, tientsreceivinganticancertreatment
drug–drugInteractions,Patientpreferences),isoutlinedinFigure36.527
Recommendations Classa Levelb
6.6.4.1.Treatmentandsecondarypreventionofvenous
Apixaban,edoxaban,orrivaroxabancare
thromboembolism recommendedforthetreatmentofsymptomatic I A
orincidentalVTEinpatientswithcancerwithout
SeverallargeRCTsandmeta-analyseshaveshownthatLMWHde-
contraindications.d,578–581,584,585
creasetheriskofrecurrentVTEby40%comparedtoVKA,witha
similarriskofmajorbleeding.572–576However,VKAarecharacter- LMWHarerecommendedforthetreatmentof
izedbyanunpredictableanticoagulationeffectandlowtimeinthera- symptomaticorincidentalVTEinpatientswith I A
peuticrangeinpatientswithmalignanciesduetomultipledrug–drug cancerwithplateletcount.50000/µL.298,299,578–
interactions,GItoxicity,malnutrition,andliverdysfunction.577 581,584,585
NOAChavebeenassessedaspotentialalternativestoLMWHfor Inpatientswithcancerwithplateletcountsof
cancer-associatedVTE,basedonRCTsthatcomparededoxaban,rivar- 25000–50000/µL,anticoagulationwithhalf-dose
IIb C
oxabanorapixabantodalteparin.578–583Thetotalityofevidencede- LMWHmaybeconsideredaftera
rived bythesetrialsandsubsequentmeta-analyses584–586showsthat multidisciplinarydiscussion.591
NOACarenon-inferiortodalteparininreducingtheriskofVTErecur- Prolongationofanticoagulationtherapybeyond6
rence.Theriskofmajorbleedingwassimilar,althoughNOACwereas- monthsshouldbeconsideredinselectedpatients
IIa A
sociatedwithanincreasedriskofclinicallyrelevantnon-majorbleeding, withactivecancereincludingmetastatic
particularlyinpatientswithluminalGIandGUmalignancies.586Asare- disease.589,590
sult, edoxaban, rivaroxaban, and apixaban are recommended for the Catheter-associatedVTE
treatmentofVTE(DVTandPE)inpatientswithcancerwithoutany
Durationofanticoagulationinpatientswith
ofthefollowingbleedingriskfactors:unoperatedGIorGUmalignan-
cancerwithacatheter-associatedVTEis
cies,historyofrecentbleedingorwithin7daysofmajorsurgery,signifi- I C
recommendedforaminimumof3monthsand
cant thrombocytopaenia (platelet count,50000/µL), severe renal
continuinglongerifthecatheterremainsinsitu. dysfunction(creatinineclearance(CrCl,15mL/min),orGIcomorbid-
ities.582,586Inaddition,drug–druginteractionsbetweenNOAC,cancer CrCl, creatinine clearance; GI, gastrointestinal; GU, genitourinary; LMWH,
therapies, and other concomitant treatments should be checked.587 low-molecular-weight heparins; ULN, upper limit of normal; VTE, venous
thromboembolism.
There are also concerns about NOAC in patients with GI toxicity aClassofrecommendation.
suchasvomitingorthosehavingundergonegastrectomyorextensive bLevelofevidence.
cDrugsarelistedinalphabeticalorder
intestineresection,aswellasthosewithseverelyimpairedrenalfunc-
dHigh risk of GI or GU bleeding, GI absorption concerns, significant drug–drug
tion.Shareddecision-makingconsideringinformedpatientpreferences interactions, severe renal dysfunction (CrCl,15mL/min), significant liver disease
shouldguidethechoiceofanticoagulation. (alanine aminotransferase/aspartate aminotransferase.2×ULN), or significant
thrombocytopaenia (platelet count,50000/µL). In addition, patients with primary
IncidentallyencounteredproximalDVTorPEshouldbetreatedin
brain tumours or brain metastases and acute leukaemia were excluded from the
thesamemannerassymptomaticVTEastheybearsimilarratesof seminalapixabantrial.580
recurrenceandmortality.588 ePatients receiving cancer treatment, patients diagnosed with cancer in the past 6
months,andpatientswithprogressiveoradvanceddisease.
Theminimaldurationofanticoagulationis6monthsandextended
anticoagulation is suggested in the presence of active malignancy,
metastatic disease, or chemotherapy use. Cohort studies have
shownthatextendedLMWHtherapybeyond6andupto12months 6.6.4.2.Primarypreventionofvenousthromboembolism
issafeincancer-associatedVTE.589,590However,patientswithcan- Patients undergoing surgery and those who are hospitalized or in
cerarealsoathighriskofbleedingduringanticoagulanttreatment prolongedbedrestrequirethromboprophylaxiswithlow-dosean-
andaperiodicassessmentoftherisk/benefitratioshouldperformed. ticoagulation.298,299,592–594 The ENOXACAN (Enoxaparin and
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 78 ---
4306 ESCGuidelines
Cancer)IIstudyshowedfavourableoutcomeswithLMWHaspri- 6.7. Bleeding complications
marythromboprophylaxisfor4weeksaftermajorabdominalorpel- Bleeding complications are more common in patients with cancer
vic cancersurgery.595Forambulatorypatients,VTEriskshouldbe thaninpatientswithoutcancer.Thismaybedirectlyrelatedtothe
individually determined and proposed scores such as the Khorana tumour itself, or indirectly related to chemotherapy- or
or the COMPASS-CAT (prospective COmparison of Methods for RT-inducedweakeningofmucosalbarriers.530
thromboembolic risk assessment with clinical Perceptions and
AwareneSS in real-life patients—Cancer Associated Thrombosis)
score may be useful.596,597 Further trials and a meta-analysis have 6.7.1.High-riskpatients
shownthatLMWHsignificantlyreducedtheincidenceofsymptomatic GIandGUcancersareassociatedwithasignificantexcessbleeding
VTEinambulatorypatientswithcancerreceivingchemotherapywith risk compared with other solid tumours.603 Thrombocytopaenia
acceptable safety.598–600 Two randomized, placebo-controlled, and platelet dysfunction due to haematological malignancies or
double-blindclinicaltrialshaveassessedtheroleofNOACinprimary bonemarrowsuppressioncanexacerbatebleeding.Otherbleed-
preventionofVTEinhigh-riskambulatorypatientsreceivingsystemic ing risk factors include advancing age, renal or hepatic impair-
cancertherapy(Khoranascore≥2).601,602Overafollow-upperiodof ment, metastatic disease, low body mass index, and treatment
180days,apixaban(2.5mgtwiceaday)601therapyresultedinasignifi- with ibrutinib, VEGFi, cetuximab, or bevacizumab.578,603–605
cantlylowerrateofVTE,althoughtherateofmajorbleedingepisodes Gastric protection with routine proton pump inhibitor use
was higher than with placebo. Rivaroxaban (10mg once a day)602 should be considered in all patients with cancer on DAPT606,607
treatment resulted in a non-significantly lower incidence of VTE or oranticoagulation.530
death due to VTE with low bleeding risk (no significant differences
withplacebo).FurtherdataontheuseofNOACinthissettingare
6.7.2.Antiplatelettherapy
warranted. Consideration of such therapy should be accompanied
byadiscussionwiththepatientabouttherelativebenefitsandharms, Antiplatelettherapy,inparticularDAPT,increasestheriskofbleed-
inginpatientswithcancer.477FollowingACSand/orPCI,theriskof
cancerprognosis,drugcost,anddurationofprophylaxis.
bleeding is approximately 1.6-fold greater in patients with cancer
thaninthosewithout.477,605Theriskisgreatestinthosediagnosed
RecommendationTable35—Recommendationsfor
with cancer in the preceding year, whereas more remote cancers
venousthromboembolismprophylaxisduringantican-
carrylowerexcessrisk.477ThePRECISE-DAPT(PREdictingbleeding
certreatment
Complications In patients undergoing Stent implantation and
Recommendation Classa Levelb subsEquentDualAntiPlateletTherapy)scoreappearsnottoper-
formwellforpredictingbleedinginpatientswithcancer.477Inorder
ExtendedprophylaxiswithLMWHfor4weeks
toreducebleedingrisk,thedurationandintensityofDAPTshouldbe
post-operativelyisrecommendedforpatients minimized477,607 and triple therapy avoided whenever possible. At
withcancerundergoingmajoropenor I B thesametime,DAPT—ifindicated—shouldnotbewithheldwithout
laparoscopicabdominalorpelvicsurgerywithlow
goodreason.Arecentexpertconsensusstatementsuggestsreduced
bleedingriskandhighVTErisk.c,298,299,595
platelet count thresholds for CV therapies, recommending aspirin
ProphylacticLMWHfortheprimaryprevention initiationforplateletcounts.10000/µLandDAPTinitiation(with
ofVTEisindicatedinhospitalizedpatientswith aspirin and clopidogrel) for platelet counts .30000/µL.608 In pa-
cancerorthosewithprolongedbedrestor I B tients with platelet counts ,50000/µL, clopidogrel is preferred
reducedmobilityintheabsenceofbleedingor over prasugrel or ticagrelor, and glycoprotein IIb/IIIa inhibitors
othercontraindications.298,299,592,594 should be avoided.608 To reduce peri-procedural bleeding, PCI
Forambulatorypatientswithcancerathighriskof should preferably be undertaken via the radial approach484 and
thrombosisreceivingsystemictherapy,dprimary prophylactic platelet transfusion may be considered for patients
thromboprophylaxiswithaNOAC(apixabanor
IIb B
withplateletcount,20000/µL.609
rivaroxaban)orLMWHmaybeconsidered,
providedtherearenosignificant
contraindications.e,298,593,594,601,602 6.7.3.Managementofbleeding
Adiscussionwiththepatientabouttherelative Basic principles of bleeding management should be followed with
benefitsandharms,cancerprognosis,drugcost, controlofthebleedingsourcewheneverpossible.Platelettransfu-
anddurationoftreatmentisrecommendedprior I C sionsforsignificantthrombocytopaeniaandwithholdingandreversal
toprophylacticanticoagulationfortheprimary ofanticoagulationforlife-threateningbleedingmaybeneededasin
preventionofVTE.
thegeneralpopulation.530,610Antifibrinolyticagents,suchastranex-
amic acid or e-aminocaproic acid, can be considered. Non-specific
LMWH, low-molecular-weight heparins; NOAC, non-vitamin K antagonist oral
support of haemostasis using coagulation factor concentrates and
anticoagulants;VTE,venousthromboembolism.
aClassofrecommendation. specific reversal agents may be needed for patients on a NOAC
bLevelofevidence. with life-threatening bleeding.530 Recombinant activated factor VII
cReducedmobility,obesity,VTEhistory.
dLocallyadvancedormetastaticpancreasorlungcancerorKhoranascore≥2. oractivatedprothrombincomplexconcentratesshouldbeavoided
eRiskfactorsforbleeding,significantdrug–druginteractions,orsevererenaldysfunction. inpatientswithrecentthrombosis.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 79 ---
ESCGuidelines 4307
6.8. Peripheral artery disease complicatingcancermanagement.Othergroup4PHduetopulmon-
There isgrowing evidence that cancer therapy affects thevascula- aryarteryobstructionsincludesangiosarcomaandothermalignant
ture.Arecentmeta-analysisshowedasignificantlyincreasedarterial tumours(e.g.renalcarcinoma,uterinecarcinoma,germcelltumours
stiffness after anthracycline and non-anthracycline treatment.611 ofthetestis).618
Paraneoplasticacralvascularsyndromewasdescribedafterinitiation PH with unclear and/or multifactorial mechanisms (group 5) in-
ofnivolumab,withfirstsymptoms3weeksafterinitiationofther- cludesseveralconditionsthatmaybecomplicatedbycomplexand
apy.612Raynaudphenomenonhasbeenassociatedwiththeuseof sometimes overlapping pulmonary vascular involvement. Tumoral
bleomycin,cyclophosphamide,platinumcompounds,vincaalkaloids, PHincludespulmonarytumourmicro-embolismandpulmonarytu-
and fluoropyrimidines.491 Usual treatment of Raynaud’s includes mour thrombotic microangiopathy.619 Multiple causes of PH have
non-pharmacological measures to help prevent an episode (avoid- beendescribedinpatientswithchronicmyeloproliferativedisorders.
anceofprovokingfactorssuchascoldtemperature,vasoconstricting Inchronicmyelogenousleukaemia,spleenenlargementandanaemia
drugs) and a long-acting dihydropyridine CCB (amlodipine, cangiverisetohyperkineticsyndrome.Inpolycythaemiaveraandes-
modified-releasenifedipine). sential thrombocythemia, there is an increased risk of VTE and
Treatmentwithnilotiniborponatinibmaybeassociatedwithan chronicthromboembolicPH.Moreover,formationofabloodclot
increasedriskofvascularadverseevents,includingarterialstiffness
withinthehepaticveinscanleadtoBudd–Chiarisyndromeandsub-
and PAD development.494 In a subgroup of patients, these events sequentporto-PH.Pulmonaryextramedullaryhaematopoiesiscom-
aresevereorevenlife-threatening.613Althoughtheexactmechan- plicatingidiopathicorsecondarymyelofibrosismayalsocontribute
isms remain unknown, we recommend screening for pre-existing todyspnoeaandPH.620
PADandforvascularriskfactorssuchasDMinallpatientsbefore
SymptomsofPHarenon-specific,suchasshortnessofbreathand
and during nilotinib or ponatinib therapy. Pooled data from three fatigue.Inlaterstages,symptomsofright-sidedHFmaydevelop.An
clinical trials showed arterial occlusive disease to be related to ECGshouldbeperformedandexaminedforRVhypertrophy,buta
doseintensityinponatinib-treatedpatients,614butPADwasnotad- normal ECG does not exclude PH. Echocardiography is the first
dressedseparately.IfrapidlyprogressivePADoccurswithsecond- choiceforassessingPHprobabilityinpatientswhodevelopsymp-
generationTKI,itmaybeadvisabletoswitchtoanalternativelower- toms and/or signs suggestive of PH during cancer treatment.
riskTKI(e.g.imatinib).Plateletaggregationinhibitorsoranticoagula- When peak tricuspid regurgitation velocity (TRV) is ≤2.8m/s
tionandstatinsshouldbeconsidered.Despitelackofevidence,all (equating to an estimated systolic PAP [sPAP] of ≤35mmHg)
riskfactorsshouldbecorrected.615 andnoothersignsofPHarepresent,thentheprobabilityofPH
islow.Intheabsenceofatricuspidregurgitantjet,otherechocar-
diography signs may increase suspicion of PH (e.g. RV/LV basal
diameterratio.1,RVoutflow tractaccelerationtime,105ms,
Recommendation Table 36 — Recommendation for
inferiorvenacavadiameter.21mmwithdecreasedinspiratorycol-
managementofperipheralarterydiseaseduringantic-
ancertreatment lapse).620BaselineTTEshouldbeconsidered inpatientsreceiving
cancerdrugsthatcancausePH;however,aright-heartcatheter-
Recommendation Classa Levelb ization is required for definitive diagnosis of PH and to support
PAH treatment decisions.In the DASISION(DASatinib vs. Imatinib
InpatientswhodevelopnewsymptomaticPAD,a
StudyIntreatment-Naïvechronicmyeloidleukemiapatients)trial,
multidisciplinaryapproachregardingthedecision
I C 5% of patients randomized to dasatinib were diagnosed with
tocontinuevs.interruptculpritcancertherapycis
PH, compared with 0.4% of those randomized to imatinib.621 In
recommended.
patients who develop PH, dasatinib treatment should be inter-
PAD,peripheralarterydisease;VEGFi,vascularendothelialgrowthfactorinhibitors. ruptedandanalternativeTKIshouldbeused.616
aClassofrecommendation.
OverallmanagementofPHinoncologypatientsshouldbebased
bLevelofevidence.
cVEGFi,nilotinib,ponatinib,platins,etc. onthe2022ESC/EuropeanRespiratorySociety(ERS)Guidelinesfor
thediagnosisandtreatmentofpulmonaryhypertension.620Referral
to a PHcentre isrecommended for multidisciplinary management
6.9. Pulmonary hypertension
with the oncology team. In patients with CML treated with drugs
AllfivegroupsofthePHclassificationcanbeobservedinpatients
causing PH-induced PAH, discontinuation of the potential culprit
withcancer.Severalcancerdrugscancausegroup1PH(pulmonary therapy is recommended if there is a high probability of new PH
arterialhypertension[PAH]),includingcarfilzomib,bosutinib,dasati- (peak TRV.3.4m/s, equating to an estimated sPAP of
nib,616ponatinib,interferonalpha,andalkylatingagents(e.g.mitomy- ≥50mmHg)untilthediagnosisisconfirmedorruledoutbyaright-
cin C and cyclophosphamide, which mostly cause pulmonary heart catheterization. In CML patients on dasatinib, an alternative
veno-occlusive disease).617 PH associated with left heart disease BCR-ABL TKI is recommended if they develop symptomatic PAH
(group2)isrelatedtodrugscausingHF(e.g.anthracyclines).PHas- or an asymptomatic increase in peak TRV .3.4m/s. Dasatinib
sociatedwithlungdisease(group3)isrelatedtodrugsandtherapies dosereductionandclosemonitoringofpeakTRVwithTTEevery
causingpulmonaryfibrosis(e.g.bleomycin,thoracicradiation).The
4 weeks should be considered in CML patients who develop new
most common pulmonary vascular disease complicating cancer is asymptomatic peak TRV ranging from 2.9 to 3.4m/s.620 If peak
VTE, which can cause chronic thromboembolic PH (group 4). Of TRVremainsnormalormildlyelevatedonserialmonitoring,thenda-
note,centralvenouscathetersareimportantcausesofgroup4PH satinib can continue, with reduced TTE monitoring to every 3
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 80 ---
4308 ESCGuidelines
months.IfpeakTRVcontinuestorise,thenright-heartcatheteriza- withstandardtherapyorafterdiscontinuationofthetreatment.444
tion shouldbe performed, dasatinibtreatment shouldbe stopped, Cancer treatment interruption should be discussed with the
andPAHdrugsshouldbeconsideredifPAHisconfirmed. cardio-oncology team. Treatment with anti-inflammatory drugs
(e.g.ibuprofen)andcolchicine,intheabsenceofcontraindications,
isrecommendedasitreducestherateofrecurrencerequiringre-
RecommendationTable37—Recommendationsfor peatintervention.623Low-to-moderatedosesofsteroidsareonlyin-
the management of pulmonary hypertension during dicatedforresistantcasesexceptICI-relatedpericarditis.444
anticancertreatment
ICI-associatedpericarditishasamediantimeofonsetof30daysin
Recommendations Classa Levelb retrospectivesurveillancestudiesandisassociatedwithapoorprog-
nosis,especiallyincaseofconcomitantmyocarditis.444,624
Right-heartcatheterizationanddiscontinuationof InpatientswithsevereICI-associatedpericarditiswithmoderateor
dasatinibisrecommendedinpatientswho I C severeeffusion,ICIdiscontinuationandhigh-dosesteroids(methylpred-
developsymptomaticorasymptomaticincreasein nisolone1mg/kg/day)withorwithoutcolchicinearerecommended,as
peakTRV.3.4m/s. wellaspericardiocentesisincaseofcardiactamponade.624,625Incaseof
Dasatinibdosereductionandclosemonitoringof refractorypericarditis,immunosuppressivedrugsshouldbeconsidered.
peakTRVwithechocardiographyshouldbe ForuncomplicatedICI-relatedpericarditis,theICImightbecontinued
consideredinpatientswhodevelopnew IIa C andcolchicineornon-steroidalanti-inflammatorydrugscouldbecon-
asymptomaticpeakTRVrangingfrom2.9to sidered.326,444ForpatientsrequiringICIdiscontinuation,restartingICI
3.4m/s. canbeconsideredinaMDTdiscussionafterresolutionofpericardial
Inpatientswithconfirmeddasatinib-induced diseaseandunderclosemonitoring.
PAHcornewasymptomaticpeakTRV.3.4m/s,
I C
analternativeBCR-ABLinhibitorisrecommended 6.10.2.Pericardialeffusion
afterpeakTRVrecoveryto,2.8m/s. Pericardialeffusionsareoftenobservedasanincidentalfindinginpa-
tientswithcancer.Cancertherapyisthecauseofapericardialeffu-
BCL-ABL,breakpointclusterregion–Abelsononcogenelocus;PAH,pulmonaryarterial
hypertension;TRV,tricuspidregurgitationvelocity.
sionin,30%ofcases,althoughthismayincreasewiththeexpanding
aClassofrecommendation. useofICIincancer.Malignancy-relatedpericardialeffusionscaused
bLevelofevidence.
bydirect(lung,oesophageal,breast)ormetastaticinvasion(haem-
cDefinitediagnosisofPAHrequiresaright-heartcatheterization.
atological malignancies, ovarian, melanoma) or by lymph node ob-
structionaregenerallyassociatedwithpoorprognosis.
6.10. Pericardial diseases Clinicalpresentationdependsonthesizeoftheeffusionandthe
Pericarditisandpericardialeffusioncanberelatedtoawiderangeof speed of its growth.444 Malignancy-related pericardial effusions
cancertreatmentsincludingchestradiation,cytotoxictherapies(an- make up .30% of patients presenting with cardiac tamponade626
thracyclines, bleomycin, cyclophosphamide, cytarabine), targeted and usually develop slowly, resulting in larger pericardial effusions
therapies (all-trans retinoic acid, arsenic trioxide, dasatinib), and atthetimeofdiagnosiscomparedwithnon-malignantpericardialef-
immune-based therapies (interleukin-2, interferon-αICI). A combin- fusions. Management consists of determination of the cause and
ationoftherapiesmayhavea synergisticeffectonthepericardium. evaluationofthehaemodynamicimpact.Small-to-medium-sizedef-
These therapy-induced complications must be differentiated from fusions (.4and,20mm)canbe monitoredwitha reassessment
progressivecancer(localinvasion,metastaticinvolvement,ormedias- 7–14 days after initial diagnosis and at further 4–6-weekly inter-
tinal lymphatic drainageobstruction)and non-cancer-relatedcauses
vals.444,627Inunstablepatientswithsignsoftamponade,immediate
such as infection, especially in immune-compromised patients.622 A echocardiographic-guided percutaneous pericardiocentesis is pre-
carefulhistoryandclinicalexaminationareofhelptodeterminethe ferredoversurgicalpericardiotomytominimizepotentialcomplica-
cause. TTE plays a central role in diagnosis and management. CT tions.628 In patients with cardiac tamponade due to malignant
andCMRcanprovideadditionalinformationonpericardialinflamma- pericardialeffusions,colchicinemaybeusefultoimproveclinicalout-
tionandconstrictivephysiology.Theprinciplesforthediagnosisand comesandreducetherateofrepeatintervention.623Drainageofa
managementshouldfollowthe2015ESCGuidelinesforthediagnosis
pericardialeffusionrelatedtoICIisrarelyrequired629andcorticos-
andmanagementofpericardialdiseases,444buttherearesomespecific teroids should be considered.630 Intrapericardial instillation of
issuestoconsiderinpatientswithcancer.482 cytostatic/sclerosing agents, colchicine,623 and radiation for
radiation-sensitive tumours can reduce recurrence after drainage.
6.10.1.Pericarditis The creation of a pleuropericardial or pleuroperitoneal window
Thediagnosisofpericarditisinpatientswithcancerfollowsthesame with balloon pericardiotomy or surgery should be considered in
principles as in those without, but symptoms can be atypical.444 case of recurrent malignant pericardial effusions after emergency
Acutepericarditiscausedbyradiationhasbecomerareduetolower pericardiocentesis.444
doses and improved radiation techniques. It occurs within days to Asurgicalpericardialwindowshouldbeconsideredifthepercu-
weeksaftertreatmentandisusuallyself-limiting,butcanevolveto- taneous approach is not feasible and in stable patients with large
wards constrictive pericarditis many years later (Section 8.6). (≥20mm)orrapidlyexpandingmalignantpericardialeffusionsprior
Pericarditiscausedbyconventionalcancertherapiesoftenresolves tothedevelopmentofcardiactamponade.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 81 ---
ESCGuidelines 4309
RecommendationTable38—Recommendationsfor continueonlong-termoncologytherapies,e.g.womenwithoestro-
themanagementofpericardialdiseasesinpatientsre- gen receptor-positive early invasive BC. In this example, the
ceivinganticancertreatment
end-of-therapy risk assessment refers to the timepoint from the
lastanthracyclineortrastuzumabdose.
Recommendations Classa Levelb
High-riskpatientscanbeidentifiedatcompletionoftheircardio-
General toxic cancer therapies by their clinical characteristics, history of
CTR-CVT during treatment, and by elevated cardiac biomarkers
Diagnosisandmanagementofacutepericarditisin
and/orabnormalCVimagingatfollowup.53,54,92Cardiacserumbio-
patientswithcancerbasedonthe2015ESC
markers(NPandcTn)areusefulgiventheirhighnegativepredictive
Guidelinesforthediagnosisandmanagementof
I C valueforfutureCVevents.197,631Inaprospectivestudyof2625adult
pericardialdiseasesisrecommendedanda
patients with cancer that assessed LVEF after anthracycline-based
multidisciplinarydiscussionisneededbefore
interruptingcancertherapy.444 chemotherapy, the overall incidence of CTRCD was 9%; 98% of
casescouldbedetectedwithin12monthsafterchemotherapyand
Asurgicalpericardialwindowshouldbe
the median time from chemotherapy to CTRCD detection was
consideredifthepercutaneousapproachisnot
IIa C 3.5 months (interquartile range 3–6 months).208 The response to
feasibleorincasesofrecurrentmalignant
ACE-I treatment declined when the interval between the end of
pericardialeffusions.
chemotherapy and CTRCD detection lengthened; complete LVEF
Intrapericardialinstillationofcytostaticor
recoverywasnotobservedinpatientswheretreatmentwasdelayed
sclerosingagentsmaybeconsideredfor IIb C
by.6months.425
preventionofrecurrence.
Measurement of cTn after completion of anthracycline chemo-
DiagnosisandmanagementofICI-associatedpericarditis
therapyduringtheend-of-treatmentassessmentshouldbeconsid-
MultimodalityCVimaging(echocardiography, ered. Rises in cTnI after anthracycline chemotherapy identify
CMR+ CT),ECGandmeasurementofcardiac patients at risk of future cardiac dysfunction who then benefit
biomarkersarerecommendedtoconfirmthe fromCVprotection.4Educatingpatientswithcanceroftheirpoten-
I C
diagnosis,assessthehaemodynamic tial increased CVD risk and supporting them to make appropriate
consequencesofpericardialdisease,andruleout healthylifestylechoicesisrecommended.CSshouldalsobeadvised
associatedmyocarditis. topromptlyreportearlysignsandsymptomsofpossibleCVDand
Prednisoloneandcolchicinearerecommended informmedicalteamsoftheirpreviouscardiotoxiccancertherapies.
forpatientswithICI-associated I C CVRFincludinghypertension,DM,anddyslipidaemiacorrelatewith
pericarditis.326,624,625,630 theprobabilityoffutureCVeventsinCSandshouldbewellcon-
InterruptionofICItreatmentinpatientswith trolledaftercompletionofcancertherapy.31,632,633
confirmedICI-associatedpericarditiswith
I C
moderate-to-severepericardialeffusionis 7.2. Which cancer survivors require
recommended. cardiovascular surveillance in the first
Amultidisciplinarydiscussionisrecommended year after cancer treatment?
I C
beforerestartingICItreatment. Theend-of-treatmentriskassessmentideallyidentifiesthosehigh-risk
CMR, cardiac magneticresonance;CT, computed tomography; CV,cardiovascular; CS,whorequirelong-termCVsurveillance,basedonthefollowing
ECG, electrocardiogram; ESC, European Society of Cardiology; ICI, immune criteria(Table10):
checkpointinhibitors.
aClassofrecommendation. (1) BaselinehighorveryhighriskbasedonHFA-ICOSriskassess-
bLevelofevidence.
menttools12(Section4).
(2) Cardiotoxic cancer therapy with a high risk of long-term CV
complications7,21(Section8).
7. End-of-cancer therapy (3) Moderate or severe CTR-CVT diagnosed during cancer treat-
ment(Table3).68
cardiovascular risk assessment
(4) Newabnormalitiesincardiacfunctiondetectedbyechocardiog-
raphy, new elevated cardiac serum biomarkers, or newly CV
7.1.Cardiovascular evaluationduring the
symptomsdetectedattheend-of-therapyassessment(3or12
first year after cardiotoxic anticancer
monthsaftertreatment).68,208
therapy
End-of-cancer therapy CV risk assessment covers the first 12 The timing of the first CV assessment after cardiotoxic cancer
months after the last cardiotoxic cancer treatment. These recom- treatmentdependsontheriskdefinedbybaselineCVassessment,
mendationsarewherecardiotoxiccancertherapyhasbeensuccess- thetypeofcancertherapy,andwhetherCTR-CVTwasdiagnosed
fully completed with good long-term prognosis. These duringtreatment.
recommendationsarenotindicatedwhencancertherapiesaredis- In asymptomatic high-risk patients (Table 10), echocardiography
continued due to cancer progression and prognosis is poor, or andcardiacserumbiomarkersarerecommendedat3and12months
where end-of-life care is indicated. Selected patients with cancer after completion of cancer therapy.53,54,59,61,68,148,208,425 In
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 82 ---
4310 ESCGuidelines
Table 10 Risk factors for future cardiovascular dis- 7.3. Management of cancer
easeattheend-of-cancertherapycardiovascularrisk
therapy-related cardiac dysfunction at
assessment
the end-of-therapy assessment
High-riskconditions Duringthisend-of-treatmentassessment,areviewofcardioprotec-
tivemedicationsinitiatedduringcancertherapytotreatCTRCDis
High-andvery-highbaselineCVtoxicityriskbasedonHFA-ICOS
recommended (Figure 37). In selected patients with asymptomatic
assessment
mild or moderate CTRCD who have fully recovered with normal
Specificanticancertreatmentproventohaveahighriskoflong-termCV
TTE and cardiac serum biomarkers, a trial of weaning off CV
complicationsa
medication should be considered after MDT discussion. This is
Doxorubicinb≥250mg/m2
mostcommonafterasymptomaticmildormoderateCTRCDsec-
RT.15GyMHDc
ondary to trastuzumab, particularly in younger otherwise healthy
Bothdoxorubicinb≥100mg/m2andRT5–15GyMHDd
HER2+BCsurvivorswithnoexposuretoanthracyclinechemother-
High-riskHSCTpatientse
apy. Further assessment of cardiac function with TTE and cardiac
ModerateorsevereCTR-CVTduringcancertreatment(especially
serum biomarkers is recommended following withdrawal of CV
CTRCD),ICI-relatedmyocarditis,cardiacarrhythmias,orseverevascular
medicationinpatientswithpreviousCTRCDtoensurecardiacfunc-
toxicities(ACS,stroke,PVD)
tionremainsnormal.
NewCVsymptomsornewasymptomaticabnormalitiesin Continuinglong-termCVmedicationisgenerallyrecommended
echocardiographyand/orcardiacserumbiomarkersattheendoftherapy inpatientswithmoderateandseveresymptomaticorsevereasymp-
assessment tomatic CTRCD due to the high rate of recurrent HF. Long-term
treatment is also recommended in CS with mild or moderate
ACS,acutecoronarysyndromes;CTRCD,cancertherapy-relatedcardiacdysfunction;
CTR-CVT,cancertherapy-relatedcardiovasculartoxicity;CV,cardiovascular;CVD, CTRCD who fail to recover normal LV function at their
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host end-of-therapyassessment(Figure37).
disease;Gy,Gray;HFA,HeartFailureAssociation;HSCT,haematopoieticstemcell
transplantation; ICI, immune checkpoint inhibitors; ICOS, International
Cardio-OncologySociety;MHD,meanheartdose;PVD,peripheralvasculardisease; 7.4. Cardiopulmonary exercise testing
RT,radiotherapy.
aRTriskcategorizationbasedonMHDisrecommendedovercategorizationbasedon and fitness during the end-of-therapy
prescribed dose, which may not accurately reflect cardiac radiation exposure.
assessment
Dependingondosedistributionandexposureofspecificcardiacsubstructures(as
wellasclinicalriskfactors),thetreatmentteammayjudgethepatienttobelongtoa CRFimpairmentisastrongpredictorofpatientoutcomefollowing
higherriskcategory.Inaddition,apatientmaybejudgedtobelongtoalowerrisk
cancertreatmentandaninterventiontargetinCS.LowCRFisasso-
categoryifonlyasmallpartoftheheartisexposedtoarelativelyhighprescribed
dose(i.e.RTtoleftbreastorleftchestwallonly). ciatedwithpoorqualityoflife,increasedmorbidity,reducedexercise
bOrdoxorubicinequivalent. cardiacfunctionandworseCVDriskprofile,andisarobustinde-
cOrprescribedRT≥35GytoavolumeexposingtheheartifMHDisnotavailable.
pendent predictor of all-cause, cancer-related, and CVD-related
dOrprescribedRT15–34GytoavolumeexposingtheheartifMHDisnotavailable.
eHigh-riskHSCTpatients:allogenicHSCT;pre-existingCVDormultipleuncontrolled mortality in CS.119,120 Recent evidence suggests the risk of
CVRF; cancer treatment history (mediastinal or mantle field radiation, alkylating CVD-related mortality in CS decreases by 14% per 1 metabolic
agents, .250mg/m2 doxorubicin or equivalent); conditioning schemes (total body equivalent(3.5mLO /kg/min)increaseinCRF.120
irradiation,alkylatingagents);developmentofGVHD. 2
CPETmaybeconsideredforCSwithexertionallimitation,who
mayhavesubstantialbenefitfromcardiacrehabilitation.Eligiblepa-
tients include those treated with higher doses of anthracycline
chemotherapyand/orRTtoavolumeincludingtheheart,highCV
asymptomatic moderate-risk patients (according to CV toxicity
toxicityriskatbaseline,patientswhodevelopedCTRCDduringcan-
baselineriskstratification),echocardiographyandcardiacserumbio-
certherapy,andthoseidentifiedwithnewabnormalitiesinLVfunc-
markersshouldbeconsideredwithin12monthsaftercompletionof
tionattheirend-of-therapyassessment.11CPETcanbeanobjective
cancertherapy.53,54,59,61,68,148,208Inasymptomaticlow-riskpatients
toolinthediagnosisofdecreasedphysicalcapacityandidentifyCVvs.
(according to CV toxicity baseline risk stratification), echocardiog-
non-CVcauses.635
raphyandcardiacserumbiomarkersmaybeconsideredwithin12
monthsaftercompletionofcancertherapy.634
All patients started on CV therapies (ACE-I/ARB/angiotensin 7.5. The role of cardiac rehabilitation
receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid re- Exercise is a potent multitargeted therapy that prevents and
ceptorantagonists,sodium-glucoseco-transporter2inhibitors,anti- treatsmultiplecompetingmechanismsofCTR-CVTinCS,includ-
hypertensive medications, antiarrhythmic medications, antiplatelet ing CRF impairment,636 CV injury, and pre-existing and new
therapies, statins) for any CTR-CVT (especially CTRCD) should CVRF.137Prescribingexercisefacilitatesthedeliveryoftherapeut-
haveaclinicalassessment,ECG,echocardiography,andcardiacser- icexercisethatisindividualizedtoaperson’sfitnesslevelandsys-
umbiomarkers(ifLVsystolicdysfunction/HFisapotentialrisk)at3, tematically progressed to optimize physiological adaptation.637
6,and12monthsaftercompletingcancertreatment.AMDT-based Currentevidencedemonstratesthatsupervisedexercisetherapy
approachto palliativeandend-of-lifecareforpatientswith cancer (including high-intensity interval training [HIIT]) is safe and well
withHForotherCTR-CVTshouldbefocusedonsymptomrelief tolerated,638 attenuates CTR-CVT risk, and improves CRF.
accordingtogeneralESCGuidelines. Furthermore, HIIT reduces CVRF460 and CV risk639 in patients
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 83 ---
ESCGuidelines 4311
Patients who develop CTRCD during cancer treatment and are being started on HF therapppy
CTRCD
Mild or moderate Severe andvery severe
Continue HF therapppy
Recovery N Partial or nonea
(Class I)
Y
Fullb
MDT to consider
weaning HF therapppyc
Patient risk
High riskkkd Low riskkke
Continue Consider weaning
HF therapppy HF therapppy
(Class I) (Class IIa)
Figure37Managementofcancertherapy-relatedcardiacdysfunctionaftercancertherapy.CTRCD,cancertherapy-relatedcardiacdysfunction;CV,
cardiovascular;GLS,globallongitudinalstrain;HF,heartfailure;HFA,HeartFailureAssociation;ICOS,InternationalCardio-OncologySociety;LV,left
ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; N, no; Y, yes. aPartial or no recovery: patients who do not
meetallofthecriteriaforfullrecovery.bFullrecovery:nosignsorsymptomsofHF+LVEF.50%+GLSwithinnormalrangeorsimilartobaseline
measurements+cardiacserumbiomarkerswithinthenormalrangeorsimilartobaselinemeasurementscTheCTRCDtrajectoryofeachpatientis
uniqueanddynamicandwithdrawalofHFtherapyrequiresaMDTtoconsiderseveralkeypointsthathelptostratifypatientsintolow-orhigh-risk
categories.KeypointstoconsiderduringaMDTdiscussionare:HFA-ICOSbaselineCVtoxicityriskassessment,pre-existingindicationsfor
CVmedication,classofcancertreatmentcausingCTRCD(generallyreversiblevs.generallyirreversible),magnitudeanddurationofCTRCDbeforere-
covery,intensityofHFtherapyneededtorecoverLVfunction,familyhistoryofcardiomyopathyorknowncardiomyopathygenecarrier(seeSection4.8).
dSeeTable10.eLow-riskpatientcharacteristics:lowtomoderatebaselineCVtoxicityrisk(HFA-ICOSriskassessment),nopre-existingindications
forCVmedication,cancertreatmentgenerallyassociatedwithreversiblemyocardialdamage,asymptomaticmildCTRCD,earlycardiacfunctionrecovery
(3–6months)underHFtherapy,nofamilyhistoryofcardiomyopathy.
with cancer in the pre-, active-, and post-treatment settings. may not be feasible in elderly and frail patients.642 Dedicated
HIIT-relatedbenefitsonCRF,physicalactivitybehaviour,fatigue, cardio-oncology rehabilitation programmes are currently under
and quality of life persist months post-intervention.640,641 HIIT development.11
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 84 ---
4312 ESCGuidelines
RecommendationTable39—Recommendationsfor
ECGfollow-upisrecommendedinpatientswho
end-of-cancertherapycardiovascularriskassessment
developedQTlengtheningorLQTSduringcancer I C
Recommendations Classa Levelb
therapy.646
CPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer
Educatingandsupportingpatientswithcancerto
therapy-relatedcardiacdysfunction;CV,cardiovascular;CVD,cardiovasculardisease;
makeappropriatehealthylifestylechoicesis I C CVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;
recommended.c ESC,EuropeanSocietyofCardiology;LQTS,longQTsyndrome;TKI,tyrosinekinase
inhibitors.
Educationisrecommendedforpatientswith aClassofrecommendation.
cancerregardingrecognitionforearlysignsand I C bLevelofevidence.
symptomsofCVD.
cIncludingregulationofhypertension,DM,dyslipidaemia,smokingcessation,weightloss
incaseofobesity,andanadequateamountofexercise.
CVRFassessmentisrecommendedduringthe dHigh-riskpatients:seeTable10.
firstyearaftercancertherapyc,12,22,31,632,643and eModerate-orlow-riskpatients:accordingtoCVtoxicitybaselineriskstratification.
I B fCardio-oncologyreferralisrecommendedwhenavailable;alternatively,thepatient
thereafteraccordingtothe2021ESCGuidelines
shouldbereferredtoacardiologistwithexpertiseinmanagingCVDinpatientswith
onCVDpreventioninclinicalpractice.19
cancer.
Inasymptomatichigh-riskpatients,d
echocardiographyandcardiacserumbiomarkers
arerecommendedat3and12monthsafter I B 8. Long-term follow-up and
completionofcancer
chronic cardiovascular
therapy.53,54,59,61,68,148,208,425
Inasymptomaticmoderate-riskpatients,e complications in cancer survivors
echocardiographyandcardiacserumbiomarkers
IIa B
shouldbeconsideredwithin12monthsafter 8.1. Cancer survivors
completionofcancertherapy.53,54,59,61,68,148,208 8.1.1.Adultsurvivorsofchildhoodandadolescent
Inasymptomaticlow-riskpatients,e cancer
echocardiographyandcardiacserumbiomarkers Thesurvivalofchildrenandadolescentswithcancerhasincreased
IIb C
maybeconsideredwithin12monthsafter considerablyinrecentdecades,with5-yearsurvivalratescurrently
completionofcancertherapy.634 exceeding 80%.647 However, the long-term health effects in the
Cardiologyreferralfisrecommendedinpatients growingpopulationofchildhoodandadolescentCSareamajorcon-
withcancerwithnewcardiacsymptomsornew cern.648 CTR-CVT, as a consequence of treatment with anthracy-
asymptomaticabnormalitiesinechocardiography I C clines, mitoxantrone, and/or chest-directed RT can manifest as
and/orcardiacserumbiomarkersattheendof CTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunc-
therapyassessment.11 tion, pericardial disease, and premature CV mortality, depending
Inselectedpatientswithexerciseintolerance onthetypeofcardiotoxictreatment.643,649
persistingat12monthsaftercancertreatment CTRCDisoneofthemostfrequentlateeffectsinchildhoodCS
andwithnormalrestingechocardiogramand whoreceivedcardiotoxiccancertreatmentandcontributestosig-
IIb C
cardiacbiomarkers,exercisestress nificant morbidity and non-cancer-related mortality later in life.650
echocardiographyand/orCPETmaybe ThecumulativeincidenceofCTRCDvariesdependingonthediag-
considered. nostic criteriaappliedand thepopulationstudiedand ranges from
Targetedcardiacrehabilitationshouldbe 4.8%to10.6%at40–45yearsofage.651RTtoafieldinvolvingthe
IIa B
consideredinCSwithhighCVrisk.638–640 heart increases the risk of CTRCD and valvular and vascular
Long-termcontinuationofcardiacmedicationis
complications.652
recommendedinpatientswhodevelopsevere I C Follow-up of paediatric CS according to the International Late
CTRCDduringcancertherapy. EffectsofChildhoodCancerGuidelineHarmonizationGroupisre-
commended.653Thisincludesriskstratificationbaseduponthetotal
CVfollow-upandtreatmentoptimizationis
cumulativedoseofanthracyclinechemotherapyandMHDdelivered
recommendedinpatientswhodeveloped
I C
(Table 11). Annual review of CVRF and education to promote a
TKI-mediatedhypertensionduringcancer
therapy.644,645 healthy lifestyle is recommended. The frequency of CV review
with TTE depends upon risk. A CV review should be considered
CVfollow-upandtreatmentoptimizationis
every5yearsformoderate-riskchildhoodandadolescentadultCS
recommendedinpatientswhodevelopedvascular I C
andevery2yearsforhigh-riskchildhoodandadolescentadultCS.
toxicitiesduringcancertherapy.10,237
A recent retrospective analysis has shown that quantification of
Continued
LVEF.5yearsaftercancerdiagnosisimproveslong-termchildhood
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 85 ---
ESCGuidelines 4313
Table11 Riskcategoriesforasymptomaticadultswhoarechildhoodandadolescentcancersurvivors
Riskcategory RTdosea(GyMHD) Totalcumulativedoxorubicinb Combinationtherapy
dose(mg/m2)
RTdosea(GyMHD) Totalcumulativedoxorubicinb
dose(mg/m2)
Veryhighrisk .25c ≥400 .15c ≥100
Highrisk .15to25c 250–399 5–15d ≥100
Moderaterisk 5–15d 100–249 ,5e ≥100
Lowrisk ,5e ,100 –
Gy,Gray;MHD,meanheartdose;RT,radiotherapy.
aRTriskcategorizationbasedonMHDisrecommendedovercategorizationbasedonprescribeddose,whichmaynotaccuratelyreflectcardiacradiationexposure.Dependingondose
distributionandexposureofspecificcardiacsubstructures(aswellasclinicalriskfactors),thetreatmentteammayjudgethepatienttobelongtoahigherriskcategory.Inaddition,a
patientmaybejudgedtobelongtoalowerriskcategoryifonlyasmallpartoftheheartisexposedtoarelativelyhighprescribeddose.
bOrdoxorubicinequivalent.
cOrprescribedRT≥35GytoavolumeexposingtheheartifMHDisnotavailable.Notethatinthiscase,thelimitedinformationaboutcardiacexposuredoesnotallowonetodistinguish
betweenhigh-andveryhigh-riskcategories.
dOrprescribedRT15–34GytoavolumeexposingtheheartifMHDisnotavailable.
eOrprescribedRT,15GytoavolumeexposingtheheartifMHDisnotavailable.
CSriskstratification.ALVEFof40–49%isassociatedwithanalmost 8.1.2.Adultcancersurvivors
eight-foldincreasedriskforLVEF,40%at10-yearfollow-upcom- Long-termcancersurvivorshipcareisanadvancingfieldofresearch.
paredwithpatientswithapreservedLVEF(≥50%).654Lifelongsur- Manysurvivorswillexperienceseveralcancer-andtreatment-related
veillanceforhigh-risksurvivorsisrecommended.7 lateeffectsthroughouttheirlives,includingCTR-CVT.Besidesaffect-
ingtheirphysicalandpsychosocialhealthstatus,thesemightreduce
RecommendationTable40—Recommendationsfor lifeexpectancyandqualityoflife.Thisisrelevantinsomecancertypes,
cardiovascular surveillance in asymptomatic adults when CVD risk—especially CTRCD risk—exceeds cancer mortal-
whoarechildhoodandadolescentcancersurvivors ity.658,659Theriskoffatalheartdiseaseisincreasedmorethantwo-
fold in survivors of several solid cancers and lymphoma compared
Recommendations Classa Levelb withthegeneralpopulation.660–662
Educationofadultswhoarechildhoodand CVriskassessmentattheendoftherapy(Section7)identifiesCS
adolescentCStreatedwithanthracyclines, who require long-term cardiology follow-up beyond the first 12
mitoxantrone,and/orRTtoavolumeincluding I B months after completing their cancer treatment. Asymptomatic
theheartandtheirhealthcareprovidersregarding CSwithneworpersistingabnormalitiesattheirend-of-therapyas-
theirincreasedCVriskisrecommended.655–657 sessmentwillbeidentifiedasathighriskforfutureCVeventsand
AnnualscreeningformodifiableCVRFcis requirelong-termsurveillance.
recommendedinadultswhoarechildhoodand
Specificcancertreatmentscarrythehighestriskoflong-termCV
adolescentCStreatedwithanthracyclines, I C toxicity including anthracycline chemotherapy and RT where the
mitoxantrone,and/orRTtoavolumeincluding heart is within the RT treatment volume. Progressive RT-related
theheart.
CVtoxicitytypicallydevelops5–10yearsaftertheinitialtreatment,
CVassessmentdisrecommendedinfemale andmaycauseCADandHFatanincidenceuptosix-foldhigherthan
childhoodandadolescentCSpriortopregnancy I C inthegeneralpopulation.AnincreasedCVmortalitycomparedwith
orinthefirsttrimester. the general population has been attributed to radiation-associated
heart disease in Hodgkin lymphoma, non-Hodgkin lymphoma, BC,
Echocardiographysurveillanceshouldbe
consideredevery2yearsinadultswhoare IIa B
andpatientswithlungcancer.663–665Theincidenceandprogression
high-riskchildhoodandadolescenteCS.7 oftheradiation-relatedCVcomplicationsdependsonthedoseto
theCVtissueandonconcomitantcancertherapiesandpatientchar-
Echocardiographysurveillanceshouldbe
acteristics,suchaspre-existingCVD,CVRF,andage.389,400
consideredevery5yearsinadultswhoare IIa B
LateCVcomplicationsarealsoobservedinCSwhorequiredHSCT.
moderate-riskchildhoodandadolescenteCS.7,654
TheincidenceofHFincreasesupto14.5%inwomen15yearsafter
BP,bloodpressure;CS,cancersurvivors;CV,cardiovascular;CVRF,cardiovascularrisk HSCT.RiskfactorsforCVDfollowingHSCTincludeage,anthracycline
factors;DM,diabetesmellitus;ECG,electrocardiogram;HbA1c,glycatedhaemoglobin; dose,chestradiationexposure,hypertension,DM,andsmoking.666
RT,radiotherapy;TTE,transthoracicechocardiography.
aClassofrecommendation. Long-term follow-up surveillance, based on CV toxicity risks
bLevelofevidence. (Table12),includespatienteducationandCVRFoptimization.Anan-
cObesity, sedentary lifestyle, cigarette smoking, alcohol intake, unhealthy diet,
nualclinicalCVriskassessmentisrecommendedforalladultCSto
dyslipidaemia,hypertension,DM.
dBP,lipids,fastingglucose,HbA1c,ECG,andTTE. optimizeCVRFcontrol,promoteahealthylifestyle,andsymptomre-
eSeeTable11. view. This can be done in collaboration with primary care or a
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 86 ---
4314 ESCGuidelines
Table12 Riskcategoriesforasymptomaticadultcan- earlyrisk,particularlyinthefirst2years.61,667,668AnnualCVassess-
cersurvivors mentwithclinicalexamination,ECG,andNPmeasurementisrecom-
mendedinCS.TTEshouldbeconsideredatyears1,3,and5after
Riskcategorya Patientcharacteristics
completionofcardiotoxiccancertherapyandevery5yearsthereafter
Veryhighrisk (cid:129) VeryhighbaselineCVtoxicityrisk inasymptomaticveryhigh-andearlyhigh-riskadultCS.
pre-treatment InadultCSwithlatehighCTR-CVTrisk(e.g.youngadultswith
(cid:129) Doxorubicinb≥400mg/m2 Hodgkinlymphomaorsarcomaswhoreceivedahightotalcumula-
(cid:129) RT.25GyMHDc tiveanthracyclinedoseorpatientstreatedwithhigh-doseradiation
(cid:129) RT.15–25GyMHDc+doxorubicinb toafieldinvolvingtheheart,e.g.MantleRT)thereisaprogressive
≥100mg/m2 riskofCTRCD.661,669Annual CVassessment with clinical examin-
Earlyhighrisk (cid:129) HighbaselineCVtoxicityrisk ation,ECG,andNPmeasurementisrecommended,starting5years
(,5yearsafter (cid:129) Symptomaticorasymptomatic aftertheendoftreatment,providedtheend-of-therapyassessment
at12monthsisnormal.TTEshouldalsobeconsideredevery5years,
therapy) moderate-to-severeCTRCDduring
aswellasnon-invasivescreeningforCAD(Section8.3)andcarotid
treatment
(cid:129) Doxorubicinb250–399mg/m2
disease(Section8.5)accordingtolocalprotocols.670
(cid:129) High-riskHSCTd The long-term effects of CTRCD caused by trastuzumab and
Latehighrisk (cid:129) RT.15–25GyMHDc othertargetedcancertherapies(e.g.TKI)beyond10yearsareun-
(cid:129) RT5–15GyMHDe+doxorubicinb known.Currently,thereisnorecommendationforlifelongsurveil-
≥100mg/m2 lanceintheseCSunlesstheyhaveanotherindication.
(cid:129) PoorlycontrolledCVRF CVassessmentwithclinicalexamination,ECG,echocardiography,
andNPmeasurementevery5yearsshouldbeconsideredinasymp-
Moderaterisk (cid:129) ModeratebaselineCVtoxicityrisk
tomaticadultCSatmoderateriskoffutureCTR-CVTandanormal
(cid:129) Doxorubicinb100–249mg/m2
end-of-therapyCVassessment.
(cid:129) RT5–15GyMHDe
(cid:129) RT,5GyMHDf+doxorubicinb≥100mg/
m2 RecommendationTable41—Recommendationsfor
cardiovascular surveillance in asymptomatic adult can-
Lowrisk (cid:129) LowbaselineCVtoxicityriskandnormal
cersurvivors
end-of-therapycardiacassessment
(cid:129) MildCTRCDduringtherapybutrecoveredby Recommendations Classa Levelb
theendofcancertherapy
(cid:129) RT,5GyMHDf
AnnualCVriskassessment,cincludingECGand
(cid:129) Doxorubicinb,100mg/m2 NP,andCVRFmanagementisrecommendedin I B
CSwhoweretreatedwithapotentially
CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiotoxiccancerdrugorRT.d,631–633,671,672
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host
CVtoxicityriskrestratificationeisrecommended
disease;Gy,Gray;HSCT,haematopoieticstellcelltransplantation;MHD,meanheart
dose;RT,radiotherapy.References:397,399,400,673,674 5yearsaftertherapytoorganizelong-term I C
aRTriskcategorizationbasedonMHDisrecommendedovercategorizationbasedon
follow-up.
prescribed dose, which may not accurately reflect cardiac radiation exposure.
Dependingondosedistributionandexposureofspecificcardiacsubstructures(aswell Echocardiographyatyears1,3,and5after
asclinicalriskfactors),thetreatmentteammayjudgethepatienttobelongtoahigher completionofcardiotoxiccancertherapyand
riskcategory.Inaddition,apatientmaybejudgedtobelongtoalowerriskcategoryin every5yearsthereaftershouldbeconsideredin IIa C
caseonlyasmallpartoftheheartisexposedtoarelativelyhighprescribeddose.
bOrequivalent. asymptomaticveryhigh-andearlyhigh-riskadult
cOrprescribedRT≥35GytoavolumeexposingtheheartifMHDisnotavailable.Note CS.f
thatinthiscase,thelimitedinformationaboutcardiacexposuredoesnotallowoneto
Echocardiographyshouldbeconsideredin
distinguishbetweenhigh-andveryhigh-riskcategories.
dHigh-riskHSCTpatients:allogenicHSCT;pre-existingCVDormultipleuncontrolled asymptomaticlatehigh-riskadultCSfstartingat5
IIa C
CVRF;cancertreatmenthistory(mediastinalormantlefieldradiation,alkylatingagents,
yearsafterradiationtoavolumeincludingthe
.250mg/m2doxorubicinorequivalent);conditioningschemes(totalbodyirradiation,
heartandthenevery5years.
alkylatingagents);developmentofGVHD.
eOrprescribedRT15–34GytoavolumeexposingtheheartifMHDisnotavailable. Echocardiographymaybeconsideredevery5
IIb C
fOrprescribedRT,15GytoavolumeexposingtheheartifMHDisnotavailable. yearsinasymptomaticmoderate-riskadultCS.f
Non-invasivescreeningforCADgshouldbe
specialistinCVmedicinewithexpertiseinCVRFmanagement.CSat
consideredevery5–10yearsinasymptomatic
IIa C
highorveryhighriskoffutureCVDcanbedividedintothoseathigh
patientswhoreceived.15GyMHD,dstartingat
earlyrisk(within5yearsofcompletingcancertherapy)andthoseat 5yearsafterradiation.
highlaterisk(.30yearsfromcompletingtreatment).Thetimingand Carotidultrasoundimagingshouldbeconsidered
frequencyofothercomplementarytestsdependsupontheriskfor every5yearsinasymptomaticpatientswitha
IIa C
CTR-CVT(Figure38). historyofhead/neckRT,startingat5yearsafter
CSwithahighorveryhighbaselineriskandpatientswithabnormal
radiationandevery5–10yearsthereafter.
LVfunctionattheend-of-therapyassessmenthaveahighorveryhigh Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 87 ---
ESCGuidelines 4315
8.2. Myocardial dysfunction and heart
Renalarteryultrasoundshouldbeconsideredin
patientswithahistoryofabdominalandpelvic failure
IIa C
radiationwhopresentwithworseningrenal HFtreatmentinCSshouldfollowthecurrent2021ESCGuidelines
functionand/orsystemichypertension. for the diagnosis and treatment of acute and chronic HF.14
TreatmentwithACE-I/ARBand/orbeta-blockersisrecommended
BP,bloodpressure;CAD,coronaryarterydisease;CMR,cardiacmagneticresonance;
CS,cancersurvivors;CT,computedtomography;CTR-CVT,cancertherapy-related for both symptomatic and asymptomatic CS who have LVEF,
cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, 50%detectedonCVassessment.14,61,208,675InCSwithmildasymp-
cardiovascular risk factors; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
tomaticCTRCDdetectedonCVassessment(LVEF.50%butnew
MHD,meanheartdose;NP,natriureticpeptides;RT,radiotherapy.
aClassofrecommendation. fallinGLSand/orcardiacserumbiomarkerincrease),treatmentwith
bLevelofevidence.
ACE-I/ARBand/orbeta-blockersmaybeconsidered.
cClinicalreview,BP,lipidprofile,HbA1c.
dRTriskcategorizationbasedonMHDisrecommendedovercategorizationbasedon
prescribeddose(≥35GytoavolumeexposingtheheartifMHDisnotavailable).
eRestratificationincludesevaluationofneworpre-existingCVRFandCVD(including
CTR-CVT).
fSeeTable12.
gStressechocardiography,cardiacCT,stressCMR,single-photonemissionCTstress
test,accordingtolocalprotocol.234
Long-term surveillance in asymptomatic CS
Annual CV risk
Low assessmenta
risk
Cardiology referralb
if new CV TTE every 5 years in
symptoms develop adults who are childhood
and adolescent CS
Moderate
risk
TTE every 5 years in
CV toxicity risk adult CS
re-stratificationc
at 5 years
TTE every 2 years in
adults who are childhood
High and and adolescent CS
very high
Patient education and risk TTE at years 1, 3, and 5 after
CVRF optimization
cardiotoxic cancer therapy and
every 5 years thereafter in adult CS
Class 1 Class 1Ia Class 1Ib
Figure 38 Long-term follow-up in cancer survivors. BP, blood pressure; CAD, coronary artery disease; CS, cancer survivors; CTR-CVT, cancer
therapy-relatedcardiovasculartoxicity;CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfactors;ECG,electrocardiogram;
HbA1c,glycatedhaemoglobin;NP,natriureticpeptides;TTE,transthoracicechocardiography.aClinicalreview,BP,lipidprofile,HbA1c,ECG,NP.In
selectedpatients,non-invasivescreeningforCADandcarotidorrenaldiseasesevery5–10years,startingat5yearsafterradiationmaybeconsidered.
bCardio-oncologyreferralisrecommendedwhenavailable;alternatively,thepatientshouldbereferredtoaspecializedcardiologistwithexpertisein
managingCVDinpatientswithcancer.cRestratificationincludesevaluationofneworpre-existingCVRFandCVD(includingCTR-CVT).
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 88 ---
4316 ESCGuidelines
RecommendationTable42—Recommendationsfor mammaryarteryviability,venousaccess,andsternalwoundhealing
adult cancer survivors who develop cancer isrecommendedinCSwithRT-inducedCADwhereCABGiscon-
therapy-relatedcardiacdysfunctionlateaftercardio-
sidered.PCIwithdrug-elutingstentsmaybeconsideredoverCABG
toxiccancertherapy
inCSwithRT-inducedsevereleftmainorthree-vesseldisease,witha
Recommendations Classa Levelb highSYNTAX(SYNergybetweenpercutaneouscoronaryinterven-
tion with TAXus and cardiac surgery) score (.22), in whom the
ACE-I/ARBand/orbeta-blockersare plannedPCIistechnicallyfeasiblegiventheincreasedcomplications
recommendedinadultCSwithmoderate I C associatedwithCABGaftermediastinalRT.
asymptomaticCTRCD.c,208,425,675–678
ScreeningforCADshouldbeconsideredinhigh-riskpatientswho
ACE-I/ARBand/orbeta-blockersmaybe have received chest RT to a treatment volume including the heart.
consideredinadultCSwithmildasymptomatic IIb C Screeningshouldtaketheformoffunctionalimagingand/orCCTAbe-
CTRCD.d ginningat5yearspost-RT.234,484ThenaturalhistoryofRT-relatedvas-
culopathyisdifferenttoatherosclerosisandmayacceleraterapidly.173
ACE-I,angiotensin-convertingenzymeinhibitors;ARB,angiotensinreceptorblockers;
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; GLS, FunctionalcardiacimagingshouldbeconsideredinasymptomaticCS
globallongitudinalstrain;LVEF,leftventricularejectionfraction. withpre-existingCADorwhennewsignificantCADisdetectedon
aClassofrecommendation.
anatomicalimaging.Inasymptomaticpatientswithinducibleischaemia
bLevelofevidence.
cNewLVEFreductionby≥10percentagepointstoanLVEFof40–49%ORnewLVEF secondarytoRT-inducedCAD,aMDTisrecommendedtodiscussre-
reductionby,10percentagepointstoanLVEFof40–49%ANDeithernewrelative vascularizationneedsaccordingtothelocationoftheRT-inducedCAD,
declineinGLSby.15%frombaselineORnewriseincardiacbiomarkers.
theischaemiaburden,LVfunction,arrhythmiaburden,timesincetreat-
dLVEF≥50%andnewrelativedeclineinGLSby.15%frombaselineAND/ORnew
riseincardiacbiomarkers. ment, time since previous normal review (if available), concomitant
valvular disease, risks of surgical or percutaneous revascularization,
medicaloptions,andpatientpreference.173
8.3. Coronary artery disease
Platinum-based chemotherapies are now recognized to cause
AnyvascularlocationwithintheRTtreatmentvolumeisatincreased CAD in CS. Cisplatin-based chemotherapy for testicular cancer is
riskforbothacceleratedatherosclerosisandRT-relatedvasculopa- associated with a 1.5–7-fold increased risk of developing
thy.173,392 RT to the chest (e.g. treatment of Hodgkin lymphoma, CAD.421,493,685TesticularCSwhoreceivedplatinum-basedchemo-
early-stageBC,lungandoesophagealcancer,andforsomepatients therapyshouldhavetheirCVRFtightlycontrolledandbeeducated
receiving infradiaphragmatic irradiation if the apex of the heart is toreportanynewchestpainorcardiacsymptomstotheirdoctor
withinthetreatmentvolume)increasestheriskofCAD.Thelatency promptly.TheroleofscreeningforCADinpatientswhoreceived
betweenRTandtheappearanceofCADvariesfromafewyearsto platinum-basedchemotherapyisunknown.
several decades, depending upon the presence or absence of pre- Aggressive risk-factor modification and CV diagnostic work-up
existing atherosclerosis and the age of the patient at the time of stronglyenhancesurvival.5,672Medicaltherapywithaspirinandsta-
RT.ThisisaseriouscomplicationforyoungCSwithagoodprogno- tins for primary/secondary prevention, and beta-blockers and ni-
sisandlong-lifeexpectancy(e.g.BCandHodgkinlymphoma).389,390 tratesforsymptomcontrol,arerecommendedinCS.686,687
PatientstreatedformediastinalHodgkinlymphomahaveshownan
increasedriskofCADasafirstcardiacevent.400RT-inducedCAD
dependsonthelocationoftheRTtreatmentvolumeandmostcom- RecommendationTable43—Recommendationsfor
monly affects either the proximal left anterior descending or the adultcancersurvivorswithcoronaryarterydisease
rightcoronaryarteries.RT-relatedvasculopathyisprogressiveand
Recommendations Classa Levelb typically manifests in severe, diffuse, long, smooth and concentric
angiographiclesions.679,680
Asymptomaticradiation-inducedCADdetectedduring
TheriskandseverityofCADincreaseswithradiationdose,larger surveillance
volumeexposed,youngerageattimeoftreatment(,25years),390
Non-invasivestresstestingcisrecommendedin
time from treatment, smoking,400 the presence of other typical asymptomaticCSwithnewmoderateorsevere
CVRF, type of radiation source, and concurrent metabolic risk I C
radiation-inducedCADdetectedonCCTAto
factors.493RTacceleratespre-existingatherosclerosisleadingtoin-
guideischaemia-directedmanagement.635,688
creasedACSriskwithin10yearsoftreatment.681
AMDTdiscussionisrecommendedforclinical
PatientswithRT-inducedCADundergoingPCIwithbare-metal
decision-makinginpatientswithradiation-induced
stentorballoonangioplastyhaveanincreasedriskofall-causeand I C
CADandinducibleischaemiaorsevereleftmain
CV mortality.682 Conversely, after PCI with a drug-eluting stent,
CAD.
there is no difference in target lesion revascularization or cardiac
mortalitybetweenpatientswithandwithoutpriorchestRT.683 SymptomaticCAD
SurgicalrevascularizationinpatientswithpriorRTmaybecompli- Pre-operativeassessmentofLIMAandRIMA
catedbypoortissuehealing(skinandsternum),RT-inducedinjuryto viability,venousaccess,andsternalwoundhealing
I C
the left and right internal mammary arteries (LIMA and RIMA, re- isrecommendedinCSwithradiation-induced
spectively), inadequate target coronary vessels, and increased CADwhereCABGisconsidered.
sternotomy-related pain.684 Pre-operative assessment of internal Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 89 ---
ESCGuidelines 4317
PCImaybeconsideredinCSwith TAVIshouldbeconsideredforpatientswith
radiation-inducedCADwithsevereleftmainor symptomaticsevereaorticstenosiscausedby
IIa B three-vesseldiseasewithahighSYNTAXscore IIb B radiationatintermediatesurgical
(.22)inwhomtheprocedureistechnically risk.504,506,693,694,696,697
feasible.682,689,690
CS, cancer survivors; EuroSCORE, European System for Cardiac Operative Risk
CABG,coronaryarterybypassgraft;CAD,coronaryarterydisease;CCTA,coronary
Evaluation;MDT,multidisciplinaryteam;STSPROM,SocietyofThoracicSurgeons–
computed tomography angiography; CS, cancer survivors; LIMA, left internal Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation; VHD,
mammary artery; MDT, multidisciplinary team; PCI, percutaneous coronary valvularheartdisease.
intervention; RIMA, right internal mammary artery; SYNTAX, SYNergy between
aClassofrecommendation.
percutaneouscoronaryinterventionwithTAXusandcardiacsurgery.
bLevelofevidence.
aClassofrecommendation. cSurgicalrisksinclude:vascularaccess,sternalandskinwoundhealing,concomitant
bLevelofevidence. cardiac disease, radiation-induced lung and thoracic vessels disease, aortic
cAccording to local protocols and Non-invasive imaging in coronary syndromes: calcification,STSPROM/EuroSCOREII.
recommendations of the European Association of Cardiovascular Imaging and the
8.5. Peripheral artery disease and stroke
AmericanSocietyofEchocardiography,incollaborationwiththeAmericanSocietyof
NuclearCardiology,SocietyofCardiovascularComputedTomography,andSociety PeripheralarterialandcerebrovasculardiseaseinCScanbedueto
forCardiovascularMagneticResonancerecommendations.234
thecontinuumofvasculardiseasepre-existingbefore,ordeveloping
during or after cancer therapy. Cancer therapies such as cisplatin,
BCR-ABLinhibitors,andRTcanhaveadirectlong-lastingeffecton
the vasculature. Approximately 30% of CML patients on nilotinib
8.4. Valvular heart disease may develop PAD, which is clinically recognized 2–4 years after
VHD can appear in CS at any point in time but typically occurs thestartoftherapy.698Thediseaseprocessmayprogressevenafter
10 or more years after cancer treatment.691 Chest RT is the discontinuationofnilotinib.Long-termvasculareffects,generallyas-
mainriskfactorinCS,inparticularathigherdoseranges,which sociatedwithvascularreactivity,canalsobeseeninpatientstreated
can cause either stenosis or regurgitation, or both.391 withponatinib,cisplatin,andbleomycin.699,700Acceleratedvascular
The reported incidences of valvular regurgitation are up to aging, inflammation, fibrosis, and atherosclerosis are characteristic
40%ofCSsurvivorswhoreceivedhigh-dosechestRTtoavol-
consequencesofRT.701Upto30%ofpatientsmaydevelopsignifi-
ume involving the heart, with ,10% presenting with clinically cantcarotidarterystenoses(.70%)afterhead/neckradiation.702,703
significant VHD.670 Vasculardiseasecanalsobeanindirectconsequenceofcancerand
Prognosisandmanagementdependontheextentandseverityof itstherapy,e.g.viareductioninphysicalactivity,hyperlipidaemia,DM,
VHD,asitdoesinpatientswithoutcancer.692TAVIshouldbecon- obesity,hypothyroidism,and/orkidneydisease.TheseCVRF-related
sidered for patients with symptomatic RT-induced severe aortic effects are mostly additive to the direct treatment-related effects.
stenosisatintermediatesurgicalrisk.504,506,693,694Similarstrategies PromotingvascularhealthandpreventingvasculardiseaseinCSisre-
withpercutaneousmitralvalverepairorreplacementcanbeconsid- commended.672Thisshouldbeinlinewiththe2021ESCGuidelines
ered.695 Importantly, commonly used calculators such STS PROM onCVDpreventioninclinicalpractice.19
(Society of Thoracic Surgeons–Predicted Risk of Mortality) or
8.6. Pericardial complications
EuroSCORE (European System for Cardiac Operative Risk
Evaluation) II507 may underestimate the surgery-related risk in CS, The risk of long-term pericardial complications after cancer
andespeciallythosewhodevelopRT-inducedVHD,duetoaddition- drug-inducedacutepericarditis,causedbyanthracyclines,cyclophos-
alRT-relatedriskfactorssuchaspericardialcalcification,aorticcalci- phamide,cytarabine,andbleomycin,isunknownbutgenerallycon-
fication,increasedbleedingrisk,impairedskinhealing,andRT-related sideredlow.Long-termdasatinibtreatmentmayleadtopericardial
pulmonaryfibrosis.AHeartTeamwithcardiacsurgeons,interven- effusionandpericarditis.Theincidenceoflong-termICI-associated
tional cardiologists, and cardio-oncology specialists should review
pericardialcomplicationsislow.10
eachcasetoguideappropriatetreatment.TheHeartTeamrecom- RT-induced chronic pericardial diseases can appear months to
mendationshouldbediscussedwiththepatient,whocanthenmake decadesaftertheinitialRTandconstrictivepericarditisisthemost
aninformedtreatmentchoice. serious.173,392 Incidence is difficult to determine, and many cases
areinitially asymptomatic.704Five-yearlyechocardiographicsurveil-
lanceforpericardialconstrictioninCSfollowingRT-inducedacute
pericarditismaybeconsidered.Theabsoluteriskisconsiderablyre-
RecommendationTable44—Recommendationsfor
ducedwithmodernradiationprotocols,704butahighrateofpericar-
adultcancersurvivorswithvalvularheartdisease dialeffusionhasstillbeenreportedinpatientswithlung(grade≥2,
.40%705)andoesophagealcancer(.25%706)treatedwithRT.
Recommendations Classa Levelb
Pericardial disease has been less investigated than other
AMDTapproachisrecommendedtodiscussand RT-inducedCVD,andclearprotocolsforpost-therapysurveillance
I C
definethesurgicalriskcinCSwithsevereVHD. arelacking.707,708InCSwithchronicpericardialeffusionsfollowing
Continued RT, cardiac imaging can assess for evidence of inflammation,
2202CSE©
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 90 ---
4318 ESCGuidelines
constriction, or tamponade.709 Percutaneous balloon pericardiot- standardizedrisk-basedscreeningandmanagementofthesecondi-
omyorpericardialwindowcreationshouldbeusedinselectedcases tionsaccordingtogeneralESCGuidelinesisrecommended19toim-
forlargeorgrowingchroniceffusionsifhaemodynamiccompromise provelong-termoutcomesinCS.672
develops. Management of these conditions should follow general Increasingnumbersofpatientswithcancerarealreadyoverweight
guidelinerecommendations.14,444 orobeseatcancerdiagnosis,717andadditionalweightgainisafre-
quent complication of anticancer treatments.718 Obesity is asso-
ciated with metabolic syndrome, worsening CVRF, and cancer.
RecommendationTable45—Recommendationfor
Increasing evidence indicates that being overweight increases the
adultcancersurvivorswithpericardialcomplications
riskofcancerrecurrenceandreducesthelikelihoodofdisease-free
Recommendation Classa Levelb
survivalandoverallsurvivalamongthosediagnosedwithcancer.719–
724Thereisalsogrowingevidencetosupportintentionalweightloss
PatientswithacutepericarditisduringRTtoa
post-treatmentinCS,whichmayresultinimprovedprognosisand
volumeincludingtheheartareathigherriskof survival.719Dietarypatternscharacterizedbyahighintakeofvegeta-
developingchronicconstrictivepericarditis,hence IIb C
bles/fruitsandwholegrainshasbeenshowntobeassociatedwithre-
echocardiographysurveillanceevery5yearsmay
ducedmortalityandcancerrecurrencewhencomparedwithahigh
beconsidered. intakeofrefinedgrains,processedandredmeats,andhigh-fatdairy
RT,radiotherapy.
products.725–727
aClassofrecommendation. TheidentificationandtreatmentofhyperlipidaemiainCSisasso-
bLevelofevidence. ciatedwithaprofoundimpactonoutcomes.182,183Thereisabenefit
forCSfromanall-causemortalityperspectiveaswellasfordecreas-
8.7. Arrhythmias and autonomic disease ingcancerrecurrence.728–730
Arrhythmias,conductiondisease,andautonomicdiseasearecom-
Severalstudieshavedemonstratedthetherapeuticbenefitsofex-
moncomplicationsinCS.ConductiondiseaseafterthoracicRTis erciseduringprimaryanticancertreatment,731,732andexerciseisre-
typically associated with other CTR-CVT.710 It may include AV commendedduringandafteranticancertreatment.11,733ForCS,734
block, bundle branch block, and sick sinus syndrome that should aerobic exercise results in improved survival.735 Based on current
be monitored and treated according to the 2021 ESC Guidelines guidelines, patients undergoing anticancer therapy and long-term
on cardiac pacing and cardiac resynchronization therapy.443 CS should be encouraged to exercise for at least 150min per
Patients who require valve replacement after thoracic RT have a week.736
high risk of post-operative AV block requiring permanent pace-
maker therapy.711 Supraventricular and ventricular arrhythmias
are more common in patients after thoracic RT,712 possibly due 8.9. Pregnancy in cancer survivors
toRT-inducedmyocardialfibrosis.Acommonlong-termcomplica- Improvementsinthetreatmentofcancerhaveledtoanincreasing
tionafterHSCTissupraventriculararrhythmiaincludingAFandat- number of female paediatric and adolescent CS who experience
rialflutter,457particularlyinCStreatedwithanthracyclinesorwith pregnancy many years after their oncological treatments.
newCVRForCVtoxicity. Approximately60%ofthemwillhavebeenpreviouslyexposedto
Autonomic dysfunction is an emerging but poorly understood anthracyclinechemotherapyorchestRTandtheyhavea15-foldin-
complicationobservedinCS,andismostfrequentlyobservedasa creaseintheirlifetimeriskofdevelopingHF.737AsyoungCSenter
late complication after thoracic RT. Orthostatic hypotension, pos- theirreproductiveyearsandcontemplatepregnancy,itisimportant
tural orthostatic tachycardia syndrome, inappropriate sinus tachy- to understand the impact of cancer and its treatment on fertility,
cardia, and loss of circadian heart rate variability can occur.713,714 pregnancyoutcomes,andCVhealth.Therearelimiteddataavailable
Physicianscaringforthesepatientsshouldconsiderreferralforauto- regarding CV risk in pregnancy following cancer treatments. The
nomicevaluation.Inaddition,theperceptionofanginapainmaybe overallincidenceofLVDorHFassociatedwithpregnancyinfemale
impaired,714makingthediagnosisofpost-radiationCADchallenging. adultCSvariesaccordingtothestudiedpopulation.Inasingleinsti-
Evidence-basedpharmacologicaltreatmentstrategiesarebasedon tutionreportincluding337femaleCStreatedwithcardiotoxicther-
studies of patients with other autonomic dysfunction aetiologies apies, 58 (17%) had a subsequent pregnancy.738 Cardiac events,
(e.g. DM or infiltrative diseases) and the reported effectiveness is definedasLVEF,50%ontwoTTEornewCAD,wereidentified
generallypoor.714 in 17 patients.738 Patients with cardiac events were likely to be
youngeratcancerdiagnosis,receivedahighercumulativedoseofan-
thracycline,andhadalongerdelay(inyears)fromcancertreatment
8.8. Metabolic syndrome, lipid
tofirstpregnancycomparedwithpregnantwomenwithnocardiac
abnormalities, diabetes mellitus, and
event.738Inarecentmeta-analysisofsixstudies,theweightedriskof
hypertension pregnancy-associatedLVDorHFinCStreatedwithanthracyclines
ThereisagrowingunderstandingaboutsharedCVRFthatmaybe was 1.7% with no reported maternal cardiac deaths.739 Major risk
responsibleforcancerdevelopmentorprogressionandpremature factorsforCVeventsduringpregnancyinCSincludeCTRCD(inci-
CVmorbi-mortality.34ModifiableCVRFcontinuetobeunderdiag- dence28%;47.4-foldhigherodds),739youngerageatcancerdiagno-
nosed and undertreated in CS, especially hypertension,715 obesity, sis,738,740longertimefromcancertreatmenttofirstpregnancy,and
DM, metabolic syndrome,716 and dyslipidaemia. Early diagnosis via cumulativeanthracyclinedose.738
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 91 ---
ESCGuidelines 4319
ManagementbyanexpertMDT(thepregnancyheartteam)isre- predominantinadults,rhabdomyomasinchildren).744Malignantpri-
commended for all CS with CTRCD who are considering preg- marytumoursmostcommonlyconsistofsarcomas(approximately
nancy.739,741,742 The risk of HF in CS without CTRCD is low, 65%) or lymphomas (approximately 25%).745 Cardiac metastases
althoughvigilanceremainsimportantforpotentialmaternalcardiac (frommelanoma,lymphoma,leukaemia,breast,lung,andoesopha-
complications. gealcancers)aremuchmorecommonthanprimarycardiactumours
(Figure39).746Presentingsymptomsareparaneoplastic(fever,weak-
ness,fatigue),thromboembolic,haemodynamic(duetocompression
RecommendationTable46—Recommendationsfor orobstructionfromthetumour)orarrhythmic.747,748
cardiovascular monitoring in cancer survivors during
The diagnostic pathway should be based on knowledge about
pregnancy
tumour type epidemiology, imaging features, and usually the
Recommendations Classa Levelb requirement for a histopathological diagnosis. This topic has been
extensively reviewed in ESC CardioMed,749 and here we
Inhigh-riskfemaleCS,pre-pregnancycounselling summarize the main recommendations for differential diagnosis
andmanagementduringpregnancyandaround I C and management. Differential diagnosis should exclude cardiac
deliverybyamultidisciplinarypregnancyheart thrombiorthepresenceofchemotherapycatheters.Imagingmust
teamisrecommended. assessthepossibilitiesofcardiacsurgery,andmayinclude:(1)echo-
AbaselineCVevaluationincludinghistory, cardiography (initial approach using TTE or transoesophageal
physicalexamination,ECG,NP,and echocardiography)748,750;(2)CMR(forcardiactumourtissuechar-
echocardiographyisrecommendedinfemaleCS I C acterization)751,752; and (3) CT and PET (to distinguish malignant
withahistoryofCTRCDwhoareconsidering from benign lesions and assess for non-cardiac metastatic disease
pregnancy. orprimarycancers)(Figure40).753,754
AbaselineCVevaluationincludinghistory, Myxomasareprimarilytreatedwithsurgerywithagoodprogno-
physicalexamination,ECG,andechocardiography sis.Malignanttumoursareassociatedwithapoorprognosisandevi-
shouldbeconsideredinallfemaleCSwho IIa C denceofthebesttreatmentislacking.Completesurgicalresectionis
receivedpotentiallycardiotoxiccancertherapy often impossible and adjuvant RT, systemic chemotherapy, and/or
andareconsideringpregnancy. debulkingpalliativesurgeryareneeded.755CardiacaggressiveB-cell
ACVevaluationincludingechocardiographyis lymphomas require histopathological diagnosis (often obtained via
recommendedat12weeksofpregnancyinfemale analysis of pericardial effusion, EMB, or direct surgical biopsy) and
CSwhoareeitherhigh-riskorwhoreceived I C are treated with chemotherapy, possibly followed by RT
potentiallycardiotoxiccancertherapyanddidnot (Table13).756
haveabaselineCVassessment.
9.2. Pregnant patients with cancer
AsecondCVevaluationincluding
echocardiographyshouldbeconsideredat20 Thediagnosisofcancerduringpregnancyisuncommon(1inevery
IIa C
weeksofpregnancyinhigh-riskfemaleCScwho 1000pregnantwomen isdiagnosedwith cancer),with BC,melan-
receivedpotentiallycardiotoxiccancertherapy. oma, and cervical cancer being the most frequent diagnoses.757
Chemotherapy is generally not applied during the first trimester
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,
duetothehighriskoffoetalcongenitalabnormalities(upto20%)
cardiovascular;ECG,electrocardiogram,NP,natriureticpeptides.
aClassofrecommendation. and cytotoxic chemotherapies have different risk profiles during
bLevelofevidence. the second or third trimesters.758,759 Furthermore, chemotherapy
cSeeTables11and12.
administrationisusuallynotgivenbeyondweek34ofgestationto
provide a 3-week window between the last cycle and delivery.757
Supplementary data, Table S19 summarizes the chemotherapies
8.10. Pulmonary hypertension forpregnantpatientswithcancer.760,761
Long-termclinicalevaluationmaybeconsideredinpatientswhode- Cardiac assessment prior to chemotherapy in pregnant women
velopPHduringtherapy(Section6).Inpatientswithnewexertional with cancershouldconsistofclinicalhistory,physicalexamination,
dyspnoea, fatigue, or angina, a TTE is recommended to assess the ECG, cardiac biomarker assessment and TTE (Figure 41).741
probabilityofPH.AsTTEaloneisnotenoughtoconfirmthediagnosis Baseline and follow-up TTE should be interpreted in the context
of PH, CS diagnosed with high PHprobability require a right-heart ofphysiologicalhaemodynamicalterationsduringpregnancy.Innor-
catheterizationtoconfirmthediagnosis.PHshouldbetreatedaccord- malpregnancy,increaseinstrokevolume,heartrate,andpre-load
ingtogeneralguidelineswithreferraltoaspecialistPHservice.620 bloodvolume,anddecreaseinsystemicvascularresistance,leadto
an increase in cardiac output from the first trimester to 80–85%
above baseline by the third
trimester.762–764
An increase in LV
9. Special populations
mass and LV and RV volumes is observed in the third trimester.
During normal pregnancy, LVEF is usually unchanged and can be
9.1. Cardiac tumours usedforCTRCDmonitoring.AlthoughNPandcTnmaybeslightly
Cardiactumoursareclassifiedaseitherbenignormalignant.743Over elevatedduringnormalpregnancy(NT-proBNP,300ng/L,BNP,
90% of primary cardiac tumours are benign (myxomas are 100pg/mL,14andhs-cTnT765,766),serialevaluationmaybeusefulfor
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 92 ---
4320 ESCGuidelines
Pulmonary artery Left atrium
Sarcoma Lipoma
Metastasis
Myxoma
Right atrium
Sarcoma
Lipoma
Lymphoma
Metastasis
Myxoma
Pulmonary veins
Sarcoma
Lung tumours
Right ventricle Sarcoma
Fibroma
Lipoma
Lymphoma
Metastasis Valves
Rhabdomyoma
Fibroelastoma
Metastasis
Inferior cava vein
Leiomyoma
Renal tumour
Left ventricle
Pericardium
Fibroma
Lipo-sarcoma Lipoma
Lipoma Lymphoma
Lymphoma Metastasis
Mesothelioma Rhabdomyoma
Metastasis Sarcoma
Figure39Locationofprimaryandsecondarycardiactumours.
closeCTRCDmonitoringduringcancertreatmentwiththehigher TTEduringtreatmentswithpotentialCTRCDriskshouldbeadvised
cut-offNPlevelsforpregnancy. (e.g.every4–8weeksoreverytwocyclesfora3-weeklyanthracycline
The topic of CVD during pregnancy has been extensively re- chemotherapycycle).ThemanagementofclinicalHForasymptomatic
viewed in the 2018 ESC Guidelines for the management of CVD LVDduringpregnancyisfullydescribedinthe2018ESCGuidelinesfor
during pregnancy.741 Here we focus on specific recommendations themanagementofCVDduringpregnancy.741
in pregnant women with cancer receiving anthracycline
chemotherapy.
9.2.2.Venousthromboembolismandpulmonary
embolism
9.2.1.Leftventriculardysfunctionandheartfailure Pregnant patients with cancer have an increased risk of
MedicalhistoryevaluatingsignsandsymptomsofHFshouldbeper- developing VTE, especially when
hospitalized.767–769
formedateveryclinicalvisitofpregnantwomenwithcancerreceiv- Identified risks for VTE in pregnant patients include having a
inganthracyclinechemotherapy.MorefrequentCVevaluationswith historyofBCorpreviouschemotherapyinthepast6months.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 93 ---
ESCGuidelines 4321
Diagnostic algorithm for cardiac masses
Non-invasive assessment of single or multiple cardiac masses
Echocardiographya CTb CMRc PETd
Consider cardiac mass biopsy if malignant primary
tumour suspected or diagnosis uncertain on imaginge
Tumour Thrombus,vegetation, structural
Type
Secondary tumour Benign primary Malignant primary
(metastasis)f tumour tumour
Leukaemias Angioma, lipoma, papillary Lymphoma
Lymphomas fibroelastoma Sarcoma
Melanomas Myxoma
Solid tumours: breast, lung,
and oesophageal cancers
Figure40Diagnosticalgorithmforcardiacmasses.CMR,cardiacmagneticresonance;CT,computedtomography;PET,positronemissiontomog-
raphy;TTE,transthoracicechocardiography.aTTE/transoesophagealechocardiography:location,size,andhaemodynamicdisturbances.Contrastecho-
cardiographytoassessvascularization.bIdentifyprimaryextra-cardiacmalignancy.Revealextra-cardiacchanges.Stagingofmalignantlesions.cTissue
characterization(fatinfiltration,necrosis,haemorrhage,calcification,andvascularization).Excludethrombus.dDistinguishmalignantvs.benignlesions.
Stagingofmalignantlesions.eMassbiopsyofsuspectedprimarymalignantcardiactumoursand/orbiopsyofextracardiacmassesifdetectedandsafer
tobiopsy.f20–30timesmorelikelythanprimarytumours.
Table13 Managementstrategiesandsurgeryindicationsforsymptomaticandasymptomaticpatientswithbenign
andmalignantcardiactumours
Classification Managementstrategies Surgeryindications
Benign Asymptomatic MDTdiscussionisrequiredconsidering:tumourtype, Ifleft-sidedandendocardial:evenifsmallandincidental,a
tumours location,size,growthrate,andlikelihoodofembolism. MDTisneededtoconsidertheindicationforsurgical
Anticoagulationshouldbeconsideredforleft-sided removalduetotheembolicrisk
tumoursorright-sidedtumoursassociatedwithan
intracardiacshunt,accordingtotheindividual’sembolicand
bleedingrisk
Symptomatic Non-surgicalmanagementfor: Surgicalresectionisindicatedinallothercases.
(cid:129) Rhabdomyomas(possiblespontaneousregression) Forlarge,benign,unresectable,symptomaticcardiac
(cid:129) Intramuralhaemangioma(possibleresponseto tumours(obstruction,severeHF,ormalignant
corticosteroids) arrhythmias),hearttransplantationmaybeindicatedin
(cid:129) Unresectablecases:ifantiarrhythmictherapyissufficient somecases
Malignant Asymptomatic Histopathologicaldiagnosisisrequired Ifprimarycardiacsarcoma,acompletesurgicalresection
tumours mayincreasesurvival
Symptomatic Chemotherapyand/orRTaretheonlytherapeuticoptions
Secondarycardiactumoursmayalsobetreatedwith
forsecondarycardiactumours.
palliativecardiacsurgery
Ifprimarycardiaclymphoma:chemotherapy
HF,heartfailure;MDT,multidisciplinaryteam;RT,radiotherapy.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 94 ---
4322 ESCGuidelines
Cardiac monitoring protocol for pregnant women receiving
anthracycline-based chemotherapy
11sstt ttrriimmeesstteerr AAnntthhrraaccyycclliinnee cchheemmootthheerraappyy FFoollllooww--uupp
Week Week Every Week
Baseline Delivery 12 M
12 20 4–8W 34
Every visit
Physicalexamination
EECCGG
TTE
cTn/NP
Class 1 Class 1Ia Class 1Ib
Figure41Cardiacmonitoringprotocolforpregnantwomenreceivinganthracycline-basedchemotherapy.cTn,cardiactroponin;ECG,electrocardio-
gram;M,months;NP,natriureticpeptides;TTE,transoesophagealechocardiography;W,week.
RecommendationsforthediagnosisandtreatmentofPEduringpreg- morbidity and/or mortality due to VTE.770 LMWH have be-
nancyarethesameasinthegeneral2018ESCGuidelinesfortheman- come the drug of choice for the prophylaxis and treatment
agementofCVDduringpregnancy741and2019ESCGuidelinesforthe of VTE in pregnant patients.741 The recommendation for
diagnosisandmanagementofacutepulmonaryembolism.566 thromboprophylaxis should be individualized, weighing the
Determination of VTE risk score and the use of thrombo- risks of bleeding vs. thromboembolism in pregnant patients
prophylaxis protocols may be useful to prevent maternal with cancer.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 95 ---
ESCGuidelines 4323
Recommendation Table 47 — Recommendations for syndrome require both tricuspid and pulmonary valve surgery.783
cardiovascular assessment and monitoring of pregnant Administrationofi.v.somatostatinanalogues(e.g.octreotide)isre-
womenwithcancer
commendedtoavoidaperi-operativecarcinoidcrisis.Theinfusion
shouldbestartedonthemorningoftheprocedure(upto12hpre-
Recommendations Classa Levelb
operatively), continued throughout the procedure (surgery, pre-
ManagementbyanexpertMDT(thepregnancy operativecoronaryangiography,pacemakerimplantation),andpost-
heartteam)inanexpertcentreisrecommended operativelyforatleast48hfollowingvalvesurgeryoruntilstableifa
I C
forpregnantwomenwithcancerwhorequire carcinoidcrisisistriggeredpost-operatively.772
cardiotoxiccancertherapy.741 Theoptimalchoiceofvalveprosthesisisstillamatterofdebate
Cardiacassessmentpriortocardiotoxiccancer duetothebalanceofriskofbothacceleratedbioprostheticvalvede-
therapyinpregnantwomenisrecommendedand generationvs.bleedingrisksinpatientswithextensivelivermetasta-
I C
consistsofclinicalhistory,physicalexamination, sesrequiringtherapeuticanticoagulationformechanicalvalves.784,785
ECG,andechocardiography.741 ComplicationsincludeAVblock,requiringpacemakerimplantation
MonthlyorbimonthlyCVevaluation,including in 25% of patients.786 Frequently, the reduced RV function does
TTE,shouldbeconsideredduringcardiotoxic IIa C notimprovedespitetricuspidvalvereplacementandHFpersists.787
cancertherapycinpregnantwomenwithcancer. Thrombusformationonthetricuspidbioprosthesiscanoccur,espe-
ciallyduringthefirst3monthspost-operatively,andoralanticoagu-
cTnmaybeconsideredatbaselineandduring
anthracyclinechemotherapyinpregnantwomen IIb C lationwithVKAmaybeconsidered.Persistentserotoninelevation
cancauserecurrentbioprosthesisvalvefibrosis.Valve-in-valvetrans-
withcancer.
catheterinterventionhasbeenreportedinbioprostheticvalvefailure
cTn, cardiac troponin; CV, cardiovascular; ECG, electrocardiogram; MDT, in metastatic carcinoid heart disease; however, future research is
multidisciplinaryteam;TTE,transthoracicechocardiography.
aClassofrecommendation.
neededtodefineitsrole.783,788,789
bLevelofevidence. Inpatientswithleft-sidedcarcinoidvalvularinvolvement,closure
cForpatientsreceivinganthracycline-basedchemotherapy.
of interatrial shunts should be considered, although only sparse
dataexistforthisapproach.
9.3. Carcinoid valvular heart disease
Carcinoidtumoursrepresentrareneuroendocrinemalignanciesori-
ginating from the enterochromaffin cells (Figure 42).771 Carcinoid RecommendationTable48—Recommendationsfor
syndrome is a rare cause of acquired VHD including mainly right- carcinoidvalvularheartdiseases
sidedvalvularlesions,butalsoleft-sidedinvolvement,pericardialef-
fusion, and myocardial metastases.772 Coronary artery vasospasm Recommendations Classa Levelb
and paroxysmal atrial or ventricular tachycardias may rarely occur
Echocardiographycisrecommendedforthe
due to sympathetic stimulation. Cardiac metastases are reported
detectionofcarcinoidcardiacinvolvementinall
withanincidenceof3.8%ontheventricles,confirmedbyPET-CT
patientswithcarcinoidsyndromeandelevatedNP
scans.773,774 Data from the SEER (Surveillance, Epidemiology, and
levelsand/orclinicalsignsofcarcinoidheart I B
EndResults)registryidentifiedthatapproximately20%ofpatients
disease,andforsurveillanceevery3or6months
with neuroendocrine malignancies develop carcinoid syndrome
dependingontheseverityofcardiacinvolvement
(7.6–32.4%), which is associated with shorter survival (4.7 years
andclinicalstatus.772,790,791
compared with 7.1 years in patients without carcinoid syndrome) NPshouldbeconsideredforscreeningand
andpoorqualityoflife.775Itisestimatedthat20–50%ofthesepa-
surveillanceofcarcinoidheartdiseaseevery6 IIa B
tientspresentcardiacinvolvement,especiallyoftheright-sidedcar- months.777–780
diacvalves.771Inthepresenceofapatentforamenovale,interatrial
AMDTdiscussionforoptimalmedial
shunt,primarybronchialneuroendocrinetumour,orextensiveliver
managementtopreventcarcinoidcrisisis
metastases,humoralsubstancesdirectlyenterthesystemiccircula- I C
recommendedbeforeanyinvasiveorsurgical
tion, causing left-sided valvular involvement in up to one-third of
cardiacprocedure.
cases.776
Valvereplacementsurgeryisrecommendedin
NPshouldbeconsideredforscreeningandsurveillanceofpatients
symptomaticpatientswithseverecarcinoid
atriskofcarcinoidcardiacinvolvementandTTEisrecommendedin I C
patients with NT-proBNP.260pg/mL or clinical signs or symp- tricuspidorpulmonaryVHDandanexpected
toms.777–780 In asymptomatic patients with NT-proBNP,260pg/
survival≥12months.d,783,785
Valvereplacementsurgeryshouldbeconsidered
mL,repeatclinicalandNPassessmentshouldbeconsideredevery
inpatientswithasymptomaticseverecarcinoid
6months.
tricuspidorpulmonaryVHD,progressiveRV IIa C
Survivalhasimprovedincarcinoidtumours,withtheuseofsom-
dysfunction/dilatation,andanexpectedsurvival
atostatin analogues and surgical techniques in liver metastasis.
However, right HF still represents a major cause of death.781,782
≥12months.d,772
Many patients with severe tricuspid regurgitation due to carcinoid Continued
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 96 ---
4324 ESCGuidelines
9.4. Amyloid light-chain cardiac
Valvereplacementorrepairsurgeryis
recommendedinsymptomaticpatientswith amyloidosis
I C
severecarcinoidmitraloraorticVHDandan Amyloidlight-chainamyloidosisisaplasmacelldyscrasia,which
expectedsurvival≥12months.783,785
is typically treated with therapies very similar to those used in
MM, including PI-based therapy.792 It can occur in conjunction
MDT, multidisciplinary team; NP, natriuretic peptides; RV, right ventricular; VHD,
valvularheartdisease. with myeloma or independently as a light-chain protein-
aClassofrecommendation.
producingdisorder.Amyloidlight-chainamyloidosisisasystemic
bLevelofevidence.
cIncludingsalinecontrastinfusionatbaselinetoruleoutpatentforamenovale.
disease793,794anditiscriticaltohaveahighdegreeofsuspicionfor
dWithcontrolledserotoninconcentrations. the diagnosis of cardiac involvement (amyloid light-chain cardiac
amyloidosis [AL-CA]) because a combination of specialized tests
is needed to make an accurate diagnosis (Figure 43).290,793,795,796
Carcinoid heart disease: clinical features(cid:2)and diagnostic tests
Clinical features Diagnostic and pronostic tools
Flushing
CMR
Pleural
effusion
Broncho- TTE
constriction
Ascites
Circulating serotonin
Diarrhoea
NP
Peripheral
oedema
Urinary 5HIAA
Figure42Carcinoidheartdisease:clinicalfeaturesanddiagnostictests.5HIAA,5-hydroxyindoleaceticacid;CMR,cardiacmagneticresonance;NP,
natriureticpeptides;TTE,transthoracicechocardiography.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 97 ---
ESCGuidelines 4325
Non-invasive diagnosis of AL-CA
Clinical features Investigations(cid:2)
Skin
Bruising
CV
Laboratorya
AF/flutter
Dyspnoea
HFpEF or unexplained
ECGb
right HF
Hypotension or syncope
Peripheral oedema
TTEc
Nerves
Orthostatic hypotension
Peripheral polyneuropathy ECHO score ≥8d
Polyneuropathy
Kidney
Characteristic echo findingse
Proteinuria
Renal impairment
CMRf
GI
Constipation /diarrhoea
Macroglossia
Malabsorption/weight
loss/nausea
Figure43Non-invasivediagnosisofamyloidlight-chaincardiacamyloidosis.a′,latediastolicvelocityofmitralannulusobtainedbytissueDopplerim-
aging;AF,atrialfibrillation;AL-CA,amyloidlight-chaincardiacamyloidosis;CMR,cardiacmagneticresonance;CV,cardiovascular;E,mitralinflowearly
diastolicvelocityobtainedbypulsedwave;e′,earlydiastolicvelocityofmitralannulusobtainedbytissuedopplerimaging;ECG,electrocardiogram;echo,
echocardiography;ECV,extracellularvolumefraction;GI,gastrointestinal;GLS,globallongitudinalstrain;HF,heartfailure;HFpEF,heartfailurewithpre-
servedejectionfraction;IVS,interventricularseptum;LGE,lategadoliniumenhancement;LV,leftventricular;LVEDD,leftventricularenddiastolicdiam-
eter;NT-proBNP,N-terminalpro-B-typenatriureticpeptide;PW,leftventricularposteriorwall;s′,systolicvelocityoftricuspidannulusobtainedby
Dopplertissueimaging;SPEP,serumproteinelectrophoresis;TAPSE,tricuspidannularplanesystolicexcursion;TTE,transthoracicechocardiography;
UPEP,urineproteinelectrophoresis.Individually,theclinicalmanifestationsandfindingsoncardiactestingforAL-CAarenon-specific.Integrationof
allclinicalanddiagnosticfindingsisnecessarywhenassessingthelikelihoodofthediagnosis.aDisproportionatelyhighNT-proBNP;persistingelevated
troponinlevels;abnormalfreelight-chainlevels(AL-CA);positiveSPEPand/orUPEP(AL-CA).bDisproportionallylowQRSvoltage;earlyconduction
systemdisease;pseudo-infarctpattern.cUnexplainedLVthickness≥12mm+1or2characteristicechofindingsorECHOscore≥8;idiopathicperi-
cardialeffusion.dECHOscore:relativeLVwallthickness(IVS+PW/LVEDD).0.6(3points),DopplerE/e′.11(1point);TAPSE≤19mm(2points);
GLS≥−13%(1point);systoliclongitudinalstrainapextobaseratio.2.9(3points).eCharacteristicechocardiographyfindings:grade≥2diastolicdys-
function;reduceds′,e′,anda′velocities(,5cm/s);decreasedGLSto≥−15%.fDiffusesubendocardialortransmuralLGE;elevatednativeT1values;
abnormalgadoliniumkinetics(myocardialnullingprecedingorcoincidingwiththebloodpool);ECV≥0.40%(stronglysupportive).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 98 ---
4326 ESCGuidelines
Cardiac serum biomarkers are an essential step in the diagnostic RecommendationTable49—Recommendationsfor
andprognosticassessmentsforthesepatients.797–799AL-CAhas amyloid light-chain cardiac amyloidosis diagnosis and
monitoring
been extensively reviewed in a recent position paper from the
WorkingGrouponMyocardialandPericardialDiseases.290
Recommendations Classa Levelb
Theclassicalnon-invasivedefinitionofAL-CAisbasedonclinical
suspicion,biomarkers,TTE,CMR,andnuclearscintigraphycriteria Echocardiography,NP,andcTnare
(Figure 43). Persistent troponin elevation and disproportionately recommendedforthediagnosisofAL-CAin I B
highNT-proBNP(generally.300ng/Lintheabsenceofrenalfail- patientswithplasmacelldyscrasia.290,820–822
ureorAF)toventricularfunctionparametersonTTEisacharac- CMRisrecommendedinpatientswithsuspected
I A
teristic red flag for AL-CA.800 A decrease in GLS with a AL-CA.290,803,804
distinctive apical sparing pattern (preserved GLS values in the LV EMBshouldbeconsideredinpatientswith
apical region) is considered specific for cardiac amyloidosis, al- suspectedAL-CAinvolvementifCMRisnot IIa C
thoughitisnothelpfultodistinguishbetween amyloidlight-chain diagnostic.290
and transthyretin amyloidosis.801 Additionally, GLS≥−15% may
AdmissionwithinpatientECGmonitoringshouldbe
serveasanindependentprognosticfactorofpooroverallsurvival consideredforhigh-riskpatientswithAL-CA IIa C
inpatientswithAL-CA.802CMRwithLGEandparametricimaging
requiringPIduringtheirfirstcycleoftherapy.c,808,811
has emerged as a new non-invasive gold-standard for diagnosis
(Figure43).803,804Nuclearscintigraphycandifferentiatetransthyre- AL-CA,amyloidlight-chaincardiacamyloidosis;CMR,cardiacmagneticresonance;cTn,
cardiactroponin;ECG,electrocardiogram;EMB,endomyocardialbiopsy;HFA,Heart
tinamyloidosisfromAL-CAsupportedbythepresenceofmono-
Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic
clonal protein.290 EMB should be considered in patients with peptides;PI,proteasomeinhibitors.
suspectedAL-CAinvolvementifCMRisnotdiagnostic.290Arare aClassofrecommendation.
bLevelofevidence.
conditionthatmaycoexistwithAL-CAislight-chaindepositiondis- cAccording to baseline evaluation using HFA-ICOS PI risk assessment tools (see
ease,whichfrequentlyassociatesextensiverenalinvolvementand Section4).
poorprognosis.799
Recently,astagingsystemforAL-CAhasdemonstratedtheprog-
9.5. Cardiac implantable electronic
nosticimpactofcTnTandNT-proBNPlevels.797Heartprogression
criteria are defined by NT-proBNP progression (.30% and devices
.300ng/Lincrease),cTnTprogression(≥33%increase)orejection RT can cause malfunction of cardiac implantable electronic de-
fraction decrease (≥10% decrease).805–807 However, evaluating a vices (CIEDs).443,823 The risk of RT-induced CIED malfunction
cardiacresponsetotreatmentusingadecreaseinNT-proBNPlevels generally increases with the radiation dose,824,825 although the
and New York Heart Association class improvement is still strongest predictor of malfunction is the magnitude of
challenging. exposuretoneutronemissionfromhigh-energyphotonRT,conven-
AL-CAfrequentlyresultsinHF,majorcardiacarrhythmias,ortho- tionally defined as a beam energy .10 megavolts (MV).824,826,827
statichypotension,suddencardiacdeath,andanincreasedriskofar- Non-neutron-producing treatment is therefore preferable in pa-
terialandvenousthrombosis.808–810Beta-blockers,ACE-I,ARB,or tients with a CIED.826
angiotensinreceptor-neprilysininhibitormaynotbewelltolerated RT-inducedCIEDmalfunctioncanmanifestin:(1)transientinter-
becauseofhypotension.290ThemanagementofAFisverycomplex ference,withinappropriatetriggeringduringtheirradiationonly;(2)
inthispopulation.Amiodaroneisthepreferredantiarrhythmictreat- areset,revertingtobackupsettings,recoverablewithdevicerepro-
mentanddigitalisshouldbeusedwithcaution.Anticoagulationisre- gramming;and,rarely(3)permanentdamagetothedevicedueto
commended in all AL-CA patients with AF independent of the
directCIEDirradiation.826,827
CHA DS -VASc score due to the high prothrombotic risk unless TheclinicalconsequencesofaCIEDmalfunctionincludetheinhib-
2 2 thereisacontraindication.290Currently,theguidelinesforimplanted itionofpacingandinappropriatepacingatmaximumsensorrate.826
devices,includingpacemakersandICDs,donotprovidespecificre- Theclinicaleffectsofdevicemalfunctionaregreatestwhenthepa-
commendations for AL-CA and decisions should be individualized tient is pacing-dependent. Theoretically, oversensing might lead to
afteraMDTdiscussion.811 inappropriate ICD shocks, although this has not been reported in
OptimalsystemictherapyforAL-CAisrapidlychanging,andthe
theliterature.826
efficacy of certain combination therapies continues to im- Morerecentregistrieshavereportedminimalornoadverseef-
prove.812,813AutologousHSCTforAL-CAisnotuniversallyutilized fectsofRTonCIEDmalfunction.827,828Nevertheless,asitisnotpos-
butisaviabletreatmentoption.814TherapiesforAL-CAareevolv- sible to predict the behaviour ofa CIED withinorclose to anRT
ing, and daratumumab and PI show promise for improved out- treatment volume, general recommendations should be followed
comes.792,815–817
Clinical observations, but no RCT evidence,
tominimizepatientrisk(Figures44–46).188,824,825
suggestthepotentialroleofdoxycyclinetoimprovesurvivalinpa- Patients with a CIED should be reviewed by their cardiologist/
tientswithAL-CA.818,819 electrophysiologist to assess the risk of CIED malfunction and
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 99 ---
ESCGuidelines 4327
Assessing risk of RT to CIED
Patient
Pacing-
Pacing- dependent or
independent frequent ICD
CIED in the RT Dose region
therapies
treatment and risk
volume category
Risk areas
<5 Gy
YES
≥5 Gy
<10 Gy or
neutrons <10 MV
NO
≥10 Gy or
neutrons ≥10 MV
Low risk Medium risk High risk
Figure44Riskstratificationinpatientswithacardiacimplantableelectronicdeviceundergoingradiotherapy.CIED,cardiacimplantableelectronicde-
vice;Gy,Gray;ICD,implantablecardioverterdefibrillator;MV,megavolt;RT,radiotherapy.
patientsshouldbeinformedofthepotentialrisksofRT.443Forpa- adequate tumour treatment. The photon beam energy should
tientswithrate-adaptivepacemakers,considerationshouldbegiven be kept ,10 MV as the risk of device malfunction/damage in-
totemporarydeactivationofthesensorduringRT.Althoughinacti- creases above this threshold. If higher doses are needed or if
vationofantitachycardiatherapiesinpatientswithICDsisrecom- theCIEDcannotbekeptoutofthebeam,considerationshould
mended in several publications, by either reprogramming or be given to removing and relocating the CIED away from the
applicationofamagnettoICDs,itisinfrequentlyperformedinclin- beam, although this will onlyvery rarelybenecessary. Themain
icalpractice.826 reason for device relocation is to allow adequate RT treatment
CIEDs should not be placed directly in the RT treatment vol- ofthetumour,butconsiderationshouldalsobegiventopossible
umeandthecumulativedoseshouldnotexceed2Gytoapace- RT-inducedCIEDmalfunction/damagewithconsequentneedfor
maker or 1Gy to an ICD.827 If the CIED is situated in the path CIEDreplacement.826However,CIEDexplantandresitingcarries
of the planned radiation beam, it could also interfere with significant risks, including the risk of infection, which may be of
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 100 ---
4328 ESCGuidelines
Risk stratification of patients with CIED underrgoing thoracic RRRT
Y CIED in the RRRT treatmentvolume N
MDTa Consider RRRT type and dose
(Figure 46)
Leave device in situ
Consider moving CIED OR Reduce radiation enerrgy to minimize exposure to neutrons
Limit cumulative dose
Maximum cumulative
incident dose of >5 Gy
N Y
Pacing dependent or
frequent ICD therapies
N Y
ow-riskpatients High-risk patients
CIED evaluation: CIED evaluation:
fffore(cid:2)RRRTb
Befffore(cid:2)RRRTb (Class I) ECG and/or pulse oximetry monitoring and external pacing aaavailable
during RRRT sessions
Audio-visual monitoring WWWeekly during RRRT
(Class I)
CIED check-up after completing RRRT
(Class I)
Figure45Managementofpatientswithacardiacimplantableelectronicdevicelocatedintheradiotherapytreatmentbeam.CIED,cardiacimplantable
electronicdevice;ECG,electrocardiogram;Gy,Gray;ICD,implantablecardioverterdefibrillator;MDT,multidisciplinaryteam;N,no;RT,radiotherapy;Y,
yes.aMultidisciplinarydiscussionmustconsider:(1)whethertheCIEDisinterferingwiththeRTdosedeliveredtothetumour;(2)whetherthe
RTisinterferingwithCIEDfunction(aimtonotexceed2Gytopermanentpacemakerand1GytoICD);(3)risksofmovingtheCIED:infection(es-
peciallyinimmunocompromisedpatients),proceduralcomplications(e.g.bleedingwiththrombocytopaenia);foryoungerpatientswithgoodprognosis,
considerlong-termeffectsoflosinganaccesssite(leadextraction/RT-inducedthrombosis).bIflastCIEDcheck.3monthsearlier.
particular importance in patients receiving chemotherapy or conjunction with the patient. Device relocation is not recom-
those who are immunosuppressed. For most patients in whom mended for CIEDs receiving a maximum cumulative incident
definitivetumourtreatmentisplanned,therisk/benefitratiowill doseof,5Gy,wheretheriskisconsiderednegligible.826,828
usually favour device relocation, whereas for patients receiving Thereshouldbecontinuousvisualandvoicecontactwiththepa-
palliative RT or with significant comorbidities, relocation could tient during each treatment fraction. CIEDs should be periodically
be avoided.826 These decisions should be made by a MDT in checked in patients with ICDs, especially those receiving .10 MV
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 101 ---
ESCGuidelines 4329
Management of patients with CIED located outside the RRRT treatmentvolume
RRRT type and dose
Non-neutron-generating RRRT Neutron-generating RRRT
or dose <2 Gy or dose≥2 Gy
<10 MV photons or ≥10 MV photons or
2–9 Gy ≥10 Gy
Pacing-dependent or
Pacing-dependent
frequent ICD therapies
N Y N Y
Low-risk patients High-risk patients Low-risk patients High-risk patients High-risk patients
CIED evaluation: CIED evaluation: CIED evaluation: CIED evaluation:
Befffore(cid:2)RRRTa(Class I) Befffore(cid:2)RRRTa BeffforeRRRTa(Class I) BeffforeRRRTa
ECG and/or pulse ECG and/or pulse
Audio-visual monitoring oximetry monitoring and Audio-visual monitoring oximetry monitoring and
external pacing aaavailable external pacing aaavailable
during RRRT sessions during RRRT sessions
WWWeekly during RRRT WWWeekly during RRRT
(Class I) (Class I)
CIED check-up after completing radiotherappy
(Class I)
Figure46Managementofpatientswithacardiacimplantableelectronicdevicelocatedoutsidetheradiotherapytreatmentvolume.CIED,cardiac
implantableelectronicdevice;ECG,electrocardiogram;Gy,Gray;ICD,implantablecardioverterdefibrillator;MV,megavolt;N,no;RT,radiotherapy;
Y,yes.aIflastCIEDcheck.3monthsearlier.
photon beam energy.827,829 For patients receiving electron or kV ofCIEDresetispotentiallysignificant.824,830TheCIEDshouldbere-
photon beam RT, CIED evaluation appears largely unnecessary.827 checkedwithin2weeksofcompletionofRTtreatment.Systematic
For patients treated with proton beam RT, special consideration remote CIED monitoring may be helpful to optimize the patient’s
shouldbepaidtotheneutroncomponentofthebeam,astherisk surveillance.831
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 102 ---
4330 ESCGuidelines
Recommendation Table 50 — Recommendations for 10. Patient information,
riskstratificationandmonitoringforpatientswithcardiac
communication, and
implantableelectronicdevicesundergoingradiotherapy
self-management
Recommendations Classa Levelb
Riskstratificationincludingplannedradiationtype Collaboration between different healthcare professionals and pa-
andenergy,dosetoCIED,thepatient’sdevice tients is of paramount importance for the most effective manage-
I C
type,andpacingdependenceisrecommended ment of patients with cancer and CVD. Appropriate language and
priortostartingtreatment.824,825,827,828 communication should be used to allow patients to receive clear
and accurate information about theircondition, and play an active
InpatientsundergoingRT,aCIEDcheckis
roleinmanagingtheirtreatment.11
recommendedinallpatientsbeforeandafter
I C Thefirstgoalofthisprocessistoraisethepatient’sawarenessof
completingRT,andduringRTaccordingto
individualrisk.824,826 thepossiblepresenceordevelopmentofaCVD,eitherduringcan-
cerorafterhavingsomeoncologicaltherapy.Patientsshouldunder-
InpatientswithaCIEDundergoingRTathighrisk
standthatcancerandCVDsharemanyCVRF andreducingriskis
ofarrhythmiaand/ordevicedysfunction,ECG
I C vitalforthepreventionofcancer,cancerrelapse,andthedevelop-
monitoringand/orpulseoximetryare
recommendedduringeveryRTsession.827,829,831 ment or worsening of a CVD during or after treatment. Patients
shouldbeinformed—attheendofchemotherapy—thatapersona-
CIED,cardiacimplantableelectronicdevice;ECG,electrocardiogram;RT,radiotherapy. lizedfollow-upplanandregularCVcontrolsareneededtodetect
aClassofrecommendation.
bLevelofevidence. potential reversible stages of CV toxicities. Education, counselling,
and support to promote healthy lifestyle and to treat modifiable
Interaction between healthcare professionals and patients with cancer
Appropriate language
and communication
Information Education, counselling, and support
Raise awareness Recognition and Don’t stop Appropriate lifestyle
of possible CVD report of early CV cardioprotective therapy
modification
with cancer symptoms and signs without medical advice
Understand shared
Active treatment Regular CV follow-up Timely EoL and
risk factors for
of CVRF (also if asymptomatic) DNR discussion
cancer and CVD
Consider specific psychologic and social conditions
Aid of digital health tools or information leaflets
Figure47Patientinformation,communication,andself-management.CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfac-
tors;DNR,donotresuscitate;EoL,endoflife.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 103 ---
ESCGuidelines 4331
CVRFshouldbeofferedtopatientswithcancer,inordertoreduce Moreover,cancerandmedicalassociationshavealsodevelopedanin-
the burden of complications during and after anticancer therapy. creasinginterestincardio-oncology.Importantrolesofthesescientific
Patients should receive guidance to recognize and to report signs societiesareclinicalresearch,education,andadvocacy.TheESC-CCO
andsymptomsofCVD,inordertoreceivepromptandeffectivetreat- strategicplanandmissionincludeimprovementofprevention,diagno-
ment,ideallywithoutinterferingwiththeircancertreatment.Patients sis,treatment,andmanagementofCTR-CVTandenhancementofthe
shouldalsobeadvisednottostopcardioprotectivetherapieswithout standardofcareforpatientswithcancer(Figure48).
medicalguidance,eveniftheyrecovertheircardiacfunction.Tohelp
inthiscomplextask,leafletsspecificallydesignedforthiscontextmay
beused,832,833eventuallywiththeaidofdigitaltools(Figure47). 12. Key messages
11. The role of
scientifi
c societies
ThisisthefirstESCcardio-oncologyGuidelineandcontains272new
recommendations.Thekeymessagesfromthisguidelineare:
in the promotion and
(cid:129) A guiding principle of cardio-oncology is integration, and
development of cardio-oncology
cardio-oncology providers must have knowledge of the broad
in modern medicine scopeofcardiology,oncology,andhaematology.Communication
between different healthcare professionals is critical to optimize
Cardio-oncologyisasubspecialtythathasseenhugedevelopmentand thecareofpatientswithcancerandCVD.
growthinrecentyearswiththeformation—inalmostallnationaland (cid:129) Cardio-oncologyprogrammesfacilitatecancertreatmentbymin-
international societies—of cardio-oncology working groups. imizing unnecessary cancer therapy interruptions and CTR-CVT
The role of scientific societies in the promotion and
development of cardio-oncology
Research
Basic and translational Appropriate
research resources
Clinical research Communication
Long-term survivorship Knowledge
programmes Organization
Education Advocacy
Cardio-
oncology
Communication Political strategies
strategies against cancer and CVD
Community Engagement Community level
Healthcare authorities International level
Healthcareprofessionals National level
Patients Regional level
Figure48Theroleofscientificsocietiesinthepromotionanddevelopmentofcardio-oncology.CVD,cardiovasculardisease.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 104 ---
4332 ESCGuidelines
acrosstheentirecontinuumofcancercare.Inpatientswhode- and worldwide. Strategic investments in cardio-oncology care
velop CTR-CVT, a MDT discussion is required to balance the networks and cardio-oncology services provision are needed to
risk/benefitofcancertreatmentdiscontinuation. meet the projected increased clinical demand in the near fu-
(cid:129) ThereisanewinternationaldefinitionofCTR-CVT(Table3). ture,834andtofacilitateresearch,training,andeducationalactiv-
(cid:129) CVtoxicityriskisadynamicvariable.Thisguidelineisstructuredto ities. A dedicated training core curriculum for a minimum of
provideapersonalizedapproachtocarebaseduponthebaseline 1-year medical training is urgently needed. It may include: (1)
CVtoxicityrisk.AbaselineCVriskassessmentisrecommended knowledge of the broad scope of cardiology, oncology, and
forallpatientswithcancerscheduledtoreceiveapotentiallycar- haematology; (2) CV competencies for CTR-CVT prevention,
diotoxic anticancer therapy. This enables the oncology team to surveillance,andmanagementofpatientswithcancerindedicated
considerCVriskwhilemakingcancertreatmentchoices,educating outpatients’ cardio-oncology clinics; (3) inpatient consultative
patientsregardingtheirCVrisk,andpersonalizingCVsurveillance services;and(4)dedicatedtimetoachievecompetencesinCVim-
andfollow-upstrategy. aging,HF,andvascularcardiology.
(cid:129) Primary prevention of CV toxicity from cancer therapy aims to Collaborationbetweenhealthcareproviders,clinicalandbasicin-
avoidorminimizethedevelopmentofCTR-CVTinpatientswith- vestigators, healthcare authorities, regulatory bodies, advocacy
outCVD. groups,andpatients’associationsisneededtoaddressfutureneeds
(cid:129) Secondarypreventionreferstointerventionsinpatientswithpre- (seeSection11).
existingCVD,includingpriorornewCTR-CVT.AMDTisrecom- AsthisGuidelinewasdeveloped,itbecameclearthatthereisasig-
mendedwhenpatientswithcancerhavecomplexCVDthatmay nificantlackofRCTtoguidedecision-making,withmanyrecommen-
impactontheircancertreatment. dationssupportedbylevelofevidenceC.Thisiscomplicatedbythe
(cid:129) Defininganddeliveringanappropriatepreventionandsurveillance fast-movingpaceofnewoncologytreatmentdevelopmentsagainsta
plan for potential CV complications is recommended. Optimal backgroundofdynamicCVtoxicitylikelihood.Therefore,largenum-
managementofCVRFandpre-existingCVDismandatorytofacili- bersofpatientsandlongerfollow-uparerequiredtoprovidesuffi-
tatecancertherapyandtoimprovepatients’prognosis. cient statistical power and definitive answers. In the future, the
(cid:129) Detailed monitoring pathways during cancer therapy—including followingstrategiesandareasofresearcharepriorities:
3D echocardiography, GLS, and cardiac biomarkers—are pro-
videdtodetectCVtoxicitybaseduponspecificcancertherapies (cid:129) New trial designs focusing upon the ‘at-risk’ cancer patient
andbaselineCVtoxicityrisk. populations.
(cid:129) TreatmentrecommendationsforCTRCDduringandaftercancer (cid:129) Validating current HFA-ICOS risk assessment tools and surveil-
therapydependuponCTRCDseverityandsymptoms.Newguid- lancealgorithms.
ance on continuing trastuzumab in BC patients who develop (cid:129) Assessment of new technologies for the detection of early
asymptomatic moderate CTRCD (LVEF 40–49%) while starting CTRCD,broadeningthebiomarkerpanelandrecognizingthespe-
cardioprotectivemedicationisprovided. cificpatternsinearlymyocardialdamage.
(cid:129) Useofastructuredalgorithmtoguidedecisionsregardinganticoa- (cid:129) Refining CV risk scores (e.g. EuroSCORE II, SCORE2,
gulationmanagementinpatientswithcancerpresentingwithAF SCORE2-OP, CHA DS -VASc, HAS-BLED, SYNTAX) for appli-
2 2
orVTEencompassingtheTBIPassessmentisencouraged. cationincancerpopulations.
(cid:129) After cancer treatment is completed, the focus of the (cid:129) Optimaltreatmentofsteroid-resistantICICVtoxicityandlong-
cardio-oncologyteamshiftstocoordinationoflong-termfollow- termCVeffectsofICItherapy.
up.Thisstartswithan‘end-of-treatment’assessmentinthefirst (cid:129) Selection criteria for modern percutaneous structural (TAVI,
yearaftertreatment,reviewingpatientswithcancerwhohavere- Mitraclip, LAA occluder devices) and electrophysiological (abla-
ceivedcardiotoxicanticancertherapiestoreassesstheirCVtox- tion)CVtherapiesinpatientswithactivecancer.
icityriskandguidelong-termsurveillanceplanning. (cid:129) Patient-specific predictive algorithms for QTc prolongation with
(cid:129) Anewalgorithm(Figure37)isprovidedtoguideweaningoffofCV cancerdrugs.
medicationinCS. (cid:129) Assessment of genetic profiles in more specific CTRCD risk
(cid:129) Patientswithcancer,CS,andthepatient’sfamily/carersshouldre- prediction.
ceiveguidancetopromotehealthylifestyleandrecognizeandre- (cid:129) Identificationofthecancerpatientpopulationswithmildormod-
portsignsandsymptomsofCVD,toreceivepromptandeffective erateCTRCDduringtreatmentwhocansafelyweanofflong-term
treatment,withoutinterferingwiththeircancertreatment. CVmedication.
(cid:129) Patients must receive psychological support when needed and (cid:129) Optimalmodalitiesforscreeninglong-termsurvivorpopulations
clearandaccurateinformationabouttheirconditiontoplayanac- forthecomplicationsofanthracyclinechemotherapyandmedias-
tiverole inmanaging theirtreatment andincrease adherence to tinalradiation.
cancerandCVtreatments. (cid:129) Creationoflargecardio-oncologyregistriestocollect‘bigdata’on
largepatientpopulations.
(cid:129) Applicationofartificialintelligenceandothernewdataanalyticsto
13. Future needs identifynewpatientswithcanceratriskandnewparametersthat
canpredictriskofCTR-CVT,responsetospecificcardioprotec-
Therearealownumberofdedicatedcardio-oncologyservicesand tiveinterventions,andlong-termriskandsafetytoweanoffCV
most patients are reviewed in general cardiology clinics in Europe therapiesinitiatedduringcancertreatment.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 105 ---
ESCGuidelines 4333
14. Gaps in evidence (cid:129) Personalizedmedicineanduseofbigdataandartificialintelligence
tools.
CancerandCVDarethetwomajorpublichealthproblemswithgreat
economicandsocialimpact.Inaddition,CTR-CVTareassociatedwith Cardiovasculartoxicityriskstratification
anexcessofbothCVandoncologicalmortality,especiallywhentheylimit
patients’abilitytocompleteeffectivetreatments.However,theintersec- (cid:129) Development ofCVtoxicity riskprediction toolsincludingboth
tionofcancerandCVDhasonlyrecentlygainedwiderinterestandmany treatment-andpatient-relatedriskfactors.
areaswithlackofevidenceneedtobeaddressedinfutureresearch. (cid:129) Validated prospective CV toxicity risk scores based on clinical
outcomes.
Role of cardio-oncology services and cardio-oncology (cid:129) Further research on the role of genetics in CV toxicity risk
carenetworks stratification.
(cid:129) Robustevidenceontheimpactofdedicatedcardio-oncologypro- (cid:129) ValidationofCPETparametersforCVoutcomesinpatientswith
grammesandcardio-oncologyrehabilitationontheprognosisof cancer.
patientswithcancerandsurvivors.
(cid:129) Specificationofrolesofdifferenthealthcareprofessionals(includ-
Prevention,diagnosis,andmanagementofCTR-CVT
ingnursesandpharmacists)incardio-oncologyteams.
(cid:129) Cardio-oncology care networks to improve the management of (cid:129) RaiseawarenessofthebenefitsofminimizingCVriskinpatients
patientswithcancerandtodiscussdifficultcases. withcancerinordertoreducetheriskofCTR-CVT.
(cid:129) Cardio-oncologyteamsupportandinvolvementinoncologytrials (cid:129) Moredataonnewtechnologies(biomarkers,advancedechocardi-
design(includingpatients’representatives). ography,CMR,etc.)andgeneticprofilesforthedetectionofearly
(cid:129) UnderstandhowtoengagepatientswithcancerintheirownCV CVtoxicity.
care(inclusionofdigitaltools). (cid:129) Prospectivestudiesshowingtheimpactonoutcomesand/orqual-
ityoflife(andfrailty)ofearlyCTR-CVTdiagnosisandtreatment.
Research,education,andtrainingincardio-oncology (cid:129) FurtherevidencefromprospectiveRCTstodefinewhencardio-
(cid:129) ConsensusaboutCVtoxicitydefinitionsusedinoncologytrials. protectivemedicationsimprovepatients’outcomes.
(cid:129) Definestandards forCVtoxicitymonitoringinoncologytrialsto (cid:129) Furtherresearchonthepotentialforaerobicexercisetoreduce
avoidunexpectedCVtoxicitieswhennewdrugsareapprovedfor CTR-CVT.
clinicaluse. (cid:129) RCTs of (new) CV therapies in patients with different types of
(cid:129) Relevant model systems to allow high-throughput screening of CTR-CVT.
newcancertreatmentsforCVtoxicity.
(cid:129) ImprovedknowledgeonCVtoxicitymechanismsofnewtargeted Long-termcancersurvivorshipprogrammes
cancertherapiesandICIandoptimaltreatmentofCVtoxicities.
(cid:129) Improvedknowledgeontheeffectsofradiationtospecificcardiac (cid:129) Development of optimal CV follow-up programmes after treat-
substructuresandtheinteractionsbetweencardiotoxicsystemic mentforcancer(researchonriskstratification,efficacy,andfre-
therapyandRT. quencyofscreeningprotocols).
(cid:129) Further research into the underlying mechanisms that connect (cid:129) BestscreeningstrategiesforRT-inducedCAD.
CVDandcancer,suchasageneticpredispositiontoCVtoxicity. (cid:129) FurtherresearchonCVpreventivestrategiesforlong-termCS.
‘ ’ ‘ ’
15. What to do and what not to do messages from the Guidelines
Recommendations Classa Levelb
RecommendationTable1forageneralapproachtocardiovasculartoxicityriskcategorization
CV toxicity risk stratification before starting potentially cardiotoxic anticancer therapy is recommended in all patients with
I B
cancer.
CommunicatingtheresultsoftheCVtoxicityriskassessmenttothepatientandotherappropriatehealthcareprofessionalsis
I C
recommended.
It is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without
I C
delay.
Cardiologyreferralisrecommendedinhigh-riskandveryhigh-riskpatientsbeforeanticancertherapy. I C
Discussionoftherisk/benefitbalanceofcardiotoxicanticancertreatmentinhigh-andveryhigh-riskpatientsinamultidisciplinary
I C
approachpriortostartingtreatmentisrecommended.
Cardiologyreferralisrecommendedforpatientswithcancerandpre-existingCVDorabnormalfindingsatbaselineCVtoxicityrisk
I C
assessmentwhorequirepotentiallycardiotoxicanticancertherapy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 106 ---
4334 ESCGuidelines
RecommendationTable2forelectrocardiogrambaselineassessment
AnECGisrecommendedinallpatientsstartingcancertherapyaspartoftheirbaselineCVriskassessment. I C
InpatientswithanabnormalbaselineECG,referraltoacardiologistisrecommended. I C
RecommendationTable3forcardiacbiomarkerassessmentpriortopotentiallycardiotoxictherapies
BaselinemeasurementofNPand/orcTnisrecommendedinallpatientswithcanceratriskofCTRCDifthesebiomarkersaregoingto
I C
bemeasuredduringtreatmenttodetectCTRCD.
RecommendationTable4forcardiacimagingmodalitiesinpatientswithcancer
General
Echocardiographyisrecommendedasthefirst-linemodalityfortheassessmentofcardiacfunctioninpatientswithcancer. I C
3DechocardiographyisrecommendedasthepreferredechocardiographicmodalitytomeasureLVEF. I B
GLSisrecommendedinallpatientswithcancerhavingechocardiography,ifavailable. I C
Baselinecardiacimagingpriortopotentiallycardiotoxictherapies
BaselinecomprehensiveTTEisrecommendedinallpatientswithcancerathighriskandveryhighriskofCVtoxicitybeforestarting
I C
anticancertherapy.
RecommendationTable5forprimarypreventionofcancertherapy-relatedcardiovasculartoxicity
ManagementofCVRFaccordingtothe2021ESCGuidelinesonCVDpreventioninclinicalpracticeisrecommendedbefore,during,and
I C
aftercancertherapy.
RecommendationTable6forsecondarypreventionofcancertherapy-relatedcardiovasculartoxicity
ManagementofCVDaccordingtoapplicableESCGuidelinesisrecommendedbefore,during,andaftercancertherapy. I C
RecommendationTable7forbaselineriskassessmentandmonitoringduringanthracyclinechemotherapyandinthefirst12months
aftertherapy
TTE
Baselineechocardiographyisrecommendedinallpatientswithcancerbeforeanthracyclinechemotherapy. I B
Inalladultsreceivinganthracyclinechemotherapy,anechocardiogramisrecommendedwithin12monthsaftercompletingtreatment. I B
Inhigh-andveryhigh-riskpatients,echocardiographyisrecommendedeverytwocyclesandwithin3monthsaftercompleting
I C
treatment.
Cardiacserumbiomarkers
BaselinemeasurementofNPandcTnisrecommendedinhigh-andveryhigh-riskpatientspriortoanthracyclinechemotherapy. I B
cTnandNPmonitoringbeforeeverycycleduringanthracyclinechemotherapyand3and12monthsaftertherapycompletionis
I B
recommendedinhigh-andveryhigh-riskpatients.
RecommendationTable8forbaselineriskassessmentandmonitoringduringHER2-targetedtherapiesandinthefirst12months
aftertherapy
TTE
BaselineechocardiographyisrecommendedbeforeHER2-targetedtherapiesinallpatients. I B
InpatientsreceivingneoadjuvantoradjuvantHER2-targetedtherapies,echocardiographyisrecommendedevery3monthsandwithin
I B
12monthsaftercompletingtreatment.
InmetastaticHER2+disease,echocardiographyisrecommendedevery3monthsduringthefirstyear;ifthepatientremains
I C
asymptomaticwithoutCVtoxicity,thensurveillancecanbereducedtoevery6monthsduringfuturetreatment.
Cardiacbiomarkers
BaselineNPandcTnmeasurementarerecommendedinhigh-andveryhigh-riskpatientspriortoanti-HER2-targetedtherapies. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 107 ---
ESCGuidelines 4335
RecommendationTable9forbaselineriskassessmentandmonitoringduringfluoropyrimidinetherapy
BaselineCVriskassessmentandevaluationincludingBPmeasurement,ECG,lipidprofile,HbA1cmeasurement,andSCORE2/SCORE2-
I C
OPorequivalentisrecommendedbeforestartingfluoropyrimidines.
AbaselineechocardiogramisrecommendedinpatientswithahistoryofsymptomaticCVDbeforestartingfluoropyrimidines. I C
RecommendationTable10forbaselineriskassessmentandmonitoringduringVEGFi
BPmonitoring
BPmeasurementisrecommendedforpatientstreatedwithVEGFi,bevacizumab,orramucirumabateveryclinicalvisit. I C
DailyhomemonitoringofBPforpatientstreatedwithVEGFiduringthefirstcycle,aftereachincreaseofVEGFidose,andevery2–3
I C
weeksthereafterisrecommended.
ECGmonitoring
InpatientstreatedwithVEGFiatmoderateorhighriskofQTcprolongation,QTcmonitoringisrecommendedmonthlyduringthefirst
I C
3monthsandevery3–6monthsthereafter.
Echocardiography
Baselineechocardiographyisrecommendedinhigh-andveryhigh-riskpatientstreatedwithVEGFiorbevacizumab. I C
RecommendationTable11forbaselineriskassessmentandmonitoringduringsecond-andthird-generationBCR-ABLtyrosine
kinaseinhibitors
BaselineCVriskassessmentisrecommendedinpatientswhorequiresecond-orthird-generationBCR-ABLTKI. I C
Inpatientstreatedwithnilotiniborponatinib,CVriskassessmentisrecommendedevery3monthsduringthefirstyearandevery6–12
I C
monthsthereafter.
Baselineechocardiographyisrecommendedinpatientsscheduledtoreceivedasatinib. I C
RecommendationTable12forbaselineriskassessmentandmonitoringBrutontyrosinekinaseinhibitortherapy
BPmonitoringandmanagement
BPmeasurementisrecommendedforpatientstreatedwithBTKinhibitorsateveryclinicalvisit. I B
Echocardiography
Baselineechocardiographyisrecommendedinhigh-riskpatientsscheduledtoreceiveBTKinhibitors. I C
TTEisrecommendedinallpatientswhodevelopAFduringBTKinhibitortherapy. I C
AF
OpportunisticscreeningforAFbypulse-takingorECGrhythmstripisrecommendedateveryclinicalvisitduringBTKinhibitortherapy. I C
RecommendationTable13forbaselineriskassessmentandmonitoringduringmultiplemyelomatherapies
BPmonitoring
BPmeasurementisrecommendedforpatientstreatedwithPIateveryclinicalvisit. I C
Cardiacserumbiomarkers
MeasurementofNPisrecommendedpriortoPIinhigh-andveryhigh-riskpatients. I C
NPandcTnmeasurementsarerecommendedatbaselineandevery3–6monthsinpatientswithAL-CA. I B
TTE
Baselineechocardiography,includingassessmentforAL-CA,isrecommendedinallpatientswithMMscheduledtoreceivePI. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 108 ---
4336 ESCGuidelines
VTEprophylaxis
TherapeuticdosesofLMWHarerecommendedinpatientswithMMwithpreviousVTE. I B
ProphylacticdosesofLMWHarerecommendedinpatientswithMMwithVTE-relatedriskfactors(excludingpreviousVTE)atleast
I A
duringthefirst6monthsoftherapy.
RecommendationTable14forbaselineriskassessmentandmonitoringduringcombinedRAFandMEKinhibitortherapy
BPmonitoringateachclinicalvisitandweeklyoutpatientmonitoringduringthefirst3monthsoftreatmentandmonthlythereafteris
I C
recommended.
Inpatientstreatedwithcobimetinib/vemurafenib,anECGisrecommendedat2and4weeksafterinitiationoftreatmentandevery3
I C
monthsthereafter.
Baselineechocardiographyisrecommendedinallhigh-andveryhigh-riskpatientsscheduledtoreceivecombinedRAFandMEK
I C
inhibitors.
RecommendationTable15forbaselineriskassessmentandmonitoringduringimmunotherapy
ECG,NP,andcTnmeasurementsarerecommendedinallpatientsbeforestartingICItherapy. I B
Baselineechocardiographyisrecommendedinhigh-riskpatientsbeforestartingICItherapy. I B
CVassessmentisrecommendedevery6–12monthsinhigh-riskpatientswhorequirelong-term(.12months)ICItreatment. I C
RecommendationTable16forbaselineriskassessmentandmonitoringduringandrogendeprivationtherapyforprostatecancer
BaselineCVriskassessmentandestimationof10-yearfatalandnon-fatalCVDriskwithSCORE2orSCORE2-OPisrecommendedin
I B
patientstreatedwithADTwithoutpre-existingCVD.
BaselineandserialECGsarerecommendedinpatientsatriskofQTcprolongationduringADTtherapy. I B
AnnualCVriskassessmentisrecommendedduringADT. I B
RecommendationTable17forbaselineriskassessmentandmonitoringduringendocrinetherapyforbreastcancer
BaselineCVriskassessmentandestimationof10-yearfatalandnon-fatalCVDriskwithSCORE2orSCORE2-OPisrecommendedin
I C
BCpatientsreceivingendocrinetherapieswithoutpre-existingCVD.
AnnualCVriskassessmentisrecommendedduringendocrinetherapyinBCpatientswithhigh10-yearriskof(fatalandnon-fatal)CV
I C
eventsaccordingtoSCORE2/SCORE2-OP.
RecommendationTable18forbaselineriskassessmentandmonitoringduringcyclin-dependentkinase4/6inhibitortherapy
QTcmonitoringisrecommendedatbaselineand14and28daysinallpatientswithcancerreceivingribociclib. I A
QTcmonitoringisrecommendedinpatientstreatedwithribociclibwithanydoseincrease. I B
RecommendationTable19forbaselineriskassessmentandmonitoringduringALKandEGFRinhibitors
BaselineCVriskassessmentisrecommendedinpatientsbeforeALKinhibitorsandEGFRinhibitors. I C
Baselineechocardiographyisrecommendedinallpatientswithcancerbeforestartingosimertinib. I B
RecommendationTable20forbaselineriskassessmentandmonitoringinpatientsreceivingchimericantigenreceptorTcell
andtumour-infiltratinglymphocytestherapies
BaselineECG,NP,andcTnarerecommendedinallpatientswithcancerbeforestartingCAR-TandTILtherapies. I C
Abaselineechocardiographyisrecommendedinpatientswithpre-existingCVDbeforestartingCAR-TandTILtherapies. I C
MeasurementofNP,cTn,andechocardiographyarerecommendedinpatientswhodevelopCRSofASTCT≥2. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 109 ---
ESCGuidelines 4337
RecommendationTable21forbaselineriskassessmentofpatientsbeforeradiotherapytoavolumeincludingtheheart
BaselineCVriskassessmentandestimationof10-yearfatalandnon-fatalCVDriskwithSCORE2orSCORE2-OPisrecommended. I B
RecommendationTable22forbaselineriskassessmentinhaematopoieticstemcelltransplantationpatients
BaselineandserialCVriskassessment(3and12months,thenyearly)includingBPmeasurement,ECG,lipidmeasurement,andHbA1cis
I C
recommendedinHSCTpatients.
EchocardiographyisrecommendedinallpatientsbeforeHSCT. I C
RecommendationTable23forthemanagementofcardiovasculardiseaseandcancertherapy-relatedcardiovasculartoxicityin
patientsreceivinganticancertreatment
AspecialistCVassessmentisrecommendedforoptimaldiagnosticworkupandmanagementofpatientswithcancerwhopresentwith I C
newCVtoxicityduringandaftercancertreatment.
RecommendationTable24forthemanagementofcancertreatment-relatedcardiacdysfunctionduringanthracycline
chemotherapy
Anthracyclinechemotherapy-inducedsymptomaticCTRCD
HFtherapyisrecommendedforpatientswhodevelopsymptomaticCTRCDduringanthracyclinechemotherapy. I B
DiscontinuationofanthracyclinechemotherapyisrecommendedinpatientswhodevelopsymptomaticsevereCTRCD. I C
TemporaryinterruptionofanthracyclinechemotherapyisrecommendedinpatientswhodevelopsymptomaticmoderateCTRCDand
I C
amultidisciplinaryapproachregardingthedecisiontorestartisrecommended.
Amultidisciplinaryapproachregardinginterruptionvs.continuationofanthracyclinechemotherapyisrecommendedinpatientswho
I C
developmildsymptomaticCTRCD.
Anthracyclinechemotherapy-inducedasymptomaticCTRCD
TemporaryinterruptionofanthracyclinechemotherapyandinitiationofHFtherapyisrecommendedinpatientswhodevelop
I C
asymptomaticmoderateorsevereCTRCD.
Amultidisciplinaryapproachregardingthedecisionwhentorestartisrecommendedinallpatientswithmoderateorsevere
I C
asymptomaticCTRCD.
ContinuationofanthracyclinechemotherapyisrecommendedinasymptomaticpatientswhohaveLVEF≥50%andwhohave
I C
developedasignificantfallinGLSoratroponinoraNPelevation.ULN.
RecommendationTable25forthemanagementofcancertreatment-relatedcardiacdysfunctionduringHER2-targetedtherapies
HER2-targetedtherapy-inducedsymptomaticCTRCD
HFtherapyisrecommendedforpatientswhodevelopsymptomaticmoderate-to-severeCTRCDwithLVEF,50%duringHER2-
I B
targetedtreatment.
TemporaryinterruptionofHER2-targetedtreatmentisrecommendedinpatientswhodevelopmoderateorseveresymptomaticCTRCD
I C
andthedecisiontorestartshouldbebasedonamultidisciplinaryapproachafterimprovementofLVfunctionandsymptomsresolved.
InpatientswhodevelopmildsymptomaticCTRCD,HFtherapyandamultidisciplinaryapproachregardingthedecisiontocontinuevs.
I C
interruptHER2-targetedtherapyarerecommended.
HER2-targetedtherapy-inducedasymptomaticCTRCD
TemporaryinterruptionofHER2-targetedtherapyandinitiationofHFtherapyisrecommendedinpatientswhodevelopasymptomatic
I C
severeCTRCD.
AmultidisciplinaryapproachregardingthedecisiontorestartHER2-targetedtreatmentisrecommendedinpatientswithsevere
I C
asymptomaticCTRCD.
ContinuationofHER2-targetedtherapyisrecommendedinpatientswhodevelopasymptomaticmild(LVEF≥50%)CTRCDcwith
I C
morefrequentcardiacmonitoring.
ACE-I/ARBandbeta-blockersarerecommendedinpatientswhodevelopasymptomaticmoderate(LVEF40–49%)CTRCDcduring
I C
HER2-targetedtreatment.
RecommendationTable26forthediagnosisandmanagementofimmunecheckpointinhibitor-associatedmyocarditis
cTn,ECG,andCVimaging(echocardiographyandCMR)arerecommendedtodiagnoseICI-associatedmyocarditis. I B
InpatientswithsuspectedICI-associatedmyocarditis,temporaryinterruptionofICItreatmentisrecommendeduntilthediagnosisis
I C
confirmedorrefuted.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 110 ---
4338 ESCGuidelines
InterruptionofICItreatmentisrecommendedinpatientswithconfirmedICI-associatedmyocarditis. I C
ContinuousECGmonitoringtoassessfornewAVblockandtachyarrhythmiasduringtheacutephaseisrecommendedforallpatients
I C
withsymptomaticICI-associatedmyocarditis.
Earlyhigh-dosecorticosteroidsarerecommendedinpatientswithcancerandconfirmedICI-associatedmyocarditis. I C
Continuationofhigh-dosecorticosteroidsisrecommendedforthetreatmentofICI-associatedmyocarditisuntilresolutionof
I C
symptoms,LVsystolicdysfunction,conductionabnormalities,andsignificantcTnreduction.
AdmissiontoICU(level3),treatmentwithi.v.methylprednisolone,andoptimalCVtreatmentincludingmechanicalsupport(when
I C
indicated)isrecommendedforpatientswithICI-associatedfulminantmyocarditis.
AmultidisciplinarydiscussionisrecommendedbeforerestartingICItreatmentinselectedpatientswithpreviousuncomplicatedICI-
I C
associatedmyocarditis.
RecommendationTable27forthediagnosisandmanagementofTakotsubosyndromeinpatientswithcancer
Coronaryangiography(invasiveorCCTA)isrecommendedtoexcludeACS. I C
CMRisrecommendedtoexcludemyocarditisandMI. I B
QT-prolongingdrugsarenotrecommendedduringtheacuteTTSphase. III C
RecommendationTable28forthemanagementofacutecoronarysyndromesinpatientsreceivinganticancertreatment
AninvasivestrategyisrecommendedinpatientswithcancerpresentingwithSTEMIorhigh-riskNSTE-ACSwithlifeexpectancy≥6
I B
months.
Atemporaryinterruptionofcancertherapyisrecommendedinpatientswherethecancertherapyissuspectedasacontributingcause. I C
Inpatientswithcancer,thrombocytopaeniaandACS,aspirinisnotrecommendedifplatelets,10000/µL. III C
Inpatientswithcancer,thrombocytopaeniaandACS,clopidogrelisnotrecommendedifplatelets,30000/µLandprasugrelor
III C
ticagrelorarenotrecommendedifplatelets,50000/µL.
RecommendationTable29forthemanagementofchroniccoronarysyndromesinpatientsreceivinganticancertreatment
IndividualizeddurationofDAPTisrecommendedinpatientswithcancerwithCCS,followingrevascularization,baseduponthrombotic/
I C
ischaemicandbleedingrisk,typeandstageofcancer,andcurrentcancertreatment.
RecommendationTable30forthemanagementofvalvularheartdiseaseinpatientsreceivinganticancertreatment
Inpatientswithcancerandpre-existingsevereVHD,managementaccordingtothe2021ESC/EACTSGuidelinesforthemanagement
I C
ofVHDisrecommended,takingintoconsiderationcancerprognosisandpatientpreferences.
InpatientswithcancerdevelopingnewVHDduringcancertherapy,managementaccordingtothe2021ESC/EACTSGuidelinesforthe
I C
managementofVHDisrecommended,takingintoconsiderationcancerprognosisandpatientcomorbidities.
RecommendationTable31forthemanagementofatrialfibrillationinpatientsreceivinganticancertreatment
Long-termanticoagulationisrecommendedforstroke/systemicthromboembolismpreventioninpatientswithcancerwithAFanda
I C
CHA DS-VAScscore≥2(men)or≥3(women)asperthe2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillation.
2 2
Thromboembolicandbleedingriskreassessmentisrecommendedduringfollow-upinpatientswithcancerwithAF. I C
AntiplatelettherapyorprophylacticLMWHarenotrecommendedforstrokeorsystemicthromboembolismpreventioninAFwith
III C
cancer.
RecommendationTable32forthemanagementoflongQTcandventriculararrhythmiasinpatientsreceivinganticancertreatment
HowtomanageQTcprolongationinpatientswithcancer
DiscontinuationofQTc-prolongingcancertherapyisrecommendedinpatientswhodevelopTdPorsustainedventricular
I C
tachyarrhythmiasduringtreatment.
TemporaryinterruptionofQTc-prolongingcancertherapyisrecommendedinpatientswhodevelopasymptomaticQTcF≥500ms
I C
andanECGshouldberepeatedevery24huntilresolutionoftheQTcFprolongation.
Immediatewithdrawalofanyoffendingdrugandcorrectionofelectrolyteabnormalitiesandotherriskfactorsisrecommendedin
I C
patientswithcancerwhodevelopQTcF≥500ms.
WeeklyECGmonitoringisrecommendedinasymptomaticpatientswithcancerwithQTcF480–500mswhoaretreatedwithaQTc-
I C
prolongingcancertherapy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 111 ---
ESCGuidelines 4339
A12-leadECGisrecommendedafteranydoseincreaseofQTc-prolongingcancertherapy. I C
RestartingQTc-prolongingcancertherapy
AmultidisciplinarydiscussionisrecommendedbeforerestartingQTc-prolongingdrugsinpatientswhohavedevelopedsignificantQTcF
I C
prolongation,todiscussalternativecancertreatments.
WeeklyECGmonitoringduringthefirst4–6weeksandthenmonthlythereafterisrecommendedinpatientswithcancerafter
I C
restartingQTc-prolongingcancertherapy.
RecommendationTable33forthemanagementofarterialhypertensioninpatientsreceivinganticancertreatment
General
Effectivetreatmentofcancertherapy-inducedarterialhypertensiontopreventcancertreatmentinterruptionandCVcomplicationsis
I C
recommended.
ABPtarget,140mmHgsystolicand,90mmHgdiastolicisrecommendedduringcancertherapy. I C
ThecompetingcancerandCVriskevaluationisrecommendedifthesystolicBPis≥180mmHgordiastolicBP≥110mmHg,andany
cancertherapyassociatedwithhypertensionshouldbedeferredortemporarilywithhelduntiltheBPiscontrolledtovalues I C
,160mmHg(systolic)and,100mmHg(diastolic).
Cancertherapy-inducedarterialhypertensiontreatment
ACE-IorARBarethefirst-lineantihypertensivedrugsrecommendedforBPmanagementinpatientswithcancer. I B
DihydropyridineCCBarerecommendedassecond-lineantihypertensivedrugsforpatientswithcancerwithuncontrolledBP. I C
CombinationtherapywithACE-IorARBanddihydropyridineCCBisrecommendedinpatientswithcancerwithsystolic
I C
BP≥160mmHganddiastolicBP≥100mmHg.
Diltiazemandverapamilarenotrecommendedtotreatarterialhypertensioninpatientswithcancerduetotheirdrug–drug
III C
interactions.
RecommendationTable34forthemanagementofvenousthromboembolisminpatientsreceivinganticancertreatment
Apixaban,edoxaban,orrivaroxabanarerecommendedforthetreatmentofsymptomaticorincidentalVTEinpatientswithcancer
I A
withoutcontraindications.
LMWHarerecommendedforthetreatmentofsymptomaticorincidentalVTEinpatientswithcancerwithplateletcount.50000/µL. I A
Catheter-associatedVTE
Durationofanticoagulationinpatientswithcancerwithacatheter-associatedVTEisrecommendedforaminimumof3monthsand
I C
continuinglongerifthecatheterremainsinsitu.
RecommendationTable35forvenousthromboembolismprophylaxisduringanticancertreatment
ExtendedprophylaxiswithLMWHfor4weekspost-operativelyisrecommendedforpatientswithcancerundergoingmajoropenor I B
laparoscopicabdominalorpelvicsurgerywithlowbleedingriskandhighVTErisk.
ProphylacticLMWHfortheprimarypreventionofVTEisindicatedinhospitalizedpatientswithcancerorthosewithprolongedbed
I B
restorreducedmobilityintheabsenceofbleedingorothercontraindications.
Adiscussionwiththepatientabouttherelativebenefitsandharms,cancerprognosis,drugcost,anddurationoftreatmentis
I C
recommendedpriortoprophylacticanticoagulationfortheprimarypreventionofVTE.
RecommendationTable36formanagementofperipheralarterydiseaseduringanticancertreatment
InpatientswhodevelopnewsymptomaticPAD,amultidisciplinaryapproachregardingthedecisiontocontinuevs.interrupt
I C
culpritcancertherapyisrecommended.
RecommendationTable37forthemanagementofpulmonaryhypertensionduringanticancertreatment
Right-heartcatheterizationanddiscontinuationofdasatinibisrecommendedinpatientswhodevelopsymptomaticorasymptomatic
I C
increaseinpeakTRV.3.4m/s.
Inpatientswithconfirmeddasatinib-inducedPAHornewasymptomaticpeakTRV.3.4m/s,analternativeBCR-ABLinhibitoris
I C
recommendedafterpeakTRVrecoveryto,2.8m/s.
RecommendationTable38forthemanagementofpericardialdiseasesinpatientsreceivinganticancertreatment
General
Diagnosisandmanagementofacutepericarditisinpatientswithcancerbasedonthe2015ESCGuidelinesforthediagnosisand
I C
managementofpericardialdiseasesisrecommendedandamultidisciplinarydiscussionisneededbeforeinterruptingcancertherapy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 112 ---
4340 ESCGuidelines
DiagnosisandmanagementofICI-associatedpericarditis
MultimodalityCVimaging(echocardiography,CMR+CT),ECGandmeasurementofcardiacbiomarkersarerecommendedto
I C
confirmthediagnosis,assessthehaemodynamicconsequencesofpericardialdisease,andruleoutassociatedmyocarditis.
PrednisoloneandcolchicinearerecommendedforpatientswithICI-associatedpericarditis. I C
InterruptionofICItreatmentinpatientswithconfirmedICI-associatedpericarditiswithmoderate-to-severepericardialeffusionis
I C
recommended.
AmultidisciplinarydiscussionisrecommendedbeforerestartingICItreatment. I C
RecommendationTable39forend-of-cancertherapycardiovascularriskassessment
Educatingandsupportingpatientswithcancertomakeappropriatehealthylifestylechoicesisrecommended. I C
EducationisrecommendedforpatientswithcancerregardingrecognitionforearlysignsandsymptomsofCVD. I C
CVRFassessmentisrecommendedduringthefirstyearaftercancertherapyandthereafteraccordingtothe2021ESCGuidelineson
I B
CVDpreventioninclinicalpractice.
Inasymptomatichigh-riskpatients,echocardiographyandcardiacserumbiomarkersarerecommendedat3and12monthsafter
I B
completionofcancertherapy.
Cardiologyreferralisrecommendedinpatientswithcancerwithnewcardiacsymptomsornewasymptomaticabnormalitiesin
I C
echocardiographyand/orcardiacserumbiomarkersattheendoftherapyassessment.
Long-termcontinuationofcardiacmedicationisrecommendedinpatientswhodevelopsevereCTRCDduringcancertherapy. I C
CVfollow-upandtreatmentoptimizationisrecommendedinpatientswhodevelopedTKI-mediatedhypertensionduringcancer
I C
therapy.
CVfollow-upandtreatmentoptimizationisrecommendedinpatientswhodevelopedvasculartoxicitiesduringcancertherapy. I C
ECGfollow-upisrecommendedinpatientswhodevelopedQTlengtheningorLQTSduringcancertherapy. I C
RecommendationTable40forcardiovascularsurveillanceinasymptomaticadultswhoarechildhoodandadolescentcancer
survivors
EducationofadultswhoarechildhoodandadolescentCStreatedwithanthracyclines,mitoxantrone,and/orRTtoavolumeincluding
I B
theheartandtheirhealthcareprovidersregardingtheirincreasedCVriskisrecommended.
AnnualscreeningformodifiableCVRFisrecommendedinadultswhoarechildhoodandadolescentCStreatedwithanthracyclines,
I C
mitoxantrone,and/orRTtoavolumeincludingtheheart.
CVassessmentisrecommendedinfemalechildhoodandadolescentCSpriortopregnancyorinthefirsttrimester. I C
RecommendationTable41forcardiovascularsurveillanceinasymptomaticadultcancersurvivors
AnnualCVriskassessment,includingECGandNP,andCVRFmanagementisrecommendedinCSwhoweretreatedwithapotentially
I B
cardiotoxiccancerdrugorRT.
CVtoxicityriskrestratificationisrecommended5yearsaftertherapytoorganizelong-termfollow-up. I C
RecommendationTable42foradultcancersurvivorswhodevelopcancertherapy-relatedcardiacdysfunctionlateaftercardiotoxic
cancertherapy
ACE-I/ARBand/orbeta-blockersarerecommendedinadultCSwithmoderateasymptomaticCTRCD. I C
RecommendationTable43foradultcancersurvivorswithcoronaryarterydisease
Asymptomaticradiation-inducedCADdetectedduringsurveillance
Non-invasivestresstestingisrecommendedinasymptomaticCSwithnewmoderateorsevereradiation-inducedCADdetectedon
I C
CCTAtoguideischaemia-directedmanagement.
AMDTdiscussionisrecommendedforclinicaldecision-makinginpatientswithradiation-inducedCADandinducibleischaemiaor
I C
severeleftmainCAD.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 113 ---
ESCGuidelines 4341
SymptomaticCAD
Pre-operativeassessmentofLIMAandRIMAviability,venousaccess,andsternalwoundhealingisrecommendedinCSwithradiation-
I C
inducedCADwhereCABGisconsidered.
RecommendationTable44foradultcancersurvivorswithvalvularheartdisease
AMDTapproachisrecommendedtodiscussanddefinethesurgicalriskinCSwithsevereVHD. I C
RecommendationTable46forcardiovascularmonitoringincancersurvivorsduringpregnancy
Inhigh-riskfemaleCS,pre-pregnancycounsellingandmanagementduringpregnancyandarounddeliverybyamultidisciplinary
I C
pregnancyheartteamisrecommended.
AbaselineCVevaluationincludinghistory,physicalexamination,ECG,NP,andechocardiographyisrecommendedinfemaleCSwitha
I C
historyofCTRCDwhoareconsideringpregnancy.
ACVevaluationincludingechocardiographyisrecommendedat12weeksofpregnancyinfemaleCSwhoareeitherhigh-riskorwho
I C
receivedpotentiallycardiotoxiccancertherapyanddidnothaveabaselineCVassessment.
RecommendationTable47forcardiovascularassessmentandmonitoringofpregnantwomenwithcancer
ManagementbyanexpertMDT(thepregnancyheartteam)inanexpertcentreisrecommendedforpregnantwomenwithcancerwho
I C
requirecardiotoxiccancertherapy.
Cardiacassessmentpriortocardiotoxiccancertherapyinpregnantwomenisrecommendedandconsistsofclinicalhistory,physical
I C
examination,ECG,andechocardiography.
RecommendationTable48forcarcinoidvalvularheartdiseases
Echocardiographyisrecommendedforthedetectionofcarcinoidcardiacinvolvementinallpatientswithcarcinoidsyndromeand
elevatedNPlevelsand/orclinicalsignsofcarcinoidheartdisease,andforsurveillanceevery3or6monthsdependingontheseverityof I B
cardiacinvolvementandclinicalstatus.
AMDTdiscussionforoptimalmedialmanagementtopreventcarcinoidcrisisisrecommendedbeforeanyinvasiveorsurgicalcardiac
I C
procedure.
ValvereplacementsurgeryisrecommendedinsymptomaticpatientswithseverecarcinoidtricuspidorpulmonaryVHDandan
I C
expectedsurvival≥12months.
ValvereplacementorrepairsurgeryisrecommendedinsymptomaticpatientswithseverecarcinoidmitraloraorticVHDandan
I C
expectedsurvival≥12months.
RecommendationTable49foramyloidlight-chaincardiacamyloidosisdiagnosisandmonitoring
Echocardiography,NP,andcTnarerecommendedforthediagnosisofAL-CAinpatientswithplasmacelldyscrasia. I B
CMRisrecommendedinpatientswithsuspectedAL-CA. I A
RecommendationTable50forriskstratificationandmonitoringforpatientswithcardiacimplantableelectronicdevicesundergoing
radiotherapy
Riskstratificationincludingplannedradiationtypeandenergy,dosetoCIED,thepatient’sdevicetype,andpacingdependenceis
I C
recommendedpriortostartingtreatment.
InpatientsundergoingRT,aCIEDcheckisrecommendedinallpatientsbeforeandaftercompletingRT,andduringRTaccordingto
I C
individualrisk.
InpatientswithaCIEDundergoingRTathighriskofarrhythmiaand/ordevicedysfunction,ECGmonitoringand/orpulseoximetryare I C
recommendedduringeveryRTsession.
3D,three-dimensional;ACE-I,angiotensin-convertingenzymeinhibitors;ACS,acutecoronarysyndromes;ADT,androgendeprivationtherapy;AF,atrialfibrillation;AL-CA,amyloidlight-chain
cardiacamyloidosis;ALK,anaplasticlymphomakinase;ARB,angiotensinreceptorblocker;ASTCT,AmericanSocietyforTransplantationandCellular;AV,atrioventricular;BC,breastcancer;BCR-
ABL,breakpointclusterregion–Abelsononcogenelocus;BP,bloodpressure;BTK,Brutontyrosinekinase;CABG,coronaryarterybypassgraft;CAD,coronaryarterydisease;CAR-T,chimeric
antigenreceptorTcell;CCB,calciumchannelblockers;CCS,chroniccoronarysyndromes;CCTA,coronarycomputedtomographyangiography;CHA2DS2-VASc,Congestiveheartfailure,
Hypertension,Age.75years(2points),Diabetesmellitus,Stroke(2points)—Vasculardisease,Age65–74years,Sexcategory(female);CIED,cardiacimplantableelectronicdevice;CMR,
cardiacmagneticresonance;CRS,cytokinereleasesyndrome;CT,computedtomography;cTn,cardiactroponin;CTRCD,cancertherapy-relatedcardiacdysfunction;CS,cancersurvivors;
CV,cardiovascular;CVD,cardiovasculardisease;CVRF,cardiovascularriskfactors;DAPT,dualantiplatelettherapy;EACTS,EuropeanAssociationforCardio-ThoracicSurgery;ECG,
electrocardiogram;EGFR,epidermalgrowthfactorreceptor;ESC,EuropeanSocietyofCardiology;GLS,globallongitudinalstrain;HbA1c,glycatedhaemoglobin;HER2,humanepidermal
receptor2;HF,heartfailure;HSCT,haematopoieticstemcelltransplantation;ICI,immunecheckpointinhibitors;ICU,intensivecareunit;i.v.,intravenous;LIMA,leftinternalmammary
artery;LMWH,low-molecular-weightheparins;LQTS,longQTsyndrome;LV,leftventricular;LVEF,leftventricularejectionfraction;MDT,multidisciplinaryteam;MEK,mitogen-activated
extracellularsignal-regulatedkinase;MI,myocardialinfarction;MM,multiplemyeloma;NP,natriureticpeptides;NSTE-ACS,non-ST-segmentelevationacutecoronarysyndromes;PAD,
peripheralarterydisease;PAH,pulmonaryarterialhypertension;PI,proteasomeinhibitors;QTc,correctedQTinterval;QTcF,correctedQTintervalusingFridericiacorrection;RAF,rapidly
acceleratedfibrosarcoma;RIMA,rightinternalmammaryartery;RT,radiotherapy;SCORE2,SystematicCoronaryRiskEstimation2;SCORE2-OP,SystematicCoronaryRiskEstimation2—
Older Persons; STEMI, ST-segment elevation myocardial infarction; TdP, torsade de pointes; TIL, tumour-infiltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic
echocardiography;TTS,Takotsubosyndrome;TRV,tricuspidregurgitationvelocity;ULN,upperlimitofnormal;VEGFi,vascularendothelialgrowthfactorinhibitors;VHD,valvularheart
disease;VTE,venousthromboembolism.
aClassofrecommendation.
bLevelofevidence.
2202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 114 ---
4342 ESCGuidelines
16. Quality indicators for Department, Institut Jules Bordet, Brussels, Belgium; Rudolf
A. de Boer, Cardiology, University Medical Center Groningen,
cardio-oncology
Groningen, Netherlands; Susan F. Dent, Department of
Medicine, Duke Cancer Institute, Durham, NC, United States of
Qualityindicators(QIs)aretoolsthatmaybeusedtoevaluatecare
America; Dimitrios Farmakis, Medical School, University of
quality,includingstructural,process,andoutcomesofcare.835They
Cyprus, Nicosia, Cyprus; Sofie A. Gevaert, Cardiology, Ghent
mayalsoserveasamechanismforenhancingadherencetoguideline
UniversityHospital,Ghent,Belgium;DianaA.Gorog,Postgraduate
recommendations, through associated quality improvement initia-
Medicine,UniversityofHertfordshire,Hatfield,UnitedKingdom,and
tives and the benchmarking of care providers.836,837 As such, the
NationalHeart and Lung Institute, ImperialCollege, London, United
roleofQIsinimprovingcareandoutcomesforCVDisincreasingly
Kingdom, and Cardiology Department, East and North
recognized by healthcare authorities, professional organizations,
Hertfordshire NHS Trust, Stevenage, United Kingdom; Joerg
payers,andthepublic.835
Herrmann, Department of Cardiovascular Diseases, Mayo Clinic,
TheESCunderstandstheneedformeasuringandreportingqual-
Rochester, MN, United States of America; Daniel Lenihan,
ityandoutcomesofCVcareandhasestablishedmethodsforthede-
Cardio-Oncology,InternationalCardio-OncologySociety,Tampa,FL,
velopment of the ESC QIs for the quantification of care and
United States of America, and Cardiology, Saint Francis Healthcare,
outcomes for CVD.835 These methods were used to develop QIs
Cape Girardeau, MO, United States of America; Javid Moslehi,
pertinent to cardio-oncology in parallel with the writing of this
Section of Cardio-Oncology & Immunology, Cardiovascular
ClinicalPracticeGuidelinedocumentandthroughthecollaboration
ResearchInstitute,UniversityofCalifornia,SanFrancisco(UCSF),
withpatientrepresentativesanddomainexperts.TheQIs,alongside
San Francisco, CA, United States of America; Brenda Moura,
theirmeasurementspecificationsanddevelopmentprocesswillbe
Cardiology Department, Armed Forces Hospital, Porto, Portugal,
publishedseparately.
andFacultyofMedicine,UniversityofPorto,Porto,Portugal;Sonja
S. Salinger, Clinic for Cardiovascular Disease, University Clinical
17. Supplementary data
Center, Nis, Serbia, and Medical Faculty, University of Nis, Nis,
Serbia;RichardStephens(UnitedKingdom),ESCPatientForum,
SupplementarydataisavailableatEuropeanHeartJournalonline.
Sophia Antipolis, France; Thomas M. Suter, Department of
Cardiology, Inselspital, Bern University Hospital, University of Bern,
18. Data availability statement Bern, Switzerland; Sebastian Szmit, Department of Pulmonary
Circulation, Thromboembolic Diseases and Cardiology, Centre of
Nonewdataweregeneratedoranalysedinsupportofthisresearch. Postgraduate Medical Education, Otwock, Poland, and Institute of
Hematology and Transfusion Medicine, Transfusion Medicine,
19. Author information Warsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,
Universidad Complutense, Madrid, Spain; Paaladinesh
Author/Task Force Member Affiliations: Liam S. Couch, Thavendiranathan, Department of Medicine, Division of
King’s College London BHF Centre, the Rayne Institute, St Cardiology,TedRogersPrograminCardiotoxicityPrevention,Peter
Thomas’ Hospital, King’s College London, London, United MunkCardiacCenter,TorontoGeneralHospital,UniversityHealth
Kingdom; Riccardo Asteggiano, Cardiology, LARC Network, University of Toronto, Toronto, Canada; Carlo
(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of G.Tocchetti,Cardio-OncologyUnit,DepartmentofTranslational
Medicine, Insubria University, Varese, Italy; Marianne C. Aznar, MedicalSciences,FedericoIIUniversity,Naples,Italy,andCenterfor
Division of Cancer Sciences, Faculty of Biology, Medicine and Basic and Clinical Immunology Research (CISI), Federico II
Health, University of Manchester, Manchester, United Kingdom; University, Naples, Italy, and Interdepartmental Center for Clinical
Jutta Bergler-Klein, Department of Cardiology, Medical andTranslationalResearch(CIRCET),FedericoIIUniversity,Naples,
University of Vienna, Vienna, Austria; Giuseppe Boriani, Italy;PetervanderMeer,Cardiology,UniversityMedicalCenter
Cardiology Division, Department of Biomedical, Metabolic and Groningen, Groningen, Netherlands; Helena J.H. van der Pal,
Neural Sciences, University of Modena and Reggio Emilia, Princess Máxima Center for Pediatric Oncology, Princess Máxima
Policlinico di Modena, Modena, Italy; Daniela Cardinale, CenterforPediatricOncology,Utrecht,Netherlands.
Cardioncology Unit, European Institute of Oncology—I.R.C.C.S.,
Milan, Italy; Raul Cordoba, Department of Hematology,
Fundacion Jimenez Diaz University Hospital, Madrid, Spain, and 20. Appendix
CancerResearchGroup,HealthResearchInstituteIIS-FJD,Madrid,
Spain; Bernard Cosyns, Cardiology, Centrum voor Hart en ESCScientificDocumentGroup
Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel (UZB), IncludesDocumentReviewersandESCNationalCardiacSocieties.
Brussels, Belgium, and In Vivo Molecular and Cellular (ICMI)
Center, Vrij Universiteit Brussel, Brussels, Belgium; David Document Reviewers: Patrizio Lancellotti (CPG Review
J. Cutter, Nuffield Department of Population Health, University Coordinator)(Belgium),FranckThuny(CPGReviewCoordinator)
of Oxford, Oxford, United Kingdom, and Oxford Cancer Centre, (France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),
Oxford University Hospitals NHS Foundation Trust, Oxford, Berthe Aleman (Netherlands), Joachim Alexandre (France), Ana
United Kingdom; Evandro de Azambuja, Medical Oncology Barac (United States of America), Michael A. Borger (Germany),
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 115 ---
ESCGuidelines 4343
RubenCasado-Arroyo(Belgium),JenniferCautela(France),Jolanta Society of Cardiology, Aatif Benyass; Netherlands: Netherlands
Čelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal Society of Cardiology, Olivier Manintveld; North Macedonia:
(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy North Macedonian Society of Cardiology, Marijan Bosevski;
(France), Thor Edvardsen (Norway), Laurent Fauchier (France), Norway: Norwegian Society of Cardiology, Geeta Gulati;
Michael Fradley (United States of America), Julia Grapsa (United Poland: Polish Cardiac Society, Przemysław Leszek; Portugal:
Kingdom),SigrunHalvorsen(Norway),MichaelHeuser(Germany), Portuguese Society of Cardiology, Manuela Fiuza; Romania:
Marc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan Romanian Society of Cardiology, Ruxandra Jurcut; Russian
(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos Federation: Russian Society of Cardiology, Yury Vasyuk; San
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Marino: San Marino Society of Cardiology, Marina Foscoli;
BonnieKy(UnitedStatesofAmerica),UlfLandmesser(Germany), Serbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Slovak Society of Cardiology, Miroslav Slanina; Slovenia:
Y. H. Lip (United Kingdom), Maja-Lisa Løchen (Norway), Slovenian Society of Cardiology, Luka Lipar; Spain: Spanish
Katarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra Society of Cardiology, Ana Martin-Garcia; Sweden: Swedish
(Italy), Richard Mindham (United Kingdom), Marie Moonen Society of Cardiology, Laila Hübbert; Switzerland: Swiss Society
(Belgium), Tomas G. Neilan (United States of America), Jens of Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian
Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva Cardiovascular Association, Ahmad Alayed; Tunisia: Tunisian
Prescott(Denmark),AminaRakisheva(Kazakhstan),Joe-ElieSalem Society of Cardiology and Cardio-Vascular Surgery, Leila Abid;
(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien Turkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:
ten Berg (Netherlands), Rhian M. Touyz (Canada/United Ukrainian Association of Cardiology, Elena Nesukay; United
Kingdom), Agnieszka Tycinska (Poland), Matthias Wilhelm Kingdom of Great Britain and Northern Ireland: British
(Switzerland),JoseLuisZamorano(Spain) Cardiovascular Society, Charlotte Manisty, Uzbekistan:
AssociationofCardiologistsofUzbekistan,NigoraSrojidinova.
ESCNationalCardiacSocietiesactivelyinvolvedinthereview
processofthe2022ESCGuidelinesoncardio-oncology:Algeria: ESCClinicalPracticeGuidelines(CPG)Committee:Colin
AlgerianSocietyofCardiology,NadiaLaredj;Armenia:Armenian Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
Cardiologists Association, Parounak Zelveian; Austria: Austrian (Egypt), Victor Aboyans (France), Sotiris Antoniou (United
Society of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),
Society of Cardiology, Fuad Samadov; Belarus: Belorussian Andreas Baumbach (United Kingdom), Michael A. Borger
Scientific Society of Cardiologists, Uladzimir Andrushchuk; (Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),
Belgium: Belgian Society of Cardiology, Bernhard L. Gerber; Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent
Bosnia and Herzegovina: Association of Cardiologists of Fauchier (France), Chris P. Gale (United Kingdom), Sigrun
Bosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma
Society of Cardiology, Elena Kinova; Croatia: Croatian Cardiac (Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
Society, Jure Samardzic; Cyprus: Cyprus Society of Cardiology, C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Evagoras Economides; Czechia: Czech Society of Cardiology, Landmesser (Germany), BasilS.Lewis(Israel),Ales Linhart (Czech
Radek Pudil; Denmark: Danish Society of Cardiology, Kirsten Republic), Maja-Lisa Løchen (Norway), Richard Mindham (United
M. Nielsen; Egypt: Egyptian Society of Cardiology, Tarek Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
A. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus; (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva
Finland: Finnish Cardiac Society, Suvi Tuohinen; France: French (Kazakhstan),MartaSitges(Spain),RhianM.Touyz(Canada/United
Society of Cardiology, Stéphane Ederhy; Georgia: Georgian Kingdom).
Society ofCardiology, ZurabPagava; Germany: GermanCardiac
Society, Tienush Rassaf; Greece: Hellenic Society of Cardiology,
21. References
AlexandrosBriasoulis;Hungary:HungarianSocietyofCardiology,
Dániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl 1.HerrmannJ,LenihanD,ArmenianS,BaracA,BlaesA,CardinaleD,etal.Defining
K. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth; cardiovasculartoxicities of cancertherapies:anInternational Cardio-Oncology
Israel: Israel Heart Society, Zaza Iakobishvili; Italy: Italian
Society(IC-OS)consensusstatement.EurHeartJ2022;43:280–299.
2.HerrmannJ,LermanA,SandhuNP,VillarragaHR,MulvaghSL,KohliM.Evaluation
FederationofCardiology,IrisParrini;Kazakhstan:Associationof
andmanagementofpatientswithheartdiseaseandcancer:Cardio-oncology.Mayo
Cardiologists of Kazakhstan, Amina Rakisheva; Kosovo ClinProc2014;89:1287–1306.
(Republic of):KosovoSociety of Cardiology,Edita Pllana Pruthi; 3.SungH,FerlayJ,SiegelRL,LaversanneM,SoerjomataramI,JemalA,etal.Global
cancerstatistics2020:GLOBOCANestimatesofincidenceandmortalityworld-
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov; widefor36cancersin185countries.CACancerJClin2021;71:209–249.
Latvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon: 4.Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,
Lebanese Society of Cardiology, Hadi Skouri; Libya: Libyan GalderisiM,etal.2016ESCPositionPaperoncancertreatmentsandcardiovascu-
lartoxicitydevelopedunder theauspicesof theESCCommitteeforPractice
Cardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society Guidelines.EurHeartJ2016;37:2768–2801.
of Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg 5.LancellottiP,SuterTM,López-FernándezT,GalderisiM,LyonAR,VanDerMeerP,
Society of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac etal.Cardio-oncologyservices:rationale,organization,andimplementation.Eur
HeartJ2019;40:1756–1763.
Society, Alice M. Moore; Moldova (Republic of): Moldavian
6.Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.
SocietyofCardiology,DanielaBursacovschi;Morocco:Moroccan Evidence-based recommendations for the organization of long-term follow-up
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 116 ---
4344 ESCGuidelines
care for childhood and adolescent cancer survivors: a report from the metastaticbreastcancerreceivinganthracyclines.BreastCancerResTreat2008;
PanCareSurFupGuidelinesWorkingGroup.JCancerSurviv2019;13:759–772. 107:443–450.
7. ArmenianSH,HudsonMM,MulderRL,ChenMH,ConstineLS,DwyerM,etal. 28.Abdel-QadirH,ThavendiranathanP,AustinPC,LeeDS,AmirE,TuJV,etal.
Recommendationsforcardiomyopathysurveillanceforsurvivorsofchildhoodcan- Developmentandvalidationofamultivariablepredictionmodelformajoradverse
cer:areportfromtheInternationalLateEffectsofChildhoodCancerGuideline cardiovasculareventsafterearlystagebreastcancer:apopulation-basedcohort
HarmonizationGroup.LancetOncol2015;16:e123–e136. study.EurHeartJ2019;40:3913–3920.
8. vanKalsbeekRJ,MulderRLRL,SkinnerR,KremerLCMCM.Theconceptofcancer 29.Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al.
survivorshipandmodelsforlong-termfollow-up.FrontHormRes2021;54:1–15. Symptomaticheartfailureinacuteleukemiapatientstreatedwithanthracyclines.
9. HerrmannJ.Adversecardiaceffectsofcancertherapies:cardiotoxicityandar- JACCCardioOncology2019;1:208–217.
rhythmia.NatRevCardiol2020;17:474–502. 30.MartínGarcíaA,MitroiC,MazónRamosP,GarcíaSanzR,VirizuelaJA,ArenasM,
10. HerrmannJ.Vasculartoxiceffectsofcancertherapies.NatRevCardiol2020;17: etal.Stratificationandmanagementofcardiovascularriskincancerpatients.Acon-
503–522.
sensusdocumentoftheSEC,FEC,SEOM,SEOR,SEHH,SEMG,AEEMT,AEEC,
11. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. andAECC.RevEspañolaCardiol(EnglishEd)2021;74:438–448.
Cardio-oncologyrehabilitationtomanagecardiovascularoutcomesincancerpa- 31.Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P,
tientsandsurvivors:ascientificstatementfromtheAmericanHeartAssociation.
RodríguezIR,GómezPrietoP,etal.Cardiovascularriskfactorsduringcancertreat-
Circulation2019;139:e997–e1012.
ment.Prevalenceandprognosticrelevance:insightsfromtheCARDIOTOXregis-
12. LyonAR,DentS,StanwayS,EarlH,Brezden-MasleyC,Cohen-SolalA,etal. try.EurJPrevCardiol2022;29(6):859–868.
Baselinecardiovascularriskassessmentincancerpatientsscheduledtoreceivecar- 32.FeijenEAM,LeisenringWM,StrattonKL,NessKK,VanDerPalHJH,VanDalenEC,
diotoxiccancertherapies:apositionstatementandnewriskassessmenttoolsfrom etal.Derivationofanthracyclineandanthraquinoneequivalenceratiostodoxo-
the Cardio-Oncology Study Group of the Heart Failure Association of the rubicinforlate-onsetcardiotoxicity.JAMAOncol2019;5:864–871.
EuropeanSociety.EurJHeartFail2020;22:1945–1960.
33.PareekN,CevallosJ,MolinerP,ShahM,TanLL,ChambersV,etal.Activityand
13. BattistiNML,AndresMS,LeeKA,RamalingamS,NashT,MappouridouS,etal. outcomesofacardio-oncologyserviceintheUnitedKingdom—afive-yearexperi-
Incidence of cardiotoxicity and validation of the Heart Failure Association– ence.EurJHeartFail2018;20:1721–1731. InternationalCardio-OncologySocietyriskstratificationtoolinpatientstreated
34.KoeneRJ,PrizmentAE,BlaesA,KonetySH.Sharedriskfactorsincardiovascular
withtrastuzumabforHER2-positiveearlybreastcancer.BreastCancerResTreat diseaseandcancer.Circulation2016;133:1104–1114.
2021;188:149–163.
35.CaocciG,MulasO,AbruzzeseE,LucianoL,IurloA,AttolicoI,etal.Arterialocclu-
14. McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,BöhmM,etal.2021
siveeventsinchronicmyeloidleukemiapatientstreatedwithponatinibinthereal-
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure.
lifepracticearepredictedbytheSystematicCoronaryRiskEvaluation(SCORE)
EurHeartJ2021;42:3599–3726.
chart.HematolOncol2019;37:296–302.
15. JaffeAS,VasileVC,MiloneM,SaengerAK,OlsonKN,AppleFS.Diseasedskeletal
36.LibbyP,SidlowR,LinAE,GuptaD,JonesLW,MoslehiJ,etal.Clonalhematopoiesis:
muscle:a noncardiac sourceof increased circulating concentrations of cardiac
crossroadsofaging,cardiovasculardisease,andcancer:JACCreviewtopicofthe
troponinT.JAmCollCardiol2011;58:1819–1824.
week.JAmCollCardiol2019;74:567–577.
16. SchmidJ,LiesingerL,Birner-GruenbergerR,StojakovicT,ScharnaglH,Dieplinger
37.Garcia-PaviaP,KimY,Restrepo-CordobaMA,LundeIG,WakimotoH,SmithAM,
B,etal.ElevatedcardiactroponinTinpatientswithskeletalmyopathies.JAmColl
Cardiol2018;71:1540–1549. etal.Geneticvariantsassociatedwithcancertherapy-inducedcardiomyopathy.
Circulation2019;140:31–41.
17. DelombaerdeD,VervloetD,FranssenC,CroesL,GremonprezF,PrenenH,etal.
38.Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC
Clinicalimplicationsofisolatedtroponinemiafollowingimmunecheckpointinhibi-
CardioOncology2020;2:539–552.
tortherapy.ESMOOpen2021;6:100216.
39.KatzkeVA,KaaksR,KühnT.Lifestyleandcancerrisk.CancerJ2015;21:104–110.
18. FerreiraVM,Schulz-MengerJ,HolmvangG,KramerCM,CarboneI,SechtemU,
etal.Cardiovascularmagneticresonanceinnonischemicmyocardialinflammation:
40.Sharifi-RadJ,RodriguesCF,SharopovF,DoceaAO,KaracaAC,Sharifi-RadM,etal.
expertrecommendations.JAmCollCardiol2018;72:3158–3176. Diet,lifestyleandcardiovasculardiseases:linkingpathophysiologytocardioprotec-
tiveeffectsofnaturalbioactivecompounds.IntJEnvironResPublicHealth2020;17:
19. VisserenFLJ,MachF,SmuldersYM,CarballoD,KoskinasKC,BäckM,etal.2021
2326.
ESCGuidelinesoncardiovasculardiseasepreventioninclinicalpractice.EurHeartJ
2021;42:3227–3337. 41.TurnerMC,AndersenZJ,BaccarelliA,DiverWR,GapsturSM,PopeCA,etal.
Outdoorairpollutionandcancer:anoverviewofthecurrentevidenceandpublic
20. VandenberkB,VandaelE,RobynsT,VandenbergheJ,GarwegC,FoulonV,etal.
healthrecommendations.CACancerJClin2020;70:460–479.
Which QT correction formulae to use for QT monitoring? J Am Heart Assoc
42.LindPM,LindL.Arepersistentorganicpollutantslinkedtolipidabnormalities,ath-
2016;5:e003264.
21. ArmenianSH,LacchettiC,BaracA,CarverJ,ConstineLS,DenduluriN,etal. erosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020;9:
Preventionandmonitoringofcardiacdysfunctioninsurvivorsofadultcancers:
334–348.
American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 43.ZamoranoJL,GottfridssonC,AsteggianoR,AtarD,BadimonL,BaxJJ,etal.The
2017;35:893–911. cancerpatientandcardiology.EurJHeartFail2020;22:2290–2309.
22. CuriglianoG,LenihanD,FradleyM,GanatraS,BaracA,BlaesA,etal.Management 44.FradleyMG,MoslehiJ.QTprolongationandoncologydrugdevelopment.Card
ofcardiacdiseaseincancerpatientsthroughoutoncologicaltreatment:ESMOcon-
ElectrophysiolClin2015;7:341–355.
sensusrecommendations.AnnOncol2020;31:171–190. 45.Porta-SánchezA,GilbertC,SpearsD,AmirE,ChanJ,NanthakumarK,etal.
23. Rossello X, Dorresteijn JAN, Janssen A, Lambrinou E, Scherrenberg M, Incidence,diagnosis,andmanagementofQTprolongationinducedbycancerther-
Bonnefoy-CudrazE,etal.Riskpredictiontoolsincardiovasculardiseasepreven- apies:asystematicreview.JAmHeartAssoc2017;6:e007724.
tion: a report from the ESC Prevention of CVD Programme led by the 46.CuriglianoG,SpitaleriG,FingertHJ,deBraudF,SessaC,LohE,etal.Drug-induced
EuropeanAssociationofPreventiveCardiology(EAPC)incollaborationwiththe QTcintervalprolongation:aproposaltowardsanefficientandsafeanticancerdrug
Acute Cardiovascular Care Association (ACCA) and the Association of
development.EurJCancer2008;44:494–500.
CardiovascularNursingandAlliedProfessions(ACNAP).EurJCardiovascNurs 47.ViganegoF,SinghR,FradleyMG.Arrhythmiasandotherelectrophysiologyissuesin
2019;18:534–544. cancerpatientsreceivingchemotherapyorradiation.CurrCardiolRep2016;18:52.
24. RomondEH,JeongJH,RastogiP,SwainSM,GeyerCE,EwerMS,etal.Seven-year 48.CuriglianoG,SpitaleriG,DeBraudF,CardinaleD,CipollaC,CivelliM,etal.QTc
follow-upassessmentofcardiacfunctioninNSABPB-31,arandomizedtrialcom- prolongationassessmentinanticancerdrugdevelopment:clinicalandmethodo-
paringdoxorubicinandcyclophosphamidefollowedbypaclitaxel(ACP)withACP logicalissues.Ecancermedicalscience2009;3:130.
plustrastuzumabasadjuvanttherapyforpatientswithnode-positive,humanepi- 49.SalemJ-E,NguyenLS,MoslehiJJ,EderhyS,Lebrun-VignesB,RodenDM,etal.
dermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30: Anticancerdrug-inducedlife-threateningventriculararrhythmias:aWorldHealth
3792–3799. Organizationpharmacovigilancestudy.EurHeartJ2021;42:3915–3928.
25. EzazG,LongJB,GrossCP,ChenJ.Riskpredictionmodelforheartfailureandcar- 50.LentzR,FeinglassJ,MaS,AkhterN.Riskfactorsforthedevelopmentofatrialfib-
diomyopathyafteradjuvanttrastuzumabtherapyforbreastcancer.JAmHeart rillationonibrutinibtreatment.LeukLymphoma2019;60:1447–1453.
Assoc2014;3:e000472. 51.MatoAR,ClasenS,PickensP,GashoniaL,RhodesJ,SvobodaJ,etal.Leftatrialab-
26. RushtonM,JohnsonC,DentS.Trastuzumab-inducedcardiotoxicity:testingaclin- normality(LAA)asapredictorofibrutinib-associatedatrialfibrillationinpatients
icalriskscoreinareal-worldcardio-oncologypopulation.CurrOncol2017;24: withchroniclymphocyticleukemia.CancerBiolTher2018;19:1–2.
176–180. 52.SinglaA,HoganWJ,AnsellSM,BuadiFK,DingliD,DispenzieriA,etal.Incidenceof
27. DranitsarisG,RaysonD,VincentM,ChangJ,GelmonK,SandorD,etal.Thede- supraventriculararrhythmiasduringautologousperipheralbloodstemcelltrans-
velopmentofapredictivemodeltoestimatecardiotoxicriskforpatientswith plantation.BiolBloodMarrowTransplant2013;19:1233–1237.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 117 ---
ESCGuidelines 4345
53.PudilR,MuellerC,ČelutkienėJ,HenriksenPA,LenihanD,DentS,etal.Roleof 73.GalderisiM,CosynsB,EdvardsenT,CardimN,DelgadoV,DiSalvoG,etal.
serumbiomarkersincancerpatientsreceivingcardiotoxiccancertherapies:apos- Standardizationofadulttransthoracicechocardiographyreportinginagreement
ition statement from the Cardio-Oncology Study Group of the Heart Failure withrecentchamberquantification,diastolicfunction,andheartvalvediseasere-
Association and the Cardio-Oncology Council of the European Society of commendations:anexpertconsensusdocumentoftheEuropeanAssociationof
Cardiology.EurJHeartFail2020;22:1966–1983. CardiovascularImaging.EurHeartJCardiovascImaging2017;18:1301–1310.
54.Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, 74.DeAzambujaE,ProcterMJ,VanVeldhuisenDJ,Agbor-TarhD,Metzger-FilhoO,
Bergler-KleinJ,etal.Roleofcardiovascularimagingincancerpatientsreceivingcar- SteinseiferJ,etal.Trastuzumab-associatedcardiaceventsat8yearsofmedian
diotoxictherapies:apositionstatementonbehalfoftheHeartFailureAssociation follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:
(HFA), the European Association of Cardiovascular Imaging (EACVI) and the 2159–2165.
Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J 75.SantoroC,ArpinoG,EspositoR,LemboM,PaciollaI,CardalesiC,etal.2Dand3D
HeartFail2020;22:1504–1524. strainfordetectionofsubclinicalanthracyclinecardiotoxicityinbreastcancerpa-
55.Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al.
tients:Abalancewithfeasibility.EurHeartJCardiovascImaging2017;18:930–936.
Troponinsandbrainnatriureticpeptidesforthepredictionofcardiotoxicityincan- 76.ZhangKW,FinkelmanBS,GulatiG,NarayanHK,UpshawJ,NarayanV,etal.
cerpatients:ameta-analysis.EurJHeartFail2020;22:350–361. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline
56.LipshultzSE,MillerTL,ScullyRE,LipsitzSR,RifaiN,SilvermanLB,etal.Changesin chemotherapy are associated with systolic and diastolic dysfunction. JACC
cardiacbiomarkersduringdoxorubicintreatmentofpediatricpatientswithhigh-
CardiovascImaging2018;11:1059–1068.
riskacutelymphoblasticleukemia:associationswithlong-termechocardiographic 77.Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.
outcomes.JClinOncol2012;30:1042–1049. Recommendations for cardiac chamber quantification by echocardiography in
57.LipshultzSE,RifaiN,DaltonVM,LevyDE,SilvermanLB,LipsitzSR,etal.Theeffect adults: an update from the American Society of Echocardiography and the
ofdexrazoxaneonmyocardialinjuryindoxorubicin-treatedchildrenwithacute EuropeanAssociationofCardiovascularImaging.EurHeartJCardiovascImaging
lymphoblasticleukemia.NEnglJMed2004;351:145–153. 2015;16:233–270.
58.XueK,GuJJ,ZhangQ,LiuX,WangJ,LiXQ,etal.Cardiotoxicityasindicatedby
78.ThavendiranathanP,GrantAD,NegishiT,PlanaJC,PopovićZB,MarwickTH.
LVEFandtroponinTsensitivityfollowingtwoanthracycline-basedregimensin Reproducibilityofechocardiographictechniquesforsequentialassessmentofleft
ventricularejectionfractionandvolumes:applicationtopatientsundergoingcancer
lymphoma:resultsfromarandomizedprospectiveclinicaltrial.Oncotarget2016;
7:32519–32531.
chemotherapy.JAmCollCardiol2013;61:77–84.
79.DoroszJL,LezotteDC,WeitzenkampDA,AllenLA,SalcedoEE.Performanceof
59.CardinaleD,SandriMT,ColomboA,ColomboN,BoeriM,LamantiaG,etal.
PrognosticvalueoftroponinIincardiacriskstratificationofcancerpatientsunder- 3-dimensionalechocardiographyinmeasuringleftventricularvolumesandejection
goinghigh-dosechemotherapy.Circulation2004;109:2749–2754. fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:
1799–1808.
60.PuttM,HahnVS,JanuzziJL,SawayaH,SebagIA,PlanaJC,etal.Longitudinalchanges
80.HoffmannR,BarlettaG,VonBardelebenS,VanoverscheldeJL,KasprzakJ,GreisC,
inmultiplebiomarkersareassociatedwithcardiotoxicityinbreastcancerpatients
etal.Analysisofleftventricularvolumesandfunction:amulticentercomparisonof
treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:
1164–1172. cardiacmagneticresonanceimaging,cineventriculography,andunenhancedand
contrast-enhanced two-dimensional and three-dimensional echocardiography. J
61.Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al.
AmSocEchocardiogr2014;27:292–301.
Trastuzumab-inducedcardiotoxicity:clinicalandprognosticimplicationsoftropo-
ninIevaluation.JClinOncol2010;28:3910–3916. 81.JenkinsC,MoirS,ChanJ,RakhitD,HaluskaB,MarwickTH.Leftventricularvolume
measurementwithechocardiography:acomparisonofleftventricularopacifica-
62.ZardavasD,SuterTM,VanVeldhuisenDJ,SteinseiferJ,NoeJ,LauerS,etal.Roleof
tion,three-dimensionalechocardiography,orbothwithmagneticresonanceim-
troponinsIandTandN-terminalprohormoneofbrainnatriureticpeptideinmon-
aging.EurHeartJ2009;30:98–106.
itoringcardiacsafetyofpatientswithearly-stagehumanepidermalgrowthfactor
82.PorterTR,MulvaghSL,AbdelmoneimSS,BecherH,BelcikJT,BierigM,etal.Clinical
receptor2-positivebreastcancerreceivingtrastuzumab:aherceptinadjuvantstudy
applicationsofultrasonicenhancingagentsinechocardiography:2018American
cardiacmarkersubstudy.JClinOncol2017;35:878–884.
SocietyofEchocardiographyGuidelinesUpdate.JAmSocEchocardiogr2018;31:
63.MuellerC,McDonaldK,deBoerRA,MaiselA,ClelandJGF,KozhuharovN,etal. 241–274.
HeartFailureAssociationoftheEuropeanSocietyofCardiologypracticalguidance
83.HouboisCP,NolanM,SomersetE,ShalmonT,EsmaeilzadehM,LamacieMM,etal.
ontheuseofnatriureticpeptideconcentrations.EurJHeartFail2019;21:715–731.
Serialcardiovascularmagneticresonancestrainmeasurementstoidentifycardio-
64.FeolaM,GarroneO,OccelliM,FranciniA,BiggiA,ViscontiG,etal.Cardiotoxicity
toxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc
afteranthracyclinechemotherapyinbreastcarcinoma:effectsonleftventricular Imaging2021;14:962–974.
ejectionfraction,troponinIandbrainnatriureticpeptide.IntJCardiol2011;148:
84.DobbinSJH,MangionK,BerryC,RoditiG,BasakS,SourbronS,etal.Cardiotoxicity
194–198.
andmyocardialhypoperfusionassociatedwithanti-vascularendothelialgrowthfac-
65.DemisseiBG,HubbardRA,ZhangL,SmithAM,ShelineK,McDonaldC,etal.
tortherapies:prospectivecardiacmagneticresonanceimaginginpatientswithcan-
Changesincardiovascularbiomarkerswithbreastcancertherapyandassociations cer.EurJHeartFail2020;22:1276–1277.
withcardiacdysfunction.JAmHeartAssoc2020;9:e014708. 85.Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M.
66.CornellRF,KyB,WeissBM,DahmCN,GuptaDK,DuL,etal.Prospectivestudyof Echocardiographicparametersofleftventricularsizeandfunctionaspredictors
cardiaceventsduringproteasomeinhibitortherapyforrelapsedmultiplemyeloma. ofsymptomaticheartfailureinpatientswithaleftventricularejectionfractionof
JClinOncol2019;37:1946–1955. 50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015;16:
67.Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al. 977–984.
Cardiovascularbiomarkersinpatientswithcancerandtheirassociationwithall- 86.ČelutkienėJ,PlymenCM,FlachskampfFA,deBoerRA,GrapsaJ,MankaR,etal.
causemortality.Heart2015;101:1874–1880.
Innovativeimagingmethodsinheartfailure:ashiftingparadigmincardiacassess-
68.López-SendónJ,Álvarez-OrtegaC,ZamoraAuñonP,BuñoSotoA,LyonAR, ment. Position statement on behalf of the Heart Failure Association of the
Farmakis D, et al. Classification, prevalence, and outcomes of anticancer EuropeanSocietyofCardiology.EurJHeartFail2018;20:1615–1633.
therapy-inducedcardiotoxicity:theCARDIOTOXregistry.EurHeartJ2020;41: 87.KalamK,OtahalP,MarwickTH.PrognosticimplicationsofglobalLVdysfunction:a
1720–1729.
systematicreviewandmeta-analysisofgloballongitudinalstrainandejectionfrac-
69.KyB,PuttM,SawayaH,FrenchB,JanuzziJL,SebagIA,etal.Earlyincreasesinmul- tion.Heart2014;100:1673–1680.
tiplebiomarkerspredictsubsequentcardiotoxicityinpatientswithbreastcancer 88.BaronT,BerglundL,HedinEM,FlachskampfFA.Test–retestreliabilityofnewand
treatedwithdoxorubicin,taxanes,andtrastuzumab.JAmCollCardiol2014;63: conventionalechocardiographicparametersofleftventricularsystolicfunction.Clin
809–816. ResCardiol2019;108:355–365.
70.Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al. 89.LambertJ,LamacieM,ThampinathanB,AltahaMA,EsmaeilzadehM,NolanM,etal.
CirculatingmicroRNAsaspotentialpredictorsofanthracycline-inducedtroponin VariabilityinechocardiographyandMRIfordetectionofcancertherapycardiotoxi-
elevationinbreastcancerpatients:divergingeffectsofdoxorubicinandepirubicin. city.Heart2020;106:817–823.
JClinMed2020;9:1418. 90.ThavendiranathanP,NegishiT,CotéMA,PenickaM,MasseyR,ChoGY,etal.
71.BeerLA,KossenkovAV,LiuQ,LuningPrakE,DomchekS,SpeicherDW,etal. Singleversusstandardmultiviewassessmentofgloballongitudinalstrainforthe
Baseline immunoglobulin e levels as a marker of doxorubicin- and diagnosisofcardiotoxicityduringcancertherapy.JACCCardiovascImaging2018;
trastuzumab-associatedcardiacdysfunction.CircRes2016;119:1135–1144. 11:1109–1118.
72.PlanaJC,ThavendiranathanP,Bucciarelli-DucciC,LancellottiP.Multi-modalityim- 91.NegishiK,NegishiT,HaluskaBA,HareJL,PlanaJC,MarwickTH.Useofspeckle
aging in the assessment of cardiovascular toxicity in the cancer patient. JACC straintoassessleftventricularresponsestocardiotoxicchemotherapyandcardi-
CardiovascImaging2018;11:1173–1186. oprotection.EurHeartJCardiovascImaging2014;15:324–331.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 118 ---
4346 ESCGuidelines
92. ThavendiranathanP,PoulinF,LimKD,PlanaJC,WooA,MarwickTH.Useofmyo- 112. JettéM,SidneyK,BlümchenG.Metabolicequivalents(METS)inexercisetesting,
cardialstrainimagingbyechocardiographyfortheearlydetectionofcardiotoxicity exerciseprescription,andevaluationoffunctionalcapacity.ClinCardiol1990;13:
inpatientsduringandaftercancerchemotherapy:asystematicreview.JAmColl 555–565.
Cardiol2014;63:2751–2768. 113. RossR,BlairSN,ArenaR,ChurchTS,DesprésJP,FranklinBA,etal.Importanceof
93. OikonomouEK,KokkinidisDG,KampaktsisPN,AmirEA,MarwickTH,GuptaD, assessingcardiorespiratoryfitnessinclinicalpractice:acaseforfitnessasaclinical
etal.Assessmentofprognosticvalueofleftventriculargloballongitudinalstrainfor vitalsign:ascientificstatementfromtheAmericanHeartAssociation.Circulation
earlypredictionofchemotherapy-inducedcardiotoxicity:asystematicreviewand 2016;134:e653–e699.
meta-analysis.JAMACardiol2019;4:1007–1018. 114. SchmidD,LeitzmannMF.Cardiorespiratoryfitnessaspredictorofcancermortal-
94. PlanaJC,GalderisiM,BaracA,EwerMS,KyB,Scherrer-CrosbieM,etal.Expert ity:asystematicreviewandmeta-analysis.AnnOncol2015;26:272–278.
consensusformultimodalityimagingevaluationofadultpatientsduringandafter 115. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al.
cancertherapy:areportfromtheAmericanSocietyofEchocardiographyand Cardiorespiratoryfitnessandclassificationofriskofcardiovasculardiseasemortal-
the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc ity.Circulation2011;123:1377–1383.
Imaging2014;15:1063–1093. 116. HoltermannA,MarottJL,GyntelbergF,SøgaardK,MortensenOS,PrescottE,etal.
95. FarsalinosKE,DarabanAM,ÜnlüS,ThomasJD,BadanoLP,VoigtJU.Head-to-head Self-reportedcardiorespiratoryfitness:predictionandclassificationofriskofcar-
comparisonofgloballongitudinalstrainmeasurementsamongninedifferentven- diovascular disease mortality and longevity—a prospective investigation in the
dors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr CopenhagenCityHeartStudy.JAmHeartAssoc2015;4:e001495.
2015;28:1171–1181.e2. 117. StamatakisE,HamerM,O’DonovanG,BattyGD,KivimakiM.Anon-exercisetest-
96. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, et al. ingmethodforestimatingcardiorespiratoryfitness:associationswithall-causeand
Noninvasivemeasuresofventricular–arterialcouplingandcircumferentialstrain
cardiovascularmortalityinapooledanalysisofeightpopulation-basedcohorts.Eur
predictcancertherapeutics–relatedcardiacdysfunction.JACCCardiovascImaging HeartJ2013;34:750–758.
2016;9:1131–1141.
118. Wickramasinghe CD, Ayers CR, Das S, De Lemos JA, Willis BL, Berry JD.
97. NagiubM,NixonJV,KontosMC.Abilityofnonstraindiastolicparameterstopre- Predictionof30-yearriskforcardiovascularmortalitybyfitnessandriskfactorle-
dictdoxorubicin-inducedcardiomyopathy:asystematicreviewwithmeta-analysis.
vels:theCooperCenterLongitudinalStudy.CircCardiovascQualOutcomes2014;7:
CardiolRev2018;26:29–34.
597–602.
98. UpshawJN,FinkelmanB,HubbardRA,SmithAM,NarayanHK,ArndtL,etal.
119. Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al.
Comprehensiveassessmentofchangesinleftventriculardiastolicfunctionwith Cardiorespiratory fitness and survival following cancer diagnosis. Eur J Prev
contemporarybreastcancertherapy.JACCCardiovascImaging2020;13:198–210.
Cardiol2021;28:1242–1249.
99. PhillipsWJ,JohnsonC,LawA,TurekM,SmallAR,DentS,etal.Comparisonof
120. GroarkeJD,PayneDL,ClaggettB,MehraMR,GongJ,CaronJ,etal.Associationof
Framinghamriskscoreandchest-CTidentifiedcoronaryarterycalcificationin
post-diagnosiscardiorespiratoryfitnesswithcause-specificmortalityincancer.Eur
breastcancerpatientstopredictcardiovascularevents.IntJCardiol2019;289: HeartJQualCareClinOutcomes2020;6:315–322.
138–143.
121. JonesLM,StonerL,BrownC,BaldiJC,McLarenB.Cardiorespiratoryfitnesspre-
100. KnuutiJ,WijnsW,SarasteA,CapodannoD,BarbatoE,Funck-BrentanoC,etal.
dictscardiovascularhealthinbreastcancersurvivors,independentofbodycom-
2019ESCGuidelinesforthediagnosisandmanagementofchroniccoronarysyn-
position, age and time post-treatment completion. Breast Cancer 2019;26:
dromes:TheTaskForceforthediagnosisandmanagementofchroniccoronary 729–737.
syndromesoftheEuropeanSocietyofCardiology(ESC).EurHeartJ2020;41:
122. HaD,MazzonePJ,RiesAL,MalhotraA,FusterM.Theutilityofexercisetestingin
407–477.
patientswithlungcancer.JThoracOncol2016;11:1397–1410.
101. Lopez-MatteiJC,YangEH,FerencikM,BaldassarreLA,DentS,BudoffMJ.Cardiac
123. WestMA,LythgoeD,BarbenCP,NobleL,KempGJ,JackS,etal.Cardiopulmonary
computedtomographyincardio-oncology:JACC:CardioOncologyprimer.Cardio
Oncol2021;3:635–649. exercisevariablesareassociatedwithpostoperativemorbidityaftermajorcolonic
surgery:aprospectiveblindedobservationalstudy.BrJAnaesth2014;112:665–671.
102. ThavendiranathanP,NegishiT,SomersetE,NegishiK,PenickaM,LemieuxJ,etal.
124. WestMA,ParryMG,LythgoeD,BarbenCP,KempGJ,GrocottMPW,etal.
Strain-guided management of potentially cardiotoxic cancertherapy. J Am Coll
Cardiol2021;77:392–401. Cardiopulmonaryexercisetestingforthepredictionofmorbidityriskafterrectal
cancersurgery.BrJSurg2014;101:1166–1172.
103. EsmaeilzadehM,FresnoCMU,SomersetE,ShalmonT,AmirE,FanCPS,etal.A
125. HalvorsenS,MehilliJ,CasseseS,HallTS,AbdelhamidM,BarbatoE,etal.2022ESC
combinedechocardiographyapproachforthediagnosisofcancertherapy-related
guidelinesoncardiovascularassessmentandmanagementofpatientsundergoingnon-
cardiacdysfunctioninwomenwithearly-stagebreastcancer.JAMACardiol2022;7:
330–340.
cardiacsurgery.EurHeartJ2022;43:3826–3924.
104. DraftsBC,TwomleyKM,D’AgostinoR,LawrenceJ,AvisN,EllisLR,etal.Lowto 126. AminkengF,BhavsarAP,VisscherH,RassekhSR,LiY,LeeJW,etal.Acodingvari-
antinRARGconferssusceptibilitytoanthracycline-inducedcardiotoxicityinchild-
moderatedoseanthracycline-basedchemotherapyisassociatedwithearlynon-
invasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc
hoodcancer.NatGenet2015;47:1079–1084.
Imaging2013;6:877–885. 127. BlancoJG,SunCL,LandierW,ChenL,Esparza-DuranD,LeisenringW,etal.
105. GiuscaS,KorosoglouG,MontenbruckM,GeršakB,SchwarzAK,EschS,etal. Anthracycline-relatedcardiomyopathyafterchildhoodcancer:roleofpolymorph-
Multiparametricearlydetectionandpredictionofcardiotoxicityusingmyocardial
ismsincarbonylreductasegenes—areportfromtheChildren’sOncologyGroup.J
strain,T1andT2mapping,andbiochemicalmarkers:alongitudinalcardiacresonance
ClinOncol2012;30:1415–1421.
imagingstudyduring2yearsoffollow-up.CircCardiovascImaging2021;14:e012459. 128. WojnowskiL,KulleB,SchirmerM,SchlüterG,SchmidtA,RosenbergerA,etal.
106. DhirV,YanAT,NisenbaumR,SloninkoJ,ConnellyKA,BarfettJ,etal.Assessment NAD(P)Hoxidaseandmultidrugresistanceproteingeneticpolymorphismsareas-
ofleftventricularfunctionbyCMRversusMUGAscansinbreastcancerpatients sociated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:
receivingtrastuzumab:aprospectiveobservationalstudy.IntJCardiovascImaging
3754–3762.
2019;35:2085–2093. 129. JohnsonDB,BalkoJM,ComptonML,ChalkiasS,GorhamJ,XuY,etal.Fulminant
107. WalkerJ,BhullarN,Fallah-RadN,LytwynM,GolianM,FangT,etal.Roleofthree- myocarditiswithcombinationimmunecheckpointblockade.NEnglJMed2016;
dimensionalechocardiographyinbreastcancer:comparisonwithtwo-dimensional
375:1749–1755.
echocardiography,multiple-gatedacquisitionscans,andcardiacmagneticreson- 130. European Society of Cardiology. ESC CardioMed. 3rd ed. Oxford: Oxford
anceimaging.JClinOncol2010;28:3429–3436. UniversityPress;2018.
108. HuangH,NijjarPS,MisialekJR,BlaesA,DerricoNP,KazmirczakF,etal.Accuracy 131. MoslehiJJ.Cardiovasculartoxiceffectsoftargetedcancertherapies.NEnglJMed
ofleftventricularejectionfractionbycontemporarymultiplegatedacquisition 2016;375:1457–1467.
scanninginpatientswithcancer:comparisonwithcardiovascularmagneticreson- 132. AmeriP,CanepaM,AnkerMS,BelenkovY,Bergler-KleinJ,Cohen-SolalA,etal.
ance.JCardiovascMagnReson2017;19:34. Cancerdiagnosisinpatientswithheartfailure:epidemiology,clinicalimplications
109. HoppelerH,WeibelER.Limitsforoxygenandsubstratetransportinmammals.J andgapsinknowledge.EurJHeartFail2018;20:879–887.
ExpBiol1998;201:1051–1064. 133. D’AscenziF,AnselmiF,FiorentiniC,MannucciR,BonifaziM,MondilloS.Theben-
110. KaminskyLA,ImbodenMT,ArenaR,MyersJ.Referencestandardsforcardio- efitsofexerciseincancerpatientsandthecriteriaforexerciseprescriptionin
respiratoryfitnessmeasuredwithcardiopulmonaryexercisetestingusingcycleer- cardio-oncology.EurJPrevCardiol2021;28:725–735.
gometry:datafromtheFitnessRegistryandtheImportanceofExerciseNational 134. OgunmorotiO, AllenNB,Cushman M, MichosED,RundekT, RanaJS,et al.
Database(FRIEND)registry.MayoClinProc2017;92:228–233. Associationbetweenlife’ssimple7andnoncardiovasculardisease:themulti-ethnic
111. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Kaminsky LA. studyofatherosclerosis.JAmHeartAssoc2016;5:e003954.
Cardiorespiratory fitness and mortality in healthy men and women. J Am Coll 135. MichosED,MarshallCH.Healthylifestylebenefitsbothcancerandcardiovascular
Cardiol2018;72:2283–2292. disease:morebangforthebuck.JACCCardioOncology2021;3:675–677.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 119 ---
ESCGuidelines 4347
136.MurrayJ,BennettH,BezakE,PerryR.Theroleofexerciseinthepreventionof 158. MacedoAVS,HajjarLA,LyonAR,NascimentoBR,PutzuA,RossiL,etal.Efficacyof
cancertherapy-relatedcardiacdysfunctioninbreastcancerpatientsundergoing dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC
chemotherapy:systematicreview.EurJPrevCardiol2022;29:463–472. CardioOncology2019;1:68–79.
137.ScottJM,NilsenTS,GuptaD,JonesLW.Exercisetherapyandcardiovasculartox- 159. LiX,LiY,ZhangT,XiongX,LiuN,PangB,etal.Roleofcardioprotectiveagentson
icityincancer.Circulation2018;137:1176–1191. chemotherapy-induced heart failure: a systematic review and network
138.WilliamsB,ManciaG,SpieringW,RoseiEA,AziziM,BurnierM,etal.2018ESC/ meta-analysisofrandomizedcontrolledtrials.PharmacolRes2020;151:104577.
ESHGuidelinesforthemanagementofarterialhypertension.EurHeartJ2018; 160. FangK,ZhangY,LiuW,HeC.Effectsofangiotensin-convertingenzymeinhibitor/
39:3021–3104. angiotensinreceptorblockeruseoncancertherapy-relatedcardiacdysfunction:a
139.CosentinoF,GrantPJ,AboyansV,BaileyCJ,CerielloA,DelgadoV,etal.2019ESC meta-analysisofrandomizedcontrolledtrials.HeartFailRev2021;26:101–109.
Guidelinesondiabetes,pre-diabetes,andcardiovasculardiseasesdevelopedincol- 161. ShapiraJ,GotfriedM,LishnerM,RavidM.Reducedcardiotoxicityofdoxorubicinby
laborationwiththeEASD.EurHeartJ2020;41:255–323. a6-hourinfusionregimen.Aprospectiverandomizedevaluation.Cancer1990;65:
140.MachF,BaigentC,CatapanoAL,KoskinasKC,CasulaM,BadimonL,etal.2019 870–873.
ESC/EASGuidelinesforthemanagementofdyslipidaemias:lipidmodificationtore- 162. HensleyML,HagertyKL,KewalramaniT,GreenDM,MeropolNJ,WassermanTH,
ducecardiovascularrisk.EurHeartJ2020;41:111–188. etal.AmericanSocietyofClinicalOncology2008clinicalpracticeguidelineupdate:
141.Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al. use of chemotherapyand radiation therapy protectants. J Clin Oncol 2009;27:
Cardio-oncology drug interactions: a scientific statement from the American 127–145.
HeartAssociation.Circulation2022;145:e811–e838. 163. EuropeanMedicinesAgency.Savene:EPAR—ProductInformation(Internet)2008
142.FerdinandyP,BaczkóI,BencsikP,GiriczZ,GörbeA,PacherP,etal.Definitionof (updated2019).
hiddendrugcardiotoxicity:paradigmchangeincardiacsafetytestinganditsclinical 164. VejpongsaP,YehETH.Preventionofanthracycline-inducedcardiotoxicity:chal-
implications.EurHeartJ2019;40:1771–1777. lengesandopportunities.JAmCollCardiol2014;64:938–945.
143.KalamK,MarwickTH.Roleofcardioprotectivetherapyforpreventionofcardio- 165. YamaguchiN,FujiiT,AoiS,KozuchPS,HortobagyiGN,BlumRH.Comparisonof
toxicitywithchemotherapy:asystematicreviewandmeta-analysis.EurJCancer cardiaceventsassociatedwithliposomaldoxorubicin,epirubicinanddoxorubicinin
2013;49:2900–2909. breastcancer:aBayesiannetworkmeta-analysis.EurJCancer2015;51:2314–2320.
144.ChenJ,LongJB,HurriaA,OwusuC,SteingartRM,GrossCP.Incidenceofheart 166. SwainSM,WhaleyFS,GerberMC,EwerMS,BianchineJR,GamsRA.Delayedad-
failureorcardiomyopathyafteradjuvanttrastuzumabtherapyforbreastcancer. ministrationofdexrazoxaneprovidescardioprotectionforpatientswithadvanced
JAmCollCardiol2012;60:2504–2512. breastcancertreatedwithdoxorubicin-containingtherapy.JClinOncol1997;15:
145.BoschX,RoviraM,SitgesM,DomènechA,Ortiz-PérezJT,DeCaraltTM,etal. 1333–1340.
Enalaprilandcarvedilolforpreventingchemotherapy-inducedleftventricularsys- 167. vanDalenEC,CaronHN,DickinsonHO,KremerLCM.Cardioprotectiveinter-
tolicdysfunctioninpatientswithmalignanthemopathies:theOVERCOMEtrial ventionsforcancerpatientsreceivinganthracyclines.CochraneDatabaseSystRev
(preventiOnofleftVentriculardysfunctionwithEnalaprilandcaRvedilolinpatients 2011;2011:CD003917.
submitted to intensive ChemOtherapy for the treatment of Malignant 168. WaterhouseDN,TardiPG,MayerLD,BallyMB.Acomparisonofliposomalfor-
hEmopathies).JAmCollCardiol2013;61:2355–2362. mulationsofdoxorubicinwithdrugadministeredinfreeform:changingtoxicity
146.Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, profiles.DrugSaf2001;24:903–920.
Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of 169. VerellenD,DeRidderM,LinthoutN,TournelK,SoeteG,StormeG.Innovationsin
chemotherapy-relatedcardiotoxicity:theCECCYtrial.JAmCollCardiol2018;71: image-guidedradiotherapy.NatRevCancer2007;7:949–960.
2281–2290. 170. DeRuysscherD,NiedermannG,BurnetNG,SivaS,LeeAWM,Hegi-JohnsonF.
147.Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Radiotherapytoxicity.NatRevDisPrim2019;5:13.
Anthracycline-inducedcardiotoxicity:amulticenterrandomisedtrialcomparing 171. MeattiniI,PoortmansPM,AznarMC,BecheriniC,BonzanoE,CardinaleD,etal.
two strategies for guiding prevention with enalapril: The International Associationofbreastcancerirradiationwithcardiactoxiceffects:anarrativere-
CardioOncologySociety-onetrial.EurJCancer2018;94:126–137. view.JAMAOncol2021;7:924–932.
148.AkpekM,OzdogruI,SahinO,InancM,DoganA,YaziciC,etal.Protectiveeffectsof 172. BanfillK,GiulianiM,AznarM,FranksK,McWilliamA,SchmittM,etal.Cardiactox-
spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail icityofthoracicradiotherapy:existingevidenceandfuturedirections.JThoracOncol
2015;17:81–89. 2021;16:216–227.
149.AcarZ,KaleA,TurgutM,DemircanS,DurnaK,DemirS,etal.Efficiencyofator- 173. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al.
vastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiovascularmanifestationsfromtherapeuticradiation:amultidisciplinaryex-
Cardiol2011;58:988–989. pertconsensusstatementfromtheInternationalCardio-OncologySociety.JACC
150.GulatiG,HeckSL,ReeAH,HoffmannP,Schulz-MengerJ,FagerlandMW,etal. CardioOncology2021;3:360–380.
Prevention of cardiac dysfunction during adjuvant breast cancer therapy 174. KirwanCC,ColesCE,BlissJ,KirwanC,KilburnL,FoxL,etal.It’sPRIMETIME.
(PRADA):a2×2factorial,randomized,placebo-controlled,double-blindclinical Postoperativeavoidanceofradiotherapy:biomarkerselectionofwomenatvery
trialofcandesartanandmetoprolol.EurHeartJ2016;37:1671–1680. lowriskoflocalrecurrence.ClinOncol2016;28:594–596.
151.GulatiG,HeckSL,RøsjøH,ReeAH,HoffmannP,HagveTA,etal.Neurohormonal 175. CardinaleD,ColomboA,SandriMT,LamantiaG,ColomboN,CivelliM,etal.
blockadeandcirculatingcardiovascularbiomarkersduringanthracyclinetherapyin Preventionofhigh-dosechemotherapy-inducedcardiotoxicityinhigh-riskpatients
breast cancer patients: results from the PRADA (Prevention of Cardiac byangiotensin-convertingenzymeinhibition.Circulation2006;114:2474–2481.
DysfunctionDuringAdjuvantBreastCancerTherapy)study.JAmHeartAssoc 176. Abdel-QadirH,BobrowskiD,ZhouL,AustinPC,Calvillo-ArgüellesO,AmirE,
2017;6:e006513. etal.Statinexposureandriskofheartfailureafteranthracycline-ortrastuzumab-
152.GuglinM,KrischerJ,TamuraR,FinkA,Bello-MatricariaL,McCaskill-StevensW, basedchemotherapyforearlybreastcancer:apropensityscore⍰matchedcohort
etal.Randomizedtrialoflisinoprilversuscarvediloltopreventtrastuzumabcardi- study.JAmHeartAssoc2021;10:e018393.
otoxicityinpatientswithbreastcancer.JAmCollCardiol2019;73:2859–2868. 177. Calvillo-ArgüellesO,Abdel-QadirH,MichalowskaM,BilliaF,SuntheralingamS,
153.Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. AmirE,etal.CardioprotectiveeffectofstatinsinpatientswithHER2-positive
Multidisciplinary approach to novel therapies in cardio-oncology research breastcancerreceivingtrastuzumabtherapy.CanJCardiol2019;35:153–159.
(MANTICORE 101-Breast): a randomized trial for the prevention of 178. SeiceanS,SeiceanA,PlanaJC,BuddGT,MarwickTH.Effectofstatintherapyonthe
trastuzumab-associatedcardiotoxicity.JClinOncol2017;35:870–877. riskforincidentheartfailureinpatientswithbreastcancerreceivinganthracycline
154.BoekhoutAH,GietemaJA,KerklaanBM,VanWerkhovenED,AltenaR,Honkoop chemotherapy:anobservationalclinicalcohortstudy.JAmCollCardiol2012;60:
A, et al. Angiotensin II receptor inhibition with candesartan to prevent 2384–2390.
trastuzumab-relatedcardiotoxiceffectsinpatientswithearlybreastcanceraran- 179. ChotenimitkhunR,D’AgostinoR,LawrenceJA,HamiltonCA,JordanJH,VasuS,
domizedclinicaltrial.JAMAOncol2016;2:1030–1037. etal.Chronicstatinadministrationmayattenuateearlyanthracycline-associated
155.Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A. declinesinleftventricularejectionfunction.CanJCardiol2015;31:302–307.
Prevention of anthracycline-induced cardiotoxicity: a systematic review and 180. ObasiM,AbovichA,VoJB,GaoY,PapatheodorouSI,NohriaA,etal.Statinsto
meta-analysis.InternEmergMed2021;16:477–486. mitigatecardiotoxicityincancerpatientstreatedwithanthracyclinesand/ortrastu-
156.HuangS,ZhaoQ,YangZG,DiaoKY,HeY,ShiK,etal.Protectiveroleofbeta- zumab: a systematic review and meta-analysis. Cancer Causes Control 2021;32:
blockers in chemotherapy-induced cardiotoxicity—a systematic review and 1395–1405.
meta-analysisofcarvedilol.HeartFailRev2019;24:325–333. 181. KimJ,NishimuraY,KewcharoenJ,YessJ.Statinusecanattenuatethedeclineinleft
157.VaduganathanM,HirjiSA,QamarA,BajajN,GuptaA,ZahaVG,etal.Efficacyof ventricularejectionfractionandtheincidenceofcardiomyopathyincardiotoxic
neurohormonal therapies in preventing cardiotoxicity in patients with cancer chemotherapyrecipients:asystematicreviewandmeta-analysis.JClinMed2021;
undergoingchemotherapy.JACCCardioOncology2019;1:54–65. 10:3731.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 120 ---
4348 ESCGuidelines
182. SanfilippoKM,KellerJ,GageBF,LuoS,WangTF,MoskowitzG,etal.Statinsare 207. YancyCW,JessupM,BozkurtB,ButlerJ,CaseyDE,ColvinMM,etal.2017ACC/
associated with reduced mortality in multiple myeloma. J Clin Oncol 2016;34: AHA/HFSAfocusedupdateofthe2013ACCF/AHAguidelineforthemanagement
4008–4014. ofheartfailure:areportoftheAmericanCollegeofCardiology/AmericanHeart
183. AfzalA,FialaMA,GageBF,WildesTM,SanfilippoK.Statinsreducemortalityin Association Task Force on Clinical Practice Guidelines and the Heart Failure
multiplemyeloma:apopulation-basedUSstudy.ClinLymphomaMyelomaLeuk SocietyofAmerica.Circulation2017;136:e137–e161.
2020;20:e937–e943. 208. CardinaleD,ColomboA,BacchianiG,TedeschiI,MeroniCA,VegliaF,etal.Early
184. NabatiM,JanbabaiG,EsmailianJ,YazdaniJ.Effectofrosuvastatininpreventing detectionofanthracyclinecardiotoxicityandimprovementwithheartfailurether-
chemotherapy-inducedcardiotoxicityinwomenwithbreastcancer:arandomized, apy.Circulation2015;131:1981–1988.
single-blind,placebo-controlledtrial.JCardiovascPharmacolTher2019;24:233–241. 209. WangL,TanTC,HalpernEF,NeilanTG,FrancisSA,PicardMH,etal.Majorcardiac
185. ShahidI,YamaniN,AliA,KumarP,FigueredoV,UnzekS,etal.Meta-analysisevalu- events and the value of echocardiographic evaluation in patients receiving
atingtheuseofstatinstoattenuatecardiotoxicityincancerpatientsreceivingan- anthracycline-basedchemotherapy.AmJCardiol2015;116:442–446.
thracyclines and trastuzumab-based chemotherapy. Am J Cardiol 2021;156: 210. Abu-KhalafMM,SafonovA,StrattonJ,WangS,HatzisC,ParkE,etal.Examiningthe
142–145. cost-effectivenessofbaselineleftventricularfunctionassessmentamongbreast
186. NabatiM,JanbabaiG,BaghyariS,EsmailiK,YazdaniJ.Cardioprotectiveeffectsof cancerpatientsundergoinganthracycline-basedtherapy.BreastCancerResTreat
carvedilolininhibitingdoxorubicin-inducedcardiotoxicity.JCardiovascPharmacol 2019;176:261–270.
2017;69:279–285. 211. LenihanDJ,StevensPL,MasseyM,PlanaJC,AraujoDM,FanaleMA,etal.Theutility
187. WarringtonL,AbsolomK,ConnerM,KellarI,ClaytonB,AyresM,etal.Electronic ofpoint-of-carebiomarkerstodetectcardiotoxicityduringanthracyclinechemo-
systemsforpatientstoreportandmanagesideeffectsofcancertreatment:system- therapy:afeasibilitystudy.JCardFail2016;22:433–438.
aticreview.JMedInternetRes2019;21:e10875. 212. Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, et al.
188. López-FernándezT,MartínGarcíaA,SantaballaBeltránA,MonteroLuisÁ,García Circulating biomarkers and cardiac function over 3 years after chemotherapy
SanzR,MazónRamosP,etal.Cardio-onco-hematologyinclinicalpractice.Position withanthracyclines:theICOS-ONEtrial.ESCHeartFail2020;7:1452–1466.
paperandrecommendations.RevEspañolaCardiol(EnglishEd)2017;70:474–486. 213. JonesM,O’GormanP,KellyC,MahonN,FitzgibbonMC.High-sensitivecardiac
189. LynceF,BaracA,GengX,DangC,YuAF,SmithKL,etal.Prospectiveevaluationof troponin-Ifacilitatestimelydetectionofsubclinicalanthracycline-mediatedcardiac
thecardiacsafetyofHER2-targetedtherapiesinpatientswithHER2-positivebreast injury.AnnClinBiochem2017;54:149–157.
cancerandcompromisedheartfunction:theSAFE-HEaRtstudy.BreastCancerRes 214. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al.
Treat2019;175:595–603. CombinationtherapiesforthetreatmentofHER2-positivebreastcancer:current
190. Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al. andfutureprospects.ExpertRevAnticancerTher2018;18:629–649.
Comparisonoflong-termoutcomeinanthracycline-relatedversusidiopathicdi- 215. YardenY,SliwkowskiMX.UntanglingtheErbBsignallingnetwork.NatRevMolCell
latedcardiomyopathy:asinglecentreexperience.EurJHeartFail2018;20:898–906. Biol2001;2:127–137.
191. ChowSL,MaiselAS,AnandI,BozkurtB,DeBoerRA,FelkerGM,etal.Roleofbio- 216. BelmonteF,DasS,Sysa-ShahP,SivakumaranV,StanleyB,GuoX,etal.ErbB2over-
markersfortheprevention,assessment,andmanagementofheartfailure:ascien- expressionupregulatesantioxidantenzymes,reducesbasallevelsofreactiveoxy-
tific statement from the American Heart Association. Circulation 2017;135: genspecies,andprotectsagainstdoxorubicincardiotoxicity.AmJPhysiolHeartCirc
e1054–e1091.Erratumin:Circulation2017;136:e345. Physiol2015;309:H1271–H1280.
192. DeBoerRA,DanielsLB,MaiselAS,JanuzziJL.Stateoftheart:newerbiomarkersin 217. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer
heartfailure.EurJHeartFail2015;17:559–569. treatment-inducedcardiotoxicity.ExpertOpinDrugSaf2017;16:1021–1038.
193. PiekA,DuW,deBoerRA,SilljéHHW.Novelheartfailurebiomarkers:whydowe 218. deAzambujaE,PondeN,ProcterM,RastogiP,CecchiniRS,LambertiniM,etal.A
failtoexploittheirpotential?CritRevClinLabSci2018;55:246–263. pooledanalysisofthecardiaceventsinthetrastuzumabadjuvanttrials.Breast
194. DuW,PiekA,MarloesSchoutenE,vandeKolkCWA,MuellerC,MebazaaA,etal. CancerResTreat2020;179:161–171.
Plasmalevelsofheartfailurebiomarkersareprimarilyareflectionofextracardiac 219. EigerD,PondéNF,Agbor-TarhD,Moreno-AspitiaA,PiccartM,HilbersFS,etal.
production.Theranostics2018;8:4155–4169. Long-termcardiacoutcomesofpatientswithHER2-positivebreastcancertreated
195. SuthaharN,LauES,BlahaMJ,PaniaguaSM,LarsonMG,PsatyBM,etal.Sex-specific in the adjuvant lapatinib and/or trastuzumab treatment optimization trial. Br J
associationsofcardiovascularriskfactorsandbiomarkerswithincidentheartfail- Cancer2020;122:1453–1460.
ure.JAmCollCardiol2020;76:1455–1465. 220. Tan-ChiuE,YothersG,RomondE,GeyerCE,EwerM,KeefeD,etal.Assessment
196. BracunV,AboumsallemJP,vanderMeerP,deBoerRA.Cardiacbiomarkersinpa- ofcardiacdysfunctioninarandomizedtrialcomparingdoxorubicinandcyclophos-
tientswithcancer:considerations,clinicalimplications,andfutureavenues.Curr phamidefollowedbypaclitaxel,withorwithouttrastuzumabasadjuvanttherapyin
OncolRep2020;22:67. node-positive, HER2-overexpressing breast cancer. J Clin Oncol 2005;23:
197. AnanthanK,LyonAR.Theroleofbiomarkersincardio-oncology.JCardiovasc 7811–7819.
TranslRes2020;13:431–450. 221. MartinM,PressM,PhD,MackeyJ,GlaspyJ,ChanA,etal.Adjuvanttrastuzumabin
198. López-FernándezT,ThavendiranathanP.Emergingcardiacimagingmodalitiesfor HER2-positivebreastcancer.NEJM2011;365:1273–1283.
theearlydetectionofcardiotoxicityduetoanticancertherapies.RevEspañola 222. SmithI,ProcterM,GelberRD,GuillaumeS,FeyereislovaA,DowsettM,etal.
Cardiol(EnglishEd)2017;70:487–495. 2-yearfollow-upoftrastuzumabafteradjuvantchemotherapyinHER2-positive
199. EschenhagenT,ForceT,EwerMS,DeKeulenaerGW,SuterTM,AnkerSD,etal. breastcancer:arandomisedcontrolledtrial.Lancet2007;369:29–36.
Cardiovascularsideeffectsofcancertherapies:apositionstatementfromthe 223. Piccart-GebhartMJ,ProcterM,Leyland-JonesB,GoldhirschA,UntchM,SmithI,
HeartFailureAssociationoftheEuropeanSocietyofCardiology.EurJHeartFail etal.TrastuzumabafteradjuvantchemotherapyinHER2-positivebreastcancer.
2011;13:1–10. NEnglJMed2005;353:1659–1672.
200. KeramidaK,FarmakisD,LópezFernándezT,LancellottiP.Focusedechocardiog- 224. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al.
raphyincardio-oncology.Echocardiography2020;37:1149–1158. TrastuzumabplusadjuvantchemotherapyforoperableHER2-positivebreastcan-
201. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in cer.NEnglJMed2005;353:1673–1684.
cardio-oncology.JACCCardioOncology2020;2:677–689. 225. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de
202. NegishiK,NegishiT,HareJL,HaluskaBA,PlanaJC,MarwickTH.Independentand AzambujaE,etal.11years’follow-upoftrastuzumabafteradjuvantchemotherapy
incrementalvalueofdeformationindicesforpredictionoftrastuzumab-induced in HER2-positive early breastcancer: final analysis of the HERceptin Adjuvant
cardiotoxicity.JAmSocEchocardiogr2013;26:493–498. (HERA)trial.Lancet2017;389:1195–1205.
203. NegishiT,ThavendiranathanP,PenickaM,LemieuxJ,AakhusS,MiyazakiS,etal. 226. TanTC,BourasS,SawayaH,SebagIA,CohenV,PicardMH,etal.Timetrendsof
Cardioprotectionusingstrain-guidedmanagementofpotentiallycardiotoxiccan- leftventricularejectionfractionandmyocardialdeformationindicesinacohortof
cer therapy: 1 year results of the SUCCOUR trial. Eur Heart J 2020;41: womenwithbreastcancertreatedwithanthracyclines,taxanes,andtrastuzumab.J
ehaa946.3282. AmSocEchocardiogr2015;28:509–514.
204. VallabhaneniS,ZhangKW,AlvarezJA,JoshuaC,HenningDM,WoodardPK,etal. 227. BenKridisW,SghaierS,CharfeddineS,ToumiN,DaoudJ,KammounS,etal.A
Roleofcardiovascularmagneticresonanceinearlydetectionandtreatmentofcar- prospective study about trastuzumab-induced cardiotoxicity in HER2-positive
diacdysfunctioninoncologypatients.IntJCardiovascImaging2021;37:3003–3017. breastcancer.AmJClinOncolCancerClinTrials2020;43:510–516.
205. LapinskasT,Hireche-ChikaouiH,ZieschangV,ErleyJ,StehningC,GebkerR,etal. 228. YangZY,WangW,WangX,QinZQ.Cardiotoxicityofepidermalgrowthfactor
Effectofcomprehensiveinitialtrainingonthevariabilityofleftventricularmeasures receptor2-targeteddrugsforbreastcancer.FrontPharmacol2021;12:741451.
usingfast-SENCcardiacmagneticresonanceimaging.SciRep2019;9:12223. 229. TaskForceMembers,MontalescotG,SechtemU,AchenbachS,AndreottiF,Arden
206. KorosoglouG,GiuscaS,MontenbruckM,PatelAR,LapinskasT,GötzeC,etal.Fast C,etal.2013ESCguidelinesonthemanagementofstablecoronaryarterydisease:
strain-encodedcardiacmagneticresonancefordiagnosticclassificationandrisk the Task Force on the management of stable coronary artery disease of the
stratificationofheartfailurepatients.JACCCardiovascImaging2021;14:1177–1188. EuropeanSocietyofCardiology.EurHeartJ2013;34:2949–3003.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 121 ---
ESCGuidelines 4349
230.Padegimas A, Carver JR. How to diagnose and manage patients with vascularendothelialgrowthfactorsignalingpathwayinhibitors.JNatlCancerInst
fluoropyrimidine-induced chest pain: a single center approach. JACC 2010;102:596–604.
CardioOncology2020;2:650–654. 256. BarberMC,MauroMJ,MoslehiJ.Cardiovascularcareofpatientswithchronicmye-
231.KwakmanJJM,SimkensLHJ,MolL,KokWEM,KoopmanM,PuntCJA.Incidenceof loidleukemia(CML)ontyrosinekinaseinhibitor(TKI)therapy.Hematology2017;
capecitabine-relatedcardiotoxicityindifferenttreatmentschedulesofmetastatic 2017:110–114.
colorectalcancer:aretrospectiveanalysisoftheCAIROstudiesoftheDutch 257. MoslehiJJ,DeiningerM.Tyrosinekinaseinhibitor-associatedcardiovasculartoxicity
ColorectalCancerGroup.EurJCancer2017;76:93–99. inchronicmyeloidleukemia.JClinOncol2015;33:4210–4218.
232.FrickhofenN,BeckFJ,JungB,FuhrHG,AndraschH,SigmundM.Capecitabinecan 258. LiW,CroceK,SteensmaDP,McDermottDF,Ben-YehudaO,MoslehiJ.Vascular
induce acutecoronarysyndromesimilar to5-fluorouracil.Ann Oncol2002;13: andmetabolicimplicationsofnoveltargetedcancertherapies:focusonkinasein-
797–801. hibitors.JAmCollCardiol2015;66:1160–1178.
233.PolkA,VistisenK,Vaage-NilsenM,NielsenDL.Asystematicreviewofthepatho- 259. BuzaV,RajagopalanB,CurtisAB.Cancertreatment-inducedarrhythmias:focuson
physiologyof5-fluorouracil-inducedcardiotoxicity.BMCPharmacolToxicol2014; chemotherapy and targeted therapies. Circ Arrhythmia Electrophysiol 2017;10:
15:47. e005443.
234.Edvardsen T, AschFM, Davidson B,Delgado V,DeMaria A, DilsizianV, et al. 260. HerrmannJ,YangEH,IliescuCA,CilingirogluM,CharitakisK,HakeemA,etal.
Non-invasiveimagingincoronarysyndromes:recommendationsoftheEuropean Vasculartoxicitiesofcancertherapies:theoldandthenew—anevolvingavenue.
Association of Cardiovascular Imaging and the American Society of Circulation2016;133:1272–1289.
Echocardiography, in collaboration with the American Society of Nuclear 261. CirmiS,ElAbdA,LetinierL,NavarraM,SalvoF.Cardiovasculartoxicityoftyrosine
Cardiology, Society of Cardiovascular Comuted Tomography, and Society for kinaseinhibitorsusedinchronicmyeloidleukemia:ananalysisoftheFDAadverse
Cardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022;23: eventreportingsystemdatabase(FAERS).Cancers(Basel)2020;12:826.
e6–e33. 262. GribbenJG,BoschF,CymbalistaF,GeislerCH,GhiaP,HillmenP,etal.Optimising
235.SaraJD,KaurJ,KhodadadiR,RehmanM,LoboR,ChakrabartiS,etal.5-fluorouracil outcomesforpatientswithchroniclymphocyticleukaemiaonibrutinibtherapy:
andcardiotoxicity:areview.TherAdvMedOncol2018;10:1758835918780140. Europeanrecommendationsforclinicalpractice.BrJHaematol2018;180:666–679.
236.BairSM,ChoueiriTK,MoslehiJ.Cardiovascularcomplicationsassociatedwithno- 263. ShanafeltTD,ParikhSA,NoseworthyPA,GoedeV,ChaffeeKG,BahloJ,etal.
velangiogenesisinhibitors:emergingevidenceandevolvingperspectives.Trends Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk
CardiovascMed2013;23:104–113. Lymphoma2017;58:1630–1639.
237.ChoueiriTK,SchutzFAB,JeY,RosenbergJE,BellmuntJ.Riskofarterialthrombo- 264. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al.
emboliceventswithsunitinibandsorafenib:asystematicreviewandmeta-analysis Hypertension and incident cardiovascular events following ibrutinib initiation.
ofclinicaltrials.JClinOncol2010;28:2280–2285. Blood2019;134:1919–1928.
238.ShahRR,MorganrothJ,ShahDR.Cardiovascularsafetyoftyrosinekinaseinhibi- 265. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al.
tors:Withaspecialfocusoncardiacrepolarisation(QTinterval).DrugSaf2013; Characterizationofatrialfibrillationadverseeventsreportedinibrutinibrando-
36:295–316. mizedcontrolledregistrationtrials.Haematologica2017;102:1796–1805.
239.Abdel-QadirH,EthierJL,LeeDS,ThavendiranathanP,AmirE.Cardiovasculartox- 266. López-Fernández,T,CanalesM,FarmakisD,García-SanzR,BoschF,LoscertalesJ,
icityofangiogenesisinhibitorsintreatmentofmalignancy:asystematicreviewand etal.Ibrutinib-associatedatrialfibrillation:apracticalapproach.AnnHematolOncol
meta-analysis.CancerTreatRev2017;53:120–127. 2018;5:1203.
240.DesaiA,NoorA,JoshiS,KimAS.Takotsubocardiomyopathyincancerpatients. 267. SalemJE,ManouchehriA,BretagneM,Lebrun-VignesB,GroarkeJD,JohnsonDB,
Cardio-Oncology2019;5:7. etal.Cardiovasculartoxicitiesassociatedwithibrutinib.JAmCollCardiol2019;74:
241.NazerB,HumphreysBD,MoslehiJ.Effectsofnovelangiogenesisinhibitorsforthe 1667–1678.
treatment of cancer on the cardiovascular system: focus on hypertension. 268. Abdel-QadirH,SabrieN,LeongD,PangA,AustinPC,PricaA,etal.Cardiovascular
Circulation2011;124:1687–1691. riskassociatedwithibrutinibuseinchroniclymphocyticleukemia:apopulation-
242.ShahCP,MorebJS.Cardiotoxicityduetotargetedanticanceragents:agrowing basedcohortstudy.JClinOncol2021;39:3453–3462.
challenge.TherAdvCardiovascDis2019;13:1753944719843435. 269. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al.
243.AziziM,ChedidA,OudardS.Homeblood-pressuremonitoringinpatientsreceiv- Acalabrutinibversusibrutinibinpreviouslytreatedchroniclymphocyticleukemia:
ingsunitinib.NEnglJMed2008;358:95–97. resultsofthefirstrandomizedphaseIIItrial.JClinOncol2021;39:3441–3452.
244.HamnvikOPR,ChoueiriTK,TurchinA,McKayRR,GoyalL,DavisM,etal.Clinical 270. CommonTerminologyCriteriaforAdverseEvents(CTCAE)v6.0.NationalCancerInstitute,
riskfactorsforthedevelopmentofhypertensioninpatientstreatedwithinhibitors 2022.https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
oftheVEGFsignalingpathway.Cancer2015;121:311–319. 271. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al.
245.GhataliaP,MorganCJ,JeY,NguyenPL,TrinhQD,ChoueiriTK,etal.Congestive Cardiovascularadverseeventsinpatientswithchroniclymphocyticleukemiareceiv-
heartfailurewithvascularendothelialgrowthfactorreceptortyrosinekinaseinhi- ingacalabrutinibmonotherapy:pooledanalysisof762patients.Haematologica2022;
bitors.CritRevOncolHematol2015;94:228–237. 107:1335–1346.
246.NholaLF,AbdelmoneimSS,VillarragaHR,KohliM,GrotheyA,BordunKA,etal. 272. SvennbergE,TjongF,GoetteA,AkoumN,DiBiaiseL,BordacharP,etal.Howtouse
Echocardiographicassessmentforthedetectionofcardiotoxicityduetovascular digitaldevicestodetectandmanagearrhythmias:anEHRApracticalguide.Europace.
endothelialgrowthfactorinhibitortherapyinmetastaticrenalcellandcolorectal 2022;24:979–1005.
cancers.JAmSocEchocardiogr2019;32:267–276. 273. HindricksG,PotparaT,DagresN,ArbeloE,BaxJJ,Blomström-LundqvistC,etal.
247.UraizeeI,ChengS,MoslehiJ.Reversiblecardiomyopathyassociatedwithsunitinib 2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillationdevel-
andsorafenib.NEnglJMed2011;365:1649–1650. opedincollaborationwiththeEuropeanAssociationforCardio-ThoracicSurgery
248.PandeyAK,SinghiEK,ArroyoJP,IkizlerTA,GouldER,BrownJ,etal.Mechanisms (EACTS).EurHeartJ2021;42:373–498.
ofVEGF(vascularendothelialgrowthfactor)inhibitor-associatedhypertensionand 274. McMullenJR,BoeyEJ,OoiJYY,SeymourJF,KeatingMJ,TamCS.Ibrutinibincreases
vasculardisease.Hypertension2018;71:E1–E8. theriskofatrialfibrillation,potentiallythroughinhibitionofcardiacPI3K-Aktsignal-
249.ZangJ,WuS,TangL,XuX,BaiJ,DingC,etal.IncidenceandriskofQTcinterval ing.Blood2014;124:3829–3830.
prolongationamongcancerpatientstreatedwithvandetanib:asystematicreview 275. LeeHJ,ChiharaD,WangM,MouhayarE,KimP.Ibrutinib-relatedatrialfibrillationin
andmeta-analysis.PLoSOne2012;7:e30353. patientswithmantlecelllymphoma.LeukLymphoma2016;57:2914–2916.
250.GhataliaP,JeY,KaymakcalanMD,SonpavdeG,ChoueiriTK.QTcintervalpro- 276. RajkumarSV.Multiplemyeloma:2020updateondiagnosis,risk-stratificationand
longationwithvascularendothelialgrowthfactorreceptortyrosinekinaseinhibi- management.AmJHematol2020;95:548–567.
tors.BrJCancer2015;112:296–305. 277. KumarSK,DispenzieriA,LacyMQ,GertzMA,BuadiFK,PandeyS,etal.Continued
251.AlexandreJ,SalemJE,MoslehiJ,SassierM,RopertC,CautelaJ,etal.Identificationof improvementinsurvivalinmultiplemyeloma:changesinearlymortalityandout-
anticancerdrugsassociatedwithatrialfibrillation:analysisoftheWHOpharmacov- comesinolderpatients.Leukemia2014;28:1122–1128.
igilancedatabase.EurHeartJCardiovascPharmacother2021;7:312–320. 278. WillisMS,PattersonC.Proteotoxicityandcardiacdysfunction—Alzheimer’sdis-
252.EMA.Medicines|EuropeanMedicinesAgency.EurMedAgencySciMedHealn.d. easeoftheheart?NEnglJMed2013;368:455–464.
253.FDA.Drugs@FDA:FDA-ApprovedDrugs.FDAUSFoodDrugAdmn.d. 279. StewartAK,RajkumarSV,DimopoulosMA,MassziT,ŠpičkaI,OriolA,etal.
254.SteingartRM,BakrisGL,ChenHX,ChenMH,ForceT,IvySP,etal.Managementof Carfilzomib,lenalidomide,anddexamethasoneforrelapsedmultiplemyeloma.N
cardiactoxicityinpatientsreceivingvascularendothelialgrowthfactorsignaling EnglJMed2015;372:142–152.
pathwayinhibitors.AmHeartJ2012;163:156–163. 280. ChariA,KeithStewartA,RussellSD,MoreauP,HerrmannJ,BanchsJ,etal.Analysis
255.MaitlandML,BakrisGL,BlackHR,ChenHX,DurandJB,ElliottWJ,etal.Initialas- ofcarfilzomibcardiovascularsafetyprofileacrossrelapsedand/orrefractorymul-
sessment,surveillance,andmanagementofbloodpressureinpatientsreceiving tiplemyelomaclinicaltrials.BloodAdv2018;2:1633–1644.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 122 ---
4350 ESCGuidelines
281. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. 303. LendvaiN,TsakosI,DevlinSM,SchafferWL,HassounH,LesokhinAM,etal.
Carfilzomib-associated cardiovascular adverse events: a systematic review and Predictive biomarkers and practical considerations in the management of
meta-analysis.JAMAOncol2018;4:e174519. carfilzomib-associatedcardiotoxicity.LeukLymphoma2018;59:1981–1985.
282. MauriL,ElmariahS,YehRW,CutlipDE,StegPG,WindeckerS,etal.Causesoflate 304. PalumboA,CavoM,BringhenS,ZamagniE,RomanoA,PatriarcaF,etal.Aspirin,
mortalitywithdualantiplatelettherapyaftercoronarystents.EurHeartJ2016;37: warfarin,orenoxaparinthromboprophylaxisinpatientswithmultiplemyeloma
378–385. treatedwiththalidomide:aphaseIII,open-label,randomizedtrial.JClinOncol
283. GavazzoniM,LombardiCM,VizzardiE,GorgaE,SciattiE,RossiL,etal.Irreversible 2011;29:986–993.
proteasomeinhibitionwithcarfilzomibasfirstlinetherapyinpatientswithnewly 305. LaroccaA,CavalloF,BringhenS,DiRaimondoF,FalangaA,EvangelistaA,etal.
diagnosedmultiplemyeloma:earlyinvivocardiovasculareffects.EurJPharmacol Aspirinorenoxaparinthromboprophylaxisforpatientswithnewlydiagnosedmul-
2018;838:85–90. tiplemyelomatreatedwithlenalidomide.Blood2012;119:933–939.
284. SiegelD,MartinT,NookaA,HarveyRD,VijR,NiesvizkyR,etal.Integratedsafety 306. ChalayerE,BourmaudA,TinquautF,ChauvinF,TardyB.Cost-effectivenessana-
profileofsingle-agentcarfilzomib:experiencefrom526patientsenrolledin4phase lysisoflow-molecular-weightheparinversusaspirinthromboprophylaxisinpa-
IIclinicalstudies.Haematologica2013;98:1753–1761.
tientsnewlydiagnosedwithmultiplemyeloma.ThrombRes2016;145:119–125.
285. RidolfiRL,BulkleyBH,HutchinsGM.Theconductionsystemincardiacamyloidosis. 307. ZoppellaroG,VeroneseN,GranzieraS,GobbiL,StubbsB,CohenAT.Primary
Clinicalandpathologicfeaturesof23patients.AmJMed1977;62:677–686. thromboembolic prevention in multiple myeloma patients: an exploratory
meta-analysisonaspirinuse.SeminHematol2018;55:182–184.
286. FakhriB,FialaMA,ShahN,VijR,WildesTM.Measuringcardiopulmonarycompli-
cations of carfilzomib treatment and associated risk factors using the 308. MincuRI,MahabadiAA,MichelL,MrotzekSM,SchadendorfD,RassafT,etal.
SEER-Medicaredatabase.Cancer2020;126:808–813. CardiovascularadverseeventsassociatedwithBRAFandMEKinhibitors:asystem-
aticreviewandmeta-analysis.JAMANetwOpen2019;2:e198890.
287. FengDL,EdwardsWD,OhJK,ChandrasekaranK,GroganM,MartinezMW,etal.
309. GlenC,TanYY,WaterstonA,EvansTRJ,JonesRJ,PetrieMC,etal.Mechanisticand
Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.
clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC:
Circulation2007;116:2420–2426.
CardioOncologystate-of-the-artreview.CardioOncol2022;4:1–18.
288. MancusoS,CarlisiM,SarocchiM,NapolitanoM,SiragusaS.Cardio-oncologyin
310. FlahertyKT,RobertC,HerseyP,NathanP,GarbeC,MilhemM,etal.Improved
multiple myeloma: is it time for a specific focus? Leuk Lymphoma 2018;59:
survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med 2012;
1764–1766.
367:107–114.
289. DanhofS,SchrederM,RascheL,StriflerS,EinseleH,KnopS.‘Real-life’experience
311. RobertC,KaraszewskaB,SchachterJ,RutkowskiP,MackiewiczA,StroiakovskiD,
ofpreapprovalcarfilzomib-basedtherapyinmyeloma—analysisofcardiactoxicity
etal.Improvedoverallsurvivalinmelanomawithcombineddabrafenibandtrame-
andpredisposingfactors.EurJHaematol2016;97:25–32. tinib.NEnglJMed2015;372:30–39.
290. Garcia-PaviaP,RapezziC,AdlerY,AradM,BassoC,BrucatoA,etal.Diagnosisand 312. LongGV,StroyakovskiyD,GogasH,LevchenkoE,DeBraudF,LarkinJ,etal.
treatmentofcardiacamyloidosis.ApositionstatementoftheEuropeanSocietyof Dabrafenib and trametinib versus dabrafenib and placebo for Val600
CardiologyWorkingGrouponMyocardialandPericardialDiseases.EurJHeartFail BRAF-mutantmelanoma:amulticentre,double-blind,phase3randomisedcon-
2021;23:512–526. trolledtrial.Lancet2015;386:444–451.
291. FengDL,SyedIS,MartinezM,OhJK,JaffeAS,GroganM,etal.Intracardiacthrom- 313. BronteE,BronteG,NovoG,RinaldiG,BronteF,PassigliaF,etal.Cardiotoxicity
bosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119: mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.
2490–2497. PharmacolTher2018;192:65–73.
292. SonneveldP,AsselbergsE,ZweegmanS,VanDerHoltB,KerstenMJ,VellengaE, 314. GogasHJ,FlahertyKT,DummerR,AsciertoPA,AranceA,MandalaM,etal.
etal.Phase2studyofcarfilzomib,thalidomide,anddexamethasoneasinduction/ AdverseeventsassociatedwithencorafenibplusbinimetinibintheCOLUMBUS
consolidationtherapyfornewlydiagnosedmultiplemyeloma.Blood2015;125: study:incidence,courseandmanagement.EurJCancer2019;119:97–106.
449–456. 315. BanksM,CrowellK,ProctorA,JensenBC.CardiovasculareffectsoftheMEKin-
293. WangM,MartinT,BensingerW,AlsinaM,SiegelDS,KavalerchikE,etal.Phase2 hibitor,trametinib:acasereport,literaturereview,andconsiderationofmechan-
dose-expansionstudy(PX-171-006)ofcarfilzomib,lenalidomide,andlow-dose ism.CardiovascToxicol2017;17:487–493.
dexamethasoneinrelapsedorprogressivemultiplemyeloma.Blood2013;122: 316. HuJR,FloridoR,LipsonEJ,NaidooJ,ArdehaliR,TocchettiCG,etal.Cardiovascular
3122–3128. toxicitiesassociatedwithimmunecheckpointinhibitors.CardiovascRes2019;115:
294. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, et al. 854–868.
Recurrentcardiotoxicitypotentiatedbytheinteractionofproteasomeinhibitor 317. PostowMA,SidlowR,HellmannMD.Immune-relatedadverseeventsassociated
and immunomodulatory therapy for the treatment of multiple myeloma. Br J
withimmunecheckpointblockade.NEnglJMed2018;378:158–168.
Haematol2018;180:271–275. 318. DrobniZD,AlviRM,TaronJ,ZafarA,MurphySP,RambaratPK,etal.Association
295. LiW,GarciaD,CornellRF,GailaniD,LaubachJ,MaglioME,etal.Cardiovascular betweenimmunecheckpointinhibitorswithcardiovasculareventsandathero-
andthromboticcomplicationsofnovelmultiplemyelomatherapies:areview.JAMA
scleroticplaque.Circulation2020;142:2299–2311.
Oncol2017;3:980–988. 319. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G,
296. PalumboA,RajkumarSV,DimopoulosMA,RichardsonPG,SanMiguelJ,BarlogieB, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor
therapy:ameta-analysis.EurJHeartFail2021;23:1739–1747.
etal.Preventionofthalidomide-andlenalidomide-associatedthrombosisinmye-
loma.Leukemia2008;22:414–423. 320. SalemJE,ManouchehriA,MoeyM,Lebrun-VignesB,BastaracheL,ParienteA,etal.
Cardiovasculartoxicitiesassociatedwithimmunecheckpointinhibitors:anobser-
297. Martinez-NaharroA,Gonzalez-LopezE,CorovicA,MirelisJG,BaksiAJ,MoonJC,
vational,retrospective,pharmacovigilancestudy.LancetOncol2018;19:1579–1589.
etal.Highprevalenceofintracardiacthrombiincardiacamyloidosis.JAmColl
Cardiol2019;73:1733–1734. 321. DolladilleC,EderhyS,AlloucheS,DupasQ,GervaisR,MadelaineJ,etal.Latecar-
diacadverseeventsinpatientswithcancertreatedwithimmunecheckpointinhi-
298. LymanGH,CarrierM,AyC,DiNisioM,HicksLK,KhoranaAA,etal.American bitors.JImmunotherCancer2020;8:e000261.
SocietyofHematology2021guidelinesformanagementofvenousthromboembol- 322. D’SouzaM,NielsenD,SvaneIM,IversenK,RasmussenPV,MadelaireC,etal.The
ism:preventionandtreatmentinpatientswithcancer.BloodAdv2021;5:927–974.
riskofcardiaceventsinpatientsreceivingimmunecheckpointinhibitors:anation-
299. KeyNS,KhoranaAA,KudererNM,BohlkeK,LeeAYY,ArcelusJI,etal.Venous wideDanishstudy.EurHeartJ2021;42:1621–1631.
thromboembolismprophylaxisandtreatmentinpatientswithcancer:ASCOclin-
323. DolladilleC, Akroun J, Morice P-M, DompmartinA, Ezine E, Sassier M, et al.
icalpracticeguidelineupdate.JClinOncol2020;38:496–520.
Cardiovascularimmunotoxicitiesassociatedwithimmunecheckpointinhibitors:
300. PiedraK,PetersonT,TanC,OrozcoJ,HultcrantzM,HassounH,etal.Comparison asafetymeta-analysis.EurHeartJ2021;42:4964–4977.
ofvenousthromboembolismincidenceinnewlydiagnosedmultiplemyelomapa- 324. ZamamiY,NiimuraT,OkadaN,KoyamaT,FukushimaK,Izawa-IshizawaY,etal.
tientsreceivingbortezomib,lenalidomide,dexamethasone(RVD)orcarfilzomib, Factorsassociatedwithimmunecheckpointinhibitor–relatedmyocarditis.JAMA
lenalidomide,dexamethasone(KRD)withaspirinorrivaroxabanthromboprophy- Oncol2019;5:1635–1637.
laxis.BrJHaematol2022;196:105–109.
325. ZhangL,ReynoldsKL,LyonAR,PalaskasN,NeilanTG.Theevolvingimmunother-
301. CornellRF,GoldhaberSZ,EngelhardtBG,MoslehiJ,JagasiaM,HarrellS,etal. apylandscapeandtheepidemiology,diagnosis,andmanagementofcardiotoxicity:
Primarypreventionofvenousthromboembolismwithapixabanformultiplemye- JACC:CardioOncologyprimer.JACCCardioOncology2021;3:35–47.
loma patients receiving immunomodulatory agents. Br J Haematol 2020;190: 326. LyonAR,YousafN,BattistiNML,MoslehiJ,LarkinJ.Immunecheckpointinhibitors
555–561. andcardiovasculartoxicity.LancetOncol2018;19:e447–e458.
302. SwanD,RocciA,BradburyC,ThachilJ.Venousthromboembolisminmultiple 327. SchifferWB,DeychE,LenihanDJ,ZhangKW.Coronaryandaorticcalcificationare
myeloma—choiceofprophylaxis,roleofdirectoralanticoagulantsandspecialcon- associatedwithcardiovasculareventsonimmunecheckpointinhibitortherapy.IntJ
siderations.BrJHaematol2018;183:538–556. Cardiol2021;322:177–182.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 123 ---
ESCGuidelines 4351
328.NaingA,InfanteJ,GoelS,BurrisH,BlackC,MarshallS,etal.Anti-PD-1monoclonal 350. OlssonH,PetriN,ErichsenL,MalmbergA,GrundemarL.Effectofdegarelix,a
antibodyMEDI0680inaphaseIstudyofpatientswithadvancedsolidmalignancies.J gonadotropin-releasinghormonereceptorantagonistforthetreatmentofpros-
ImmunotherCancer2019;7:225. tatecancer,oncardiacrepolarisationinarandomised,placeboandactivecompara-
329.Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, torcontrolledthoroughQT/QTctrialinhealthymen.ClinDrugInvestig2017;37:
Lebrun-VignesB,etal.Immunecheckpointinhibitor-inducedmyositis,theearliest 873–879.
and most lethal complication among rheumatic and musculoskeletal toxicities. 351. BaumM,BuzdarAU,CuzickJ,ForbesJ,HoughtonJ,KlijnJGM,etal.Anastrozole
AutoimmunRev2020;19:102586. aloneorincombinationwithtamoxifenversustamoxifenaloneforadjuvanttreat-
330.AnquetilC,SalemJE,Lebrun-VignesB,JohnsonDB,MammenAL,StenzelW,etal. mentofpostmenopausalwomenwithearlybreastcancer:firstresultsoftheATAC
Immunecheckpointinhibitor–associatedmyositis:expandingthespectrumofcar- randomisedtrial.Lancet2002;359:2131–2139.
diac complications of the immunotherapy revolution. Circulation 2018;138: 352. ARIMIDEX®(anastrozole).HighlightsofPrescribingInformation.Wilmington,DE:
743–745. AstraZenecaPharmaceuticalsLP,2014.
331.Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. 353. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B,
Myocarditisinthesettingofcancertherapeutics:proposedcasedefinitionsfor KeshaviahA,CoatesAS,MouridsenH,MauriacL,etal.Acomparisonofletrozole
emergingclinicalsyndromesincardio-oncology.Circulation2019;140:80–91. andtamoxifeninpostmenopausalwomenwithearlybreastcancer.NEnglJMed
332.LehmannLH,CautelaJ,PalaskasN,BaikAH,MeijersWC,AllenbachY,etal.Clinical 2005;353:2747–2757.
strategyforthediagnosisandtreatmentofimmunecheckpointinhibitor-associated 354. AmirE,SerugaB,NiraulaS,CarlssonL,OcañaA.Toxicityofadjuvantendocrine
myocarditis:anarrativereview.JAMACardiol2021;6:1329–1337. therapy in postmenopausal breast cancer patients: a systematic review and
333.Rini B, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et al. meta-analysis.JNatlCancerInst2011;103:1299–1309.
Prospective cardiovascular surveillance of immune checkpoint inhibitor-based 355. Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al.
combinationtherapyinpatientswithadvancedrenalcellcancer:datafromthe Toxicityofextendedadjuvanttherapywitharomataseinhibitorsinearlybreast
phase3JAVELINRenal101trial.JClinOncol2022;40:1929–1938. cancer:asystematicreviewandmeta-analysis.JNatlCancerInst2018;110:31–39.
334.AwadallaM,MahmoodSS,GroarkeJD,HassanMZO,NohriaA,RokickiA,etal. 356. Curigliano G,AzambujaE, LenihanD, CalabròMG,CardinaleD,Cipolla CM.
Globallongitudinalstrainandcardiaceventsinpatientswithimmunecheckpoint Prevention,monitoring,andmanagementofcardiacdysfunctioninpatientswith
inhibitor-relatedmyocarditis.JAmCollCardiol2020;75:467–478. metastaticbreastcancer.Oncologist2019;24:e1034–e1043.
335.KondapalliL,BottinorW,LennemanC.Byreleasingthebrakeswithimmunother- 357. KISQALI(ribociclib).HighlightsofPrescribingInformation.EastHanover,NJ:Novartis
apy,areweacceleratingatherosclerosis?Circulation2020;142:2312–2315. PharmaceuticalsCorporation,2018.
336.JohnsonDB,NebhanCA,MoslehiJJ,BalkoJM.Immune-checkpointinhibitors:long- 358. IBRANCE(palbociclib).HighlightsofPrescribingInformation.NewYork,NY:Pfizer,
termimplicationsoftoxicity.NatRevClinOncol2022;19:254–267. 2018.
337.ZhaoJ,ZhuS,SunL,MengF,ZhaoL,ZhaoY,etal.Androgendeprivationtherapy 359. VERZENIO(abemaciclib).HighlightsofPrescribingInformation.Indianapolis,IN:Eli
forprostatecancerisassociatedwithcardiovascularmorbidityandmortality:a LillyandCompany,2018.
meta-analysis of population-based observational studies. PLoS One 2014;9: 360. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al.
e107516. Differentcardiotoxicityofpalbociclibandribociclibinbreastcancer:geneexpres-
338.Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. sionandpharmacologicaldataanalyses,biologicalbasis,andtherapeuticimplica-
Cardiovasculareffectsofandrogendeprivationtherapyforthetreatmentofpros- tions.BioDrugs2019;33:613–620.
tatecancer:ABCDEStepstoreducecardiovasculardiseaseinpatientswithpros- 361. HortobagyiGN,StemmerSM,BurrisHA,YapY-S,SonkeGS,Paluch-ShimonS,
tatecancer.Circulation2016;133:537–541. etal.Ribociclibasfirst-linetherapyforHR-positive,advancedbreastcancer.N
339.OkwuosaTM,MorgansA,RheeJ-W,RedingKW,MaliskiS,PlanaJ-C,etal.Impact EnglJMed2016;375:1738–1748.
ofhormonaltherapiesfortreatmentofhormone-dependentcancers(breastand 362. TripathyD,ImSA,ColleoniM,FrankeF,BardiaA,HarbeckN,etal.Ribociclibplus
prostate)onthecardiovascularsystem:effectsandmodifications:ascientificstate- endocrinetherapyforpremenopausalwomenwithhormone-receptor-positive,
mentfromtheAmericanHeartAssociation.CircGenomicPrecisMed2021;14: advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet
e000082. Oncol2018;19:904–915.
340.BarberM,NguyenL,WassermannJ,SpanoJ,Funck-BrentanoC,SalemJ.Cardiac 363. FinnRS,MartinM,RugoHS,JonesS,ImS-A,GelmonK,etal.Palbociclibandletro-
arrhythmiaconsiderationsofhormonecancertherapies.CardiovascRes2019;115: zoleinadvancedbreastcancer.NEnglJMed2016;375:1925–1936.
878–894. 364. CristofanilliM,TurnerNC,BondarenkoI,RoJ,ImSA,MasudaN,etal.Fulvestrant
341.ShoreND,SaadF,CooksonMS,GeorgeDJ,SaltzsteinDR,TutroneR,etal.Oral plus palbociclib versus fulvestrant plus placebo for treatment of
relugolixforandrogen-deprivationtherapyinadvancedprostatecancer.NEnglJ hormone-receptor-positive, HER2–negative metastatic breast cancer that pro-
Med2020;382:2187–2196. gressedonpreviousendocrinetherapy(PALOMA-3):finalanalysisofthemulticen-
342.AbufarajM,IwataT,KimuraS,HaddadA,Al-AniH,AbusubaihL,etal.Differential tre,double-blind,phas.LancetOncol2016;17:425–439.
impactofgonadotropin-releasinghormoneantagonistversusagonistonclinical 365. SlamonDJ,NevenP,ChiaS,FaschingPA,DeLaurentiisM,ImSA,etal.PhaseIII
safety andoncologic outcomesonpatientswith metastaticprostatecancer: a randomizedstudyofribociclibandfulvestrantinhormonereceptor-positive,hu-
meta-analysisofrandomizedcontrolledtrials.EurUrol2021;79:44–53. man epidermal growth factor receptor 2-negative advanced breast cancer:
343.Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. MONALEESA-3.JClinOncol2018;36:2465–2472.
Cardiovascularsafetyofdegarelixversusleuprolideinpatientswithprostatecan- 366. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.
cer:theprimaryresultsofthePRONOUNCErandomizedtrial.Circulation2021; PalbociclibhasnoclinicallyrelevanteffectontheQTcintervalinpatientswithad-
144:1295–1307. vancedbreastcancer.AnticancerDrugs2018;29:271–280.
344.WilkM,Waśko-GrabowskaA,SkonecznaI,SzmitS.Angiotensinsysteminhibitors 367. ImS-A,LuY-S,BardiaA,HarbeckN,ColleoniM,FrankeF,etal.Overallsurvival
mayimproveoutcomesofpatientswithcastration-resistantprostatecancerduring withribociclibplusendocrinetherapyinbreastcancer.NEnglJMed2019;381:
abiraterone acetate treatment—a cardio-oncology study. Front Oncol 2021;11: 307–316.
664741. 368. SlamonDJ,NevenP,ChiaS,FaschingPA,DeLaurentiisM,ImS-A,etal.Overall
345.SalemJE,WaintraubX,CourtillotC,ShafferCM,GandjbakhchE,MaupainC,etal. survivalwithribociclibplusfulvestrantinadvancedbreastcancer.NEnglJMed
HypogonadismasareversiblecauseofTorsadesdePointesinmen.Circulation 2020;382:514–524.
2018;138:110–113. 369. TamargoJ,CaballeroR,DelpónE.Cancerchemotherapyandcardiacarrhythmias:
346.SalemJE,AlexandreJ,BachelotA,Funck-BrentanoC.Influenceofsteroidhor- areview.DrugSaf2015;38:129–152.
monesonventricularrepolarization.PharmacolTher2016;167:38–47. 370. WangL,WangW.Safetyandefficacyofanaplasticlymphomakinasetyrosineki-
347.Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al. naseinhibitorsinnon-smallcelllungcancer(Review).OncolRep2021;45:13–28.
Androgeniceffectsonventricularrepolarizationatranslationalstudyfromthe 371. RaoVU,ReevesDJ,ChughAR,O’QuinnR,FradleyMG,RaghavendraM,etal.
international pharmacovigilance database to iPSC-cardiomyocytes. Circulation Clinicalapproachtocardiovasculartoxicityoforalantineoplasticagents:JACC
2019;140:1070–1080. state-of-the-artreview.JAmCollCardiol2021;77:2693–2716.
348.HasegawaK,ItoH,KasenoK,MiyazakiS,ShiomiY,TamaN,etal.Impactofmedical 372. ShawAT,BauerTM,deMarinisF,FelipE,GotoY,LiuG,etal.First-linelorlatinibor
castrationonmalignantarrhythmiasinpatientswithprostatecancer.JAmHeart crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:
Assoc2021;10:e017267. 2018–2029.
349.Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al. 373. TheinKZ,SwarupS,BallS,QuirchM,VorakunthadaY,HtweKK,etal.Incidenceof
Recognition,prevention,andmanagementofarrhythmiasandautonomicdisorders cardiactoxicitiesinpatientswithadvancednon-smallcelllungcancertreatedwith
incardio-oncology:ascientificstatementfromtheAmericanHeartAssociation. osimertinib:acombinedanalysisoftwophaseIIIrandomizedcontrolledtrials.Ann
Circulation2021;144:E41–E55. Oncol2018;29:viii500.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 124 ---
4352 ESCGuidelines
374. AnandK,EnsorJ,TrachtenbergB,BernickerEH.Osimertinib-inducedcardiotoxi- 399. MulrooneyDA,YeazelMW,KawashimaT,MertensAC,MitbyP,StovallM,etal.
city:aretrospectivereviewoftheFDAAdverseEventsReportingSystem(FAERS). Cardiacoutcomesinacohortofadultsurvivorsofchildhoodandadolescentcan-
JACCCardioOncology2019;1:172–178. cer:retrospectiveanalysisofthechildhoodcancersurvivorstudycohort.BMJ2009;
375. KunimasaK,KamadaR,OkaT,OboshiM,KimuraM,InoueT,etal.Cardiacadverse 339:b4606.
eventsinEGFR-mutatednon-smallcelllungcancertreatedwithosimertinib.JACC 400. VanNimwegenFA,SchaapveldM,JanusCPM,KrolADG,PetersenEJ,Raemaekers
CardioOncology2020;2:1–10.
JMM,etal.CardiovasculardiseaseafterHodgkinlymphomatreatment40-yeardis-
376. EwerMS,TekumallaSH,WaldingA,AtuahKN.Cardiacsafetyofosimertinib:are- easerisk.JAMAInternMed2015;175:1007–1017.
viewofdata.JClinOncol2021;39:328–337.
401. JacobseJN,DuaneFK,BoekelNB,SchaapveldM,HauptmannM,HooningMJ,etal.
377. FreyN,PorterD.CytokinereleasesyndromewithchimericantigenreceptorTcell Radiationdose-responseforriskofmyocardialinfarctioninbreastcancersurvi-
therapy.BiolBloodMarrowTransplant2019;25:e123–e127. vors.IntJRadiatOncolBiolPhys2019;103:595–604.
378. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. 402. FuchsM,GoergenH,KobeC,KuhnertG,LohriA,GreilR,etal.Positronemission
Cardiovascular events among adults treated with chimeric antigen receptor tomography-guidedtreatmentinearly-stagefavorableHodgkinlymphoma:finalre-
T-cells(CAR-T).JAmCollCardiol2019;74:3099–3108.
sultsoftheinternational,randomizedphaseIIIHD16trialbytheGermanHodgkin
379. GoldmanA,MaorE,BomzeD,LiuJE,HerrmannJ,FeinJ,etal.Adversecardiovas- StudyGroup.JClinOncol2019;37:2835–2845.
cularandpulmonaryeventsassociatedwithchimericantigenreceptorT-cellther-
403. RadfordJ,IllidgeT,CounsellN,HancockB,PettengellR,JohnsonP,etal.Resultsof
apy.JAmCollCardiol2021;78:1800–1813.
atrialofPET-directedtherapyforearly-stageHodgkin’slymphoma.NEnglJMed
380. FradleyMG,DamrongwatanasukR,ChandrasekharS,AlomarM,KipKE,Sarnaik 2015;372:1598–1607.
AA.Cardiovasculartoxicityandmortalityassociatedwithadoptivecelltherapy
404. KunklerIH,WilliamsLJ,JackWJL,CameronDA,DixonJM.Breast-conservingsur-
andtumor-infiltratinglymphocytesforadvancedstagemelanoma.JImmunother
2021;44:86–89. gerywithorwithoutirradiationinwomenaged65yearsorolderwithearlybreast
cancer(PRIMEII):arandomisedcontrolledtrial.LancetOncol2015;16:266–273.
381. GhoshAK,ChenDH,GuhaA,MackenzieS,WalkerJM,RoddieC.CARTcell
405. SongAJ,ManukianG,TaylorAK,AnnePR,SimoneNL.Concernsforactivebreath-
therapy-relatedcardiovascularoutcomesandmanagement:systemicdiseaseor
directcardiotoxicity?JACCCardioOncology2020;2:97–109. ingcontrol(ABC)withbreastcancerintheeraofCOVID-19:maximizinginfection
controlwhileminimizingheartdose.AdvRadiatOncol2020;5:573–574.
382. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M.
406. PetersenPM,AznarMC,BerthelsenAK, LoftA,SchutDA,MaraldoM,etal.
Cardiovascular effects of CAR T cell therapy: a restrospective study. JACC
CardioOncology2020;2:193–203. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma:
383. SalemJE,EderhyS,Lebrun-VignesB,MoslehiJJ.Cardiaceventsassociatedwithchi-
benefitofdeepinspirationbreath-hold.ActaOncol(Madr)2015;54:60–66.
mericantigenreceptorT-cells(CAR-T):aVigiBaseperspective.JAmCollCardiol 407. PerssonGF,SchermanRydhögJ,JosipovicM,MaraldoMV,NygårdL,CostaJ,etal.
2020;75:2521–2523. Deepinspirationbreath-holdvolumetricmodulatedarcradiotherapydecreases
384. GanatraS,ReddR,HayekSS,ParikhR,AzamT,YanikGA,etal.Chimericantigen dosetomediastinalstructuresinlocallyadvancedlungcancer.ActaOncol(Madr)
receptorT-celltherapy-associatedcardiomyopathyinpatientswithrefractoryor 2016;55:1053–1056.
relapsednon-Hodgkinlymphoma.Circulation2020;142:1687–1690. 408. DabajaBS,HoppeBS,PlastarasJP,NewhauserW,RosolovaK,FlampouriS,etal.
385. LeeJB,VasicD,KangH,FangKKL,ZhangL.State-of-artofcellulartherapyforacute Proton therapy for adults with mediastinal lymphomas: the International
leukemia.IntJMolSci2021;22:4590. Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.
386. BrahmerJR,Abu-SbeihH,AsciertoPA,BrufskyJ,CappelliLC,CortazarFB,etal. Erratumin:Blood2019;133:1384–1385.
SocietyforImmunotherapyofCancer(SITC)clinicalpracticeguidelineonimmune 409. RotzSJ,RyanTD,HayekSS.Cardiovasculardiseaseanditsmanagementinchildren
checkpointinhibitor-relatedadverseevents.JImmunotherCancer2021;9:e002435. and adults undergoing hematopoietic stem cell transplantation. J Thromb
387. RagoonananD,KhazalSJ,Abdel-AzimH,McCallD,CuglievanB,TambaroFP,etal. Thrombolysis2021;51:854–869.
Diagnosis,gradingandmanagementoftoxicitiesfromimmunotherapiesinchildren, 410. OliveiraGH,Al-KindiSG,GuhaA,DeyAK,RheaIB,DeLimaMJ.Cardiovascularrisk
adolescentsandyoungadultswithcancer.NatRevClinOncol2021;18:435–453. assessmentandmanagementofpatientsundergoinghematopoieticcelltransplant-
388. MausMV,AlexanderS,BishopMR,BrudnoJN,CallahanC,DavilaML,etal.Society ation.BoneMarrowTransplant2021;56:544–551.
forImmunotherapyofCancer(SITC)clinicalpracticeguidelineonimmuneeffector 411. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al.
cell-relatedadverseevents.JImmunotherCancer2020;8:e001511. Hematopoieticcelltransplantation(HCT)-specificcomorbidityindex:anewtool
389. DarbySC,EwertzM,McGaleP,BennetAM,Blom-GoldmanU,BrønnumD,etal. forriskassessmentbeforeallogeneicHCT.Blood2005;106:2912–2919.
Riskofischemicheartdiseaseinwomenafterradiotherapyforbreastcancer.N 412. TichelliA,BucherC,RovóA,StussiG,SternM,PaulussenM,etal.Prematurecar-
EnglJMed2013;368:987–998.
diovasculardiseaseafterallogeneichematopoieticstem-celltransplantation.Blood
390. VanNimwegenFA,SchaapveldM,CutterDJ,JanusCPM,KrolADG,Hauptmann 2007;110:3463–3471.
M,etal.Radiationdose-responserelationshipforriskofcoronaryheartdiseasein 413. AlblooshiR,KanfarS,LordB,AtenafuEG,MichelisFV,PasicI,etal.Clinicalpreva-
survivorsofHodgkinlymphoma.JClinOncol2016;34:235–243.
lenceandoutcomeofcardiovasculareventsinthefirst100dayspostallogeneic
391. CutterDJ,SchaapveldM,DarbySC,HauptmannM,VanNimwegenFA,KrolADG, hematopoieticstemcelltransplant.EurJHaematol2021;106:32–39.
etal.RiskforvalvularheartdiseaseaftertreatmentforHodgkinlymphoma.JNatl
414. DuléryR,MohtyR,LabopinM,SestiliS,MalardF,BrissotE,etal.Earlycardiactox-
CancerInst2015;107:djv008.
icity associated with post-transplant cyclophosphamide in allogeneic stem cell
392. BergomC,BradleyJA,NgAK,SamsonP,RobinsonC,Lopez-MatteiJ,etal.Past, transplantation.JACCCardioOncology2021;3:250–259.
present,andfutureofradiation-inducedcardiotoxicity:refinementsintargeting,
415. López-FernándezT,VadilloIS,delaGuíaAL,BarbierKH.Cardiovascularissuesin
surveillance,andriskstratification.JACCCardioOncology2021;3:343–359.
hematopoieticstemcelltransplantation(HSCT).CurrTreatOptionsOncol2021;22:
393. Belzile-DugasE,EisenbergMJ.Radiation-inducedcardiovasculardisease:reviewof
51.
anunderrecognizedpathology.JAmHeartAssoc2021;10:e021686.
416. OhmotoA,FujiS.Cardiaccomplicationsassociatedwithhematopoieticstem-cell 394. CarlsonLE,WattGP,TonorezosES,ChowEJ,YuAF,WoodsM,etal.Coronary
transplantation.BoneMarrowTransplant2021;56:2637–2643.
arterydiseaseinyoungwomenafterradiationtherapyforbreastcancer.JACC
CardioOncology2021;3:381–392. 417. TakatsukaH,NakajimaT,NomuraK,OkikawaY,WakaeT,TodaA,etal.Prognosis
valueofatrialnatriureticpeptideandbrainnatriureticpeptideforheartfailurein
395. JacobS,CamilleriJ,DerreumauxS,WalkerV,LairezO,LapeyreM,etal.Ismean
patientsundergoingallogeneicbonemarrowtransplantation.Hematology2006;
heartdosearelevantsurrogateparameterofleftventricleandcoronaryarteries
exposureduringbreastcancerradiotherapy:adosimetricevaluationbasedon
11:351–354.
individually-determinedradiationdose(BACCARATstudy).RadiatOncol2019; 418. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al.
14:29. Assessmentofcardiotoxicityduringhaemopoieticstemcelltransplantationwith
396. HoppeBS,BatesJE,MendenhallNP,MorrisCG,LouisD,HoMW,etal.Themean-
plasmabrainnatriureticpeptide.BoneMarrowTransplant2000;26:309–313.
inglessmeaningofmeanheartdoseinmediastinallymphomainthemodernradi- 419. Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ.
ationtherapyera.PractRadiatOncol2020;10:e147–e154. Cardiac biomarkers during cancer therapy: practical applications for
397. MaraldoMV,GiustiF,VogeliusIR,LundemannM,VanderKaaijMAE,RamadanS, cardio-oncology.JACCCardioOncology2020;2:791–794.
etal.CardiovasculardiseaseaftertreatmentforHodgkin’slymphoma:ananalysisof 420. MohammedJ,SmithSR,BurnsL,BasakG,AljurfM,SavaniBN,etal.Roleofphysical
ninecollaborativeEORTC-LYSAtrials.LancetHaematol2015;2:e492–e502. therapybeforeandafterhematopoieticstemcelltransplantation:whitepaperre-
398. AtkinsKM,BittermanDS,ChaunzwaTL,KozonoDE,BaldiniEH,AertsHJWL,etal. port.BiolBloodMarrowTransplant2019;25:e191–e198.
Meanheartdoseisaninadequatesurrogateforleftanteriordescendingcoronary 421. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al.
arterydoseandtheriskofmajoradversecardiaceventsinlungcancerradiation Cardiovascularriskfactorsandmorbidityinlong-termsurvivorsoftesticularcan-
therapy.IntJRadiatOncol2021;110:1473–1479. cer:a20-yearfollow-upstudy.JClinOncol2010;28:4649–4657.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 125 ---
ESCGuidelines 4353
422.HerrmannJ.Cardiovasculartoxicitywithcisplatininpatientswithtesticularcancer: Society of Cardiology (ESC) Endorsed by: The European Association for
looking for something heavier than heavy metal. JACC CardioOncology 2020;2: Cardio-ThoracicSurgery(EACTS).EurHeartJ2015;36:2921–2964.
456–459. 445. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.
423.CerchioneC,PeleteiroRaíndoA,MosqueraOrgueiraA,MosqueraTorreA,Bao Managementofacutemyocarditisandchronicinflammatorycardiomyopathy:an
PérezL,MarconiG,etal.SafetyofFLT3inhibitorsinpatientswithacutemyeloid expertconsensusdocument.CircHeartFail2020;13:e007405.
leukemia.ExpertRevHematol2021;14:851–865. 446. ThunyF,AlexandreJ, SalemJE, Mirabel M,DolladilleC, Cohen-SolalA,et al.
424.DongH,YaoL,WangM,WangM,LiX,SunX,etal.CanACEI/ARBpreventthe Management of immune checkpoint inhibitor–induced myocarditis: the French
cardiotoxicity caused by chemotherapy in early-stage breast cancer?—A Working Group’s Plea for a pragmatic approach. JACC CardioOncology 2021;3:
meta-analysis of randomized controlled trials. Transl Cancer Res 2020;11: 157–161.
7034–7043. 447. ChungES,PackerM,LoKH,FasanmadeAA,WillersonJT.Randomized,double-
425.CardinaleD,ColomboA,LamantiaG,ColomboN,CivelliM,DeGiacomiG,etal. blind,placebo-controlled,pilottrialofinfliximab,achimericmonoclonalantibody
Anthracycline-inducedcardiomyopathy:clinicalrelevanceandresponsetopharma- to tumor necrosis factor-α, in patients with moderate-to-severe heart failure:
cologictherapy.JAmCollCardiol2010;55:213–220. ResultsoftheAnti-TNFTherapyAgainstCongestiveHeartFailure(ATTACH)
426.ModiS,SauraC,YamashitaT,ParkYH,KimS-B,TamuraK,etal.Trastuzumabder- trial.Circulation2003;107:3133–3140.
uxtecaninpreviouslytreatedHER2-positivebreastcancer.NEnglJMed2020;382: 448. CautelaJ,ZeriouhS,GaubertM,BonelloL,LaineM,PeyrolM,etal.Intensifiedim-
610–621. munosuppressivetherapyinpatientswithimmunecheckpointinhibitor-induced
427.HussainY,DrillE,DangCT,LiuJE,SteingartRM,YuAF.Cardiacoutcomesoftras- myocarditis.JImmunotherCancer2020;8:e001887.
tuzumabtherapyinpatientswithHER2-positivebreastcancerandreducedleft 449. DolladilleC,EderhyS,SassierM,CautelaJ,ThunyF,CohenAA,etal.Immune
ventricularejectionfraction.BreastCancerResTreat2019;175:239–246. checkpointinhibitorrechallengeafterimmune-relatedadverseeventsinpatients
428.LeongDP,CosmanT,AlhusseinMM,KumarTyagiN,KarampatosS,BarronCC, withcancer.JAMAOncol2020;6:865–871.
etal.Safetyofcontinuingtrastuzumabdespitemildcardiotoxicity:aphaseItrial. 450. RothME,MulunehB,JensenBC,MadamanchiC,LeeCB.Leftventriculardysfunc-
JACCCardioOncology2019;1:1–10. tionaftertreatmentwithipilimumabformetastaticmelanoma.AmJTher2016;23:
429.OmlandT,HeckSL,GulatiG.Theroleofcardioprotectionincancertherapycar- e1925–e1928.
diotoxicity: JACC: CardioOncology state-of-the-art review. Cardio Oncol 2022;4: 451. WeinstockC,KhozinS,SuzmanD,ZhangL,TangS,WahbyS,etal.U.S.Foodand
19–37. DrugAdministrationapprovalsummary:atezolizumabformetastaticnon–small
430.Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al. celllungcancer.ClinCancerRes2017;23:4534–4539.
Independentadjudicationofsymptomaticheartfailurewiththeuseofdoxorubicin 452. BallS,GhoshRK,WongsaengsakS,BandyopadhyayD,GhoshGC,AronowWS,
andcyclophosphamidefollowedbytrastuzumabadjuvanttherapy:Acombinedre- etal.Cardiovasculartoxicitiesofimmunecheckpointinhibitors:JACCreviewtopic
viewofcardiacdatafromtheNationalSurgicalAdjuvantBreastandBowelProject oftheweek.JAmCollCardiol2019;74:1714–1727.
B-31andtheNorthCentralCancerTreatmentGroupN9831clinicaltrials.JClin 453. ThavendiranathanP,ZhangL,ZafarA,DrobniZD,MahmoodSS,CabralM,etal.
Oncol2010;28:3416–3421. MyocardialT1andT2mappingbymagneticresonanceinpatientswithimmune
431.Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. checkpointinhibitor–associatedmyocarditis.JAmCollCardiol2021;77:1503–1516.
Reversibilityoftrastuzumab-relatedcardiotoxicity:newinsightsbasedonclinical 454. BrahmerJR,LacchettiC,SchneiderBJ,AtkinsMB,BrassilKJ,CaterinoJM,etal.
courseandresponsetomedicaltreatment.JClinOncol2005;23:7820–7826. Managementofimmune-relatedadverseeventsinpatientstreatedwithimmune
432.GuarneriV,LenihanDJ,ValeroV,DurandJB,BroglioK,HessKR,etal.Long-term checkpointinhibitortherapy:AmericanSocietyofClinicalOncologyclinicalprac-
cardiactolerabilityoftrastuzumabinmetastaticbreastcancer:theM.D.Anderson ticeguideline.JClinOncol2018;36:1714–1768.
CancerCenterexperience.JClinOncol2006;24:4107–4115. 455. GuhaA,AddisonD,JainP,GutierrezJM,GhoshA,RoddieC,etal.Cardiovascular
433.KhouryK,LynceF,BaracA,GengX,DangC,YuAF,etal.Long-termfollow-up eventsassociatedwithchimericantigenreceptorTcelltherapy:cross-sectional
assessmentofcardiacsafetyinSAFE-HEaRt,aclinicaltrialevaluatingtheuseof FDAadverseeventsreportingsystemanalysis:cardiovasculareventswithCAR-T
HER2-targetedtherapiesinpatientswithbreastcancerandcompromisedheart therapy.BiolBloodMarrowTransplant2020;26:2211–2216.
function.BreastCancerResTreat2021;185:863–868. 456. KupariM,VolinL,SuokasA,HekaliP,RuutuT.Cardiacinvolvementinbonemar-
434.MahmoodSS,FradleyMG,CohenJV,NohriaA,ReynoldsKL,HeinzerlingLM,etal. rowtransplantation:serialchangesinleftventricularsize,massandperformance.J
Myocarditisinpatientstreatedwithimmunecheckpointinhibitors.JAmCollCardiol InternMed1990;227:259–266.
2018;71:1755–1764. 457. TonorezosES,StillwellEE,CallowayJJ,GlewT,WesslerJD,RebolledoBJ,etal.
435.Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow
Electrocardiographicmanifestationsofimmunecheckpointinhibitormyocarditis. Transplant2015;50:1212–1216.
Circulation2021;144:1521–1523.Erratumin:Circulation2021;144:e490. 458. ColletJ-P,ThieleH,BarbatoE,BarthélémyO,BauersachsJ,BhattDL,etal.2020
436.ZhangL,ZlotoffDA,AwadallaM,MahmoodSS,NohriaA,HassanMZO,etal. ESCGuidelinesforthemanagementofacutecoronarysyndromesinpatientspre-
Majoradversecardiovasculareventsandthetiminganddoseofcorticosteroids sentingwithoutpersistentST-segmentelevation.EurHeartJ2021;42:1289–1367.
in immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141: 459. AboS,RitchieD,DenehyL,Panek-HudsonY,IrvingL,GrangerCL.Ahospitaland
2031–2034. home-basedexerciseprogramtoaddressfunctionaldeclineinpeoplefollowing
437.Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, et al. allogeneicstemcelltransplantation.SupportCareCancer2018;26:1727–1736.
68Ga-DOTATOCPET/CTtodetectimmunecheckpointinhibitor-relatedmyo- 460. SquiresRW,ShultzAM,HerrmannJ.Exercisetrainingandcardiovascularhealthin
carditis.JImmunotherCancer2021;9:e003594. cancerpatients.CurrOncolRep2018;20:27.
438.FinkeD,HeckmannMB,HerpelE,KatusHA,HaberkornU,LeuschnerF,etal.Early 461. KeenC,SkilbeckJ,RossH,SmithL,CollinsK,DixeyJ,etal.Isitfeasibletoconducta
detectionofcheckpointinhibitor-associatedmyocarditisusing68Ga-FAPIPET/CT. randomisedcontrolledtrialofpretransplantexercise(prehabilitation)forpatients
FrontCardiovascMed2021;8:614997. withmultiplemyelomaawaitingautologoushaematopoieticstemcelltransplant-
439.ChenY,JiaY,LiuQ,ShenY,ZhuH,DongX,etal.Myocarditisrelatedtoimmune ation?ProtocolforthePREeMPTstudy.BMJOpen2018;8:e021333.
checkpointinhibitorstreatment:twocasereportsandliteraturereview.AnnPalliat 462. DesaiR,DesaiA,AbbasSA,PatelU,BansodS,DamarlapallyN,etal.National
Med2021;10:8512–8517. prevalence,trendsandoutcomesoftakotsubosyndromeinhospitalizationswith
440.PalaskasNL,SeguraA,LelenwaL,SiddiquiBA,SubudhiSK,Lopez-MatteiJ,etal. prior history of mediastinal/intrathoracic cancer and radiation therapy. Int J
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease Cardiol2020;309:14–18.
throughendomyocardialbiopsy.EurJHeartFail2021;23:1725–1735. 463. SattlerK,El-BattrawyI,LangS,ZhouX,SchrammK,TülümenE,etal.Prevalenceof
441.BrugadaJ,KatritsisDG,ArbeloE,ArribasF,BaxJJ,Blomstrom-LundqvistC,etal. cancerinTakotsubocardiomyopathy:shortandlong-termoutcome.IntJCardiol
2019ESCGuidelinesforthemanagementofpatientswithsupraventriculartachy- 2017;238:159–165.
cardia.EurHeartJ2020;41:655–720. 464. OmerovicE,CitroR,BossoneE,RedforsB,BacksJ,BrunsB,etal.Pathophysiology
442.ZeppenfeldK,Tfelt-HansenJ,deRivaM,WinkelBG,BehrER,BlomNA,etal.2022 of Takotsubo syndrome—a joint scientific statement from the HFA TTS and
ESCGuidelinesforthemanagementofpatientswithventriculararrhythmiasand MyocardialFunctionWorkingGroupoftheESC—Part2:vascularpathophysi-
thepreventionofsuddencardiacdeath.EurHeartJ2022;43:3997–4126. ology,genderandsexhormones,genetics,chroniccardiovascularproblemsand
443.GliksonM,NielsenJC,KronborgMB,MichowitzY,AuricchioA,BarbashIM,etal. clinicalimplications.EurJHeartFail2022;24:274–286.
2021ESCGuidelinesoncardiacpacingandcardiacresynchronizationtherapy.Eur 465. OmerovicE,CitroR,BossoneE,RedforsB,BacksJ,BrunsB,etal.Pathophysiology
HeartJ2021;42:3427–3520. ofTakotsubosyndrome—ajointscientificstatementfromtheHFATTSStudy
444.AdlerY,CharronP,ImazioM,BadanoL,Barón-EsquiviasG,BogaertJ,etal.2015 GroupandMyocardialFunctionWorkingGroupoftheESC—Part1:overview
ESCGuidelinesforthediagnosisandmanagementofpericardialdiseases:theTask andthecentralroleforcatecholaminesandsympatheticnervoussystem.EurJ
ForcefortheDiagnosisandManagementofPericardialDiseasesoftheEuropean HeartFail2022;24:257–273.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 126 ---
4354 ESCGuidelines
466. CouchLS,FiedlerJ,ChickG,ClaytonR,DriesE,WieneckeLM,etal.Circulating 486. IliescuC,BalanescuDV,DonisanT,GizaDE,MuñozGonzalezED,CilingirogluM,
microRNAspredisposetoTakotsubosyndromefollowinghigh-doseadrenaline etal.Safetyofdiagnosticandtherapeuticcardiaccatheterizationincancerpatients
exposure.CardiovascRes2022;118:1758–1770. withacutecoronarysyndromeandchronicthrombocytopenia.AmJCardiol2018;
467. GhadriJ-R,WittsteinIS,PrasadA,SharkeyS,DoteK,AkashiYJ,etal.International 122:1465–1470.
expertconsensusdocumentonTakotsubosyndrome(partII):diagnosticworkup, 487. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al.
outcome,andmanagement.EurHeartJ2018;39:2047–2062. Prophylacticoptionsinpatientswith5-fluorouracil-associatedcardiotoxicity.BrJ
468. GhadriJ-R,WittsteinIS,PrasadA,SharkeyS,DoteK,AkashiYJ,etal.International Cancer2003;88:1507–1509.
expertconsensusdocumentonTakotsubosyndrome(partI):clinicalcharacteris- 488. AmbrosyAP,KunzPL,FisherGA,WittelesRM.Capecitabine-inducedchestpain
tics,diagnosticcriteria,andpathophysiology.EurHeartJ2018;39:2032–2046. relievedbydiltiazem.AmJCardiol2012;110:1623–1626.
469. LyonAR,BossoneE,SchneiderB,SechtemU,CitroR,UnderwoodSR,etal. 489. AkpekG,HartshornKL.Failureoforalnitrateandcalciumchannelblockertherapy
CurrentstateofknowledgeonTakotsubosyndrome:aPositionStatementfrom to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer
theTaskforceonTakotsuboSyndromeoftheHeartFailureAssociationofthe ChemotherPharmacol1999;43:157–161.
EuropeanSocietyofCardiology.EurJHeartFail2016;18:8–27. 490. ChangHM,OkwuosaTM,ScarabelliT,MoudgilR,YehETH.Cardiovascularcom-
470. DemersM,KrauseDS,SchatzbergD,MartinodK,VoorheesJR,FuchsTA,etal. plicationsofcancertherapy:bestpracticesindiagnosis,prevention,andmanage-
CancerspredisposeneutrophilstoreleaseextracellularDNAtrapsthatcontribute ment:part2.JAmCollCardiol2017;70:2552–2565.
tocancer-associatedthrombosis.ProcNatlAcadSciUSA2012;109:13076–13081. 491. CampiaU,MoslehiJJ,Amiri-KordestaniL,BaracA,BeckmanJA,ChismDD,etal.
471. MrotzekSM,LenaA,HadzibegovicS,LudwigR,Al-RashidF,MahabadiAA,etal. Cardio-oncology:vascularandmetabolicperspectives:ascientificstatementfrom
Assessmentofcoronaryarterydiseaseduringhospitalizationforcancertreatment. theAmericanHeartAssociation.Circulation2019;139:e579–e602.
ClinResCardiol2021;110:200–210. 492. YehETH,BickfordCL.Cardiovascularcomplicationsofcancertherapy:incidence,
472. NyklR,FischerO,VykoupilK,TaborskyM.Auniquereasonforcoronaryspasm pathogenesis,diagnosis,andmanagement.JAmCollCardiol2009;53:2231–2247.
causingtemporarySTelevationmyocardialinfarction(inferiorSTEMI)—systemic 493. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of
inflammatory response syndrome after use of pembrolizumab. Arch Med Sci cancer-relatedtreatment.CircRes2016;118:1008–1020.
AtherosclerDis2017;2:100–102. 494. Novo G, Di Lisi D, Bronte E, MacAione F, Accurso V, Badalamenti G, et al.
473. FerreiraM,PichonE,CarmierD,BouquetE,PageotC,Bejan-AngoulvantT,etal. Cardiovasculartoxicityincancerpatientstreatedwithtyrosinekinaseinhibitors:
Coronarytoxicitiesofanti-PD-1andanti-PD-L1immunotherapies:acasereport areal-worldsingle-centerexperience.Oncology2020;98:445–451.
andreviewoftheliteratureandinternationalregistries.TargetOncol2018;13: 495. BharadwajAS,SwamyPM,MamasMA.Outcomesofpercutaneouscoronaryinter-
509–515. ventionsincancerpatients.ExpertRevCardiovascTher2020;18:25–32.
474. IannacconeM,D’AscenzoF,VadalàP,WiltonSB,NoussanP,ColomboF,etal. 496. KwokCS,WongCW,KontopantelisE,BaracA,BrownSA,VelagapudiP,etal.
Prevalenceandoutcomeofpatientswithcancerandacutecoronarysyndrome Percutaneouscoronaryinterventioninpatientswithcancerandreadmissionswith-
undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur in90daysforacutemyocardialinfarctionandbleedingintheUSA.EurHeartJ2021;
HeartJournalAcuteCardiovascCare2018;7:631–638. 42:1019–1034.
475. BharadwajA,PottsJ,MohamedMO,ParwaniP,SwamyP,Lopez-MatteiJC,etal. 497. vanWerkumJW,HeestermansAA,ZomerAC,KelderJC,SuttorpMJ,RensingBJ,
Acute myocardial infarction treatments and outcomes in 6.5 million patients et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis
withacurrentorhistoricaldiagnosisofcancerintheUSA.EurHeartJ2020;41: Registry.JAmCollCardiol2009;53:1399–1409.
2183–2193. 498. UrbanP,MehranR,ColleranR,AngiolilloDJ,ByrneRA,CapodannoD,etal.
476. VeldersMA,BodenH,HofmaSH,OsantoS,VanDerHoevenBL,Heestermans Defininghighbleedingriskinpatientsundergoingpercutaneouscoronaryinterven-
AACM,etal.OutcomeafterSTelevationmyocardialinfarctioninpatientswith tion.Circulation2019;140:240–261.
cancertreatedwithprimarypercutaneouscoronaryintervention.Am JCardiol 499. StewartMH,JahangirE,PolinNM.Valvularheartdiseaseincancerpatients:eti-
2013;112:1867–1872. ology,diagnosis,andmanagement.CurrTreatOptionsCardiovascMed2017;19:53.
477. UekiY,VögeliB,KaragiannisA,ZanchinT,ZanchinC,RhynerD,etal.Ischemiaand 500. HullMC,MorrisCG,PepineCJ,MendenhallNP.Valvulardysfunctionandcarotid,
bleedingincancerpatientsundergoingpercutaneouscoronaryintervention.JACC subclavian,andcoronaryarterydiseaseinsurvivorsofHodgkinlymphomatreated
CardioOncology2019;1:145–155. withradiationtherapy.JAmMedAssoc2003;290:2831–2837.
478. PottsJE,IliescuCA,LopezMatteiJC,MartinezSC,HolmvangL,LudmanP,etal. 501. SalzT,ZaborEC,deNullyBrownP,DaltonSO,RaghunathanNJ,MatasarMJ,etal.
Percutaneouscoronaryinterventionincancerpatients:areportoftheprevalence Preexistingcardiovascularriskandsubsequentheartfailureamongnon-Hodgkin
andoutcomesintheUnitedStates.EurHeartJ2019;40:1790–1800. lymphomasurvivors.JClinOncol2017;35:3837–3843.
479. GuddatiAK,JoyPS,KumarG.Analysisofoutcomesofpercutaneouscoronary 502. SerranoC,CortésJ,DeMattos-ArrudaL,BelletM,GómezP,SauraC,etal.
interventioninmetastaticcancerpatientswithacutecoronarysyndromeovera Trastuzumab-relatedcardiotoxicityintheelderly:aroleforcardiovascularriskfac-
10-yearperiod.JCancerResClinOncol2016;142:471–479. tors.AnnOncol2012;23:897–902.
480. PothineniNV,ShahNN,RochlaniY,SaadM,KovelamudiS,MarmagkiolisK,etal. 503. SatoA,YoshihisaA,Miyata-TatsumiM,OikawaM,KobayashiA,IshidaT,etal.
Temporaltrendsandoutcomesofacutemyocardialinfarctioninpatientswithcan- Valvularheartdiseaseasapossiblepredictoroftrastuzumab-inducedcardiotoxi-
cer.AnnTranslMed2017;5:482. cityinpatientswithbreastcancer.MolClinOncol2019;10:37–42.
481. YusufSW,DarabanN,AbbasiN,LeiX,DurandJB,DaherIN.Treatmentandout- 504. Watanabe Y, Kozuma K, Hioki H, Kawashima H, Nara Y, Kataoka A, et al.
comesofacutecoronarysyndromeinthecancerpopulation.ClinCardiol2012;35: Comparisonofresultsoftranscatheteraorticvalveimplantationinpatientswith
443–450. versuswithoutactivecancer.AmJCardiol2016;118:572–577.
482. GevaertSA,HalvorsenS,SinnaevePR,SambolaA,GulatiG,LancellottiP,etal. 505. NagataH,KanzakiR,KanouT,OseN,FunakiS,ShintaniY,etal.Twocasesoflob-
Evaluationandmanagementofcancerpatientspresentingwithacutecardiovascu- ectomyforlungcanceraftertranscatheteraorticvalveimplantation.SurgCase
lardisease:aConsensusDocumentoftheAcuteCardioVascularCare(ACVC)as- Reports2018;4:139.
sociation and the ESC council of Cardio-Oncology—Part 1: acute coronary 506. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al.
syndromesandacutepericardialdiseases.EurHeartJAcuteCardiovascCare2021; Transcatheteraorticvalvereplacementinoncologypatientswithsevereaortic
10:947–959. stenosis.JACCCardiovascInterv2019;12:78–86.
483. MohamedMO,VanSpallHGC,KontopantelisE,AlkhouliM,BaracA,ElgendyIY, 507. VahanianA,BeyersdorfF,PrazF,MilojevicM,BaldusS,BauersachsJ,etal.2021
etal.Effectofprimarypercutaneouscoronaryinterventiononin-hospitalout- ESC/EACTSGuidelinesforthemanagementofvalvularheartdisease.EurHeartJ
comesamongactivecancerpatientspresentingwithST-elevationmyocardialin- 2022;43:561–632.
farction:apropensityscorematchinganalysis.EurHeartJAcuteCardiovascCare 508. López-FernándezT,Martín-GarcíaA,RoldánRabadánI,MitroiC,MazónRamosP,
2021;10:829–839. Díez-VillanuevaP,etal.Atrialfibrillationinactivecancerpatients:expertposition
484. IliescuCA,GrinesCL,HerrmannJ,YangEH,CilingirogluM,CharitakisK,etal.SCAI paperandrecommendations.RevEspañolaCardiol(EnglishEd)2019;72:749–759.
Expertconsensusstatement:Evaluation,management,andspecialconsiderations 509. FarmakisD,ParissisJ,FilippatosG.Insightsintoonco-cardiology:atrialfibrillationin
ofcardio-oncologypatientsinthecardiaccatheterizationlaboratory(endorsed cancer.JAmCollCardiol2014;63:945–953.
by the Cardiological Society of India, and Sociedad Latino Americana de 510. YunJP,ChoiEK,DoHanK,ParkSH,JungJH,ParkSH,etal.Riskofatrialfibrillation
CardiologıaIntervencionista).CatheterCardiovascInterv2016;87:E202–E223. according to cancer type: a nationwide population-based study. JACC
485. IliescuCA,CilingirogluM,GizaDE,RosalesO,LebeauJ,Guerrero-MantillaI,etal. CardioOncology2021;3:221–232.
‘Bringingonthelight’inacomplexclinicalscenario:opticalcoherencetomog- 511. GuhaA, Fradley MG,Dent SF, Weintraub NL,Lustberg MB, AlonsoA, et al.
raphy–guideddiscontinuationofantiplatelettherapyincancerpatientswithcoron- Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a
aryarterydisease(PROTECT-OCTregistry).AmHeartJ2017;194:83–91. SEER-Medicareanalysis.EurHeartJ2021;43:300–312.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 127 ---
ESCGuidelines 4355
512.HuYF,LiuCJ,ChangPMH,TsaoHM,LinYJ,ChangSL,etal.Incidentthrombo- 535. ShahS,NorbyFL,DattaYH,LutseyPL,MacLehoseRF,ChenLY,etal.Comparative
embolismandheartfailureassociatedwithnew-onsetatrialfibrillationincancerpa- effectivenessofdirectoralanticoagulantsandwarfarininpatientswithcancerand
tients.IntJCardiol2013;165:355–357. atrialfibrillation.BloodAdv2018;2:200–209.
513.Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. 536. MarianiMV,MagnocavalloM,StraitoM,PiroA,SeverinoP,IannucciG,etal.Direct
Anticoagulation strategies in patients with cancer: JACC review topic of the oralanticoagulantsversusvitaminKantagonistsinpatientswithatrialfibrillation
week.JAmCollCardiol2019;73:1336–1349. andcancerameta-analysis.JThrombThrombolysis2021;51:419–429.
514.MalavasiVL,FantecchiE,GianolioL,PesceF,LongoG,MariettaM,etal.Atrialfib- 537. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al.
rillation in patients with active malignancy and use of anticoagulants: under- Effectivenessandsafetyoforalanticoagulantsamongnonvalvularatrialfibrillation
prescriptionbutnoadverseimpactonall-causemortality.EurJInternMed2019; patientswithactivecancer.JACCCardioOncology2021;3:411–424.
59:27–33. 538. LinYS,KuanFC,ChaoTF,WuM,ChenSW,ChenMC,etal.Mortalityassociated
515.Al-KindiSG,OliveiraGH.Prevalenceofpreexistingcardiovasculardiseaseinpa- withtheuseofnon-vitaminKantagonistoralanticoagulantsincancerpatients:da-
tientswithdifferenttypesofcancertheunmetneedforonco-cardiology.Mayo
bigatranversusrivaroxaban.CancerMed2021;10:7079–7088.
ClinProc2016;91:81–83. 539. IsogaiT,SaadAM,AbushoukAI,ShekharS,KurodaS,GadMM,etal.Procedural
516.Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. andshort-termoutcomesofpercutaneousleftatrialappendageclosureinpatients
Anticancerdrug-inducedcardiacrhythmdisorders:currentknowledgeandbasic
withcancer.AmJCardiol2021;141:154–157.
underlyingmechanisms.PharmacolTher2018;189:89–103. 540. BorianiG,FauchierL,AguinagaL,BeattieJM,BlomstromLundqvistC,CohenA,
517.BorianiG,CorradiniP,CuneoA,FalangaA,FoàR,GaidanoG,etal.Practicalman- etal.EuropeanHeartRhythmAssociation(EHRA)consensusdocumentonman-
agementofibrutinibinthereallife:focusonatrialfibrillationandbleeding.Hematol agementofarrhythmiasandcardiacelectronicdevicesinthecriticallyillandpost-
Oncol2018;36:624–632. surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart
518.Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al. Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa
ManagementofcardiovascularcomplicationsofBrutontyrosinekinaseinhibitors. (CASSA),andLatinAmericanHeartRhythmSociety(LAHRS).Europace2019;
BrJHaematol2022;196:70–78. 21:7–8.
519.Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al. 541. ButtJH,OlesenJB,Havers-BorgersenE,GundlundA,AnderssonC,GislasonGH,
Thromboembolism,mortality,andbleedingin2,435,541atrialfibrillationpatients etal.Riskofthromboembolismassociatedwithatrialfibrillationfollowingnoncar-
withandwithoutcancer:anationwidecohortstudy.Cancer2021;127:2122–2129. diacsurgery.JAmCollCardiol2018;72:2027–2036.
520.Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC, 542. EnriquezA,BiagiJ,RedfearnD,BolesU,KamelD,AliFS,etal.Increasedincidence
of ventricular arrhythmias in patients with advanced cancer and implantable
Heidbuchel H, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of
cardioverter-defibrillators.JACCClinElectrophysiol2017;3:50–56.
Burden;Substrate):anovelapproachtoin-depthcharacterization(ratherthanclas-
sification)ofatrialfibrillation.ThrombHaemost2021;121:270–278. 543. RodenDM.Predictingdrug-inducedQTprolongationandtorsadesdepointes.J
Physiol2016;594:2459–2468.
521.BorianiG,BoniniN,AlbiniA,VenturelliA,ImbertiJF,VitoloM.Cardioversionof
recent-onsetatrialfibrillation:currentevidence,practicalconsiderations,andcon- 544. Al-KhatibSM,StevensonWG,AckermanMJ,BryantWJ,CallansDJ,CurtisAB,etal.
troversiesinacomplexclinicalscenario.KardiolPol2020;78:1088–1098. 2017AHA/ACC/HRSguidelineformanagementofpatientswithventricularar-
rhythmiasandthepreventionofsuddencardiacdeath:Executivesummary:are-
522.KanmanthareddyA,VallakatiA,ReddyYeruvaM,DixitS,DiBiaseL,MansourM,
etal.Pulmonaryveinisolationforatrialfibrillationinthepostpneumonectomy portoftheAmericanCollegeofCardiology/AmericanHeartAssociationTask
Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart
population: a feasibility, safety, and outcomes study. J Cardiovasc Electrophysiol
2015;26:385–389.
Rhythm2018;15:e190–e252.
545. SchwartzPJ,MossAJ,VincentGM,CramptonRS.Diagnosticcriteriaforthelong
523.Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargo R, Freedman B, et al.
Antithrombotictherapyforatrialfibrillation:CHESTguidelineandexpertpanelre-
QTsyndrome.Anupdate.Circulation1993;88:782–784.
546. Tisdale JE, Chung MK, CampbellKB, Hammadah M, Joglar JA, LeclercJ, et al.
port.Chest2018;154:1121–1201.
Drug-induced arrhythmias: a scientific statement from the American Heart
524.ProiettiM,LaneDA,BorianiG,LipGYH.Strokeprevention,evaluationofbleeding Association.Circulation2020;142:E214–E233.
risk,andanticoagulanttreatmentmanagementinatrialfibrillationcontemporary
547. AZCERT.CredibleMeds.orgn.d.
internationalguidelines.CanJCardiol2019;35:619–633.
548. CoppolaC,RienzoA,PiscopoG,BarbieriA,ArraC,MaureaN.Managementof
525.Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al.
QTprolongationinducedby anti-cancerdrugs: targettherapy andoldagents.
Anticoagulationinpatientswithatrialfibrillationandactivecancer:aninternational
Differentalgorithmsfordifferentdrugs.CancerTreatRev2018;63:135–143.
surveyonpatientmanagement.EurJPrevCardiol2021;28:611–621.
549. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical
526.D’SouzaM,CarlsonN,FosbølE,LambertsM,SmedegaardL,NielsenD,etal.
evaluationofQT/QTcintervalprolongationandproarrhythmicpotential—ques-
CHA2DS2-VASCscoreandriskofthromboembolismandbleedinginpatients
tions&answers.SciMedHeal2020:EMA/CHMP/ICH/415588/2020.
withatrialfibrillationandrecentcancer.EurJPrevCardiol2018;25:651–658.
550. Atallah-YunesSA,KadadoAJ,KaufmanGP,Hernandez-MontfortJ.Immunecheck-
527.FarmakisD.Anticoagulationforatrialfibrillationinactivecancer:whatthecardiol-
pointinhibitortherapyandmyocarditis:asystematicreviewofreportedcases.J
ogiststhink.EurJPrevCardiol2021;28:608–610.
CancerResClinOncol2019;145:1527–1557.
528.CohenA,DonalE,DelgadoV,PepiM,TsangT,GerberB,etal.EACVIrecommen- 551. CirneF,ZhouS,KappelC,El-KadiA,BarronCC,EllisPM,etal.ALKinhibitor-
dationsoncardiovascularimagingforthedetectionofembolicsources:endorsed inducedbradycardia:asystematicreviewandmeta-analysis.LungCancer2021;
bytheCanadianSocietyofEchocardiography.EurHeartJCardiovascImaging2021; 161:9–17.
22:E24–E57.
552. HassenLJ,LenihanDJ,BaligaRR.Hypertensioninthecardio-oncologyclinic.Heart
529.SchulmanS,AngerSU,BergqvistD,ErikssonB,LassenMR,FisherW.Definitionof FailClin2019;15:487–495.
majorbleedinginclinicalinvestigationsofantihemostaticmedicinalproductsinsur- 553. SzmitS,JurczakW,ZauchaJM,Drozd-SokołowskaJ,SpychałowiczW,JoksM,etal.
gicalpatients.JThrombHaemost2010;8:202–204. Pre-existingarterialhypertensionasariskfactorforearlyleftventricularsystolic
530.SteffelJ,CollinsR,AntzM,CornuP,DestegheL,HaeuslerKG,etal.2021European dysfunctionfollowing(R)-CHOPchemotherapyinpatientswithlymphoma.JAm
HeartRhythmAssociationpracticalguideontheuseofnon-vitaminKantagonist SocHypertens2014;8:791–799.
oralanticoagulantsinpatientswithatrialfibrillation.Europace2021;23:1612–1676.
554. Di Lorenzo G, Autorino R, Bruni G, Cartentì G, Ricevuto E, Tudini M, et al.
531.ChenST,HellkampAS,BeckerRC,BerkowitzSD,BreithardtG,FoxKAA,etal. Cardiovasculartoxicityfollowingsunitinibtherapyinmetastaticrenalcellcarcin-
Efficacyandsafetyofrivaroxabanvs.warfarininpatientswithnon-valvularatrialfib- oma:amulticenteranalysis.AnnOncol2009;20:1535–1542.
rillationandahistoryofcancer:ObservationsfromROCKETAF.EurHeartJQual 555. PenttiläP,RautiolaJ,PoussaT,PeltolaK,BonoP.Angiotensininhibitorsastreat-
CareClinOutcomes2019;5:145–152. mentofsunitinib/pazopanib-inducedhypertensioninmetastaticrenalcellcarcin-
532.MelloniC,DunningA,GrangerCB,ThomasL,KhouriMG,GarciaDA,etal.Efficacy oma.ClinGenitourinCancer2017;15:384–390.e3.
andsafetyofapixabanversuswarfarininpatientswithatrialfibrillationandahistory 556. IzzedineH,DerosaL,LeTeuffG,AlbigesL,EscudierB.Hypertensionandangioten-
ofcancer:insightsfromtheARISTOTLEtrial.AmJMed2017;130:1440–1448.e1. sinsysteminhibitors:impactonoutcomeinsunitinib-treatedpatientsformetastat-
533.FanolaCL,RuffCT,MurphySA,JinJ,DuggalA,BabiloniaNA,etal.Efficacyand icrenalcellcarcinoma.AnnOncol2015;26:1128–1133.
safetyofedoxabaninpatientswithactivemalignancyandatrialfibrillation:analysis 557. McKayRR,RodriguezGE,LinX,KaymakcalanMD,HamnvikOPR,SabbisettiVS,
oftheengageAF-TIMI48trial.JAmHeartAssoc2018;7:e008987. etal.Angiotensinsysteminhibitorsandsurvivaloutcomesinpatientswithmeta-
534.SawantAC,KumarA,McCrayW,TetewskyS,ParoneL,SridharaS,etal.Superior staticrenalcellcarcinoma.ClinCancerRes2015;21:2471–2479.
safetyofdirectoralanticoagulantscomparedtowarfarininpatientswithatrialfib- 558. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH.
rillationandunderlyingcancer:anationalVeteransAffairsdatabasestudy.JGeriatr Thromboembolismisaleadingcauseofdeathincancerpatientsreceivingout-
Cardiol2019;16:706–709. patientchemotherapy.JThrombHaemost2007;5:632–634.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 128 ---
4356 ESCGuidelines
559. PuurunenMK,GonaPN,LarsonMG,MurabitoJM,MagnaniJW,O’DonnellCJ. 582. AyC,Beyer-WestendorfJ,PabingerI.Treatmentofcancer-associatedvenous
Epidemiology of venous thromboembolism in the Framingham Heart Study. thromboembolismintheageofdirectoralanticoagulants.AnnOncol2019;30:
ThrombRes2016;145:27–33. 897–907.
560. WalkerAJ,CardTR,WestJ,CrooksC,GraingeMJ.Incidenceofvenousthrombo- 583. AgenoW,VedovatiMC,CohenA,HuismanM,BauersachsR,GussoniG,etal.
embolisminpatientswithcancer—acohortstudyusinglinkedUnitedKingdomda- Bleedingwithapixabananddalteparininpatientswithcancer-associatedvenous
tabases.EurJCancer2013;49:1404–1413. thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;
561. LymanGH.Venousthromboembolisminthepatientwithcancer:focusonburden 121:616–624.
ofdiseaseandbenefitsofthromboprophylaxis.Cancer2011;117:1334–1349. 584. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al.
562. AbdullaA,DavisWM,RatnaweeraN,SzeferE,BallantyneScottB,LeeAYY.A Effectivenessandsafetyofapixaban,low-molecular-weightheparin,andwarfarin
meta-analysisofcasefatalityratesofrecurrentvenousthromboembolismandma- amongvenousthromboembolismpatientswithactivecancer:aUSclaimsdataana-
jorbleedinginpatientswithcancer.ThrombHaemost2020;120:702–713. lysis.ThrombHaemost2021;121:383–395.
563. MulderFI,CarrierM,vanDoormaalF,RobinP,OttenHM,SalaunPY,etal.Risk 585. GiustozziM,AgnelliG,DelToro-CerveraJ,KlokFA,RosovskyRP,MartinAC,etal.
scoresforoccultcancerinpatientswithunprovokedvenousthromboembolism: Directoralanticoagulantsforthetreatmentofacutevenousthromboembolismas-
resultsfromanindividualpatientdatameta-analysis.JThrombHaemost2020;18: sociatedwithcancer:asystematicreviewandmeta-analysis.ThrombHaemost2020;
2622–2628. 120:1128–1136.
564. KhoranaAA,ConnollyGC.Assessingriskofvenousthromboembolisminthepa- 586. SabatinoJ,DeRosaS,PolimeniA,SorrentinoS,IndolfiC.Directoralanticoagulants
tientwithcancer.JClinOncol2009;27:4839–4847.
in patients with active cancer: a systematic review and meta-analysis. JACC
565. LiX,HuY,LinP,ZhangJ,TangY,YiQ,etal.Comparisonofdifferentclinicalprog- CardioOncology2020;2:428–440.
nostic scores in patientswith pulmonary embolism andactive cancer. Thromb 587. KraaijpoelN,CarrierM.HowItreatcancer-associatedvenousthromboembolism.
Haemost2021;121:834–844. Blood2019;133:291–298.
566. KonstantinidesSV,MeyerG,BuenoH,GaliéN,GibbsJSR,AgenoW,etal.2019 588. DenExterPL,HooijerJ,DekkersOM,HuismanMV.Riskofrecurrentvenous
ESCGuidelinesforthediagnosisandmanagementofacutepulmonaryembolism thromboembolismandmortalityinpatientswithcancerincidentallydiagnosed
developed in collaboration with the European Respiratory Society (ERS). Eur
withpulmonaryembolism:acomparisonwithsymptomaticpatients.JClinOncol HeartJ2020;41:543–603.
2011;29:2405–2409.
567. MazzolaiL,AgenoW,AlatriA,BauersachsR,BecattiniC,BrodmannM,etal.Second
589. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M,
consensusdocumentondiagnosisandmanagementofacutedeepveinthrombosis:
Blasco-EsquiviasI,Marin-BarreraL,etal.Tinzaparinincancerassociatedthrom-
updateddocumentelaboratedbytheESCWorkingGrouponaortaandperipheral bosisbeyond6months:TiCATstudy.ThrombRes2017;157:90–96.
vasculardiseasesandtheESCWorkingGrouponpulmonarycirculationandright
590. FrancisCW,KesslerCM,GoldhaberSZ,KovacsMJ,MonrealM,HuismanMV,etal.
ventricularfunction.EurJPrevCardiol2022;29:1248–1263
Treatmentofvenousthromboembolismincancerpatientswithdalteparinforup
568. NaviBB,ReinerAS,KamelH,IadecolaC,OkinPM,ElkindMSV,etal.Riskofarterial to12months:theDALTECANStudy.JThrombHaemost2015;13:1028–1035.
thromboembolisminpatientswithcancer.JAmCollCardiol2017;70:926–938.
591. OttoCM,NishimuraRA,BonowRO,CarabelloBA,ErwinJP,GentileF,etal.2020
569. MukaiM,OkaT.Mechanismandmanagementofcancer-associatedthrombosis.J
ACC/AHAguidelineforthemanagementofpatientswithvalvularheartdisease:a
Cardiol2018;72:89–93.
reportoftheAmericanCollegeofCardiology/AmericanHeartAssociationJoint
570. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. CommitteeonClinicalPracticeGuidelines.JAmCollCardiol2021;77:e25–e197.
Screeningadultsurvivorsofchildhoodcancerforcardiomyopathy:comparison
592. RiondinoS,FerroniP,DelMonteG,FormicaV,GuadagniF,RoselliM.Venous
ofechocardiographyandcardiacmagneticresonanceimaging.JClinOncol2012;
30:2876–2884. thromboembolismincancerpatientsonsimultaneousandpalliativecare.Cancers
(Basel)2020;12:1167.
571. HooksM,OkashaO,VelangiPS,NijjarPS,Farzaneh-FarA,ShenoyC.Leftventricu-
593. XinZ,LiuF,DuY,MaoF,WangX,XuP,etal.Primaryprophylaxisforvenous
larthrombusoncardiovascularmagneticresonanceimaginginnon-ischaemiccar-
thromboembolisminambulatorycancerpatients:asystematicreviewandnetwork
diomyopathy. Eur Heart J Cardiovasc Imaging 2020. doi:10.1093/ehjci/jeaa244.
meta-analysis.AnnCardiothoracSurg2020;9:2970–2981.
Onlineaheadofprint7October2020.
594. FargeD,FrereC,ConnorsJM,AyC,KhoranaAA,MunozA,etal.2019internation-
572. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.
alclinicalpracticeguidelinesforthetreatmentandprophylaxisofvenousthrombo-
Low-molecular-weightheparinversusacoumarinforthepreventionofrecurrent
venousthromboembolisminpatientswithcancer.NEnglJMed2003;349:146–153.
embolisminpatientswithcancer.LancetOncol2019;20:e566–e581.
595. BergqvistD,AgnelliG,CohenAT,EldorA,NilssonPE,LeMoigne-AmraniA,etal.
573. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term
Durationofprophylaxisagainstvenousthromboembolismwithenoxaparinafter
low-molecular-weightheparinversususualcareinproximal-veinthrombosispa-
tientswithcancer.AmJMed2006;119:1062–1072.
surgeryforcancer.NEnglJMed2002;346:975–980.
596. KhoranaA,KudererNM,CulakovaE,LymanGH,FrancisCW.Developmentand
574. DeitcherSR,KesslerCM,MerliG,RigasJR,LyonsRM,FareedJ.Secondarypreven-
validationofapredictivemodelforchemotherapy-associatedthrombosis.Blood
tionofvenousthromboemboliceventsinpatientswithactivecancer:enoxaparin
aloneversusinitialenoxaparinfollowedbywarfarinfora180-dayperiod.ClinAppl
2008;111:4902–4907.
Thromb2006;12:389–396. 597. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El
575. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. ShemmariS,etal.Apredictivescoreforthrombosisassociatedwithbreast,colo-
Comparisonoflow-molecular-weightheparinandwarfarinforthesecondarypre- rectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated
ventionofvenousthromboembolisminpatientswithcancer:arandomizedcon-
thrombosisstudy.Oncologist2017;22:1222–1231.
trolledstudy.ArchInternMed2002;162:1729–1735. 598. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.
576. LeeAYY,KamphuisenPW,MeyerG,BauersachsR,JanasMS,JarnerMF,etal. Nadroparinforthepreventionofthromboemboliceventsinambulatorypatients
Tinzaparinvswarfarinfortreatmentofacutevenousthromboembolisminpatients withmetastaticorlocallyadvancedsolidcancerreceivingchemotherapy:arando-
withactivecancer:arandomizedclinicaltrial.JAMAJAmMedAssoc2015;314: mised,placebo-controlled,double-blindstudy.LancetOncol2009;10:943–949.
677–686. 599. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.
577. LeeYJ,ParkJK,UhmJS,KimJY,PakHN,LeeMH,etal.Bleedingriskandmajorad- Semuloparinforthromboprophylaxisinpatientsreceivingchemotherapyforcan-
verseeventsinpatientswithcanceronoralanticoagulationtherapy.IntJCardiol
cer.NEnglJMed2012;366:601–609.
2016;203:372–378. 600. DiNisioM,PorrecaE,CandeloroM,DeTursiM,RussiI,RutjesAWSS.Primary
578. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. prophylaxisforvenousthromboembolisminambulatorycancerpatientsreceiving
Edoxabanforthetreatmentofcancer-associatedvenousthromboembolism.N chemotherapy.CochraneDatabaseSystRev2016;12:CD008500.
EnglJMed2018;378:615–624. 601. CarrierM,Abou-NassarK,MallickR,TagalakisV,ShivakumarS,SchattnerA,etal.
579. YoungAM,MarshallA,ThirlwallJ,ChapmanO,LokareA,HillC,etal.Comparison Apixabantopreventvenousthromboembolisminpatientswithcancer.NEnglJ
ofanoralfactorXainhibitorwithlowmolecularweightheparininpatientswith Med2019;380:711–719.
cancer with venous thromboembolism: results of a randomized trial 602. KhoranaAA,SoffGA,KakkarAK,Vadhan-RajS,RiessH,WunT,etal.Rivaroxaban
(SELECT-D).JClinOncol2018;36:2017–2023. forthromboprophylaxisinhigh-riskambulatorypatientswithcancer.NEnglJMed
580. McBaneIIRD,WysokinskiWE,Le-RademacherJG,ZemlaT,AshraniA,TafurA, 2019;380:720–728.
etal.Apixabananddalteparininactivemalignancy-associatedvenousthrombo- 603. AngeliniDE,RadivoyevitchT,McCraeKR,KhoranaAA.Bleedingincidenceandrisk
embolism:theADAMVTEtrial.JThrombHaemost2020;18:411–421. factorsamongcancerpatientstreatedwithanticoagulation.AmJHematol2019;94:
581. Agnelli G, BecattiniC, MeyerG, Muñoz A, HuismanM V, ConnorsJM, et al. 780–785.
Apixabanforthetreatmentofvenousthromboembolismassociatedwithcancer. 604. MenapaceLA,McCraeKR,KhoranaAA.Predictorsofrecurrentvenousthrombo-
NEnglJMed2020;382:1599–1607. embolismandbleedingonanticoagulation.ThrombRes2016;140:S93–S98.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 129 ---
ESCGuidelines 4357
605.RouleV,VerdierL,BlanchartK,ArdouinP,LemaitreA,BignonM,etal.Systematic 629. PalaskasN,MorganJ,DaigleT,BanchsJ,DurandJB,HongD,etal.Targetedcancer
reviewandmeta-analysisoftheprognosticimpactofcanceramongpatientswith therapieswithpericardialeffusionsrequiringpericardiocentesisfocusingonim-
acute coronary syndrome and/or percutaneous coronary intervention. BMC munecheckpointinhibitors.AmJCardiol2019;123:1351–1357.
CardiovascDisord2020;20:38. 630. ShaheenS, MirshahidiH,Nagaraj G,Hsueh CT.Conservativemanagementof
606.FreedbergDE,KimLS,YangYX.Therisksandbenefitsoflong-termuseofproton nivolumab-induced pericardial effusion: a case report and review of literature.
pump inhibitors: expert review and best practice advice from the American ExpHematolOncol2018;7:11.
GastroenterologicalAssociation.Gastroenterology2017;152:706–715. 631. DixonSB,HowellCR,LuL,PlanaJC,JoshiVM,LuepkerRV,etal.Cardiacbiomar-
607.ValgimigliM,BuenoH,ByrneRA,ColletJP,CostaF,JeppssonA,etal.2017ESC kersandassociationwithsubsequentcardiomyopathyandmortalityamongadult
focusedupdateondualantiplatelettherapyincoronaryarterydiseasedeveloped survivors of childhood cancer: a report from the St. Jude Lifetime Cohort.
incollaborationwithEACTS.EurHeartJ2018;39:213–260. Cancer2021;127:458–466.
608.BaranDA,GrinesCL,BaileyS,BurkhoffD,HallSA,HenryTD,etal.SCAIclinical 632. HershmanDL,TillC,ShenS,WrightJD,RamseySD,BarlowWE,etal.Association
expertconsensusstatementontheclassificationofcardiogenicshock:Thisdocu-
ofcardiovascularriskfactorswithcardiaceventsandsurvivaloutcomesamongpa-
mentwasendorsedbytheAmericanCollegeofCardiology(ACC),theAmerican
tientswithbreastcancerenrolledinSWOGclinicaltrials.JClinOncol2018;36:
HeartAssociation(AHA),theSocietyofCriticalCareMedicine(SCCM),andthe 2710–2717.
Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv
633. NolanMT,MarwickTH,PlanaJC,LiZ,NessKK,JoshiVM,etal.Effectoftraditional
2019;94:29–37.
heartfailureriskfactorsonmyocardialdysfunctioninadultsurvivorsofchildhood
609.SchifferCA,BohlkeK,AndersonKC.Platelettransfusionforpatientswithcancer: cancer.JACCCardiovascImaging2018;11:1202–1203.
American Society of Clinical Oncology Clinical Practice Guideline Update
634. ChoH,LeeS,SimSH,ParkIH,LeeKS,KwakMH,etal.Cumulativeincidenceof
Summary.JOncolPract2018;14:129–133.
chemotherapy-inducedcardiotoxicityduringa2-yearfollow-upperiodinbreast
610.Al-SamkariH,ConnorsJM.Managingthecompetingrisksofthrombosis,bleeding,
andanticoagulationinpatientswithmalignancy.BloodAdv2019;3:3770–3779.
cancerpatients.BreastCancerResTreat2020;182:333–343.
635. SmarzK,Jaxa-ChamiecT,ChwyczkoT,GłówczyńskaR,JegierA,NiedoszytkoP,
611.Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer
etal.Cardiopulmonaryexercisetestinginadultcardiology:expertopinionofthe
therapy-relatedincreasesinarterialstiffness:asystematicreviewandmeta-analysis.
WorkingGroupofCardiacRehabilitationandExercisePhysiologyofthePolish
JAmHeartAssoc2020;9:e015598.
612.GambichlerT,StrutzmannS,TannapfelA,SusokL.Paraneoplasticacralvascular
CardiacSociety.KardiolPol2019;77:730–756.
syndromeinapatientwithmetastaticmelanomaunderimmunecheckpointblock- 636. ScottJM,ZaborEC,SchwitzerE,KoelwynGJ,AdamsSC,NilsenTS,etal.Efficacyof
ade.BMCCancer2017;17:327.
exercisetherapyoncardiorespiratoryfitnessinpatientswithcancer:asystematic
613.Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M,
reviewandmeta-analysis.JClinOncol2018;36:2297–2304.
Mitterbauer-HohendannerG,SillaberC,etal.Progressiveperipheralarterialocclu- 637. SassoJP,EvesND,ChristensenJF,KoelwynGJ,ScottJ,JonesLW.Aframeworkfor
sivediseaseandothervasculareventsduringnilotinibtherapyinCML.AmJHematol prescriptioninexercise-oncologyresearch.JCachexiaSarcopeniaMuscle2015;6:
2011;86:533–539. 115–124.
614.DorerDJ,KnickerbockerRK,BaccaraniM,CortesJE,HochhausA,TalpazM,etal. 638. WallenMP,HennessyD,BrownS,EvansL,RawstornJC,WongSheeA,etal.
Impactofdoseintensityofponatinibonselectedadverseevents:multivariateana- High-intensityintervaltrainingimprovescardiorespiratoryfitnessincancerpatients
lysesfromapooledpopulationofclinicaltrialpatients.LeukRes2016;48:84–91. andsurvivors:ameta-analysis.EurJCancerCare(Engl)2020;29:e13267.
615.ValentP,HadzijusufovicE,SchernthanerGH,WolfD,ReaD,LeCoutreP.Vascular 639. LeeK,TripathyD,Demark-WahnefriedW,CourneyaKS,SamiN,BernsteinL,
safetyissuesinCMLpatientstreatedwithBCR/ABL1kinaseinhibitors.Blood2015; etal.Effectofaerobicandresistanceexerciseinterventiononcardiovasculardis-
125:901–906. ease risk in women with early-stage breast cancer: a randomized clinical trial.
616.MontaniD,BergotE,GüntherS,SavaleL,BergeronA,BourdinA,etal.Pulmonary JAMAOncol2019;5:710–714.
arterial hypertension in patients treated by dasatinib. Circulation 2012;125: 640. AdamsSC,DeloreyDS,DavenportMH,FaireyAS,NorthS,CourneyaKS.Effects
2128–2137. ofhigh-intensityintervaltrainingonfatigueandqualityoflifeintesticularcancer
617.RanchouxB,GüntherS,QuarckR,ChaumaisMC,DorfmüllerP,AntignyF,etal. survivors.BrJCancer2018;118:1313–1321.
Chemotherapy-inducedpulmonaryhypertension:roleofalkylatingagents.AmJ 641. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al.
Pathol2015;185:356–371. High-intensityexerciseduringchemotherapyinducesbeneficialeffects12months
618.JevnikarM,MontaniD,SavaleL,SeferianA,JutantEM,BouclyA,etal.Chronic intobreastcancersurvivorship.JCancerSurviv2019;13:244–256.
thromboembolicpulmonaryhypertensionandtotallyimplantablecentralvenous 642. Marriott CFS, Petrella AFM, Marriott ECS, Boa Sorte Silva NC, Petrella RJ.
accesssystems.EurRespirJ2021;57:2002208. High-intensityintervaltraininginolderadults:ascopingreview.SportMed-Open
619.PriceLC,SecklMJ,DorfmüllerP,WortSJ.Tumoralpulmonaryhypertension.Eur 2021;7:49.
RespirRev2019;28:180065. 643. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al.
620.HumbertM,KovacsG,HoeperMM,BadagliaccaR,BergerRMF,BridaM,etal.2022 Cardiovascularhealthofpatientswithcancerandcancersurvivors:aroadmap
ESC/ERSGuidelinesforthediagnosisandtreatmentofpulmonaryhypertension. tothenextlevel.JAmCollCardiol2015;65:2739–2746.
EurHeartJ2022;43:3618–3731.
644. ChuTF,RupnickMA,KerkelaR,DallabridaSM,ZurakowskiD,NguyenL,etal.
621.KantarjianH,ShahNP,HochhausA,CortesJ,ShahS,AyalaM,etal.Dasatinibver-
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;
susimatinibinnewlydiagnosedchronic-phasechronicmyeloidleukemia.NEnglJ 370:2011–2019.
Med2010;362:2260–2270.
645. KhakooAY,KassiotisCM,TannirN,PlanaJC,HalushkaM,BickfordC,etal.Heart
622.ImazioM,ColopiM,DeFerrariGM.Pericardialdiseasesinpatientswithcancer:
failureassociatedwithsunitinibmalate:amultitargetedreceptortyrosinekinasein-
Contemporaryprevalence,managementandoutcomes.Heart2020;106:569–574.
623.KimSR,KimEK,ChoJ,ChangSA,ParkSJ,LeeSC,etal.Effectofanti-inflammatory
hibitor.Cancer2008;112:2500–2508.
646. KimPY,Irizarry-CaroJA,RameshT,IliescuC,Lopez-MatteiJC.Howtodiagnose drugsonclinicaloutcomesinpatientswithmalignantpericardialeffusion.JAmColl
Cardiol2020;76:1551–1561. and manage QT prolongation in cancer patients. JACC CardioOncology 2021;3:
145–149.
624.GongJ,DrobniZD,ZafarA,QuinagliaT,HartmannS,GilmanHK,etal.Pericardial
647. GattaG,BottaL,RossiS,AareleidT,Bielska-LasotaM,ClavelJ,etal.Childhood
diseaseinpatientstreatedwithimmunecheckpointinhibitors.JImmunotherCancer
cancersurvivalinEurope1999–2007:resultsofEUROCARE-5—apopulation-
2021;9:e002771.
625.InnoA,MaureaN,MetroG,CarboneA,RussoA,GoriS.Immunecheckpoint
basedstudy.LancetOncol2014;15:35–47.
inhibitors-associated pericardial disease: a systematic review of case reports. 648. GeenenMM,Cardous-UbbinkMC,KremerLCM,VanDenBosC,VanDerPal
CancerImmunolImmunother2021;70:3041–3053. HJH,HeinenRC,etal.Medicalassessmentofadversehealthoutcomesinlong-term
626.Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D,
survivorsofchildhoodcancer.JAmMedAssoc2007;297:2705–2715.
Palacios-RubioJ,etal.Causeandlong-termoutcomeofcardiactamponade.AmJ 649. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al.
Cardiol2016;117:664–669. Cardiovasculardiseaseinsurvivorsofchildhoodcancer:insightsintoepidemiology,
627.SaabJ,HodaRS,NarulaN,HodaSA,GeraghtyBE,NasarA,etal.Diagnosticyieldof pathophysiology,andprevention.JClinOncol2018;36:2135–2144.
cytopathologyinevaluatingpericardialeffusions:clinicopathologicanalysisof419 650. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al.
specimens.CancerCytopathol2017;125:128–137. Population-basedlong-termcardiac-specificmortalityamong34489five-yearsur-
628.PatelN,RafiqueAM,EshaghianS,MendozaF,BinerS,CercekB,etal.Retrospective vivorsofchildhoodcancerinGreatBritain.Circulation2017;135:951–963.
comparisonofoutcomes,diagnosticvalue,andcomplicationsofpercutaneouspro- 651. KremerLCM,vanDalenEC,OffringaM,VoûtePA.Frequencyandriskfactorsof
longeddrainageversussurgicalpericardiotomyofpericardialeffusionassociated anthracycline-inducedclinicalheartfailureinchildren:asystematicreview.Ann
withmalignancy.AmJCardiol2013;112:1235–1239. Oncol2002;13:503–512.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 130 ---
4358 ESCGuidelines
652. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al. 675. SOLVDInvestigators,YusufS,PittB,DavisCE,HoodWBJr,CohnJN.Effectof
Therapy-relatedcardiacriskinchildhoodcancersurvivors:ananalysisofthechild- enalaprilonmortalityandthedevelopmentofheartfailureinasymptomaticpa-
hoodcancersurvivorstudy.JClinOncol2019;37:1090–1101. tientswithreducedleftventricularejectionfractions.NEnglJMed1992;327:
653. vanDalenEC,MulderRL,SuhE,EhrhardtMJ,AuneGJ,BardiE,etal.Coronaryar- 685–691.
terydiseasesurveillanceamongchildhood,adolescentandyoungadultcancersur- 676. PfefferMA,BraunwaldE,MoyéLA,BastaL,BrownEJ,CuddyTE,etal.Effectof
vivors: a systematic review and recommendations from the International Late captoprilonmortalityandmorbidityinpatientswithleftventriculardysfunction
EffectsofChildhoodCancerGuidelineHarmonizationGroup.EurJCancer2021; aftermyocardialinfarction.NEnglJMed1992;327:669–677.
156:127–137. 677. DargieHJ.Effectofcarvedilolonoutcomeaftermyocardialinfarctioninpatients
654. LeerinkJM,vanderPalHJH,KremerLCM,FeijenEAM,MeregalliPG,PourierMS, with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet
etal.Refiningthe10-yearpredictionofleftventricularsystolicdysfunctioninlong- 2001;357:1385–1390.
termsurvivorsofchildhoodcancer.JACCCardioOncology2021;3:62–72. 678. Abdel-QadirH,TaiF,CroxfordR,AustinPC,AmirE,Calvillo-ArgüellesO,etal.
655. ArmstrongGT,OeffingerKC,ChenY,KawashimaT,YasuiY,LeisenringW,etal. Characteristicsandoutcomesofwomendevelopingheartfailureafterearlystage
Modifiableriskfactorsandmajorcardiaceventsamongadultsurvivorsofchildhood breastcancerchemotherapy:apopulation-basedmatchedcohortstudy.CircHeart
cancer.JClinOncol2013;31:3673–3680. Fail2021;14:e008110.
656. ArmenianSH,SunCL,VaseT,NessKK,BlumE,FranciscoL,etal.Cardiovascular 679. CuriglianoG,CardinaleD,SuterT,PlataniotisG,DeAzambujaE,SandriMT,etal.
riskfactorsinhematopoieticcelltransplantationsurvivors:roleindevelopmentof Cardiovasculartoxicityinducedbychemotherapy,targetedagentsandradiother-
subsequentcardiovasculardisease.Blood2012;120:4505–4512. apy:ESMOclinicalpracticeguidelines.AnnOncol2012;23:vii155–66.
657. CarpenterK,ScavottoM,McGovernA,MaC,KenneyLB,MackJW,etal.Earlypar- 680. AdamsMJ,HardenberghPH,ConstineLS,LipshultzSE.Radiation-associatedcar-
entalknowledgeoflateeffectrisksinchildrenwithcancer.PediatrBloodCancer
diovasculardisease.CritRevOncolHematol2003;45:55–75.
2022;69:e29473. 681. TaylorC,DuaneFK,DodwellD,GrayR,WangZ,WangY,etal.Estimatingthe
658. HerrmannJ.Fromtrendstotransformation:wherecardio-oncologyistomakea risksofbreastcancerradiotherapy:evidencefrommodernradiationdosesto
difference.EurHeartJ2019;40:3898–3900. thelungsandheartandfrompreviousrandomizedtrials.JClinOncol2017;35:
659. SturgeonKM,DengL,BluethmannSM,ZhouS,TrifilettiDM,JiangC,etal.A 1641–1649. population-basedstudyofcardiovasculardiseasemortalityriskinUScancerpa- 682. ReedGW,MasriA,GriffinBP,KapadiaSR,EllisSG,DesaiMY.Long-termmortality
tients.EurHeartJ2019;40:3889–3897. inpatientswithradiation-associatedcoronaryarterydiseasetreatedwithpercu-
660. StoltzfusKC,ZhangY,SturgeonK,SinowayLI,TrifilettiDM,ChinchilliVM,etal. taneouscoronaryintervention.CircCardiovascInterv2016;9:e003483.
683. LiangJJ,SioTT,SlusserJP,LennonRJ,MillerRC,SandhuG,etal.Outcomesafter
Fatalheartdiseaseamongcancerpatients.NatCommun2020;11:2011.
661. BankeA,FosbølEL,MøllerJE,GislasonGH,AndersenM,BernsdorfM,etal. percutaneouscoronaryinterventionwithstentsinpatientstreatedwiththoracic
externalbeamradiationforcancer.JACCCardiovascInterv2014;7:1412–1420.
Long-termeffectofepirubicinonincidenceofheartfailureinwomenwithbreast
cancer:insightfromarandomizedclinicaltrial.EurJHeartFail2018;20:1447–1453. 684. CuomoJR,JavaheriSP,SharmaGK,KapoorD,BermanAE,WeintraubNL.Howto
preventandmanageradiation-inducedcoronaryarterydisease.Heart2018;104:
662. JacobseJN,StegginkLC,SonkeGS,SchaapveldM,HummelYM,SteenbruggenTG,
1647–1653.
etal.Myocardialdysfunctioninlong-termbreastcancersurvivorstreatedatages
40–50years.EurJHeartFail2020;22:338–346. 685. FeldmanDR,SchafferWL,SteingartRM.Latecardiovasculartoxicityfollowing
chemotherapyforgermcelltumors.JNCCNJNatlComprCancerNetw2012;10:
663. BoyneDJ,MickleAT,BrennerDR,FriedenreichCM,CheungWY,TangKL,etal.
537–544.
Long-termriskofcardiovascularmortalityinlymphomasurvivors:asystematicre-
viewandmeta-analysis.CancerMed2018;7:4801–4813. 686. SudhakarR.Responsetotreatmentandoutcomesofacutecoronarysyndromein
thecancerpopulation.ClinCardiol2012;35:646.
664. DarbySC,McGaleP,TaylorCW,PetoR.Long-termmortalityfromheartdisease
687. NielsenSF,NordestgaardBG,BojesenSE.Statinuseandreducedcancer-related
andlungcancerafterradiotherapyforearlybreastcancer:prospectivecohort
mortality.NEnglJMed2013;368:574–577.
studyofabout300000womeninUSSEERcancerregistries.LancetOncol2005;
688. HanX-J,LiJ-Q,KhannanovaZ,LiY.Optimalmanagementofcoronaryarterydis-
6:557–565.
easeincancerpatients.ChronicDisTranslMed2019;5:221–233.
665. deVriesS,SchaapveldM,JanusCPM,DaniëlsLA,PetersenEJ,vanderMaazen
689. NeumannFJ,Sousa-UvaM,AhlssonA,AlfonsoF,BanningAP,BenedettoU,etal.
RWM,etal.Long-termcause-specificmortalityinHodgkinlymphomapatients.J
(2018ESC/EACTSGuidelinesonmyocardialrevascularization).KardiolPol2018;
NatlCancerInst2021;113:760–769.
76:1585–1664.
666. ArmenianSH,YangD,TehJB,AtencioLC,GonzalesA,WongFL,etal.Prediction
690. WuW,MasriA,PopovicZB,SmediraNG,LytleBW,MarwickTH,etal.Long-term
ofcardiovasculardiseaseamonghematopoieticcelltransplantationsurvivors.Blood
survivalofpatientswithradiationheartdiseaseundergoingcardiacsurgery:aco-
Adv2018;2:1756–1764.
hortstudy.Circulation2013;127:1476–1484.
667. GoldhirschA,GelberRD,Piccart-GebhartMJ,DeAzambujaE,ProcterM,Suter
691. GujralDM,LloydG,BhattacharyyaS.Radiation-inducedvalvularheartdisease.
TM,etal.2yearsversus1yearofadjuvanttrastuzumabforHER2-positivebreast Heart2016;102:269–276.
cancer (HERA): An open-label, randomised controlled trial. Lancet 2013;382:
692. BaumgartnerH,FalkV,BaxJJ,DeBonisM,HammC,HolmPJ,etal.2017ESC/
1021–1028.
EACTS Guidelines for the management of valvular heart disease. Eur Heart J
668. AdvaniPP,BallmanKV,DockterTJ,Colon-OteroG,PerezEA.Long-termcardiac 2017;38:2739–2791.
safetyanalysisofNCCTGN9831(Alliance)adjuvanttrastuzumabtrial.JClinOncol 693. LindA,TotzeckM,MahabadiAA,JánosiRA,ElGabryM,RuhparwarA,etal.Impact
2016;34:581–587.
ofcancerinpatientsundergoingtranscatheteraorticvalvereplacement:asingle-
669. PinderMC,DuanZ,GoodwinJS,HortobagyiGN,GiordanoSH.Congestiveheart centerstudy.JACCCardioOncology2020;2:735–743.
failure in older women treated with adjuvant anthracycline chemotherapy for 694. YazdchiF,HirjiSA,NohriaA,PercyE,HarloffM,MalarczykA,etal.Transcatheter
breastcancer.JClinOncol2007;25:3808–3815.
comparedwithsurgicalaorticvalvereplacementinpatientswithpreviouschest-
670. LancellottiP,NkomoVT,BadanoLP,BerglerJ,BogaertJ,DavinL,etal.Expert directedradiationtherapy.JACCCardioOncology2021;3:397–407.
Consensusformulti-modalityimagingevaluationofcardiovascularcomplications 695. GuhaA,DeyAK,OmerS,AbrahamWT,AttizzaniG,JneidH,etal.Contemporary
of radiotherapy in adults: a report from the European Association of trendsandoutcomesofpercutaneousandsurgicalmitralvalvereplacementorre-
CardiovascularImagingandtheAmericanSocietyofEchocardiography.JAmSoc pairinpatientswithcancer.AmJCardiol2020;125:1355–1360.
Echocardiogr2013;26:1013–1032.
696. ElbadawiA,AlbaeniA,ElgendyIY,OgunbayoGO,JimenezE,CornwellL,etal.
671. TrompJ,BoermanLM,SamaIE,MaassSWMC,MaduroJH,HummelYM,etal. Transcatheterversussurgicalaorticvalvereplacementinpatientswithpriormedi-
Long-termsurvivorsofearlybreastcancertreatedwithchemotherapyarecharac- astinalradiation.JACCCardiovascInterv2020;13:2658–2666.
terizedbyapro-inflammatorybiomarkerprofilecomparedtomatchedcontrols. 697. ZafarMR,MustafaSF,MillerTW,AlkhawlaniT,SharmaUC.Outcomesaftertrans-
EurJHeartFail2020;22:1239–1246. catheteraorticvalvereplacementincancersurvivorswithpriorchestradiation
672. CaoZ,XuC,YangH,LiS,WangY.Theroleofhealthylifestyleincancerincidence therapy:asystematicreviewandmeta-analysis.Cardio-Oncology2020;6:8.
andtemporaltransitionstocardiometabolicdisease.JACCCardioOncology2021;3: 698. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F,
663–674. EisenwortG,etal.Nilotinib-inducedvasculopathy:identificationofvascularendo-
673. LimatS,DaguindauE,CahnJY,NerichV,BrionA,PerrinS,etal.Incidenceandrisk- thelialcellsasaprimarytargetsite.Leukemia2017;31:2388–2397.
factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive 699. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary
non-Hodgkin’slymphoma.JClinPharmTher2014;39:168–174. Raynaud’sphenomenonandotherlatevascularcomplicationsfollowingchemo-
674. Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS. therapyfortesticularcancer.EurJCancer1995;31A:2229–2238.
Doxorubicin,cardiacriskfactors,andcardiactoxicityinelderlypatientswithdiffuse 700. StelwagenJ,LubbertsS,StegginkLC,SteursmaG,KruytLM,DonkerbroekJW,
B-cellnon-Hodgkin’slymphoma.JClinOncol2008;26:3159–3165. etal.Vascularaginginlong-termsurvivorsoftesticularcancermorethan20years
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 131 ---
ESCGuidelines 4359
after treatment with cisplatin-based chemotherapy. Br J Cancer 2020;123: 727. MeyerhardtJA,NiedzwieckiD,HollisD,SaltzLB,HuFB,MayerRJ,etal.Association
1599–1607. ofdietarypatternswithcancerrecurrenceandsurvivalinpatientswithstageIIIco-
701.Andreassi MG, Piccaluga E, Gargani L, Sabatino L, Borghini A, Faita F, et al. loncancer.JAmMedAssoc2007;298:754–764.
Subclinicalcarotidatherosclerosisandearlyvascularagingfromlong-termlow- 728. YangJ,LiC,ShenY,ZhouH,ShaoY,ZhuW,etal.Impactofstatinuseoncancer-
doseionizingradiationexposure:agenetic,telomere,andvascularultrasoundstudy specific mortality and recurrence: a meta-analysis of 60 observational studies.
incardiaccatheterizationlaboratorystaff.JACCCardiovascInterv2015;8:616–627. Medicine2020;99:e19596.
702.CarmodyBJ,AroraS,AvenaR,CurryKM,SimpkinsJ,CosbyK,etal.Accelerated 729. KimJ,ChoiEA,HanYE,WooLeeJ,SeulKimY,KimY,etal.Associationbetween
carotidarterydiseaseafterhigh-doseheadandneckradiotherapy:istherearole statinuseandall-causemortalityincancersurvivors,basedontheKoreanhealth
forroutinecarotidduplexsurveillance?JVascSurg1999;30:1045–1051. insuranceservicebetween2002and2015.NutrMetabCardiovascDis2020;30:
703.CarpenterDJ,MoweryYM,BroadwaterG,RodriguesA,WisdomAJ,DorthJA, 434–440.
etal.Theriskofcarotidstenosisinheadandneckcancerpatientsafterradiation 730. RenQW,YuSY,TengTHK,LiX,CheungKS,WuMZ,etal.Statinassociatedlower
therapy.OralOncol2018;80:9–15.
cancerriskandrelatedmortalityinpatientswithheartfailure.EurHeartJ2021;42:
704.SzpakowskiN,DesaiMY.Radiation-associatedpericardialdisease.CurrCardiolRep 3049–3059.
2019;21:97. 731. GalvãoDA,TaaffeDR,SpryN,JosephD,NewtonRU.Combinedresistanceand
705.Schultz-HectorS,TrottKR.Radiation-inducedcardiovasculardiseases:istheepide- aerobicexerciseprogramreversesmusclelossinmenundergoingandrogensup-
miologicevidencecompatiblewiththeradiobiologicdata?IntJRadiatOncolBiolPhys pressiontherapyforprostatecancerwithoutbonemetastases:arandomizedcon-
2007;67:10–18. trolledtrial.JClinOncol2010;28:340–347.
706.NingMS,TangL,GomezDR,XuT,LuoY,HuoJ,etal.Incidenceandpredictorsof 732. SpeckRM,CourneyaKS,MâsseLC,DuvalS,SchmitzKH.Anupdateofcontrolled
pericardialeffusionafterchemoradiationtherapyforlocallyadvancednon-small physicalactivitytrialsincancersurvivors:asystematicreviewandmeta-analysis.J
celllungcancer.IntJRadiatOncolBiolPhys2017;99:70–79. CancerSurviv2010;4:87–100.
707.WeiX,LiuHH,TuckerSL,WangS,MohanR,CoxJD,etal.Riskfactorsforperi- 733. CampiaU,BaracA.Exerciseandaerobicfitnesstoreducecancer-relatedcardio-
cardialeffusionininoperableesophagealcancerpatientstreatedwithdefinitive
vasculartoxicity.CurrTreatOptionsCardiovascMed2016;18:44.
chemoradiationtherapy.IntJRadiatOncolBiolPhys2008;70:707–714.
734. JonesLW,LiuQ,ArmstrongGT,NessKK,YasuiY,DevineK,etal.Exerciseand
708.Gagliardi G, Constine LS,Moiseenko V, Correa C, Pierce LJ, AllenAM, et al.
riskofmajorcardiovasculareventsinadultsurvivorsofchildhoodHodgkinlymph-
Radiationdose-volumeeffectsintheheart.IntJRadiatOncolBiolPhys2010;76:
oma:areportfromthechildhoodcancersurvivorstudy.JClinOncol2014;32:
S77–S85.
3643–3650.
709.ChiabrandoJG,BonaventuraA,VecchiéA,WohlfordGF,MauroAG,JordanJH,
735. ScottJM,LiN,LiuQ,YasuiY,LeisenringW,NathanPC,etal.Associationofexercise
etal.Managementofacuteandrecurrentpericarditis:JACCstate-of-the-artre- withmortalityinadultsurvivorsofchildhoodcancer.JAMAOncol2018;4:1352–1358.
view.JAmCollCardiol2020;75:76–92.
736. RockCL,DoyleC,Demark-WahnefriedW,MeyerhardtJ,CourneyaKS,Schwartz
710.Donnellan E, Phelan D, Mccarthy CP, Collier P, Desai M, Griffin B.
AL,etal.Nutritionandphysicalactivityguidelinesforcancersurvivors.CACancerJ
Radiation-inducedheartdisease:apracticalguidetodiagnosisandmanagement. Clin2012;62:242–274.
CleveClinJMed2016;83:914–922.
737. CDC.CancerDataandStatistics|SurvivalInformationfromtheNationalCancer
711.CrestanelloJA,McGregorCGA,DanielsonGK,DalyRC,DearaniJA,OrszulakTA,
InstituteandCentersforDiseaseControlandPrevention.2013.
etal.Mitralandtricuspidvalverepairinpatientswithpreviousmediastinalradiation
738. ThompsonKA,HildebrandtMAT,AterJL.Cardiacoutcomeswithpregnancy
therapy.AnnThoracSurg2004;78:826–831.
after cardiotoxic therapy for childhood cancer. J Am Coll Cardiol 2017;69:
712.Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart 2009;95:
594–595.
252–258.
739. NolanM,OikonomouEK,SilversidesCK,HinesMR,ThompsonKA,CampbellBA,
713.WalshD,NelsonKA.Autonomicnervoussystemdysfunctioninadvancedcancer.
SupportCareCancer2002;10:523–528. etal.Impactofcancertherapy-relatedcardiacdysfunctiononriskofheartfailurein
pregnancy.JACCCardioOncology2020;2:153–162.
714.NoorB,AkhavanS,LeuchterM,YangEH,AjijolaOA.Quantitativeassessmentof
740. Chait-RubinekL,MarianiJA,GoroncyN,HerschtalA,WheelerGC,DwyerMK,
cardiovascularautonomicimpairmentincancersurvivors:asinglecentercaseser-
etal.Aretrospectiveevaluationofriskofperipartumcardiacdysfunctioninsurvi-
ies.Cardio-Oncology2020;6:11.
vorsofchildhood,adolescentandyoungadultmalignancies.Cancers(Basel)2019;
715.GibsonTM,LiZ,GreenDM,ArmstrongGT,MulrooneyDA,SrivastavaDK,etal.
11:1046.
Bloodpressurestatusinadultsurvivorsofchildhoodcancer:areportfromthe
741. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017;26:
1705–1713. CífkováR,DeBonisM,etal.2018ESCGuidelinesforthemanagementofcardio-
vasculardiseasesduringpregnancy.EurHeartJ2018;39:3165–3241.
716.FriedmanDN,TonorezosES,CohenP.Diabetesandmetabolicsyndromeinsur-
vivorsofchildhoodcancer.HormResPaediatr2019;91:118–127. 742. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al.
717.PekmeziDW,Demark-WahnefriedW.Updatedevidenceinsupportofdietand
Cardiovascularconsiderationsincaringforpregnantpatients:ascientificstatement
exerciseinterventionsincancersurvivors.ActaOncol(Madr)2011;50:167–178. fromtheAmericanHeartAssociation.Circulation2020;141:e884–e903.
718.ChlebowskiRT,AielloE,McTiernanA.Weightlossinbreastcancerpatientman- 743. TravisWD,BrambillaE,BurkeAP,MarxA,NicholsonAG,eds.WHOClassificationof
agement.JClinOncol2002;20:1128–1143. TumoursoftheLung,Pleura,ThymusandHeart,4thed.2015.ISBN978-92-832-2436-5
719.ProtaniM,CooryM,MartinJH.Effectofobesityonsurvivalofwomenwithbreast 744. BurkeA,TavoraF.The2015WHOClassificationoftumorsoftheheartandperi-
cancer:systematicreviewandmeta-analysis.BreastCancerResTreat2010;123:
cardium.JThoracOncol2016;11:441–452.
627–635. 745. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, et al.
720.MeyerhardtJA,MaJ,CourneyaKS.Energeticsincolorectalandprostatecancer.J Incidence rate of primary cardiac tumors: a 14-year population study. J
ClinOncol2010;28:4066–4073. CardiovascMed2016;17:37–43.
721.WrightME,ChangSC,SchatzkinA,AlbanesD,KipnisV,MouwT,etal.Prospective 746. MaleszewskiJJ,BoisMC,BoisJP,YoungPM,StulakJM,KlarichKW.Neoplasiaand
studyofadiposityandweightchangeinrelationtoprostatecancerincidenceand theheart:pathologicalreviewofeffectswithclinicalandradiologicalcorrelation.J
mortality.Cancer2007;109:675–684. AmCollCardiol2018;72:202–227.
722.SiegelEM,UlrichCM,PooleEM,HolmesRS,JacobsenPB,ShibataD.Theeffectsof 747. TyeballyS,ChenS,BhattacharyyaS,MughrabiS,HussainZ,ManistyC,etal.Cardiac
obesity and obesity-related conditions on colorectal cancer prognosis. Cancer tumors:JACCCardioOncologystate-of-the-artreview.JACCCardioOncology2020;2:
Control2010;17:52–57. 293–311.
723.KroenkeCH,ChenWY,RosnerB,HolmesMD.Weight,weightgain,andsurvival 748. Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, et al.
afterbreastcancerdiagnosis.JClinOncol2005;23:1370–1378. Differentialdiagnosisofcardiacmassesusingcontrastechocardiographicperfusion
724.MeyerhardtJA,NiedzwieckiD,HollisD,SaltzLB,MayerRJ,NelsonH,etal.Impact imaging.JAmCollCardiol2004;43:1412–1419.
ofbodymassindexandweightchangeaftertreatmentoncancerrecurrenceand 749. ThieneG,RizzoS,MarraMP,ValenteM,BassoC.Massesandcardiactumours:clas-
survivalinpatientswithstageIIIcoloncancer:FindingsfromCancerandLeukemia sificationanddiagnosis.ESCCardioMED,2018.DOI:10.1093/med/9780198784906.
GroupB89803.JClinOncol2008;26:4109–4115. 003.0386
725.KroenkeCH,FungTT,HuFB,HolmesMD.Dietarypatternsandsurvivalafter 750. Zaragosa-MaciasE,ChenMA,GillEA.Realtimethree-dimensionalechocardiog-
breastcancerdiagnosis.JClinOncol2005;23:9295–9303. raphyevaluationofintracardiacmasses.Echocardiography2012;29:207–219.
726.KwanML,WeltzienE,KushiLH,CastilloA,SlatteryML,CaanBJ.Dietarypatterns 751. BeroukhimRS,PrakashA,ValsangiacomoBuechelER,CavaJR,DorfmanAL,Festa
andbreastcancerrecurrenceandsurvivalamongwomenwithearly-stagebreast P,etal.Characterizationofcardiactumorsinchildrenbycardiovascularmagnetic
cancer.JClinOncol2009;27:919–926. resonanceimaging:amulticenterexperience.JAmCollCardiol2011;58:1044–1054.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 132 ---
4360 ESCGuidelines
752. Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al. 779. KorseCM,TaalBG,DeGrootCA,BakkerRH,BonfrerJMG.Chromogranin-Aand
Differentiationofmalignantandbenigncardiactumorsusing18F-FDGPET/CT.J N-terminalpro-brainnatriureticpeptide:anexcellentpairofbiomarkersfordiag-
NuclMed2012;53:856–863. nosticsinpatientswithneuroendocrinetumor.JClinOncol2009;27:4293–4299.
753. KassopD,DonovanMS,CheezumMK,NguyenBT,GambillNB,BlanksteinR,etal. 780. BhattacharyyaS,ToumpanakisC,CaplinME,DavarJ.UsefulnessofN-terminal
CardiacmassesoncardiacCT:areview.CurrCardiovascImagingRep2014;7:9281. pro-brainnatriureticpeptideasabiomarkerofthepresenceofcarcinoidheartdis-
754. D’AngeloEC,PaolissoP,VitaleG,FoàA,BergamaschiL,MagnaniI,etal.Diagnostic ease.AmJCardiol2008;102:938–942.
accuracyofcardiaccomputedtomographyand18F-fluorodeoxyglucosewithposi- 781. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al.
tronemissiontomographyincardiacmasses.JACCCardiovascImaging2020;13: Telotristatethyl,atryptophanhydroxylaseinhibitorforthetreatmentofcarcinoid
2400–2411. syndrome.JClinOncol2017;35:14–23.
755. ButanyJ,NairV,NaseemuddinA,NairGM,CattonC,YauT.Cardiactumours: 782. DumouleinM,VerslypeC,VanCutsemE,MeurisB,HerijgersP,FlamengW,etal.
diagnosisandmanagement.LancetOncol2005;6:219–228. Carcinoidheartdisease:caseandliteraturereview.ActaCardiol2010;65:261–264.
756. SzmitS,ZagrodzkaM,KurzynaM,OpolskiG,SzczylikC.Sunitinibmalate,arecep- 783. NguyenA,SchaffHV,AbelMD,LuisSA,LahrBD,HalfdanarsonTR,etal.Improving
tortyrosinekinaseinhibitor,iseffectiveinthetreatmentofrestrictiveheartfailure outcomeofvalvereplacementforcarcinoidheartdisease.JThoracCardiovascSurg
duetoheartmetastasesfromrenalcellcarcinoma.Cardiology2009;114:67–71. 2019;158:99–107.e2.
757. PeccatoriFA,AzimJA,OrecchiaR,HoekstraHJ,PavlidisN,KesicV,etal.Cancer, 784. MabvuureN,CumberworthA,HindochaS.Inpatientswithcarcinoidsyndrome
pregnancyandfertility:ESMOClinicalPracticeGuidelinesfordiagnosis,treatment undergoingvalvereplacement:willabiologicalvalvehaveacceptabledurability?
andfollow-up.AnnOncol2013;24:vi160–70. InteractCardiovascThoracSurg2012;15:467–471.
758. Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al. 785. ConnollyHM,SchaffHV,AbelMD,RubinJ,AskewJW,LiZ,etal.Earlyandlate
Multidisciplinaryconsensusoncancermanagementduringpregnancy.ClinTransl outcomesofsurgicaltreatmentincarcinoidheartdisease.JAmCollCardiol2015;
Oncol2021;23:1054–1066. 66:2189–2196.
759. SilversteinJ,PostAL,ChienAJ,OlinR,TsaiKK,NgoZ,etal.Multidisciplinaryman- 786. SunjicI,ShinD,SunjicKM,PopatJV,TranT,ChaeSH,etal.Incidenceofatrioven-
agementofcancerduringpregnancy.JCOOncolPract2020;16:545–557. tricularblockaftervalvereplacementincarcinoidheartdisease.CardiolRes2020;
760. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. 11:56–60.
Gynecologiccancersinpregnancy:guidelinesbasedonathirdinternationalconsen- 787. KuntzeT,OwaisT,SecknusMA,KaemmererD,BaumR,GirdauskasE.Resultsof
susmeeting.AnnOncol2019;30:1601–1612. contemporaryvalvesurgeryinpatientswithcarcinoidheartdisease.JHeartValve
761. DunleavyK,McLintockC.HowItreatlymphomainpregnancy.Blood2020;136: Dis2016;25:356–363.
2118–2124. 788. Luthra S, Olevano C, Richens T, Tsang GM. Percutaneous transcatheter
762. Ducas RA, Elliott JE, Melnyk SF, Premecz S, Dasilva M, Cleverley K, et al. valve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease.
Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac JACCCaseReports2020;2:533–536.
HemodynamicImagingandRemodelinginPregnancy(CHIRP)study.JCardiovasc 789. ZacksJS,LavineR.Avoidingarepeatsternotomyinrecurrentcarcinoidheartdis-
MagnReson2014;16:1. ease.JACCCaseReports2020;2:537–538.
763. Savu O, Jurcuţ R, Giuşcǎ S, Van Mieghem T, Gussi I, Popescu BA, et al. 790. BhattacharyyaS,ToumpanakisC,BurkeM,TaylorAM,CaplinME,DavarJ.Features
Morphologicalandfunctionaladaptationofthematernalheartduringpregnancy. ofcarcinoidheartdiseaseidentifiedby2-and3-dimensionalechocardiographyand
CircCardiovascImaging2012;5:289–297. cardiacMRI.CircCardiovascImaging2010;3:103–111.
764. NarayananM,ElkayamU,NaqviTZ.Echocardiographyinpregnancy:part2.Curr 791. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al.
CardiolRep2016;18:90. Carcinoidheartdisease:clinicalandechocardiographicspectrumin74patients.
765. FurenäsE,ErikssonP,WennerholmUB,DellborgM.Pregnancyinahealthypopu- Circulation1993;87:1188–1196.
lation:dynamicsofNTproBNPandhs-cTroponinT.OpenHeart2020;7:e001293. 792. PalladiniG,MilaniP,MerliniG.ManagementofALamyloidosisin2020.Blood2020;
766. TanousD,SiuSC,MasonJ,GreutmannM,WaldRM,ParkerJD,etal.B-typenatri- 136:2620–2627.
ureticpeptideinpregnantwomenwithheartdisease.JAmCollCardiol2010;56: 793. WittelesRM,LiedtkeM.ALamyloidosisforthecardiologistandoncologist:epi-
1247–1253. demiology,diagnosis,andmanagement.JACCCardioOncology2019;1:117–130.
767. HeitJA,KobbervigCE,JamesAH,PettersonTM,BaileyKR,MeltonLJIII.Trendsin 794. MerliniG,WechalekarAD,PalladiniG.Systemiclightchainamyloidosis:anupdate
theincidenceofvenousthromboembolismduringpregnancyorpostpartum:a fortreatingphysicians.Blood2013;121:5124–5130.
30-yearpopulation-basedstudy.AnnInternMed2005;143:697–706. 795. MaurerMS,ElliottP,ComenzoR,SemigranM,RapezziC.Addressingcommon
768. SultanAA,WestJ,TataLJ,FlemingKM,Nelson-PiercyC,GraingeMJ.Riskoffirst questionsencounteredinthediagnosisandmanagementofcardiacamyloidosis.
venousthromboembolisminpregnantwomeninhospital:populationbasedcohort Circulation2017;135:1357–1377.
studyfromEngland.BMJ2013;347:f6099. 796. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice
769. SultanAA,WestJ,TataLJ,FlemingKM,Nelson-PiercyC,GraingeMJ.Riskoffirst GuidelinesinOncology.SystemicLightChainAmyloidosisVersion1.NatlCompr
venousthromboembolisminandaroundpregnancy:apopulation-basedcohort CancerNetw2021.https://www.nccn.org/.
study.BrJHaematol2012;156:366–373. 797. KumarS,DispenzieriA,LacyMQ,HaymanSR,BuadiFK,ColbyC,etal.Revised
770. HaseEA,deBarrosVIPVL,IgaiAMK,FranciscoRPV,ZugaibM.Riskassessmentof prognosticstagingsystemforlightchainamyloidosisincorporatingcardiacbiomar-
venousthromboembolismandthromboprophylaxisinpregnantwomenhospita- kersandserumfreelightchainmeasurements.JClinOncol2012;30:989–995.
lizedwithcancer:preliminaryresultsfromariskscore.Clinics(SaoPaulo)2018; 798. ZhangKW,MiaoJ,MitchellJD,Alvarez-CardonaJ,TomasekK,SuYR,etal.Plasma
73:e368. hepatocytegrowthfactorfordiagnosisandprognosisinlightchainandtransthyr-
771. FoxDJ,KhattarRS.Carcinoidheartdisease:presentation,diagnosis,andmanage- etincardiacamyloidosis.JACCCardioOncology2020;2:56–66.
ment.Heart2004;90:1224–1228. 799. MohanM,BurosA,MathurP,GokdenN,SinghM,SusanibarS,etal.Clinicalchar-
772. Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. acteristicsandprognosticfactorsinmultiplemyelomapatientswithlightchainde-
Diagnosingandmanagingcarcinoidheartdiseaseinpatientswithneuroendocrine positiondisease.AmJHematol2017;92:739–745.
tumors:anexpertstatement.JAmCollCardiol2017;69:1288–1304. 800. GroganM,DIspenzieriA,GertzMA.Light-chaincardiacamyloidosis:strategiesto
773. DobsonR,BurgessMI,PritchardDM,CuthbertsonDJ.Theclinicalpresentation promoteearlydiagnosisandcardiacresponse.Heart2017;103:1065–1072.
andmanagementofcarcinoidheartdisease.IntJCardiol2014;173:29–32. 801. JurcuţR,OnciulS,AdamR,StanC,CoriuD,RapezziC,etal.Multimodalityimaging
774. LichtenauerM,PichlerT,EderS,MirnaM,MagnesT,WernlyB,etal.Carcinoid incardiacamyloidosis:aprimerforcardiologists.EurHeartJCardiovascImaging
heartdiseaseinvolvingtheleftheart:acasereportandbiomarkeranalysis.ESC 2020;21:833–844.
HeartFail2019;6:222–227. 802. LeeChuyK,DrillE,YangJC,LandauH,HassounH,NahhasO,etal.Incremental
775. HalperinDM,ShenC,DasariA,XuY,ChuY,ZhouS,etal.Frequencyofcarcinoid valueofgloballongitudinalstrainforpredictingsurvivalinpatientswithadvanced
syndromeatneuroendocrinetumourdiagnosis:apopulation-basedstudy.Lancet ALamyloidosis.JACCCardioOncology2020;2:223–231.
Oncol2017;18:525–534. 803. BrownriggJ,LorenziniM,LumleyM,ElliottP.Diagnosticperformanceofimaging
776. BhattacharyyaS,DavarJ,DreyfusG,CaplinME.Carcinoidheartdisease.Circulation investigationsindetectinganddifferentiatingcardiacamyloidosis:asystematicre-
2007;116:2860–2865. viewandmeta-analysis.ESCHeartFail2019;6:1041–1051.
777. ZuetenhorstJM,KorseCM,BonfrerJMG,BakkerRH,TaalBG.Roleofnatriuretic 804. BaggianoA,BoldriniM,Martinez-NaharroA,KotechaT,PetrieA,RezkT,etal.
peptidesinthediagnosisandtreatmentofpatientswithcarcinoidheartdisease.BrJ Noncontrastmagneticresonanceforthediagnosisofcardiacamyloidosis.JACC
Cancer2004;90:2073–2079. CardiovascImaging2020;13:69–80.
778. DobsonR,BurgessMI,BanksM,PritchardDM,VoraJ,ValleJW,etal.Theassoci- 805. ComenzoRL,ReeceD,PalladiniG,SeldinD,SanchorawalaV,LandauH,etal.
ationofapanelofbiomarkerswiththepresenceandseverityofcarcinoidheart Consensusguidelinesfortheconductandreportingofclinicaltrialsinsystemic
disease:across-sectionalstudy.PLoSOne2013;8:e73679. light-chainamyloidosis.Leukemia2012;26:2317–2325.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
--- Страница 133 ---
ESCGuidelines 4361
806.EckhertE,WittelesR,KaufmanG,LafayetteR,AraiS,SchrierS,etal.Gradingcar- undergoing radiotherapy: a population-based cohort study. Pacing Clin
diacresponseinALamyloidosis:implicationsforrelapseandsurvival.BrJHaematol Electrophysiol2015;38:343–356.
2019;186:144–146. 824. MiftenM,MihailidisD,KrySF,ReftC,EsquivelC,FarrJ,etal.Managementofradio-
807.VaxmanI,GertzM.Recentadvancesinthediagnosis,riskstratification,andman- therapypatientswithimplantedcardiacpacemakersanddefibrillators:areportof
agementofsystemiclight-chainamyloidosis.ActaHaematol2019;141:93–106. theAAPMTG-203.MedPhys2019;46:e757–e788.
808.GiancaterinoS,UreyMA,DardenD,HsuJC.Managementofarrhythmiasincardiac 825. HurkmansCW,KnegjensJL,OeiBS,MaasAJJ,UiterwaalGJ,vanderBordenAJ,
amyloidosis.JACCClinElectrophysiol2020;6:351–361.
etal.ManagementofradiationoncologypatientswithapacemakerorICD:a
809.El-AmEA,DispenzieriA,MelduniRM,AmmashNM,WhiteRD,HodgeDO,etal. newcomprehensivepracticalguidelineinTheNetherlands.RadiatOncol2012;7:
Directcurrentcardioversionofatrialarrhythmiasinadultswithcardiacamyloid-
198.
osis.JAmCollCardiol2019;73:589–597.
826. IndikJH,GimbelJR,AbeH,Alkmim-TeixeiraR,Birgersdotter-GreenU,ClarkeGD,
810.TahirUA,DorosG,KimJS,ConnorsLH,SeldinDC,SamF.Predictorsofmortality
etal.2017HRSexpertconsensusstatementonmagneticresonanceimagingand
inlightchaincardiacamyloidosiswithheartfailure.SciRep2019;9:8552.
radiationexposureinpatientswithcardiovascularimplantableelectronicdevices.
811.KhannaS,LoP,ChoK,SubbiahR.Ventriculararrhythmiasincardiacamyloidosis:a
HeartRhythm2017;14:e97–e153.
reviewofcurrentliterature.ClinMedInsightsCardiol2020;14:1179546820963055.
827. ZarembaT,JakobsenAR,SøgaardM,ThøgersenAM,RiahiS.Radiotherapyinpa-
812.KastritisE,LeleuX,ArnulfB,ZamagniE,CibeiraMT,KwokF,etal.Bortezomib,
tientswithpacemakersandimplantablecardioverterdefibrillators:aliteraturere-
melphalan,anddexamethasoneforlight-chainamyloidosis.JClinOncol2020;38:
3252–3260. view.Europace2016;18:479–491.
828. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, et al.
813.PalladiniG,KastritisE,MaurerMS,ZonderJ,MinnemaMC,WechalekarAD,etal.
DaratumumabplusCyBorDforpatientswithnewlydiagnosedALamyloidosis: Radiotherapy-induced malfunction in contemporary cardiovascular implantable
safetyrun-inresultsofANDROMEDA.Blood2020;136:71–80. electronicdevices:clinicalincidenceandpredictors.JAMAOncol2015;1:624–632.
814.HuangX,RenG,ChenW,GuoJ,ZhaoL,ZengC,etal.Theroleofinductionther- 829. ZecchinM,SevergniniM,FiorentinoA,MalavasiVL,MenegottiL,AlongiF,etal.
apybeforeautologousstemcelltransplantationinlowdiseaseburdenALamyloid- Managementofpatientswithcardiacimplantableelectronicdevices(CIED)under-
osispatients.Amyloid2021;28:75–83. goingradiotherapy:aconsensusdocumentfromAssociazioneItalianaAritmologia
815.BarrettCD,DobosK,LiedtkeM,TuzovicM,HaddadF,KobayashiY,etal.Achan- e Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica
ginglandscapeofmortalityforsystemiclightchainamyloidosis.JACCHeartFail (AIRO),AssociazioneItalianaFisicaMedica(AIFM).IntJCardiol2018;255:175–183.
2019;7:958–966. 830. GomezDR,PoenischF,PinnixCC,SheuT,ChangJY,MemonN,etal.Malfunctions
816.Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the ofimplantablecardiacdevicesinpatientsreceivingprotonbeamtherapy:incidence
treatmentoflightchainandtransthyretinamyloidosis.JACCBasicTranslSci2019; andpredictors.IntJRadiatOncolBiolPhys2013;87:570–575.
4:438–448. 831. SharifzadehganA,LauransM,ThuillotM,HuertasA,BaudinaudP,NarayananK,
817.KastritisE,PalladiniG,MinnemaMC,WechalekarAD,JaccardA,LeeHC,etal. etal.Radiotherapyinpatientswithacardiacimplantableelectronicdevice.AmJ
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Cardiol2020;128:196–201.
EnglJMed2021;385:46–58.
832. StienenJJC,OttevangerPB,WennekesL,DekkerHM,vanderMaazenRWM,
818.WechalekarAD,WhelanC.Encouragingimpactofdoxycyclineonearlymortality
MandigersCMPW,etal.DevelopmentandevaluationofaneducationalE-tool
incardiaclightchain(AL)amyloidosis.BloodCancerJ2017;7:e546. tohelppatientswithnon-Hodgkin’slymphomamanagetheirpersonalcarepath-
819.ShenK,FuW,WuY,DongY,HuangZ,WeiY,etal.Doxycyclinecombinedwith
way.JMIRResProtoc2015;4:e6.
bortezomib–cyclophosphamide–dexamethasone chemotherapy for newly diag-
833. MurphyP,LevineA,LermaT,YoungS,HwangJ,GoldsbyR.Aportablesurvivor-
nosedcardiaclight-chainamyloidosis:amulticenterrandomizedcontrolledtrial.
Circulation2021;145:8–17. shipcareplan:atoolthathelpseducateandimproveknowledgeinchildhoodcan-
cersurvivors.SupportCareCancer2021;29:169–177.
820.SalinaroF,Meier-EwertHK,MillerEJ,PandeyS,SanchorawalaV,BerkJL,etal.
834. AsteggianoR,AboyansV,LeeG,SalingerS,RichterD.Cardiologycaredeliveredto
Longitudinalsystolicstrain,cardiacfunctionimprovement,andsurvivalfollowing
cancerpatients.EurHeartJ2020;41:205–206.
treatmentoflight-chain(AL)cardiacamyloidosis.EurHeartJCardiovascImaging
2017;18:1057–1064. 835. AktaaS,BatraG,WallentinL,BaigentC,ErlingeD,JamesS,etal.EuropeanSociety
821.PalladiniG,FoliA,MilaniP,RussoP,AlbertiniR,LavatelliF,etal.Bestuseofcardiac ofCardiologymethodologyforthedevelopmentofqualityindicatorsforthequan-
biomarkersinpatientswithALamyloidosisandrenalfailure.AmJHematol2012;87:
tificationofcardiovascularcareandoutcomes.EurHeartJQualCareClinOutcomes
465–471. 2022;8:4–13.
822.DispenzieriA,GertzMA,KyleRA,LacyMQ,BurrittMF,TherneauTM,etal.Serum 836. MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.Qualityofcareinthe
cardiactroponinsandN-terminalpro-brainnatriureticpeptide:astagingsystemfor UnitedKingdomafterremovaloffinancialincentives.NEnglJMed2018;379:
primarysystemicamyloidosis.JClinOncol2004;22:3751–3757. 948–957.
823.ZarembaT,JakobsenAR,SØgaardM,ThØgersenAM,JohansenMB,MadsenLæB, 837. SongZ,JiY,SafranDG,ChernewME.Healthcarespending,utilization,andquality
etal.Riskofdevicemalfunctionincancerpatientswithimplantablecardiacdevice 8yearsintoglobalpayment.NEnglJMed2019;381:252–263.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/41/4229/6673995
by
guest
on
22
January
2026
